



(86) Date de dépôt PCT/PCT Filing Date: 2013/08/12
(87) Date publication PCT/PCT Publication Date: 2014/02/20
(85) Entrée phase nationale/National Entry: 2015/02/13
(86) N° demande PCT/PCT Application No.: US 2013/054532
(87) N° publication PCT/PCT Publication No.: 2014/028384
(30) Priorités/Priorities: 2012/08/16 (US61/683,772);
2013/05/02 (US61/818,572); 2013/08/05 (US13/959,268)

(51) Cl.Int./Int.Cl. *C07D 487/16* (2006.01),
A61K 31/519 (2006.01), *A61P 31/18* (2006.01),
C07D 498/16 (2006.01)

(71) Demandeur/Applicant:
BRISTOL-MYERS SQUIBB COMPANY, US


(72) Inventeurs/Inventors:
NAIDU, B. NARASIMHULU, US;
PATEL, MANOJ, US;
D'ANDREA, STANLEY, US;
ZHENG, ZHIZHEN BARBARA, US;
CONNOLLY, TIMOTHY P., US;
LANGLEY, DAVID R., US;

...

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : INHIBITEURS DE REPLICATION DU VIRUS D'IMMUNODEFICIENCE HUMAINE

(54) Title: INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION



(I)

(57) Abrégé/Abstract:

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.



(72) **Inventeurs(suite)/Inventors(continued):** PEESE, KEVIN, US; WANG, ZHONGYU, US; WALKER, MICHAEL A., US;
KADOW, JOHN F., US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2014/028384 A1

(43) International Publication Date

20 February 2014 (20.02.2014)

(51) International Patent Classification:

C07D 487/16 (2006.01) A61K 31/519 (2006.01)

C07D 498/16 (2006.01) A61P 31/18 (2006.01)

(21) International Application Number:

PCT/US2013/054532

(22) International Filing Date:

12 August 2013 (12.08.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/683,772 16 August 2012 (16.08.2012) US

61/818,572 2 May 2013 (02.05.2013) US

13/959,268 5 August 2013 (05.08.2013) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors: NAIDU, B. Narasimhulu; Bristol-Myers

Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). PATEL, Manoj; Bristol-Myers

Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). D'ANDREA, Stanley; 15 Harvest

Lane, Wallingford, Connecticut 06492 (US). ZHENG, Zh-

izhen Barbara; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

CONNOLLY, Timothy P.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut

06492 (US). LANGLEY, David R.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut

06492 (US). PEESE, Kevin; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut

06492 (US). WANG, Zhongyu; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut

06492 (US). WALKER, Michael A.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). KADOW, John F.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

(74) Agents: EPPERSON, James et al.; Bristol-Myers Squibb

Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION



(I)

(57) **Abstract:** The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

WO 2014/028384 A1

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

BACKGROUND OF THE INVENTION

5 The disclosure generally relates to compounds, compositions, and methods for the treatment of human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

10

 Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening opportunistic infections. Recent statistics indicate that as many as 33.3 million people worldwide are infected with the virus (UNAIDS Report on the Global AIDS Epidemic 2010). In addition to the large number of individuals already infected, the virus continues to spread. Estimates from 1998 point to close to 6 million new infections in that year alone. In the same year there were approximately 2.5 million deaths associated with HIV and AIDS.

20

 There are currently a number of antiviral drugs available to combat the infection. These drugs can be divided into classes based on the viral protein they target or their mode of action. In particular, saquinavir, indinavir, ritonavir, nelfinavir atazanavir darunavir, amprenavir, fosamprenavir, lopinavir and tipranavir are competitive inhibitors of the aspartyl protease expressed by HIV. Zidovudine, didanosine, stavudine, lamivudine, zalcitabine, emtricitibine, tenofovir and abacavir are nucleos(t)ide reverse transcriptase inhibitors that behave as substrate mimics to halt viral cDNA synthesis. The non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, efavirenz and etravirine inhibit the synthesis of viral cDNA via a non-competitive (or uncompetitive) mechanism. Enfuvirtide and maraviroc inhibit the entry of the virus into the host cell. An HIV integrase inhibitor, raltegravir (MK-0518, Isentress[®]), has also been approved for use in treatment experienced

30

patients, and it is clear that this class of inhibitors is very effective as part of a combination regimen containing HIV inhibitors of different classes.

Used alone, these drugs are effective in reducing viral replication: However,
5 the effect is only temporary as the virus readily develops resistance to all known agents used as monotherapy. On the other hand, combination therapy has proven very effective at both reducing virus and suppressing the emergence of resistance in a number of patients. In the US, where combination therapy is widely available, the number of HIV-related deaths has dramatically declined (Palella, F. J.; Delany, K.
10 M.; Moorman, A. C.; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. *N. Engl. J. Med.* 1998, 338, 853-860).

Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, initial studies suggest that approximately 30-50% of patients
15 ultimately fail at least one drug in the suppressive combination. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the replication rate of HIV-1 during the course of infection combined with the relatively high viral mutation rate associated with the viral polymerase and the lack of adherence of HIV-infected individuals in taking their prescribed medications.
20 Clearly, there is a need for new antiviral agents, preferably with activity against viruses already resistant to currently approved drugs. Other important factors include improved safety and a more convenient dosing regimen than many of the currently approved drugs.

25 Compounds which inhibit HIV replication have been disclosed. See WO2007131350, WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130034, WO2010130842, WO2011015641, WO2011076765, WO2012003497, WO2012003498, WO2012033735, WO2012065963 and WO2012066442.

30

The invention provides technical advantages, for example, the compounds are novel and are useful in the treatment of HIV. Additionally, the compounds provide

advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability.


5

DESCRIPTION OF THE INVENTION

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

10

One aspect of the invention is a compound of Formula I



I

15 where:

R^1 is hydrogen, alkyl, or cycloalkyl;

R^2 is hydrogen or alkyl;

20

R^3 is hydrogen, alkyl or halo;

R^4 is cycloalkyl or Ar^3 ;

or R^4 is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,

25 homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 alkyl substituents;

R^5 is hydrogen or alkyl;

Ar¹ is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

Ar² is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or trizainyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂;

Ar³ is phenyl, chromanyl, or dihydrobenzoxazinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

X¹ is CH, CH₂, O, S, or NR⁵;

X² is alkylene or alkenylene; and

X³ is CH, CH₂, CH₂O, O, S, or NR⁵;

or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of Formula I where:

R¹ is hydrogen or alkyl;

R² is hydrogen or alkyl;

R³ is hydrogen, alkyl or halo;

R⁴ is cycloalkyl or Ar³;

or R⁴ is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 alkyl substituents;

R⁵ is hydrogen or alkyl;

Ar¹ is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

5

Ar² is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or trizainyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

10 Ar³ is phenyl, chromanyl, or dihydrobenzoxazinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

X¹ is CH₂, O, S, or NR⁵;

15 X² is alkylene or alkenylene; and

X³ is CH, CH₂, O, S, or NR⁵;

or a pharmaceutically acceptable salt thereof.

20

Another aspect of the invention is a compound of Formula I where R¹ is alkyl; R² is alkyl; R³ is hydrogen; R⁴ is Ar³ or is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl substituted with 0-3 alkyl substituents; Ar¹ is phenyl substituted with 0-3 substituents
 25 selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ar³ is dihydrobenzoxazinyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; X¹ is CH₂ or O; X² is alkylene or alkenylene; and X³ is CH, CH₂ or O; or a pharmaceutically acceptable
 30 salt thereof.

Another aspect of the invention is a compound of Formula I where R¹ is alkyl; R² is alkyl; R³ is hydrogen; R⁴ is Ar³ or is piperidinyl substituted with 0-1 alkyl

substituents; Ar¹ is phenyl; Ar² is phenyl; Ar³ is dihydrobenzoxazinyl substituted with 0-1 halo or alkyl substituents; X¹ is CH₂ or O; X² is alkylene or alkenylene; and X³ is CH, CH₂ or O; or a pharmaceutically acceptable salt thereof.

5 Another aspect of the invention is a compound of formula I where R¹ is alkyl; R² is alkyl; R³ is hydrogen; R⁴ is Ar³ or is piperidinyl substituted with 0-1 alkyl substituents; Ar¹ is phenyl; Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂; Ar³ is dihydrobenzoxazinyl substituted with 0-1 halo or alkyl substituents; X¹ is CH₂ or O;
10 X² is alkylene or alkenylene; and X³ is CH, CH₂ or O; or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of Formula I where R¹ is alkyl, R² is alkyl and R³ is hydrogen.

15

Another aspect of the invention is a compound of Formula I where R⁴ is Ar³ or is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl substituted with 0-3 alkyl substituents.

20 Another aspect of the invention is a compound of Formula I where R⁴ is Ar³.

Another aspect of the invention is a compound of Formula I where R⁴ is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl substituted with 0-3 alkyl substituents.

25

Another aspect of the invention is a compound of Formula I where R⁴ is piperidinyl substituted with 0-3 alkyl substituents.

Another aspect of the invention is a compound of Formula I where Ar¹ is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.
30

Another aspect of the invention is a compound of Formula I where Ar¹ is phenyl.

Another aspect of the invention is a compound of Formula I where Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂.

5 Another aspect of the invention is a compound of Formula I where Ar² is pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂.

10 Another aspect of the invention is a compound of Formula I where Ar³ is phenyl, chromanyl, or dihydrobenzoxazinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

Another aspect of the invention is a compound of Formula I where Ar³ is
15 phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

Another aspect of the invention is a compound of Formula I where X¹ is CH₂ or O; X² is alkylene or alkenylene; and X³ is CH, CH₂ or O.

20

Unless specified otherwise, these terms have the following meanings.

“Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons.

“Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. “Alkylene” means a straight or branched divalent alkyl

25 group composed of 1 to 6 carbons. “Alkenylene” means a straight or branched divalent alkene group composed of 2 to 6 carbons with at least one double bond.

“Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons.

“Hydroxyalkyl,” “alkoxy” and other terms with a substituted alkyl moiety include straight and branched isomers composed of 1 to 6 carbon atoms for the alkyl moiety.

30 “Alkyleneoxy” means a straight or branched divalent alkyloxy group composed of 1 to 6 carbons, for example, -CH₂CH₂CH₂O-. “Alkenyleneoxy” means a straight or branched divalent alkeneoxy group composed of 2 to 6 carbons with at least one double bond, for example, -CH=CHCH₂O-. “Halo” includes fluoro, chloro, bromo,

and iodo. "Halo" includes all halogenated isomers from monohalo substituted to perhalo substituted in substituents defined with halo, for example, "Haloalkyl" "haloalkoxy", "halophenyl", and "halophenoxy." "Aryl" includes carbocyclic and heterocyclic aromatic substituents. Substituents which are illustrated by chemical
5 drawing to bond at variable positions on a multiple ring system (for example a bicyclic ring system) are intended to bond to the ring where they are drawn to append. Parenthetical and multiparenthetical terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.

10

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made
15 according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium,
20 aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

Some of the compounds of the invention exist in stereoisomeric forms. The
25 invention includes all stereoisomeric forms of the compounds including enantiomers and diastereomers. Methods of making and separating stereoisomers are known in the art. The invention includes all tautomeric forms of the compounds. The invention includes atropisomers and rotational isomers.

30 The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ¹³C

and ^{14}C . Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

Biological Methods

10

Inhibition of HIV replication. A recombinant NL-Rluc virus was constructed in which a section of the nef gene from NL4-3 was replaced with the *Renilla* Luciferase gene. The NL-RLuc virus was prepared by co-transfection of two plasmids, pNLRLuc and pVSVenv. The pNLRLuc contains the NL-Rluc DNA cloned into pUC18 at the *Pvu*II site, while the pVSVenv contains the gene for VSV G protein linked to an LTR promoter. Transfections were performed at a 1:3 ratio of pNLRLuc to pVSVenv in 293T cells using the LipofectAMINE PLUS kit from Invitrogen (Carlsbad, CA) according to the manufacturer, and the pseudotype virus generated was titrated in MT-2 cells. For susceptibility analyses, the titrated virus was used to infect MT-2 cells in the presence of compound, and after 5 days of incubation, cells were processed and quantitated for virus growth by the amount of expressed luciferase. This provides a simple and easy method for quantitating the extent of virus growth and consequently, the antiviral activity of test compounds. Luciferase was quantitated using the Dual Luciferase kit from Promega (Madison, WI).

Susceptibility of viruses to compounds was determined by incubation in the presence of serial dilutions of the compound. The 50% effective concentration (EC_{50}) was calculated by using the exponential form of the median effect equation where $(\text{Fa}) = 1/[1 + (\text{ED}_{50}/\text{drug conc.})^m]$ (Johnson VA, Byington RT. Infectivity Assay. In *Techniques in HIV Research*. ed. Aldovini A, Walker BD. 71-76. New York: Stockton Press.1990). The anti-viral activity of compounds was evaluated

30

under two serum conditions, 10% FBS, or 45mg/ml human serum albumin/10% FBS, and the results from at least 2 experiments were used to calculate the EC₅₀ values.

The anti-viral activity shown in Table 1 was determined in 10% FBS.

5

Table 1.

Example	EC ₅₀ μM	Example	EC ₅₀ μM
1	0.853	54	0.13
2	0.722	55	0.014
3	0.418	56	0.351
4	0.125	57	0.300
5	0.030	58	0.074
6	0.054	59	0.008
7	3.51	60	0.084
8	0.051	61	0.010
9	3.676	62	0.007
10	0.237	63	0.007
11	1.269	64	0.026
12	0.007	65	0.043
13	0.216	66	0.043
14	0.383	67	0.109
15	0.004	68	0.009
16	0.177	69	0.021
17	0.145	70	0.019
18	0.016	71	0.003
19	0.021	72	0.015
20	0.005	73	0.006
21	0.007	74	0.036
22	0.036	75	0.034
23	0.011	76	0.029
24	0.008	77	0.021
25	0.038	78	0.031
26	0.041	79	0.038

Example	EC ₅₀ μM	Example	EC ₅₀ μM
27	0.010	80	n.d.
28	0.040	81	0.013
29	0.018	82	0.020
30	0.027	83	0.025
31	0.006	84	0.012
32	0.009	85	0.021
33	0.008	86	0.052
34	0.014	87	0.009
35	0.010	88	0.086
36	0.034	89	0.110
37	0.002	90	0.157
38	0.002	91	0.047
39	0.118	92	0.968
40	0.034	93	0.095
41	0.180	94	0.035
42	0.035	95	0.036
43	0.134	96	0.036
44	0.041	97	0.041
45	0.033	98	n.d.
46	0.010	99	0.020
47	0.014	100	n.d.
48	0.011	101	n.d.
49	0.009	102	n.d.
50	0.006	103	0.025
51	0.006	104	0.026
52	0.005	105	0.028
53	0.010	106	0.089

n.d. = not determined

Pharmaceutical Composition and Methods of Use

The compounds of this invention inhibit HIV replication. Accordingly, another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.

Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of AIDS or HIV infection.

Another aspect of the invention is a method for treating HIV infection in a human patient comprising the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

Another aspect of the invention is a method wherein the agent is a nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is a method wherein the nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a non-nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is a method wherein the non-nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of delavirdine, efavirenz, and nevirapine, or a pharmaceutically acceptable thereof.

5 Another aspect of the invention is a method wherein the agent is an HIV protease inhibitor.

Another aspect of the invention is a method wherein the HIV protease inhibitor is selected from the group consisting of amprenavir, atazanavir, indinavir,
10 lopinavir, nelfinavir, ritonavir, saquinavir and fosamprenavir, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV fusion inhibitor.

15

Another aspect of the invention is a method wherein the HIV fusion inhibitor is enfuvirtide or T-1249, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV
20 attachment inhibitor.

Another aspect of the invention is a method wherein the agent is a CCR5 inhibitor.

25 Another aspect of the invention is a method wherein the CCR5 inhibitor is selected from the group consisting of Sch-C, Sch-D, TAK-220, PRO-140, and UK-427,857, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a CXCR4 inhibitor.

30

Another aspect of the invention is a method wherein the CXCR4 inhibitor is AMD-3100, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV budding or maturation inhibitor.

Another aspect of the invention is a method wherein the budding or
5 maturation inhibitor is PA-457, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV integrase inhibitor.

10 Another aspect of the invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV
15 protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier.

Another aspect of the invention is the composition wherein the agent is a
20 nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is the composition wherein the nucleoside HIV transcriptase inhibitor is selected from the group consisting of abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and
25 zidovudine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is a non-nucleoside HIV reverse transcriptase inhibitor.

30 Another aspect of the invention is the composition wherein the non-nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of delavirdine, efavirenz, and nevirapine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV protease inhibitor.

Another aspect of the invention is the composition wherein the HIV protease inhibitor is selected from the group consisting of amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and fosamprenavir, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV fusion inhibitor.

Another aspect of the invention is the composition method wherein the HIV fusion inhibitor is enfuvirtide or T-1249, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV attachment inhibitor.

Another aspect of the invention is the composition wherein the agent is a CCR5 inhibitor.

Another aspect of the invention is the composition wherein the CCR5 inhibitor is selected from the group consisting of Sch-C, Sch-D, TAK-220, PRO-140, and UK-427,857, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a CXCR4 inhibitor.

Another aspect of the invention is a method wherein the CXCR4 inhibitor is AMD-3100 or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV budding or maturation inhibitor.

Another aspect of the invention is the composition wherein the budding or maturation inhibitor is PA-457, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an
5 HIV integrase inhibitor.

“Combination,” “coadministration,” “concurrent” and similar terms referring to the administration of a compound of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or highly
10 active antiretroviral therapy (HAART) as understood by practitioners in the field of AIDS and HIV infection.

“Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of AIDS and
15 HIV infection. In general, the goals of treatment are suppression of viral load, restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related morbidity and mortality.

“Patient” means a person infected with the HIV virus and suitable for therapy
20 as understood by practitioners in the field of AIDS and HIV infection.

“Treatment,” “therapy,” “regimen,” “HIV infection,” “ARC,” “AIDS” and related terms are used as understood by practitioners in the field of AIDS and HIV infection.
25

The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. A therapeutically effective amount
30 is that which is needed to provide a meaningful patient benefit. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including capsules, tablets, lozenges, and powders as well as liquid suspensions, syrups, elixers,

and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions. See, for example, *Remington's Pharmaceutical Sciences*, 17th edition, Mack Publishing Company, Easton, PA (1985).

Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.

Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.

The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other antiretroviral agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating AIDS and HIV infection. Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti-infectives. In these combination methods, the compound of Formula I will generally

be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

5

Synthetic Methods

The compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section. The structure numbering and variable numbering shown in the synthetic
10 schemes are distinct from, and should not be confused with, the structure or variable numbering in the claims or the rest of the specification. The variables in the schemes are meant only to illustrate how to make some of the compounds of this invention. The disclosure is not limited to the foregoing illustrative examples and the examples should be considered in all respects as illustrative and not restrictive, reference being
15 made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced.

Abbreviations used in the schemes and examples generally follow
20 conventions used in the art. Chemical abbreviations used in the specification and examples are defined as follows: "KHMDs" for potassium bis(trimethylsilyl)amide; "DMF" for N,N-dimethylformamide; "HATU" for O-(t-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, "MeOH" for methanol; "Ar" for aryl; "TFA" for trifluoroacetic acid, "DMSO" for dimethylsulfoxide; "h" for
25 hours; "rt" for room temperature or retention time (context will dictate); "min" for minutes; "EtOAc" for ethyl acetate; "THF" for tetrahydrofuran; "Et₂O" for diethyl ether; "DMAP" for 4-dimethylaminopyridine; "DCM" for dichloromethane, "DCE" for 1,2-dichloroethane; "ACN" for acetonitrile; "DME" for 1,2-dimethoxyethane; "HOBt" for 1-hydroxybenzotriazole hydrate; "DIEA" for diisopropylethylamine,
30 "DEAD" for diethyl azodicarboxylate and "DIAD" for diisopropyl azodicarboxylate.


Abbreviations as used herein, are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for milliliter or milliliters, "μL" for microliter or microliters, "N" for normal, "M" for molar, "mmol" for millimole or millimoles, "atm" for atmosphere, "psi" for pounds per square inch, "conc." for concentrate, "sat" or "sat'd" for saturated, "MW" for molecular weight, "mp" for melting point, "ee" for enantiomeric excess, "MS" or "Mass Spec" for mass spectrometry, "ESI" for electrospray ionization mass spectrometry, "HR" for high resolution, "HRMS" for high resolution mass spectrometry, "LCMS" for liquid chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography, "RP HPLC" for reverse phase HPLC, "TLC" or "tlc" for thin layer chromatography, "NMR" for nuclear magnetic resonance spectroscopy, "¹H" for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, and "α", "β", "R", "S", "E", and "Z" are stereochemical designations familiar to one skilled in the art.

Some compounds can be synthesized from an appropriately substituted heterocycle **I-1** according to Scheme I. Compound **I-1** and **I-2** are commercially available or synthesized by reactions known in the art. Intermediates **I-3** can be prepared by procedure known in the art or as set forth in the examples below using compound **I-1** and compound **I-2**. Intermediates **I-3** can be transformed to intermediates **I-5** via intermediates **I-4** using conditions known to those skilled in the art. Intermediates **I-5** can be oxidized to intermediates **I-6** by reactions known in the art, including Davis oxidation. Intermediates **I-6** can be oxidized to intermediates **I-7** by known conditions, including Dess-Martin oxidation. Intermediates **I-7** can be reduced to chiral intermediates **I-8** using known conditions in the presence of catalytic chiral ligands. Intermediates **I-8** can be converted to the intermediates **I-9** by known conditions, including tertiary-butyl acetate and perchloric acid. Sequential coupling of aryl groups to Intermediates **I-9** using conditions known in the art, including Suzuki coupling, can provide intermediates **10** and **11**. Boronate or boronic acid coupling reagents are commercially available or are prepared by

reactions known in the art (for example, PCT Appln. WO20090662285).

Intermediates **I-11** can be converted to intermediates **I-12** by conditions known in the art, including ring closing metathesis. Hydrolysis of intermediates **I-12** can provide products **I-13** which can be converted to **I-14** using conditions known in the art.


Scheme I.



Intermediate **I-4** can be transformed to final compounds **II-5** and **II-6** by methods known in the art as outlined in Scheme II.

Scheme II


5



Intermediates **II-5** can be transformed to final compounds **III-4** and **III-6** by methods known in the art as outlined in Scheme III.


10

Scheme III




- 5 Intermediates **I-4** can be transformed to final compounds **IV-5** and **IV-6** by methods known in the art as outlined in Scheme IV.

Scheme IV




- 5 Intermediates **V-1** can be transformed to final compounds **V-4** and **V-5** by methods known in the art as outlined in Scheme V.

Scheme V



- 5 The compounds described herein were purified by the methods known to those skilled in art by normal phase column chromatography on silica gel column using appropriate solvent systems. Preparative HPLC purifications mentioned in this experimentation section were carried out by gradient elution on C18 prep-columns (5 μ m) using either mobile phase A: 9:1 H₂O/acetonitrile with 10 mM NH₄OAc and
- 10 mobile phase B : A: 9:1 acetonitrile/H₂O with: 10 mM NH₄OAc or mobile phase A: 95:5 H₂O/MeOH with 20 mM NH₄OAc and mobile phase B: 95:5 MeOH/H₂O with 20 mM NH₄OAc.

Intermediate 1




15

3-(3-bromophenyl)-3-oxopropanenitrile: Acetonitrile (21.86 mL, 419 mmol) was added to a stirred suspension of 60% NaH (7.25 g, 181 mmol) in THF (150 mL).

Then, methyl 3-bromobenzoate (30 g, 140 mmol) was added and the mixture was heated at 75°C for 4 h. After cooling to room temperature, water followed by 1N HCl (200 mL) was added and the mixture was extracted with ethyl acetate (500 mL), washed with sat. NaHCO₃ solution (200 mL), dried (Na₂SO₄), filtered and concentrated to afford 3-(3-bromophenyl)-3-oxopropanenitrile (29 g, 129 mmol, 93 % yield) as light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 8.09 (t, *J*=1.7 Hz, 1H), 7.90 - 7.86 (m, 1H), 7.83 (ddd, *J*=8.0, 2.0, 1.1 Hz, 1H), 7.45 (t, *J*=7.9 Hz, 1H), 4.08 (s, 2H).

10


Intermediate 2



3-(3-bromophenyl)-1H-pyrazol-5-amine: A mixture of 3-(3-bromophenyl)-3-oxopropanenitrile (35 g, 156 mmol) and hydrazine hydrate (11.34 mL, 234 mmol) in ethanol (600 mL) was refluxed for 16 h. Mixture was then cooled and concentrated in vacuo. Crude product was diluted with dichloromethane and stirred for 5 min. Solids were filtered and dried to afford 3-(3-bromophenyl)-1H-pyrazol-5-amine (30 g, 126 mmol, 81 % yield) as off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 12.02 (br. s., 0.4H), 11.66 (br. s., 0.6H), 7.86 (t, *J*=1.6 Hz, 1H), 7.67 (d, *J*=7.5 Hz, 1H), 7.45 (d, *J*=6.8 Hz, 1H), 7.37 - 7.18 (m, 1H), 5.78 (br. s., 1H), 5.08 (br. s., 1.2H), 4.68 (br. s., 0.8H). LCMS (M+H) = 240.1.

25


Intermediate 3



Methyl 2-(2-(3-bromophenyl)-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate: A 3-lit three neck flask was fitted with a mechanical stirrer and a

heating mantle. A suspension of 3-(3-bromophenyl)-1H-pyrazol-5-amine (84.9 g, 357 mmol), dimethyl 2-acetylsuccinate (73.8 g, 392 mmol) and tosic acid monohydrate (1.357 g, 7.13 mmol) in o-xylene (1500 mL) was heated to refluxed (135 °C measured internal temp) for 3.5 h. The heating was turned off, the reaction was diluted with hexanes (1000 mL) and was allowed to cool slowly overnight. The solids were collected by filtration. The filter cake was washed with hexanes and dried under vacuum overnight to afford methyl 2-(2-(3-bromophenyl)-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (132.21 g, 334 mmol, 94 % yield) as a white powdery solid. ¹H NMR (500 MHz, DMSO-d₆) δ: 12.47 (s, 1H), 8.18 (t, *J*=1.7 Hz, 1H), 8.02 (dt, *J*=7.1, 1.3 Hz, 1H), 7.65 - 7.60 (m, 1H), 7.45 (t, *J*=7.9 Hz, 1H), 6.69 (s, 1H), 3.63 (s, 3H), 3.58 (s, 2H), 2.34 (s, 3H). LCMS (M+H) = 376.4.


Intermediate 4



15


2-(2-(3-Bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate: A mixture of methyl 2-(2-(3-bromophenyl)-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (133 g, 354 mmol) and N,N-dimethylaniline (62.7 ml, 495 mmol) in POCl₃ (450 ml) was heated (120 °C oil bath) for 2.5 h. The reaction was cooled, then concentrated under reduced pressure. The residue was dried from toluene (3 x 300 mL), and the residue, suspended in EtOAc (600 mL) was poured onto ice water at a rate that maintained the cold temperature. The emulsion was then diluted (EtOAc, 300 mL) and the combined layers were pulled through a filter paper to collect solids. The solids were washed with several portions of EtOAc, then air dried. The filtered solids were suspended in EtOAc and hexanes (500 mL of each) and stirred for 10 min, then filtered. The filter cake was washed with hexanes and dried under vacuum to afford methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (121.7 g, 300 mmol, 85 % yield) as pale green solid. ¹H NMR (500 MHz, DMSO-d₆) δ: 8.25 (t, *J*=1.8 Hz, 1H), 8.09 (dt, *J*=7.8, 1.3 Hz, 1H), 7.63-7.70 (m, 1H), 7.45-7.54 (m, 1H), 7.40 (s, 1H), 4.04 (s, 2H), 3.71 (s, 3H), 2.58 (s, 3H). LC/MS (085-04, M+H) = 396.1.

Intermediate 5



5 *Methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate*: Methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (1 g, 2.53 mmol) and NaI (1.519 g, 10.14 mmol) were suspended in acetonitrile (10 mL) and the resulting mixture was heated at 80 °C for 5 h. After cooling to room temp, mixture was diluted with ethyl acetate (50 mL) and washed with water (25 mL) and aqueous Na₂S₂O₃ (25 mL), dried (Na₂SO₄), filtered
 10 and concentrated. Crude was then triturated with ethyl acetate/ hexane to afford methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (1 g, 2.057 mmol, 81 % yield) as off white solid. ¹H NMR (400 MHz, CDCl₃) δ: 8.20 (t, *J*=1.8 Hz, 1H), 7.95 (dt, *J*=7.8, 1.3 Hz, 1H), 7.55 (ddd, *J*=8.0, 2.0, 1.0 Hz, 1H), 7.36 (t, *J*=7.9 Hz, 1H), 7.08 (s, 1H), 4.02 (s, 2H), 3.79 (s, 3H), 2.66 (s, 3H).
 15 LCMS (M+H) = 486.1.


Intermediate 6



20 *Methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate*: To a stirred solution of 0.9M KHMDS/THF (2.55 mL, 2.297 mmol) in THF (8 mL) at -78 °C was added dropwise a THF (10 mL) solution of methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (859 mg, 1.767 mmol) over 5 min. After 30 min, a THF (10 mL) solution of 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (600 mg, 2.297 mmol) was added to the
 25 resulting red reaction mixture and stirred for additional 30 min at -78 °C. Then, the resulting orange reaction mixture was quenched with sat. NH₄Cl (50 mL), diluted with EtOAc (200 mL), washed with water (100 mL), brine (100 mL), dried (Na₂SO₄), filtered and concentrated to give light solid. This solid was triturated with small

amount of ethyl acetate and solids were filtered, washed with hexanes and dried under high vacuo to afford methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (600 mg, 1.195 mmol, 67.6 % yield) as light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ: 8.21 (t, *J*=1.7 Hz, 1H), 7.96 (dt, *J*=7.8, 1.2 Hz, 1H), 7.59 - 7.55 (m, 1H), 7.37 (t, *J*=7.8 Hz, 1H), 7.09 (s, 1H), 5.78 (s, 1H), 3.87 (s, 3H), 3.54 (br. s., 1H), 2.61 (s, 3H). LCMS (M+H) = 504.05.

Intermediate 7




10

Methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate: To a mixture of methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (2.6 g, 5.18 mmol) in CH₂Cl₂ (100 mL) was added Dess-Martin Periodinane (2.196 g, 5.18 mmol) and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with ethyl acetate (500 mL), washed with sat. NaHCO₃ solution (100 mL), dried (Na₂SO₄), filtered and concentrated. The residue was purified by silica gel chromatography (5-70 % EtOAc/hexane) to afford desired methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate (1.7 g, 3.40 mmol, 65.6 % yield) as off-white solid. ¹H NMR (500 MHz, CDCl₃) δ: 8.21 (t, *J*=1.7 Hz, 1H), 7.96 (dt, *J*=7.7, 1.3 Hz, 1H), 7.61 - 7.58 (m, 1H), 7.39 (t, *J*=7.9 Hz, 1H), 7.14 (s, 1H), 4.03 (s, 3H), 2.57 (s, 3H). LCMS (M+H) = 501.0.


25

Intermediate 8



(*S*)-Methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-hydroxyacetate: To a stirred yellow solution of methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-oxoacetate (1.7 g, 3.40 mmol) in anhydrous toluene (100 mL) was added 1.1M (R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-*c*][1,3,2]oxazaborole/toluene (1.236 mL, 1.360 mmol). The mixture was cooled to -35 °C and a solution of catechoborane/toluene (1.166 mL, 4.76 mmol) was added over 5 min. After 30 min, the reaction mixture was slowly warmed to -15 °C and stirred for additional 2 h. and diluted with EtOAc (600 mL) and sat. Na₂CO₃ (100 mL). The mixture was stirred vigorously for 30 min, and the organic phase washed with sat Na₂CO₃ (2 X 100 mL), dried (Na₂SO₄), filtered, concentrated and the residue was purified by silica gel chromatography (5-100% EtOAc/hexane) to afford desired (*S*)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-hydroxyacetate (1 g, 1.992 mmol, 58.6 % yield) as off-white solid. ¹H NMR (500 MHz, CDCl₃) δ: 8.21 (t, *J*=1.7 Hz, 1H), 7.96 (dt, *J*=7.8, 1.2 Hz, 1H), 7.59 - 7.55 (m, 1H), 7.37 (t, *J*=7.8 Hz, 1H), 7.09 (s, 1H), 5.78 (s, 1H), 3.87 (s, 3H), 3.54 (br. s., 1H), 2.61 (s, 3H). LCMS (M+H) = 504.05.

Intermediate 9




20

(*S*)-Methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a stirred solution of (*S*)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-hydroxyacetate (1 g, 1.992 mmol) in CH₂Cl₂ (30 mL) and t-butyl acetate (21.00 mL) at rt was added 70% perchloric acid (0.513 mL, 5.97 mmol). After 3 h, the reaction mixture was diluted with CH₂Cl₂ (100 mL), carefully quenched with sat. NaHCO₃ (50 mL), organic layer separated and washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated to give yellow liquid. This was purified by flash column chromatography on silica gel column using (10-50% EtOAc/Hex as eluant) to afford (*S*)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate

(800 mg, 1.433 mmol, 72.0 % yield) as yellow solid. ^1H NMR (500 MHz, CDCl_3) δ : 8.20 (s, 1H), 7.95 (d, $J=7.7$ Hz, 1H), 7.56 (d, $J=7.9$ Hz, 1H), 7.37 (t, $J=7.9$ Hz, 1H), 7.08 (s, 1H), 5.59 (s, 1H), 3.76 (s, 3H), 2.70 (s, 3H), 1.32 (s, 9H). LCMS (M+H) = 560.15.

5




(2S)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A mixture of (S)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (350 mg, 0.627 mmol), 4-allyl-5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (231 mg, 0.690 mmol) and 2M Na_2CO_3 (0.627 mL, 1.254 mmol) in DMF (5 mL) was degassed for 15 min.

tetrakis(triphenylphosphine)palladium(0) (50.7 mg, 0.044 mmol) was then added and the degassing was continued for another 5 min. The mixture was then heated at 90 °C for 16 h. After cooling to room temperature, water (10 mL) was added and the mixture was extracted with ethyl acetate (50 mL), washed with water (25 mL), brine (25 mL), dried (Na_2SO_4), filtered and concentrated. Crude was then purified by Biotage using 5-50% EtOAc/hexane to afford (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (260 mg, 0.406 mmol, 64.8 % yield) as light yellow solid. ^1H NMR (500 MHz, CDCl_3) δ : 8.00 (t, $J=1.7$ Hz, 1H), 7.77 (dt, $J=8.0$, 1.2 Hz, 1H), 7.46 (ddd, $J=8.0$, 2.0, 0.9 Hz, 1H), 7.26 (t, $J=7.9$ Hz, 1H), 7.03 (d, $J=8.4$ Hz, 1H), 6.97 (d, $J=8.4$ Hz, 1H), 6.87 (s, 1H), 6.06 (dd, $J=17.2$, 10.2 Hz, 1H), 5.37 (dd, $J=17.2$, 1.7 Hz, 1H), 5.28 (dd, $J=10.2$, 1.7 Hz, 1H), 5.07 (s, 1H), 4.34 - 4.24 (m,

2H), 3.71 (dd, $J=12.2, 6.1$ Hz, 2H), 3.67 (s, 3H), 3.29 - 3.18 (m, 2H), 2.86 (s, 3H), 1.18 (s, 9H). LCMS (M+H) = 641.3.

Intermediate 11




5

2-(3-(*But-3-en-1-yl*)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane: To a solution of 1-bromo-3-(but-3-en-1-yl)benzene (2.5 g, 11.84 mmol) in anhydrous DMF (60 mL) was added bis(pinacolato)diborane (3.31 g, 13.03 mmol), potassium acetate (3.49 g, 35.5 mmol) and the mixture was degassed for 15 min. To the degassed solution was added $\text{PdCl}_2(\text{dppf})$ (0.867 g, 1.184 mmol) and degassing continued for a further 5 min, after which the reaction was heated at 90 °C for 3 h. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ether (2 X 100 mL), washed with brine (50 mL), dried (Na_2SO_4), filtered and concentrated. Crude was then purified by biotage using 0-15% EtOAc/hexane to afford 2-(3-(but-3-en-1-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2 g, 7.75 mmol, 65.4 % yield) as light yellow oil. ^1H NMR (500 MHz, CDCl_3) δ : 7.69 - 7.65 (m, 2H), 7.34 - 7.31 (m, 2H), 5.89 (ddt, $J=17.1, 10.3, 6.6$ Hz, 1H), 5.07 (dq, $J=17.2, 1.7$ Hz, 1H), 5.02 - 4.97 (m, 1H), 2.77 - 2.70 (m, 2H), 2.45 - 2.38 (m, 2H), 1.38 (s, 12H).

20

Intermediate 12




(2S)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A mixture of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (75 mg, 0.117 mmol), 2-(3-(but-3-en-1-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (45.4 mg, 0.176 mmol) and 2N Na₂CO₃ (0.117 mL, 0.234 mmol) in DMF (1 mL) was degassed for 15 min. tetrakis(triphenylphosphine)palladium(0) (9.48 mg, 8.20 μmol) was then added and the degassing was continue for another 5 min. The mixture was then heated at 90 °C for 16 h. After cooling to room temperature, water was added and the mixture was extracted with ether (2X 25 mL), washed with brine (15 mL), dried (Na₂SO₄), filtered and concentrated. Crude was then purified by biotage (0-15% EtOAc/hexane) to afford (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (50 mg, 0.072 mmol, 61.7 % yield) as light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ: 8.05 (t, *J*=1.6 Hz, 1H), 7.85 - 7.82 (m, 1H), 7.57 - 7.54 (m, 1H), 7.45 (dd, *J*=4.6, 2.5 Hz, 3H), 7.41 - 7.35 (m, 1H), 7.21 (d, *J*=7.6 Hz, 1H), 7.00 (d, *J*=5.0 Hz, 2H), 6.95 - 6.93 (m, 1H), 6.11 - 6.00 (m, 1H), 5.91 (ddt, *J*=17.0, 10.3, 6.6 Hz, 1H), 5.35 (dd, *J*=17.2, 1.6 Hz, 1H), 5.26 (dd, *J*=10.2, 1.6 Hz, 1H), 5.12 - 5.07 (m, 2H), 5.04 - 5.00 (m, 1H), 4.27 (t, *J*=4.4 Hz, 2H), 3.79 - 3.72 (m, 1H), 3.67 (s, 3H), 3.63 (dd, *J*=15.1, 6.1 Hz, 1H), 3.28 - 3.17 (m, 2H), 2.86 (s, 3H), 2.83 - 2.78 (m, 2H), 2.49 - 2.41 (m, 2H), 1.20 (s, 9H). LCMS (M+H) = 691.5.

Intermediates 13 and 14


A mixture of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (40 mg, 0.058 mmol) and Hoveyda-Grubbs 2nd generation catalyst (4.91 mg, 5.79 μmol) catalyst in DCE (2 mL) was heated at 85 °C for 2 h. Mixture was then cooled, concentrated and purified by prep HPLC to afford cis and trans ester.

Intermediate 13



Methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*Z*)-32-chloro-4-methyl-28-oxa-5,7,8,25-
 5 tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{2,9,33}]hexatriaconta-
 1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetate: First
 eluting *cis* isomer. ¹H NMR (400 MHz, CDCl₃) δ: 8.08 (s, 1H), 7.75 (d, *J*=7.5 Hz,
 1H), 7.56 - 7.52 (m, 1H), 7.51 - 7.46 (m, 1H), 7.41 - 7.34 (m, 3H), 7.17 (d, *J*=7.0 Hz,
 1H), 6.99 (s, 2H), 6.90 (s, 1H), 5.78 - 5.60 (m, 2H), 5.29 (s, 1H), 4.55 (d, *J*=15.6 Hz,
 10 1H), 4.34 - 4.22 (m, 2H), 3.65 (d, *J*=8.5 Hz, 1H), 3.63 (s, 3H), 3.48 (dd, *J*=15.6, 7.8
 Hz, 1H), 3.40 - 3.24 (m, 1H), 3.05 - 2.95 (m, 1H), 2.88 (s, 3H), 2.87 - 2.74 (m, 1H),
 2.58 (d, *J*=5.0 Hz, 2H), 1.26 (s, 9H). LCMS (M+H) = 663.4.

Intermediate 14



15

Methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*E*)-32-chloro-4-methyl-28-oxa-5,7,8,25-
 tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{2,9,33}]hexatriaconta-
 1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetate”
 20 Second eluting *trans* isomer. ¹H NMR (400 MHz, CDCl₃) δ: 8.05 - 8.02 (m, 1H),
 7.72 (dt, *J*=7.0, 1.8 Hz, 1H), 7.52 - 7.45 (m, 2H), 7.42 - 7.32 (m, 3H), 7.17 - 7.11 (m,
 1H), 7.00 - 6.97 (m, 2H), 6.88 - 6.86 (m, 1H), 5.83 - 5.65 (m, 2H), 5.34 (s, 1H), 4.31
 - 4.06 (m, 2H), 3.85 (dd, *J*=15.6, 6.8 Hz, 1H), 3.64 (s, 3H), 3.39 - 3.18 (m, 2H), 3.06

- 2.97 (m, 1H), 2.88 (s, 3H), 2.75 - 2.55 (m, 2H), 1.26 (s, 9H). LCMS (M+H) = 663.4.


Examples 1 and 2

5

Both cis (intermediate **13**) and trans (intermediate **14**) isomers were individually hydrolyzed with 1N NaOH (0.174 mL, 0.174 mmol) in MeOH (2.000 mL) at 50 °C for 3 h and purified by prep-HPLC to afford the desired product.


10

Example 1



(2S)-2-(tert-Butoxy)-2-[(22Z)-32-chloro-4-methyl-28-oxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{2,9,33}]hexatriaconta-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetic acid: Cis isomer (1.4 mg, 2.049 μmol, 3.54 % yield). ¹H NMR (500 MHz, CDCl₃) δ: 8.13 (s, 1H), 7.76 (d, *J*=7.6 Hz, 1H), 7.55 (d, *J*=7.9 Hz, 1H), 7.49 (t, *J*=7.6 Hz, 1H), 7.41 - 7.33 (m, 3H), 7.17 (d, *J*=7.3 Hz, 1H), 6.99 - 6.92 (m, 2H), 6.89 - 6.85 (m, 1H), 5.76 - 5.62 (m, 2H), 5.34 (s, 1H), 4.52 (d, *J*=15.9 Hz, 1H), 4.34 - 4.14 (m, 2H), 3.46 (dd, *J*=15.4, 6.7 Hz, 1H), 3.27 (br. s., 2H), 3.00 (dt, *J*=7.5, 3.6 Hz, 1H), 2.90 (s, 3H), 2.82 - 2.73 (m, 1H), 2.65 - 2.50 (m, 2H), 1.20 (s, 9H). LCMS (M+H) = 649.4.


Example 2



(2*S*)-2-(*tert*-Butoxy)-2-[(22*E*)-32-chloro-4-methyl-28-oxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1¹⁰.1⁴.1¹⁵.1⁹.0^{2,7}.0^{2,9}.3³]hexatriacont-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetic acid: Trans isomer (1.9 mg, 2.78 μmol, 4.8 % yield). ¹H NMR (500 MHz, CDCl₃) δ: 8.08 (s, 1H), 7.73 (d, *J*=7.4 Hz, 1H), 7.55 - 7.47 (m, 2H), 7.44 - 7.32 (m, 3H), 7.15 (d, *J*=7.3 Hz, 1H), 6.95 - 6.87 (m, 3H), 5.78 - 5.66 (m, 2H), 5.37 (s, 1H), 4.28 - 4.16 (m, 2H), 4.10 (d, *J*=14.2 Hz, 1H), 3.87 (dd, *J*=14.9, 6.9 Hz, 1H), 3.34 (d, *J*=14.3 Hz, 1H), 3.23 - 3.15 (m, 1H), 3.02 - 2.94 (m, 1H), 2.90 (s, 3H), 2.71 (dt, *J*=14.0, 7.0 Hz, 1H), 2.66 - 2.56 (m, 2H), 1.21 (s, 9H). LCMS (M+H) = 649.4.

10

Intermediate 15




(2*S*)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: A mixture of (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate (120 mg, 0.188 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (61.9 mg, 0.281 mmol) and 2M Na₂CO₃ (0.188 mL, 0.375 mmol) in DMF (2 mL) was degassed for 15 min by bubbling N₂ through the reaction mixture. Then, tetrakis(triphenylphosphine)palladium(0) (15.17 mg, 0.013 mmol) was added and the degassing was continue for another 5 min. The mixture was then heated at 90 °C for 16 h. After cooling to room temperature, water was added and the mixture was extracted with ether (2 X 50 mL), washed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated. The residue was then purified by biotage (10-40% EtOAc/hexane) to afford (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate (90 mg, 0.138 mmol, 73.5 % yield) as off-

25

white solid. ^1H NMR (500MHz, CDCl_3) δ : 8.02 (t, $J=1.6$ Hz, 1H), 7.82 (dt, $J=7.6$, 1.4 Hz, 1H), 7.54 - 7.51 (m, 1H), 7.47 - 7.43 (m, 1H), 7.33 - 7.29 (m, 1H), 7.19 - 7.13 (m, 1H), 7.10 (t, $J=8.1$ Hz, 1H), 7.02 - 7.00 (m, 1H), 6.98 (s, 2H), 6.93 (s, 1H), 6.81 (ddd, $J=8.0$, 2.5, 0.9 Hz, 1H), 6.42 (dd, $J=8.1$, 2.3 Hz, 2H), 6.39 - 6.35 (m, 1H), 6.10 - 5.98 (m, 1H), 5.40 - 5.30 (m, 2H), 5.07 (s, 1H), 4.29 - 4.18 (m, 2H), 3.67 (s, 3H), 3.18 (t, $J=4.4$ Hz, 2H), 2.87 (s, 3H), 1.18 (s, 9H). LCMS ($\text{M}+\text{H}$) = 653.4.

Intermediate 16




10

(2S)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-(allyloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a solution of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (90 mg, 0.138 mmol) in DMF (2 mL) was added K_2CO_3 (38.1 mg, 0.276 mmol) followed by 3-bromoprop-1-ene (0.017 mL, 0.207 mmol) and the resulting mixture was heated at 50 °C for 16 h. After cooling to room temperature, water was added and the mixture was extracted with ether (50 mL), washed with brine, dried (Na_2SO_4), filtered and concentrated. Crude was then purified by biotage (5-30% EtOAc/hexane) to afford (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-(allyloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (40 mg, 0.058 mmol, 41.9 % yield) as white solid. 28 mg of starting material was also recovered. ^1H NMR (500 MHz, CDCl_3) δ : 8.05 (t, $J=1.6$ Hz, 1H), 7.84 (dt, $J=7.7$, 1.4 Hz, 1H), 7.57 - 7.53 (m, 1H), 7.45 (t, $J=7.6$ Hz, 1H), 7.37 (t, $J=7.9$ Hz, 1H), 7.23 - 7.20 (m, 1H), 7.19 - 7.16 (m, 1H), 7.03 - 6.97 (m, 2H), 6.96 - 6.92 (m, 2H), 6.17 - 6.00 (m, 2H), 5.50 - 5.44 (m, 1H), 5.39 - 5.29 (m, 3H), 5.25 (dd, $J=10.2$, 1.6 Hz, 1H),

5.09 (s, 1H), 4.62 (dt, $J=5.3, 1.4$ Hz, 2H), 4.27 (t, $J=4.4$ Hz, 2H), 3.67 (s, 3H), 3.27 - 3.17 (m, 2H), 2.86 (s, 3H), 1.19 (s, 9H). LCMS (M+H) = 693.4.

Intermediate 17




5

(2S)-2-(tert-Butoxy)-2-[32-chloro-4-methyl-20,28-dioxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{2,9,33}]hexatriaconta-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetic acid: A mixture of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3'-(allyloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (40 mg, 0.058 mmol) and Hoveyda-Grubbs 2nd generation catalyst (4.90 mg, 5.77 μ mol) catalyst in DCE (2 mL) was heated at 50 °C for 5 h. Mixture was then cooled to room temp and concentrated under reduced pressure.

15 Mixture was then treated with 1N NaOH (0.173 mL, 0.173 mmol) in MeOH (2.0 mL) at 50 °C for 3 h. Mixture was then cooled to room temp and purified by prep-HPLC to afford desired product (10 mg, 0.015 mmol, 26.6 % yield) as inseparable mixture of cis and trans isomers. Used as is in the next step without further purification. LCMS (M+H) = 651.3.


20

Example 3



(2*S*)-2-(*tert*-Butoxy)-2-{32-chloro-4-methyl-20,28-dioxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{2,9,33}]hexatriaconta-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,29,32-tridecaen-3-yl}acetic acid: To a solution of intermediate **17** (10 mg, 0.015 mmol) in EtOAc (1 mL) was added 10% Pd/C (1.634 mg, 1.536 μ mol) and the mixture was stirred under balloon hydrogen atmosphere for 1 h. At this point, LCMS indicated no desired product was formed, so 0.5 mL of MeOH was added and the mixture was stirred under balloon hydrogen atmosphere for 2 h. At this point, LCMS indicated desired product as the major component along with small amount of open form and starting material. Mixture was then filtered and purified by prep HPLC to afford example **3** (4.5 mg, 6.55 μ mol, 42.6 % yield) as white solid. ¹H NMR (500 MHz, CDCl₃) δ : 8.12 (t, *J*=1.6 Hz, 1H), 7.71 - 7.66 (m, 2H), 7.54 - 7.50 (m, 1H), 7.37 - 7.33 (m, 1H), 7.28 - 7.22 (m, 2H), 6.94 - 6.87 (m, 3H), 6.82 (d, *J*=8.4 Hz, 1H), 5.31 (s, 1H), 4.36 - 4.17 (m, 4H), 3.44 - 3.28 (m, 2H), 3.20 (ddd, *J*=14.3, 11.1, 3.2 Hz, 1H), 2.90 (s, 3H), 2.16 - 2.07 (m, 2H), 1.97 (dt, *J*=11.9, 5.9 Hz, 1H), 1.88 - 1.71 (m, 2H), 1.20 (s, 9H). LCMS (*M*+*H*) = 653.3.

Intermediate 18




20

Dimethyl (2-(but-3-en-1-yl)phenyl)boronate: This intermediate was synthesized according to the procedure described by Kuznetsov, N.Yu.; *Russ.Chem.Bull., Int.Ed.*, **2005**, 54(3), 678-683. 1-Bromo-2-(but-3-en-1-yl)benzene (1 g, 4.74 mmol) was dissolved in THF (5 mL) and cooled to -78 °C under an atmosphere of N₂. BuLi (3.26 mL, 5.21 mmol) was added all at once. This light yellow solution was stirred for 15 min at which time B(OMe)₃ (0.794 mL, 7.11 mmol) was added all at once. This mixture was stirred and allowed to warm to 0 °C. Once at this temperature, TMS-Cl (0.787 mL, 6.16 mmol) was added and the reaction was allowed to warm to rt. The reaction mixture was concentrated in vacuo to give 1.2 g of crude product as a colorless oil. Kugelrohr distillation (1mm, 100-150 °C)

30

gave three fractions (original flask residue, first bulb, and 2nd bulb). The first bulb yielded 60 mg which appeared to be the desired product (90% pure; colorless liquid which crystallized on standing). Used in subsequent reactions without further purification. ¹H NMR (500 MHz, CDCl₃) δ: 7.31 (td, *J*=1.7, 7.0 Hz, 2H), 7.21-7.25 (m, 2H), 5.86-5.92 (m, 1H), 4.99-5.11 (m, 2H), 3.64 (s, 6H), 2.72-2.76 (t, *J*=7.4 Hz, 2H), 2.38 (dt, *J*=1.1, 7.4 Hz, 2H).

Intermediate 19




10

(2*S*)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a 2-5ml microwave tube was added (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.060 g, 0.094 mmol), dimethyl (2-(but-3-en-1-yl)phenyl)boronate (0.029 g, 0.141 mmol), and 2.0 M aqueous K₂CO₃ (0.094 ml, 0.188 mmol) in DMF (1 ml). The reaction was sparged with nitrogen for 10 minutes, treated with Pd(Ph₃P)₄ (10.83 mg, 9.38 μmol), then sparged for 15 min. The reaction tube was sealed and then heated (90 °C, heating block) for 2.5 h. The reaction was cooled, then diluted with Et₂O (20 mL) and washed with water, then brine (20 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure to an orange oil (~80 mg). The crude was purified by Biotage column chromatography, and product fractions were pooled and concentrated under reduced pressure, to afford (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.039 g, 0.056 mmol, 60.2 % yield). ¹H NMR (500 MHz, CDCl₃) δ: 7.85 (d, *J*=7.8 Hz, 1H), 7.78-7.82 (m, 1H), 7.42 (t, *J*=7.7 Hz, 1H), 7.30-7.35 (m, 2H), 7.25 (t, *J*=3.4 Hz,


2H), 6.93-7.01 (m, 2H), 6.89 (s, 1H), 5.97-6.10 (m, 1H), 5.69 (ddt, J=16.9, 10.3, 6.7 Hz, 1H), 5.32 (m, J=17.2, 1.4 Hz, 1H), 5.23 (m, J=10.3, 1.3 Hz, 1H), 4.81-4.94 (m, 2H), 4.25 (t, J=4.4 Hz, 2H), 3.66-3.75 (m, 1H), 3.65 (s, 3H), 3.55-3.62 (m, 1H), 3.19 (q, J=3.9 Hz, 2H), 2.84 (s, 3H), 2.64-2.71 (m, 2H), 2.18-2.28 (m, 2H), 1.25-1.33 (m, 1H), 1.17 (s, 9H). LCMS (M+H) = 691.5.

Intermediate 20




10 *Methyl (2S)-2-(tert-butoxy)-2-[33-chloro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,3}.4]hexatriaconta-*
1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A
 mixture of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-
 6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-
 15 yl)-2-(tert-butoxy)acetate (0.039 g, 0.056 mmol) and Hoveyda-Grubbs 2nd
 generation catalyst (4.79 mg, 5.64 μ mol) in DCE (2 mL) was heated at 50 °C for 1 h.
 The reaction was cooled, then the entire mixture was loaded onto a small plug of
 silica gel in a Pasteur pipette, and eluted with CH₂Cl₂ (~5 mL), followed separately
 by 20% EtOAc in hexanes (~5 mL). The later eluant was concentrated under reduced
 20 pressure to afford a gummy oil. The oil was loaded onto a prep-HPLC for
 purification. The product fraction was concentrated under reduced pressure and the
 residue containing water was dissolved in CH₂Cl₂ and dried (Na₂SO₄), filtered, and
 concentrated under reduced pressure to afford the product (0.0099 g, 0.015 mmol,
 26.5 % yield) as a yellow film. ¹H NMR (500 MHz, CDCl₃) δ : 7.98 (s, 1H), 7.82 (d,
 25 J=7.9 Hz, 1H), 7.54 (t, J=7.6 Hz, 1H), 7.34 (d, J=7.7 Hz, 1H), 7.19-7.28 (m, 4H),
 7.14 (s, 1H), 6.90-6.97 (m, 2H), 5.57-5.63 (m, 2H), 5.11 (s, 1H), 4.30-4.41 (m, 2H),
 3.67 (s, 3H), 3.53-3.63 (m, 1H), 3.46-3.54 (m, 1H), 3.34-3.43 (m, 1H), 2.95 (s, 3H),
 2.63 (t, J=8.3 Hz, 2H), 2.34-2.40 (m, 5H), 1.21 (s, 9H). LCMS (M+H) = 663.3.

Example 4




(2S)-2-(tert-Butoxy)-2-[(33-chloro-4-methyl-29-oxa-5,7,8,26-
 5 tetraazaheptacyclo[24.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0^{3,0},3³]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetic acid: A
 solution of intermediate **20** (0.0099 g, 0.015 mmol) and 1N NaOH (0.045 mL, 0.045
 mmol) in MeOH (1.0 mL) was stirred with heating (50 °C oil bath) for 18 h. The
 reaction was cooled, concentrated under reduced pressure and the residue was
 10 partitioned between CH₂Cl₂ and 1N HCl. The organic layer was dried (Na₂SO₄),
 filtered, and concentrated under reduced pressure. The residue was dissolved in THF
 (1 mL), treated with activated carbon, filtered and the filtrate was concentrated under
 reduced pressure. The white residue was dried under vacuum to afford the desired
 product (0.0065 g, 8.98 mmol, 58.3%) as a white solid. ¹H NMR (500 MHz, MeOD)
 15 δ: 7.92 (s, 1H), 7.84 (d, J=7.9 Hz, 1H), 7.53 (t, J=7.7 Hz, 1H), 7.26-7.31 (m, 3H),
 7.19-7.26 (m, 2H), 7.00 (s, 1H), 6.88-6.99 (m, 2H), 5.63-5.71 (m, 1H), 5.50-5.59 (m,
 1H), 5.13 (s, 1H), 4.87 (s, 12H), 4.59 (dd, J=14.9, 9.1 Hz, 1H), 4.26-4.34 (m, 2H),
 3.48-3.55 (m, 1H), 3.35-3.45 (m, 2H), 2.83-2.86 (m, 3H), 2.48-2.61 (m, 2H), 2.28-
 2.42 (m, 1H), 2.16-2.27 (m, 1H), 1.28-1.35 (m, 2H), 1.17-1.22 (m, 9H). LCMS
 20 (M+H) = 649.4.

Intermediate 21



(2S)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a 2-5ml microwave tube was added (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.240 g, 0.375 mmol),
 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (0.124 g, 0.563 mmol), and
 2M aqueous K₂CO₃ (0.375 ml, 0.750 mmol) in 1,4-dioxane (3.0 ml) and water (0.75
 ml). The reaction was sparged with nitrogen for 10 minutes, treated with Pd(Ph₃P)₄
 (0.043 g, 0.038 mmol), then sparged for 15 min. The reaction tube was sealed and
 heated (90 °C, heating block) for 90 min. The reaction was cooled, diluted with
 water (5 mL) and extracted with Et₂O. The ether layer was washed with brine, dried
 (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was
 adsorbed onto silica gel, then purified by biotage column chromatography (5% - 55%
 EtOAc in hexanes). The product fractions were pooled and concentrated under
 reduced pressure to afford (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-
 benzo[b][1,4]oxazin-6-yl)-2-(2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-
 a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. ¹H NMR (500 MHz, CDCl₃) δ 7.94 (t,
 J=1.5 Hz, 1H), 7.86 (dt, J=7.7, 1.4 Hz, 1H), 7.47-7.52 (m, 1H), 7.39-7.45 (m, 1H),
 7.25 (s, 1H), 6.95-7.02 (m, 5H), 6.88-6.92 (m, 1H), 5.96-6.10 (m, 1H), 5.51 (br. s.,
 1H), 5.29-5.37 (m, 1H), 5.24 (dd, J=10.3, 1.5 Hz, 1H), 5.04-5.09 (m, 1H), 4.24 (t,
 J=4.4 Hz, 2H), 3.67-3.76 (m, 1H), 3.65 (s, 2H), 3.58 (dd, J=15.2, 6.1 Hz, 1H), 3.16-
 3.23 (m, 2H), 2.84 (s, 3H), 1.95 (s, 1H), 1.17 (s, 9H). LCMS (M+H) = 653.4.


Intermediate 22



(2*S*)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-5-methyl-2-(2'-(pent-4-en-1-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.058 g, 0.089 mmol) and K₂CO₃ (0.042 g, 0.304 mmol) in dry acetone (5 mL) was treated with 5-bromopent-1-ene (0.026 g, 0.174 mmol), and the reaction was stirred with heating (70 °C oil bath) for 16 h. The reaction was cooled, then concentrated under reduced pressure. The residue was taken up in CH₂Cl₂ (5 mL) and washed with 1N HCl (5 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by biotage column chromatography (5% - 50% EtOAc in hexanes). Product fractions were pooled and concentrated under reduced pressure. The product, (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-5-methyl-2-(2'-(pent-4-en-1-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.031 g, 0.040 mmol, 45.4 % yield) was isoalted as a clear film. ¹H NMR (400 MHz, CDCl₃) δ 8.04 - 7.99 (m, 1H), 7.85 - 7.79 (m, 1H), 7.54 - 7.49 (m, 1H), 7.44 - 7.38 (m, 1H), 7.36 (dd, *J*=7.5, 1.8 Hz, 1H), 7.31 (td, *J*=7.8, 1.6 Hz, 1H), 7.03 (td, *J*=7.5, 0.9 Hz, 1H), 7.01 - 6.94 (m, 3H), 6.90 (s, 1H), 6.03 (ddt, *J*=16.9, 10.5, 6.0 Hz, 1H), 5.74 (ddt, *J*=17.0, 10.3, 6.7 Hz, 1H), 5.33 (dd, *J*=17.1, 1.5 Hz, 1H), 5.24 (d, *J*=10.0 Hz, 1H), 5.05 (s, 1H), 4.96 - 4.86 (m, 2H), 4.26 (t, *J*=4.4 Hz, 2H), 3.96 (t, *J*=6.4 Hz, 2H), 3.78 - 3.69 (m, 1H), 3.65 (s, 3H), 3.64 - 3.55 (m, 1H), 3.20 (q, *J*=4.2 Hz, 2H), 2.84 (s, 3H), 2.11 (q, *J*=6.9 Hz, 2H), 1.83 - 1.71 (m, 2H), 1.63 (s, 1H), 1.17 (s, 9H). LCMS (M+H) = 721.5.

25


Intermediate 23



Methyl (2S)-2-(tert-butoxy)-2-[35-chloro-4-methyl-21,31-dioxo-5,7,8,28-tetraazaheptacyclo[26.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{32,36}]octatriaconta-1(34),2,4,6(38),8,10(37),11,13,15(20),16,18,25,32,35-tetradecaen-3-yl]acetate: A mixture of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-5-methyl-2-(2'-(pent-4-en-1-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.039 g, 0.054 mmol) and Hoveyda-Grubbs 2nd generation catalyst (4.59 mg, 5.41 μ mol) in DCE (2 mL) was sparged with nitrogen, then heated at 50 °C for 3 h. The reaction was cooled, then the entire mixture was loaded onto a small plug of silica gel in a Pasteur pipette, and eluted with CH₂Cl₂ (~5 mL), followed separately by 20% - 50% EtOAc in hexanes (~ 5mL each step, 10% steps). The later eluant was concentrated under reduced pressure to afford a gummy oil. The product (0.020 g, 0.029 mmol, 53.4 % yield) was used immediately in the following step. LCMS (M+H) = 693.4.

15


Intermediate 24



Methyl (2S)-2-(tert-butoxy)-2-{35-chloro-4-methyl-21,31-dioxo-5,7,8,28-tetraazaheptacyclo[26.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{32,36}]octatriaconta-1(34),2,4,6(38),8,10(37),11,13,15(20),16,18,32,35-tridecaen-3-yl}acetate: A solution of intermediate **23** (0.020 g, 0.029 mmol) in MeOH (2 mL) and CH₂Cl₂ (0.5 mL) was treated with 10 wt% Pd/C (3.07 mg, 0.029 mmol) and the sealed flask was twice evacuated and back-filled with hydrogen gas (balloon). The reaction was stirred for 14.5 h. The reaction was filtered through celite, washing with several portions of MeOH, and the filtrate was concentrated under reduced pressure, affording a white film, which was used immediately in the following step. LCMS (M+H) = 695.5.


25

Example 5



(2S)-2-(tert-Butoxy)-2-{35-chloro-4-methyl-21,31-dioxa-5,7,8,28-tetraazaheptacyclo[26.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0^{32,36}]octatriaconta-1(34),2,4,6(38),8,10(37),11,13,15(20),16,18,32,35-tridecaen-3-yl}acetic acid: A solution of intermediate **24** (0.020 g, 0.029 mmol) in MeOH (1 mL) was treated with 1N NaOH (0.086 mL, 0.086 mmol), and the reaction was heated (50 °C heating block) for 10 h, then cooled to room temperature and quenched with 1M HCl (0.086 mL, 0.086 mmol). The reaction was diluted with water (1.5 mL), resulting in a cloudy suspension. The product was extracted with CH₂Cl₂ (3 x 1 mL), and the combined extracts were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was dried once from Et₂O to afford example **5** (0.0021 g, 2.81 μmol, 9.78 % yield) as a white powdery solid. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (t, J=1.5 Hz, 1H), 7.76 (dt, J=7.8, 1.4 Hz, 1H), 7.47 (t, J=7.7 Hz, 1H), 7.30-7.33 (m, 1H), 7.25-7.28 (m, 1H), 7.22 (dd, J=7.4, 1.7 Hz, 1H), 6.95-7.02 (m, 3H), 6.91 (d, J=8.4 Hz, 1H), 6.82 (d, J=8.4 Hz, 1H), 5.27 (s, 1H), 4.24-4.30 (m, 1H), 4.10-4.18 (m, 2H), 3.86 (dt, J=10.3, 5.3 Hz, 1H), 3.26-3.36 (m, 1H), 3.21 (d, J=14.3 Hz, 1H), 3.03-3.12 (m, 1H), 2.86 (s, 3H), 2.58-2.67 (m, 1H), 1.74-1.89 (m, 4H), 1.50-1.71 (m, 6H), 1.19 (s, 9H). LCMS (M+H) = 681.5.


Intermediate 25



4-Allyl-7-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine: A solution of 7-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.503 g, 1.802 mmol, Ref. WO20100130034) and K₂CO₃ (0.504 g, 3.65 mmol) in dry DMF (5 mL) was sparged with N₂ for 5 min, then treated with allyl bromide (0.8 mL, 9.17 mmol). The reaction tube was sealed then heated (70°C) for 22 h. The reaction was diluted with water (50 mL) and extracted into EtOAc (50 mL). The organic layer was washed with water, brine, and then dried (Na₂SO₄), filtered, and concentrated. The residue was purified by biotage (4g SiO₂, 5% (3 CV), 5-40% (15 CV), 40% (2 CV), EtOAc in hexanes), affording the desired product (0.430 g, 1.347 mmol, 74.8 % yield) as a clear viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 7.03 (d, J=5.7 Hz, 1H), 6.51 (d, J=9.9 Hz, 1H), 5.84-5.94 (m, 1H), 5.26-5.31 (m, 1H), 5.24 (m, 1H), 4.25-4.32 (m, 2H), 3.87 (m, 2H), 3.19-3.25 (m, 2H), 1.34 (s, 12H). LCMS (M+H) = 319.7.

15


Intermediate 26



(2-(But-3-en-1-yl)phenyl)boronic acid: Ref. Li, W., Nelson, D. P., Jensen, M. S., Hoerner, R. S., Cai, D., Larsen, R. D., Reider, P. J. *J. Org. Chem.*, **2002**, 67, 5394-5397. A solution of 1-bromo-2-(but-3-en-1-yl)benzene (9.46 g, 44.8 mmol) in dry THF (44.8 ml) was cooled (-78°C) and treated with 2.5 M n-BuLi in hexanes (19.7 ml, 49.3 mmol). The mixture was stirred for 20 min, and then treated with triisopropyl borate (51.5 ml, 224 mmol). After 90 min, the reaction mixture was warmed to room temperature over 1 h. Then, the reaction was quenched with 2.0 N aq. HCl (240 mL), diluted with Et₂O (120 mL), and the layers were stirred vigorously for several minutes. The resulting white precipitate was removed by filtration and then the filtrate layers were separated. The organic layer was dried (Na₂SO₄), filtered, and concentrated, affording a pale yellow oil which partially solidified upon standing. These solids were triturated with hexanes and then dried under vacuum. The decantate was concentrated to an oil, dissolved in fresh hexanes (~15 mL) and stored (-40°C) for 16 h. A second crop of solid was collected, washing with a small

volume of hexanes, and dried under vacuum. Both crops were combined to afford the desired product (5.46 g, 31.0 mmol, 69.2 % yield) as a white crystalline solid. ¹H NMR (500 MHz, CDCl₃) δ 8.24 (dd, J=7.8, 1.3 Hz, 1H), 7.52 (td, J=7.5, 1.4 Hz, 1H), 7.30-7.36 (m, 2H), 5.96 (ddt, J=17.0, 10.3, 6.5 Hz, 1H), 5.04-5.10 (m, 1H), 5.02 (dd, J=10.2, 1.6 Hz, 1H), 3.29-3.40 (m, 2H), 2.50 (td, J=7.9, 6.6 Hz, 2H). LCMS (M-H) = 175.11.

Intermediate 27




10

(2S)-Methyl 2-(7-(4-allyl-7-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (S)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.100 g, 0.179 mmol), 4-allyl-7-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.060 g, 0.188 mmol) and 2.0 M aq. Na₂CO₃ (0.179 mL, 0.358 mmol) in DMF (4 mL) was sparged with N₂ for 5 min, treated with Pd(Ph₃P)₄ (0.014 g, 0.013 mmol), sparged for 2 minutes, then sealed and heated (90°C) for 6 h. The reaction was filtered (0.45 μm syringe tip filter), and purified by prep-HPLC, affording the desired product (0.033 g, 0.053 mmol, 29.5% yield), as a yellow oily film. ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H), 7.83 (d, J=7.6 Hz, 1H), 7.45-7.50 (m, 1H), 7.28-7.33 (m, 1H), 6.97 (br. s., 1H), 6.83 (d, J=6.3 Hz, 1H), 6.74-6.81 (m, 1H), 5.73-5.84 (m, 1H), 5.14-5.30 (m, 3H), 4.35-4.46 (m, 2H), 3.95 (m, 1H), 3.79 (s, 3H), 3.69-3.76 (m, 1H), 3.41-3.50 (m, 1H), 3.36 (m, 1H), 2.67-2.76 (m, 3H), 1.00-1.05 (m, 9H). LCMS (M+H) = 625.3.

30


Intermediate 28



5 *(2S)*-Methyl 2-(7-(4-allyl-7-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-
 2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-
 (tert-butoxy)acetate: A solution of (*2S*)-methyl 2-(7-(4-allyl-7-fluoro-3,4-dihydro-
 2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-
 6-yl)-2-(tert-butoxy)acetate (0.033 g, 0.053 mmol), (2-(but-3-en-1-yl)phenyl)boronic
 acid (0.019 g, 0.106 mmol) and 2.0 M aq. Na₂CO₃ (0.066 mL, 0.132 mmol) in DMF
 10 (3.0 mL) was sparged with N₂ for 15 min, then treated with Pd(Ph₃P)₄ (4.28 mg, 3.70
 μmol), sparged for 5 min, then heated (90°C) for 5 h. The reaction was cooled,
 filtered, and purified by prep-HPLC to afford the desired product (0.016 g, 0.024
 mmol, 44.8 % yield) as a yellow film. ¹H NMR (500 MHz, CDCl₃) δ 7.92 (dt, J=7.7,
 1.3 Hz, 1H), 7.87 (t, J=1.6 Hz, 1H), 7.46 (t, J=7.7 Hz, 1H), 7.32-7.37 (m, 3H), 7.30
 15 (d, J=1.4 Hz, 2H), 6.91 (s, 1H), 6.85 (d, J=6.3 Hz, 1H), 6.76 (d, J=10.1 Hz, 1H),
 5.67-5.85 (m, 2H), 5.27 (s, 1H), 5.14-5.24 (m, 2H), 4.84-4.95 (m, 2H), 4.37-4.43 (m,
 2H), 3.96 (dd, J=16.9, 4.7 Hz, 1H), 3.79 (s, 3H), 3.68-3.75 (m, 1H), 3.31-3.48 (m,
 2H), 2.68-2.73 (m, 2H), 2.66 (s, 3H), 2.27 (q, J=7.5 Hz, 2H), 1.04 (s, 9H). LCMS
 (M+H) = 675.5.


20

Intermediate 29




Methyl (2S)-2-(tert-butoxy)-2-[32-fluoro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,34}]⁴hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A solution of (2S)-methyl 2-(7-(4-allyl-7-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.024 g, 0.036 mmol) in DCE (10 mL) was heated (70°C) under N₂ atmosphere, and then treated with Hoveyda-Grubbs Catalyst 2nd Gen. (2.2 mg, 3.6 μmol). The reaction was stirred for 90 min. The reaction was cooled, concentrated, and the crude intermediate was used immediately in the following step. LCMS (M+H) = 647.5.

Intermediate 30




Methyl (2S)-2-(tert-butoxy)-2-{32-fluoro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,34}]⁴hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate: A solution of methyl (2S)-2-(tert-butoxy)-2-[32-fluoro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,34}]⁴hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate (0.023 g, 0.036 mmol) in MeOH (5 mL) was treated with 10 wt % Pd/C (4 mg, 0.04 mmol), evacuated and hydrogen back-filled three times, then stirred under hydrogen atmosphere for 18 h. The crude mixture was filtered (0.45 μm syringe tip filter) and the filtrate solution was used immediately in the following step. LCMS (M+H) = 649.5.

Example 6



(2S)-2-(tert-Butoxy)-2-{32-fluoro-4-methyl-29-oxa-5,7,8,26-
 5 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid: A
 solution of methyl (2S)-2-(tert-butoxy)-2-{32-fluoro-4-methyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate (0.023 g,
 10 0.036 mmol) in MeOH (~2 mL) was treated with 1.0 N aq. NaOH (0.360 ml, 0.360
 mmol) and heated (70°C oil bath) for 4 h, then temperature was lowered to 50°C and
 stirring continued for 16 h. The reaction was cooled and purified by prep-HPLC to
 afford desired product. ¹H NMR (500 MHz, DMSO-d₆) δ 7.98 - 7.83 (m, 2H), 7.59 -
 7.49 (m, 1H), 7.40 - 7.29 (m, 2H), 7.29 - 7.20 (m, 2H), 7.17 (br. s., 2H), 7.00 (d,
 15 *J*=6.4 Hz, 1H), 6.82 (d, *J*=10.4 Hz, 1H), 4.84 (br. s., 1H), 4.19 (br. s., 3H), 2.94 - 2.79
 (m, 2H), 2.72 (d, *J*=12.2 Hz, 2H), 2.62 (br. s., 3H), 1.69 (br. s., 1H), 1.59 - 1.18 (m,
 6H), 0.92 (br. s., 9H). UPLC-MS (M+H) = 635.4.

Intermediate 31




20

4-Allyl-7-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-
 2H-benzo[b][1,4]oxazine: A solution of 7-methyl-6-(4,4,5,5-tetramethyl-1,3,2-
 dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.488 g, 1.774 mmol,

prepared according to the procedures outlined for related compounds in Ref. WO20100130034) and K_2CO_3 (0.490 g, 3.55 mmol) in dry DMF (5 mL) was sparged with N_2 for 5 min, treated with allyl bromide (0.773 mL, 8.87 mmol), then heated (70°C) for 22 h. The reaction was diluted with water (50 mL) and extracted into EtOAc (50 mL) and washed with water, brine and then dried (Na_2SO_4), filtered, and concentrated. The crude was purified by biotage column chromatography (12 g SiO_2 , 0% (3 CV), 0 - 40% (10 CV), 40% (2 CV), EtOAc in hexanes). Product rich fractions were re-purified by biotage (0% (3 CV), 0 - 40% (15 CV), 40% (2 CV), EtOAc in hexanes) to afford the desired product (0.345 g, 0.938 mmol, 52.9 % yield), as a colorless viscous oil. 1H NMR (500 MHz, $CDCl_3$) δ 7.20 (s, 1H), 6.62 (d, $J=0.5$ Hz, 1H), 5.92 (ddt, $J=16.9, 10.4, 5.9$ Hz, 1H), 5.29 (dq, $J=17.2, 1.6$ Hz, 1H), 5.23 (dq, $J=10.2, 1.4$ Hz, 1H), 4.30 - 4.24 (m, 2H), 3.89 (dt, $J=5.9, 1.3$ Hz, 2H), 3.27 - 3.18 (m, 2H), 2.43 (s, 3H), 1.33 (s, 12H).

15

Intermediate 32




(2S)-Methyl 2-(7-(4-allyl-7-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (S)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.100 g, 0.179 mmol), 4-allyl-7-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.062 g, 0.197 mmol) and 2.0 M Na_2CO_3 (0.179 mL, 0.358 mmol) in dry DMF (3 mL) was sparged with N_2 for 10 min, treated with $Pd(Ph_3P)_4$ (0.014 g, 0.013 mmol), sparged for 5 minutes, then heated (90°C) for 48 h. The reaction was cooled, filtered (0.45 μm syringe tip filter) and purified by prep-HPLC to afford the desired product (0.028 g, 0.045 mmol, 25.2 % yield) as a yellow oily film. 1H NMR (500 MHz, $CDCl_3$) δ 7.99 (t, $J=1.7$ Hz, 1H), 7.78 (dt, $J=7.7, 1.3$ Hz, 1H), 7.49 - 7.42 (m, 1H), 7.26 - 7.22 (m, 1H), 6.87 - 6.80 (m, 2H), 6.61 (s, 1H), 5.86

- 5.73 (m, 1H), 5.22 (dd, $J=17.2$, 1.6 Hz, 1H), 5.17 (dd, $J=10.2$, 1.4 Hz, 1H), 5.11 (s, 1H), 4.42 - 4.30 (m, 2H), 3.87 - 3.78 (m, 1H), 3.75 - 3.68 (m, 1H), 3.66 (s, 3H), 3.42 - 3.34 (m, 1H), 3.32 - 3.24 (m, 1H), 2.76 (s, 3H), 1.90 (s, 3H), 1.17 (s, 9H). LCMS (M+H) = 621.3.

5

Intermediate 33




(2S)-Methyl 2-(7-(4-allyl-7-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (2S)-methyl 2-(7-(4-allyl-7-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.028 g, 0.045 mmol), (2-(but-3-en-1-yl)phenyl)boronic acid (0.016 g, 0.090 mmol) and 2.0 M aq. Na₂CO₃ (0.056 ml, 0.113 mmol) in dry DMF (2.5 ml) was sparged with N₂ for 15 min, then treated with Pd(Ph₃P)₄ (3.7 mg, 3.2 μmol), sparged for another 5 min, then heated (90°C) for 16 h. The reaction was cooled, filtered (0.45 μm syringe tip filter), and purified by prep-HPLC to afford the desired product. ¹H NMR (500 MHz, CDCl₃) δ 7.88 (dt, $J=7.9$, 1.3 Hz, 1H), 7.83 (t, $J=1.5$ Hz, 1H), 7.44 (t, $J=7.6$ Hz, 1H), 7.32-7.36 (m, 2H), 7.29-7.31 (m, 1H), 7.26-7.28 (m, 2H), 6.88 (s, 1H), 6.81 (s, 1H), 6.64 (s, 1H), 5.65-5.85 (m, 2H), 5.21 (dd, $J=17.2$, 1.6 Hz, 1H), 5.10-5.15 (m, 2H), 4.85-4.94 (m, 2H), 4.33-4.38 (m, 2H), 3.78-3.86 (m, 1H), 3.68-3.76 (m, 1H), 3.67 (s, 3H), 3.23-3.40 (m, 2H), 2.78 (s, 3H), 2.66-2.74 (m, 2H), 2.26 (td, $J=7.9$, 6.7 Hz, 2H), 1.92 (s, 3H), 1.20 (s, 9H). LCMS (M+H) = 671.5.

25


30

Intermediate 34



Methyl (2S)-2-(tert-butoxy)-2-[4,32-dimethyl-29-oxa-5,7,8,26-
 5 tetraazaheptacyclo[24.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0³⁰,3⁴]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A
 solution of (2S)-methyl 2-(7-(4-allyl-7-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-
 6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-
 yl)-2-(tert-butoxy)acetate (0.030 g, 0.045 mmol) in dry DCE (5 mL) was heated
 10 (70°C oil bath) and then treated with Hoveyda-Grubbs Cat. 2nd Gen. (3 mg, 5 μmol).
 The reaction was stirred for 90 min. The solvent was removed and the intermediate
 was used immediately in the following step. LCMS (M+H) = 643.4.

Intermediate 35




15

Methyl (2S)-2-(tert-butoxy)-2-{4,32-dimethyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0³⁰,3⁴]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate: A solution
 20 of methyl (2S)-2-(tert-butoxy)-2-[4,32-dimethyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0³⁰,3⁴]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate in
 MeOH (4 mL), was treated with 10 wt% Pd/C (5 mg, 0.05 mmol), evacuated and
 hydrogen purged three times, then stirred under hydrogen atmosphere for 18 h. The

reaction was filtered (0.45 µm syringe tip filter), concentrated to a film, and the residue was used immediately in the following step. LCMS (M+H) = 645.4.

Example 7




5

(2S)-2-(tert-Butoxy)-2-{4,32-dimethyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid: A solution of methyl (2S)-2-(tert-butoxy)-2-{4,32-dimethyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate (0.029 g, 0.045 mmol) in MeOH (2 mL) was treated with NaOH (0.225 mL, 0.225 mmol) and the mixture was heated (70°C) for 11 h, then stirred at 50°C for an additional 60 h. The reaction mixture was purified by prep HPLC to afford desired product (0.0041 g, 6.5 µmol, 14.4% yield). ¹H NMR (500 MHz, DMSO-d₆) δ: 7.87 (d, *J*=7.0 Hz, 1H), 7.82 (br. s., 1H), 7.53 (t, *J*=7.5 Hz, 1H), 7.40 - 7.30 (m, 2H), 7.29 - 7.20 (m, 2H), 7.17 (d, *J*=7.6 Hz, 1H), 7.12 (s, 1H), 6.67 (d, *J*=4.9 Hz, 2H), 4.85 (s, 1H), 4.12 (br, 3H), 2.61 (s, 3H), 1.98 - 1.86 (m, 3H), 1.72 (br. s., 1H), 1.47 (br. s., 3H), 1.36 - 1.18 (m, 2H), 0.94 (s, 9H). Note: some proton signals are solvent obscured. LCMS (M+H) = 631.4.


25

Intermediate 36



6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-one: A mixture of 6-bromochroman-4-one (3.75 g, 16.52 mmol), bis(pinacolato)diborane (4.40 g, 17.34 mmol) and KOAc (4.86 g, 49.5 mmol) in 1,4-dioxane (100 mL) was sparged with N₂ for 15 min. Then, 1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) CH₂Cl₂ complex (0.674 g, 0.826 mmol) was added, sparged for 5 min and heated (95 °C) for 16 h. The reaction was cooled, diluted with Et₂O (250 mL), washed with water (2 x 100 mL), brine (25 mL), dried (MgSO₄), filtered and concentrated. The residue was purified by biotage (120 g SiO₂, 0% (3 CV), 0-60% (15 CV), EtOAc in hexanes) to afford the desired product (3.626 g, 13.23 mmol, 80 % yield) as a pale yellow viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (d, *J*=1.6 Hz, 1H), 7.89 (dd, *J*=8.3, 1.7 Hz, 1H), 6.96 (dd, *J*=8.4, 0.3 Hz, 1H), 4.59 - 4.53 (m, 2H), 2.83 (dd, *J*=6.8, 6.1 Hz, 2H), 1.34 (s, 12H). LCMS (M+H) = 275.15.

Intermediate 37




15

4-Allyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-ol: A cold (-78°) solution of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-one (1.21 g, 4.41 mmol) in dry THF (20 mL) was treated with 1.0 M allylmagnesium bromide in Et₂O (6.62 mL, 6.62 mmol) by dropwise addition over 2 min. The reaction was stirred for 10 min, allowed to warm to room temperature and stirred for 90 min, then quenched with sat'd aq. NH₄Cl (2 mL). The mixture was diluted with Et₂O (50 mL), washed with water (10 mL), brine (10 mL), dried (MgSO₄), filtered and concentrated. The residue was purified by biotage (40 g SiO₂, 0% (3 CV), 0-60% (15 CV), EtOAc in hexanes) to afford the desired product (0.864 g, 2.73 mmol, 61.9 % yield) as a colorless viscous oil. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J*=1.5 Hz, 1H), 7.64 (dd, *J*=8.2, 1.6 Hz, 1H), 6.83 (d, *J*=8.3 Hz, 1H), 5.81 (ddt, *J*=17.2, 10.2, 7.3 Hz, 1H), 5.21 - 5.17 (m, 1H), 5.15 (s, 1H), 4.29 - 4.24 (m, 2H), 2.84 (dd,

$J=14.1$, 7.5 Hz, 1H), 2.66 (dd, $J=14.1$, 7.0 Hz, 1H), 2.14 (ddd, $J=13.9$, 7.9, 5.5 Hz, 1H), 2.01 (s, 1H), 2.00 - 1.91 (m, 1H), 1.34 (d, $J=1.0$ Hz, 12H). LCMS ($M+H-H_2O$) = 299.2.

5


Intermediate 38



2-(4-Allylchroman-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane: A stirred solution of 4-allyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chroman-4-ol (1.80 g, 5.69 mmol) and triethylsilane (7.27 ml, 45.5 mmol) in DCE (30 ml) was treated with TFA (14.03 ml, 182 mmol) by rapid addition at ambient temperature. The reaction was stirred for 10 min, then carefully quenched with sat'd. aq. NaHCO_3 (200 mL). The organic layer was concentrated and the residue was purified by biotage (80 g SiO_2 , 0% (3 CV), 0-60% (15 CV), 60% (2 CV), EtOAc in hexanes) to afford the desired product (0.942 g, 3.14 mmol, 55.1% yield) as a viscous clear oil. ^1H NMR (400 MHz, CDCl_3) δ 7.64 (s, 1H), 7.56 (dd, $J=8.2$, 1.4 Hz, 1H), 6.80 (d, $J=8.0$ Hz, 1H), 5.90 - 5.76 (m, 1H), 5.15 - 5.04 (m, 2H), 4.23 - 4.14 (m, 2H), 2.89 (dq, $J=10.0$, 5.0 Hz, 1H), 2.75 - 2.62 (m, 1H), 2.35 - 2.22 (m, 1H), 2.09 - 1.96 (m, 1H), 1.92 - 1.81 (m, 1H), 1.34 (s, 12H). LCMS ($M+H$) = 301.3.

20


Intermediate 39



(2S)-Methyl 2-(7-(4-allylchroman-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (S)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-

butoxy)acetate (0.375 g, 0.374 mmol), 2-(4-allylchroman-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.123 g, 0.411 mmol) and 2.0 M Na₂CO₃ (0.374 ml, 0.747 mmol) in DMF (3.74 ml) was sparged with N₂ for 10 min, treated with Pd(Ph₃P)₄ (0.030 g, 0.026 mmol), sparged for 5 minutes, then heated (90°C) for 16 h. The reaction was cooled, diluted with water (20 mL) and extracted with EtOAc. The organic layer was dried (MgSO₄), filtered, and concentrated and the residue was purified by biotage (40 g SiO₂, 0% (3 CV), 0-40% (15 CV), 60% (2 CV), EtOAc in hexanes). Fractions containing desired product combined, concentrated and re-purified (40 g SiO₂, 0% (3 CV), 0-60% (15 CV), 60% (2 CV), EtOAc in hexanes) to afford the desired product (0.431 g, 0.713 mmol, 44.6 % yield). LCMS (M+H) = 606.4.


Intermediate 40



15


(2S)-Methyl 2-(7-(4-allylchroman-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (*2S*)-methyl 2-(7-(4-allylchroman-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.070 g, 0.116 mmol) and (2-(but-3-en-1-yl)phenyl)boronic acid (0.041 g, 0.232 mmol) in DMF (3 mL) was treated with 2.0 M aq. Na₂CO₃ (0.145 mL, 0.289 mmol), and the mixture was sparged with N₂ for 10 min, then treated with Pd(Ph₃P)₄ (9 mg, 8 μmol), sparged for 5 min, then stirred with heating (90°C) for 90 min. The reaction was cooled, then filtered (0.45 μm syringe tip filter) and purified by biotage column chromatography (4g SiO₂, 5% - 45% EtOAc in hexanes, 15 CV) to afford the desired product (0.052 g, 0.078 mmol, 67.5 % yield), as a clear film. LCMS (H+M) = 656.5.

Intermediate 41



5 *Methyl (2S)-2-(tert-butoxy)-2-[4-methyl-29-oxa-5,7,8-*
triazahaptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,34}]hexatriaconta-
1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A
 solution of (2S)-methyl 2-(7-(4-allylchroman-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-
 biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.054
 g, 0.082 mmol) in DCE (5.0 mL) was heated (70°C), then treated with Hoveyda-
 10 Grubbs Cat. 2nd Gen. (5 mg, 8 μmol). The reaction was stirred for 90 min. The
 reaction was cooled, then concentrated and the residue was used immediately in the
 following step. LCMS (M+H) = 628.4.

Intermediate 42



15

20 *Methyl (2S)-2-(tert-butoxy)-2-[4-methyl-29-oxa-5,7,8-*
triazahaptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,34}]hexatriaconta-
1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetate: A solution
 of methyl (2S)-2-(tert-butoxy)-2-[4-methyl-29-oxa-5,7,8-
 triazahaptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate (0.051
 g, 0.082 mmol) in MeOH (5 mL) was treated with 10 wt% Pd/C (9 mg, 0.08 mmol),
 then evacuated and hydrogen gas filled three times. The reaction was stirred for 16 h.

The reaction mixture was filtered (0.45µm syringe tip filter) and the filtrate solution was used directly in the following step. LCMS (M+H) = 630.5.


Examples 8-11

5

A solution of crude methyl (2S)-2-(tert-butoxy)-2-{4-methyl-29-oxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate (0.052 g, 0.082 mmol) in MeOH (2 mL) was treated with 1.0 M aq. NaOH (0.4 mL, 0.4 mmol) and heated (70°C) for 5 h, then cooled and purified by prep-HPLC to afford four products. Note: The mixture was resolved into two diastereomers as well as two nor-analog diastereomers.

10

Example 8




15

(2S)-2-(tert-butoxy)-2-{4-methyl-29-oxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid: First eluting diastereomer (0.009 g, 0.014 mmol, 17.5% yield). LCMS (M+H) = 616.7.

20

Example 9




(2*S*)-2-(*tert*-butoxy)-2-{4-methyl-29-oxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid:

Second eluting diastereomer (0.0099 g, 0.016 mmol, 19.6% yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.94 (d, *J*=7.6 Hz, 1H), 7.76 (br. s., 1H), 7.59 - 7.46 (m, 3H), 7.25 (d, *J*=7.0 Hz, 1H), 7.22 - 7.12 (m, 4H), 7.05 (d, *J*=7.0 Hz, 1H), 6.92 (d, *J*=7.9 Hz, 1H), 4.99 (s, 1H), 4.22 - 4.07 (m, 2H), 2.72 (d, *J*=8.9 Hz, 2H), 2.57 (br. s., 3H), 2.26 (br. s., 1H), 2.00 - 1.89 (m, 2H), 1.77 (d, *J*=15.9 Hz, 1H), 1.64 (br. s., 1H), 1.43 (br. s., 1H), 1.36 - 1.11 (m, 5H), 0.91 (br. s., 1H), 0.79 (s, 9H). LCMS (M+H) = 616.7.

10


Example 10



(2*S*)-2-(*tert*-Butoxy)-2-{4-methyl-28-oxa-5,7,8-triazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{29,33}]pentatriaconta-1(31),2,4,6(35),8,10(34),11,13,15(20),16,18,29,32-tridecaen-3-yl}acetic acid: First eluting nor-analog diastereomer (0.0015 g, 2.3 μmol, 2.9% yield). LCMS (M+H) = 602.4.

20


Example 11



(2*S*)-2-(*tert*-Butoxy)-2-{4-methyl-28-oxa-5,7,8-triazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{29,33}]pentatriaconta-1(31),2,4,6(35),8,10(34),11,13,15(20),16,18,29,32-tridecaen-3-yl}acetic acid:

Second eluting nor-analog diastereomer (0.002 g, 3 μ mol, 3.6% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.96 (s, 1H), 7.78 (d, *J*=1.7 Hz, 1H), 7.69 - 7.64 (m, 1H), 7.58 (dd, *J*=8.4, 2.2 Hz, 1H), 7.51 (t, *J*=7.7 Hz, 1H), 7.37 - 7.28 (m, 5H), 7.26 - 7.20 (m, 1H), 6.95 (d, *J*=8.4 Hz, 1H), 6.88 (s, 1H), 5.36 (s, 1H), 4.49 - 4.41 (m, 1H), 4.30 (ddd, *J*=10.9, 6.6, 4.3 Hz, 1H), 2.95 (d, *J*=4.9 Hz, 1H), 2.81 - 2.73 (m, 1H), 2.72 - 2.68 (m, 1H), 2.66 (s, 3H), 2.05 - 1.97 (m, 2H), 1.95 - 1.73 (m, 4H), 1.70 - 1.60 (m, 2H), 0.99 (s, 9H). LCMS (M+H) = 602.6.


Intermediate 43



(2*S*)-Methyl 2-(7-(4-allylchroman-6-yl)-2-(2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: A solution of ((2*S*)-methyl 2-(7-(4-allylchroman-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate (0.430 g, 0.711 mmol), (2-hydroxyphenyl)boronic acid (0.196 g, 1.423 mmol) and 2.0 M aq. Na₂CO₃ (1.1 ml, 2.1 mmol) in DMF (7 ml) was sparged with nitrogen for 10 min, treated with Pd(Ph₃P)₄ (0.058 g, 0.050 mmol), then sparged for 5 min. The reaction was stirred for 90 min, then cooled, diluted with water (20 mL) and extracted into Et₂O (2 x 50 mL). The combined extracts were dried (MgSO₄), filtered, and concentrated and the residue was purified by biotage (24 g SiO₂, 0% (3 CV), 0-60% (15 CV), 60% (2 CV), EtOAc in hexanes) to afford the desired product (0.360 g, 0.572 mmol, 80 % yield) as a pale yellow glassy solid. ¹H NMR (500 MHz, CDCl₃) δ : 8.07 - 7.89 (m, 2H), 7.70 (s, 1H), 7.60 - 7.49 (m, 2H), 7.49 - 7.36 (m, 2H), 7.34 - 7.29 (m, 2H), 7.07 - 6.97 (m, 3H), 6.95 - 6.90 (m, 1H), 5.96 - 5.71 (m, 1H), 5.37 - 5.19 (m, 2H), 5.16 - 4.97 (m, 2H), 4.39 - 4.25 (m, 2H), 3.88 - 3.79 (m, 3H), 3.12 - 2.88 (m, 1H), 2.72 - 2.63 (m,

3H), 2.61 - 2.32 (m, 1H), 2.22 - 2.08 (m, 1H), 2.02 - 1.88 (m, 1H), 1.06 - 0.92 (m, 9H). LCMS (M+H) = 618.5.

Intermediate 44




5

(2S)-Methyl 2-(7-(4-allylchroman-6-yl)-2-(2'-(allyloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (2S)-methyl 2-(7-(4-allylchroman-6-yl)-2-(2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.350 g, 0.567 mmol) in dry THF (12 ml) was treated sequentially with allyl alcohol (0.116 ml, 1.700 mmol), Ph₃P (0.446 g, 1.700 mmol) and DEAD (0.269 ml, 1.700 mmol), and the reaction was stirred for 2 h. The reaction was concentrated, and the residue was purified by biotage (24 g SiO₂, 0% (3 CV), 0-60% (15 CV), 60% (2 CV), EtOAc in hexane). The residue after concentration was taken up in Et₂O (20 mL) and washed with water (2 x 20 mL) to remove residual allyl alcohol, then dried (MgSO₄), filtered, and concentrated, affording the desired product (0.4 g, 0.6 mmol, quant.) as a viscous clear oil. ¹H NMR (500 MHz, CDCl₃) δ 8.11 - 8.04 (m, 1H), 7.90 - 7.84 (m, 1H), 7.58 - 7.36 (m, 5H), 7.35 - 7.29 (m, 1H), 7.06 (t, J=7.4 Hz, 1H), 7.02 - 6.93 (m, 2H), 6.90 (s, 1H), 6.04 - 5.91 (m, 1H), 5.90 - 5.78 (m, 1H), 5.37 - 5.30 (m, 4H), 5.27 - 5.13 (m, 4H), 5.12 - 5.02 (m, 2H), 4.55 (d, J=4.9 Hz, 2H), 4.30 (br. s., 2H), 3.82 (s, 3H), 2.68 - 2.63 (m, 3H), 1.01 - 0.93 (m, 9H). LCMS (M+H) = 658.6.

25

Intermediate 45




Methyl (2S)-2-(tert-butoxy)-2-[4-methyl-21,29-dioxa-5,7,8-
 5 triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A
 solution of (2S)-methyl 2-(7-(4-allylchroman-6-yl)-2-(2'-(allyloxy)-[1,1'-biphenyl]-3-
 yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.373 g, 0.567
 mmol) in DCE (275 ml) was heated (70°C) and then treated with Hoveyda-Grubbs
 10 cat.2nd gen. (0.025 g, 0.040 mmol). The reaction was stirred for 2.5 hrs, then
 additional catalyst (0.025 g, 0.040 mmol) was added, the temperature was raised
 (80°C) and the reaction was stirred for 30 min. The reaction was cooled,
 concentrated, and the residue was purified by biotage (24 g SiO₂, 0% (3 CV), 0-60%
 (15 CV), 60% (2 CV), EtOAc in hexanes) to afford the desired product (0.300 g,
 15 0.476 mmol, 84 % yield). LCMS (M+H) = 630.5.

Intermediates 46-47


A suspension of methyl (2S)-2-(tert-butoxy)-2-[4-methyl-21,29-dioxa-5,7,8-
 20 triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate (0.196
 g, 0.311 mmol) in MeOH (3 mL) was treated with CH₂Cl₂ (4 mL) and stirred until
 dissolution occurred. The solution was treated with 10 wt% palladium on carbon
 (0.040 g, 0.038 mmol) and the reaction was then evacuated and back-filled with
 25 hydrogen (balloon) three times. The reaction was stirred for 5 h, then concentrated
 and dried under vacuum pump for 16 h. The residue was resolved into separate
 diastereomers by prep-HPLC.

Intermediate 46



5 *Methyl (2S)-2-(tert-butoxy)-2-[(26R)-4-methyl-21,29-dioxo-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0^{3,0},3⁴]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetate*: Early eluting diastereomer (0.0544 g, 0.086 mmol, 55.3% yield). LCMS (M+H) = 632.4.


Intermediate 47



10

Methyl (2S)-2-(tert-butoxy)-2-[(26S)-4-methyl-21,29-dioxo-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰.0^{3,0},3⁴]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetate: Later
15 eluting diastereomer (0.0479 g, 0.076 mmol, 48.7% yield). LCMS (M+H) = 632.5.


Example 12



(2*S*)-2-(*tert*-Butoxy)-2-[(26*R*)-4-methyl-21,29-dioxo-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetic acid: A solution of methyl (2*S*)-2-(*tert*-butoxy)-2-[(26*R*)-4-methyl-21,29-dioxo-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetate (early eluting diastereomer, 0.045 g, 0.071 mmol) in MeOH (1.5 mL) was treated with 1.0 M aq. NaOH (0.4 mL, 0.400 mmol), and the mixture was heated (65°C) for 2.5 h, then cooled and concentrated. The residue was partitioned in CH₂Cl₂ and water (10 mL each) and the organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The film was dried twice from Et₂O to afford the desired product (0.031 g, 0.050 mmol, 70.5 % yield) as an off white glassy solid. LCMS (M+H) = 618.5.

15

Example 13



(2*S*)-2-(*tert*-Butoxy)-2-[(26*S*)-4-methyl-21,29-dioxo-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetic acid: A solution of methyl (2*S*)-2-(*tert*-butoxy)-2-[(26*S*)-4-methyl-21,29-dioxo-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetate (later eluting diastereomer, 0.048 g, 0.076 mmol) in MeOH (2 mL) was treated with 1.0 M aq. NaOH (0.380 mL, 0.380 mmol), and the mixture was heated (65°C) for 2.5 h, then cooled and concentrated. The residue was partitioned between CH₂Cl₂ and water (10 mL each) and the organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was suspended in Et₂O and

collected by vacuum filtration to afford the desired product (0.033 g, 0.052 mmol, 68.1 % yield) as an off-white solid. LCMS (M+H) = 618.4.


Example 14-15

5

A suspension of methyl (2*S*)-2-(tert-butoxy)-2-[4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate (0.053 g, 0.084 mmol) in MeOH (1.0 mL) was treated with 1.0 M aq. NaOH (0.5 mL, 0.500 mmol), and the mixture was heated (75°C) for 1 h, then THF (~2 mL) was added and the reaction was stirred for 45 min. The reaction was cooled and concentrated and the remaining aq. suspension was treated with 1.0 N HCl (0.6 mL). Solids were extracted into CH₂Cl₂ (2 x 2 mL), then concentrated. The residue was resolved into separate diastereomers by prep-HPLC.

15


Example 14



(2*S*)-2-(tert-Butoxy)-2-[(26*S*)-4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetic acid: Early eluting diastereomer (0.0213 g, 0.034 mmol, 40.7 % yield). LCMS (M+H) = 616.5.


25

Example 15



(2S)-2-(tert-Butoxy)-2-[(26R)-4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,2}.0^{3,3}.4]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetic acid: Later eluting diastereomer (0.007 g, 0.011 mmol, 13.37 % yield). LCMS (M+H) = 616.5.

Intermediate 46




10

4-Allyl-8-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine: A solution of 8-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.507 g, 1.613 mmol, Ref. WO20100130034) and K₂CO₃ (0.512 g, 3.70 mmol) in dry DMF (5 mL) was sparged with N₂ for 5 min, then treated with allyl bromide (0.8 mL, 9.17 mmol). The reaction tube was sealed and then heated (70°C) for 22 h. The reaction was cooled then diluted with water (50 mL) and extracted into EtOAc (50 mL). The organic layer was then washed with water, brine, dried (Na₂SO₄), filtered, and concentrated. The residue was purified by biotage column chromatography (12 g SiO₂, 0% (3 CV); 0 - 40% (15 CV), 40% (2 CV), EtOAc in hexanes) to afford the desired product (0.396 g, 1.241 mmol, 77 % yield) as a clear viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 6.96-7.01 (m, 2H), 5.84-5.95 (m, 1H), 5.21-5.32 (m, 2H), 4.32-4.38 (m, 2H), 3.94 (d, J=5.8 Hz, 2H), 3.30-3.37 (m, 2H), 1.32 (s, 12H). LCMS (M+H) = 320.3.


25

Intermediate 49



5 *(S)*-Methyl 2-(7-(4-allyl-8-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-
 2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A
 solution of (*S*)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-
 a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.160 g, 0.287 mmol) and 4-allyl-8-fluoro-
 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-
 benzo[b][1,4]oxazine (0.108 g, 0.287 mmol) in DMF (3 mL) was treated with 2.0 M
 10 aq. Na₂CO₃ (0.358 mL, 0.717 mmol), sparged with N₂ for 10 min, treated with
 Pd(Ph₃P)₄ (0.033 g, 0.029 mmol), sparged for 5 min, then sealed and heated (90°C)
 for 9.5 h then allowed to cool to room temperature, stirring for 16 h. The reaction
 was diluted with EtOAc (20 mL) and washed with 1:1 water / brine (2 x 10 mL). The
 organic layer was dried (Na₂SO₄), filtered and concentrated, and the residue was
 15 purified by biotage column chromatography (4g SiO₂, 0% - 70%, 22 CV, EtOAc in
 hexanes) to afford the desired product (0.102 g, 0.104 mmol, 36.3 % yield) as a
 yellow oil. LCMS (M+H) = 625.3.

Intermediate 50




20

25 *(S)*-Methyl 2-(7-(4-allyl-8-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-
 2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-
 (tert-butoxy)acetate: A solution of (*S*)-methyl 2-(7-(4-allyl-8-fluoro-3,4-dihydro-2H-
 benzo[b][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-
 yl)-2-(tert-butoxy)acetate (0.102 g, 0.164 mmol), (2-(but-3-en-1-yl)phenyl)boronic

acid (0.058 g, 0.327 mmol) and 2.0 N Na₂CO₃ (0.204 mL, 0.409 mmol) in DMF (4.0 mL) was sparged with N₂ for 15 min, then treated with Pd(Ph₃P)₄ (0.013 g, 0.011 mmol), sparged for 5 min, and then heated (90°C) for 3 h. The reaction was diluted with EtOAc (20 mL) and washed with 1:1 water / brine (2 x 10 mL). The organic
 5 layer was dried (Na₂SO₄), filtered, and concentrated and the residue was purified by biotage column chromatography (4g SiO₂, 0% (6 CV), 0% - 50% (15 CV), EtOAc in hexanes) to afford the desired product as an amber oil. LCMS (M+H) = 675.4.

Intermediate 51




10

Methyl (2S)-2-(tert-butoxy)-2-[31-fluoro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1.6.9.1.0.1.4.0.2.7.0.1.5.2.0.3.0.3.4]hexatriacont-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A
 15 solution of (S)-methyl 2-(7-(4-allyl-8-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.112 g, 0.166 mmol) in DCE (20 mL) was heated (70°C oil bath) and then treated with Hoveyda-Grubbs Cat. 2nd Gen. (7.30 mg, 0.012 mmol). The reaction was stirred for 2 h, additional catalyst (7.30 mg, 0.012 mmol)
 20 was added and the reaction was stirred for 16 h. The solvent was removed and the residue was purified by biotage chromatography (4g column, 0% (6 CV), 0% - 60% (15 CV); EtOAc in hexanes) to afford the desired product (0.062 g, 0.090 mmol, 54.5 % yield) as a light brown film. LC/MS (M+H) = 647.5.

25


Intermediate 52



Methyl (2S)-2-(tert-butoxy)-2-{31-fluoro-4-methyl-29-oxa-5,7,8,26-
 5 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate: A solution
 of methyl (2S)-2-(tert-butoxy)-2-[31-fluoro-4-methyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate (0.063
 10 g, 0.097 mmol) in MeOH (5 mL) was treated with 10 wt% Pd / C (0.002 g, 0.019
 mmol) and the sealed flask was evacuated and flushed with hydrogen gas three times,
 then allowed to stir for 16 h. The reaction was cooled, then filtered (0.45 µm syringe
 tip filter) and concentrated and the residue was used immediately in the following
 step. LCMS (M+H) = 649.4.

15

Example 16




(2S)-2-(tert-Butoxy)-2-{31-fluoro-4-methyl-29-oxa-5,7,8,26-
 20 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid: A
 solution of methyl (2S)-2-(tert-butoxy)-2-{31-fluoro-4-methyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate (0.063 g,
 25 0.097 mmol) in MeOH (2 mL) was treated with NaOH (0.24 mL, 0.48 mmol) and the

reaction was heated (70°C oil bath) for 2.5 hrs. The reaction was cooled and then purified by prep-HPLC to afford the desired product (0.0278 g, 0.044 mmol, 45.2% yield). LCMS (M+H) = 635.5.


5

Intermediate 53



4-Allyl-5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine: A solution of 5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.504 g, 1.426 mmol, Ref. WO20100130034) and K₂CO₃ (0.504 g, 3.65 mmol) in dry DMF (5 mL) was sparged with N₂ for 5 min, then treated with allyl bromide (0.8 mL, 9.17 mmol). The reaction tube was sealed and then heated (70°C) for 22 h, then cooled and diluted with water (50 mL) and extracted into EtOAc (50 mL). The organic layer was washed with water, brine, then dried (Na₂SO₄), filtered, concentrated, and purified by biotage chromatography (4 g SiO₂, 0% (3 CV), 0 - 40% (15 CV), 40% (2 CV); EtOAc in hexanes) to afford the desired product (0.403 g, 1.201 mmol, 84 % yield) as a clear viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, *J*=8.2 Hz, 1H), 6.79 (d, *J*=8.2 Hz, 1H), 6.15 - 6.02 (m, 1H), 5.31 (dd, *J*=17.2, 1.4 Hz, 1H), 5.28 - 5.21 (m, 1H), 4.18 - 4.13 (m, 2H), 3.59 (d, *J*=6.0 Hz, 2H), 3.14 - 3.07 (m, 2H), 1.36 (s, 12H). LCMS (M+H) = 336.9.


Intermediate 54



(2*S*)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: A solution of (S)-methyl 2-(2-(3-bromophenyl)-7-iodo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate (0.160 g, 0.287 mmol) and 4-allyl-5-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine (0.096 g, 0.287 mmol) in DMF (3 mL) was treated with 2.0 M aq. Na₂CO₃ (0.358 mL, 0.717 mmol), sparged with N₂ for 10 min, treated with Pd(Ph₃P)₄ (0.033 g, 0.029 mmol), sparged for 5 min, then sealed and heated (90°C) for 16 h. The reaction was cooled, diluted with EtOAc (20 mL) and washed with 1:1 water / brine (2 x 10 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated. The residue was purified by biotage column chromatography (4g Isco SiO₂, 0% (5 CV), 0% - 80% (15 CV), EtOAc/hexanes) to afford semi-purified product (0.122 g, 0.143 mmol, 49.9 % yield) as a clear oil. ¹H NMR (500 MHz, CDCl₃) δ 7.98 (t, *J*=1.7 Hz, 1H), 7.76 (dt, *J*=7.8, 1.2 Hz, 1H), 7.44 (ddd, *J*=8.0, 2.0, 1.1 Hz, 1H), 7.24 (t, *J*=7.9 Hz, 1H), 6.99-7.03 (m, 1H), 6.93-6.97 (m, 1H), 6.85 (s, 1H), 5.99-6.10 (m, 1H), 5.36 (dd, *J*=17.2, 1.6 Hz, 1H), 5.26 (dd, *J*=10.2, 1.5 Hz, 1H), 5.05 (s, 1H), 4.23-4.32 (m, 2H), 3.69 (dd, *J*=12.1, 6.0 Hz, 2H), 3.65 (s, 3H), 3.17-3.29 (m, 2H), 2.84 (s, 3H), 1.17 (s, 9H). LCMS (*M*+*H*) = 641.2.

20


Intermediate 55



(2*S*)-Methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: A solution of (2*S*)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazin-6-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate (0.092 g, 0.143 mmol), (2-(but-3-en-1-yl)phenyl)boronic acid (0.050 g, 0.286 mmol) and 2.0 M aq. Na₂CO₃ (0.179 mL,

0.358 mmol) in DMF (4 mL) was sparged with nitrogen for 10 min, treated with Pd(Ph₃P)₄ (0.012 g, 10.01 μmol), sparged for 5 min, then heated (90°C) for 5 h. The reaction was cooled, then diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (10 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated and the residue was purified by biotage (Isco 4 g SiO₂, 0% (5 CV), 0-60% (20 CV), 60% (5 CV), EtOAc in hexanes) to afford the desired product (0.099 g, 0.143 mmol, 100 % yield). LCMS (M+H) = 691.4.

Intermediate 56




10

Methyl (2S)-2-(tert-butoxy)-2-[33-chloro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{3,3}]⁴]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate: A solution of (2S)-methyl 2-(7-(4-allyl-5-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.099 g, 0.143 mmol) in DCE was heated (70°C) and then treated with Hoveyda-Grubbs Catalyst 2nd Generation (6.30 mg, 10.03 μmol). The reaction was stirred for 2 h, additional Hoveyda-Grubbs Catalyst 2nd Generation (7.30 mg, 0.012 mmol) was added, and the reaction was stirred for 2 h and then cooled. The reaction was concentrated and the residue was purified by biotage (Isco 4g SiO₂, 0% (5 CV), 0-60% (15 CV), EtOAc in hexanes) to afford the desired product (0.069 g, 0.104 mmol, 73 % yield). ¹H NMR (500 MHz, CDC₃) δ 7.99 (t, J=1.6 Hz, 1H), 7.79 (dt, J=7.9, 1.3 Hz, 1H), 7.52 (t, J=7.7 Hz, 1H), 7.29-7.32 (m, 2H), 7.21-7.28 (m, 3H), 6.96 (s, 1H), 6.91 (s, 2H), 5.57-5.62 (m, 2H), 5.09 (s, 1H), 4.61-4.70 (m, 1H), 4.28-4.38 (m, 2H), 3.64 (s, 3H), 3.52-3.61 (m, 1H), 3.43-3.49 (m, 1H), 3.33 (dd, J=15.1, 5.2 Hz, 1H), 2.85 (s, 3H), 2.60-2.66 (m, 2H), 2.36 (td, J=8.0, 5.1 Hz, 2H), 1.21 (s, 9H). LCMS (M+H) = 663.4.


25

Intermediate 57



Methyl (2S)-2-(tert-butoxy)-2-{33-chloro-4-methyl-29-oxa-5,7,8,26-
 5 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate: A solution
 of methyl (2S)-2-(tert-butoxy)-2-[33-chloro-4-methyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetate (0.051
 10 g, 0.077 mmol) in MeOH (3 mL) was evacuated and back-filled with hydrogen gas
 (balloon) three times, allowed to stir for 2 h, then filtered (0.45 µm syringe tip filter).
 The filtrate was used directly in the following step. LCMS (M+H) = 667.4.


Example 17



(2S)-2-(tert-Butoxy)-2-{33-chloro-4-methyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid: A
 20 solution of methyl (2S)-2-(tert-butoxy)-2-{33-chloro-4-methyl-29-oxa-5,7,8,26-
 tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-
 1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetate (0.051 g,
 0.077 mmol) in MeOH (2.0 ml) was treated with 1.0 N aq. NaOH (0.385 ml, 0.385
 mmol) and the mixture was heated (70°C) for 1 h. The mixture was purified by prep-
 25 HPLC to afford the desired product (0.0023 g, 3.4 µmol, 4.5% yield). ¹H NMR (500
 MHz, DMSO-d₆) δ 8.01 - 7.92 (m, 1H), 7.82 (br. s., 1H), 7.52 (t, *J*=7.5 Hz, 1H), 7.28


(d, $J=6.1$ Hz, 1H), 7.25 - 7.14 (m, 5H), 7.10 (d, $J=7.0$ Hz, 1H), 6.98 (d, $J=7.6$ Hz, 1H), 6.88 (d, $J=7.9$ Hz, 1H), 5.09 (br. s., 1H), 4.18 (d, $J=11.0$ Hz, 1H), 4.11 - 4.00 (m, 1H), 3.05 - 2.94 (m, 1H), 2.89 (s, 3H), 2.74 (d, $J=5.8$ Hz, 4H), 2.25 (br. s., 1H), 1.67 (br. s., 1H), 1.48 (br. s., 4H), 1.34 (br. s., 1H), 1.09 (br. s., 9H). LCMS (M+H) = 651.5.

Intermediate 58




10 *Methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate.* To a stirred solution of 0.91M KHMDS/THF (95 mL, 95 mmol) in THF (50 mL) at -78 °C was added dropwise a solution of methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (25 g, 63.3 mmol) in THF(300 mL). After 1 h, 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine
15 (24.8 g, 95 mmol) in THF(100mL) was added over the course of 10 min. This red reaction mixture was stirred at -78 °C for 2 h. Then, the resulting orange solution was quenched with sat. aq. NH₄Cl (400 mL), diluted with EtOAc (400 mL), and partitioned with a sep. funnel. The organic phase was washed with water and brine. The organic phase was dried(Na₂SO₄), filtered, and concentrated to give a light
20 brown solid. Trituration with hexanes followed by trituration with ether(5 x 50 mL) gave 21 g of a yellow solid: methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (as a 1:1 complex with benzenesulfonamide). ¹H NMR (400 MHz, CDCl₃) δ 8.20 (t, $J=1.8$ Hz, 1H), 7.95 (dq, $J=7.8, 0.8$ Hz, 1H), 7.57 (ddd, $J=8.0, 2.0, 1.0$ Hz, 1H), 7.37 (t, $J=7.9$ Hz, 1H),
25 6.95 (s, 1H), 5.79 (s, 1H), 3.87 (s, 3H), 3.59 (d, $J=1.8$ Hz, 1H), 2.65 (s, 3H). LCMS (M+H) = 410 and 412.

Intermediate 59



Methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate. To a stirred inseparable mixture of methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (12.9 g, 31.4 mmol) and benzenesulfonamide (2.96 g, 18.85 mmol) in CH₂Cl₂ (700 mL) was added
 5 Dess-Martin Periodinane (13.3 g, 31.4 mmol). Stir for 60 min at rt at which time the reaction appeared complete by TLC (1:1 hexane/EtOAc). The reaction was placed in the refrigerator for 2h and then filtered through a medium fritted glass funnel. The brown homogeneous solution was treated with 140 mL of sat.aq. Na₂CO₃ and stirred rapidly for 30 min. The organic phase was separated and washed with additional
 10 sat.aq. Na₂CO₃ in a separatory funnel. The organic phase was dried (Na₂SO₄) and filtered through celite. The filtrate was then filtered through 170g of silica gel with the aid of another 1L of CH₂Cl₂. The light yellow filtrate was concentrated in vacuo to give 9.5g of a yellow solid which after further drying gave 8.43g (66%) of methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate
 15 as a light yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (t, *J*=1.6 Hz, 1H), 7.96 (d, *J*=7.8 Hz, 1H), 7.60 (dt, *J*=8.0, 0.9 Hz, 1H), 7.39 (t, *J*=7.9 Hz, 1H), 7.02 (s, 1H), 4.03 (s, 3H), 2.65 (s, 3H). LCMS (M+H) = 408 and 410.

Intermediate 60




20

(S)-Methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate. To a stirred solution of methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate (14 g, 34.3 mmol) in anhydrous toluene (400 mL) was added 1.1M (R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole/toluene (12.5 mL, 13.7 mmol). The mixture was cooled to -35 °C and then a 4.17M solution of catechoborane/toluene (11.7 mL, 48 mmol) was added over the course of 10 min. After 30 min, the reaction mixture was slowly warmed to -15 °C and stirred for
 25 additional 2 h. At this point the reaction mixture was diluted with EtOAc (300 mL) and treated with sat.aq. Na₂CO₃ (50 mL). The mixture was stirred vigorously for 10
 30

min. The organic phase was separated and washed with sat. aq. Na_2CO_3 (5 X 100 mL), 0.1N HCl (1 x 100mL), and brine. The organic phase was dried (Na_2SO_4), filtered, and concentrated. The residue was triturated with ether to obtain 12 g (77%) of the desired (S)-methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-
 5 a]pyrimidin-6-yl)-2-hydroxyacetate as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.20 (t, $J=1.8$ Hz, 1H), 7.95 (dq, $J=7.8$, 0.8 Hz, 1H), 7.57 (ddd, $J=8.0$, 2.0, 1.0 Hz, 1H), 7.37 (t, $J=7.9$ Hz, 1H), 6.95 (s, 1H), 5.79 (s, 1H), 3.87 (s, 3H), 3.59 (d, $J=1.8$ Hz, 1H), 2.65 (s, 3H). LCMS ($\text{M}+\text{H}$) = 410 and 412.

10


Intermediate 61



(S)-Methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-
 a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. A mixture of (S)-methyl 2-(2-(3-
 15 bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (7.81 g, 19.02 mmol), t-butylacetate (160 mL) in DCM (330 mL) was added perchloric acid (3.43 mL, 57.1 mmol) and the mixture was stirred at rt for 3 h. It was then quenched with sat.aq. NaHCO_3 (adjusted to pH=7-8 by the addition of solid NaHCO_3). This mixture was diluted with EtOAc and the organic phase was washed
 20 with water. The organic phase was dried(MgSO_4), filtered, and concentrated in vacuo to obtain ~ 7g of crude product as an oil. Filtration through 70 g of silica gel eluting with CH_2Cl_2 gave (S)-methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (5.71 g, 12.23 mmol, 64.3 % yield). ^1H NMR (400 MHz, CDCl_3) δ 8.20 (t, $J=1.6$ Hz, 1H), 7.95 (dt, $J=7.8$,
 25 1.1 Hz, 1H), 7.63 - 7.53 (m, 1H), 7.37 (t, $J=7.9$ Hz, 1H), 6.94 (s, 1H), 5.69 (s, 1H), 3.76 (s, 3H), 2.70 (s, 3H), 1.30 (s, 9H). LCMS ($\text{M}+\text{H}$) = 466 and 468.

30


Intermediate 62



tert-Butyl 4-hydroxy-4-methylpiperidine-1-carboxylate: Under an N₂ atmosphere, a 3N MeMgBr/ether (1.67 mL, 5.02 mmol) was added dropwise to a cooled (-25°C) solution of *tert*-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate (4g, 20.08 mmol) in ether (20 mL). The reaction mixture was allowed to warm to rt and was stirred for 2 h. It was then cooled to 0 °C and quenched by the addition of sat. NH₄Cl. Another 20 mL of ether was added and the mixture was partitioned in a separatory funnel. The organic phase was set aside and the aqueous phase was extracted with another 20 mL of ether. The combined ether extracts were dried over MgSO₄, filtered and evaporated to obtain an oil, which was then purified by biotage, eluting with 0-50% EtOAc/hexane to obtain *tert*-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate (4.30 g, 18.0 mmol, 90 % yield) as a colorless oil.

¹H NMR (500 MHz, CDCl₃) δ 3.84 - 3.65 (m, 2H), 3.34 - 3.18 (m, 2H), 2.59 - 2.39 (m, 1H), 1.61 - 1.53 (m, 4H), 1.50 - 1.45 (m, 9H), 1.32 - 1.27 (m, 3H).


Intermediate 63



tert-Butyl 4-(allyloxy)-4-methylpiperidine-1-carboxylate: To a mixture of *tert*-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate (4.30 g, 20.0 mmol) in DMF (50 mL) at 0 °C was added NaH (60 wt%) (1.60 g, 39.9 mmol). The mixture was then stirred at rt for 2 h. At this time allyl bromide (8.64 mL, 100 mmol) was added slowly over the course of 5 min. The reaction mixture was stirred at rt for 3h. It was then cooled to 0 °C and quenched with sat. NH₄Cl. The reaction mixture was extracted with ether. The organic phase was dried over MgSO₄, filtered and

concentrated to obtain a colorless oil, which was then purified by biotage, eluting with 0-25% EtOAc/hexane to isolate 3.1 g (61%) of *tert*-butyl 4-(allyloxy)-4-methylpiperidine-1-carboxylate as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 6.02 - 5.90 (m, 1H), 5.32 (dd, *J*=17.2, 1.7 Hz, 1H), 5.16 (dd, *J*=10.4, 1.4 Hz, 1H), 3.94 - 3.88 (m, 2H), 3.73 (br. s., 2H), 3.19 (br. s., 2H), 1.78 (d, *J*=13.1 Hz, 2H), 1.53 - 1.42 (m, 11H), 1.21 (s, 3H).

Intermediate 64




10

4-(Allyloxy)-4-methylpiperidine hydrochloride: A mixture of *tert*-butyl 4-(allyloxy)-4-methylpiperidine-1-carboxylate (3.10 g, 12.1 mmol) and 4N HCl/dioxane (15 mL, 60.0 mmol) was stirred at rt for 3 h. It was then concentrated in vacuum to obtain 2.2 g (95%) of 4-(allyloxy)-4-methylpiperidine hydrochloride as a light brown solid. ¹H NMR (500 MHz, METHANOL-d₄) δ 6.02 - 5.92 (m, 1H), 5.33 (dd, *J*=17.2, 1.7 Hz, 1H), 5.15 (dd, *J*=10.6, 1.7 Hz, 1H), 3.96 (dt, *J*=5.1, 1.6 Hz, 2H), 3.23 - 3.18 (m, 4H), 2.06 (dd, *J*=15.3, 2.5 Hz, 2H), 1.77 - 1.69 (m, 2H), 1.31 - 1.28 (s, 3H).

20

Intermediate 65




(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. (S)-methyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (10.9 g, 23.3 mmol) was dissolved in DMF (100 mL). After flushing

with N₂, 4-(allyloxy)-4-methylpiperidine•HCl (7.34 g, 35.0 mmol) and Hunig's Base (12.22 mL, 70.0 mmol) were added to the reaction mixture. After stirring for 18 h at rt, the reaction was heated at 50 °C for 3 h to complete the reaction. The reaction mixture was concentrated in vacuo at 50 °C to remove most of the DMF. The residue was partitioned between EtOAc and 0.01N HCl. The organic phase was washed with water and brine. Then, the organic phase was dried (MgSO₄), filtered, and concentrated in vacuo. The residue was dissolved in about 600 mL of hot hexanes and cooled for 18 h in the freezer to give a crystalline solid. Filtration gave 6.5 g of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. The filtrate was purified by Biotage (10-50% EtOAc) to give another 5.71 g of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. The combined yield of the desired product was 12.21 g (89%). ¹H NMR (400 MHz, METHANOL-d₄) δ 8.23 (t, *J*=1.8 Hz, 1H), 8.01 (dt, *J*=7.8, 1.3 Hz, 1H), 7.60 - 7.55 (m, 1H), 7.43 - 7.37 (m, 1H), 6.90 (s, 1H), 6.18 - 5.95 (m, 2H), 5.48 (d, *J*=17.3 Hz, 1H), 5.25 (d, *J*=10.0 Hz, 1H), 4.11 - 4.06 (m, 2H), 3.77 (s, 3H), 2.59 (s, 3H), 2.14 - 1.95 (m, 3H), 1.82 - 1.71 (m, 1H), 1.37 (s, 3H), 1.28 (s, 9H). LCMS (M+H) = 585 and 587.

20

Intermediate 66




2-(2-(But-3-en-1-yl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione.

The boronic acid was synthesized according to the general procedure described by Kuznetsov, N.Yu.; *Russ.Chem.Bull., Int.Ed.*, **2005**, 54(3), 678-683. 1-Bromo-2-(but-3-en-1-yl)benzene (953 mg, 4.51 mmol) was dissolved in dry THF (5 mL), placed under an N₂ atmosphere and cooled to -90 °C. A 1.7M pentane solution of t-BuLi (5.31 mL, 9.02 mmol) was added over the course of 5 min. This light yellow solution was stirred for 15 min at which time trimethyl borate (716 μL, 6.41 mmol)

was added all at once. This mixture was stirred and allowed to warm to 0 °C. Once at this temperature for 30 min, TMS-Cl (710 µL, 5.55 mmol) was added and the reaction was allowed to warm to rt. The reaction mixture was concentrated in vacuo to give ~800 mg of crude product which was estimated to contain 396 mg of the desired boronate product 2-(but-3-en-1-yl)phenyl)boronic acid. Conversion of the crude boronate to the MIDA boronate was performed as described by Gillis, E.P.; and Burke, M.D. *J. Am. Chem. Soc.* **2008**, *130*, 14084-14085. 2-(But-3-en-1-yl)phenyl)boronic acid (396 mg, 2.25 mmol) was dissolved in 4 mL of toluene. This was added to a round bottom flask containing a solution of 2,2'-(methylazanediyl)diacetic acid in 2 mL of DMSO. The flask was fitted with a Dean-Stark trap filled with toluene. The reaction mixture was heated at reflux with azeotropic removal of water for 3 h. The cooled reaction mixture was concentrated in vacuo to remove toluene. The residue was subjected to a stream of N₂ for 18 h to blow off residual DMSO. The resulting brown oil was purified by Biotage chromatography (Et₂O/MeCN 0-60% gradient) to give 2-(2-(but-3-en-1-yl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (446 mg, 1.55 mmol, 69.0 % yield) as a yellow oil. ¹H NMR (400MHz, CDCl₃) δ 7.46 - 7.40 (m, 1H), 7.40 - 7.33 (m, 1H), 7.28 - 7.21 (m, 2H), 5.93 (ddt, *J*=17.1, 10.3, 6.7 Hz, 1H), 5.11 (dq, *J*=17.1, 1.7 Hz, 1H), 5.04 - 4.98 (m, 1H), 4.04 - 3.96 (m, 2H), 3.85 - 3.78 (m, 2H), 2.77 - 2.69 (m, 2H), 2.62 (s, 3H), 2.46 - 2.37 (m, 2H). LCMS (M-H) = 286.


Intermediate 67



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. To a solution of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-

bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (250 mg, 0.427 mmol) in DMF(5 mL) was added 2-(2-(but-3-en-1-yl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (147 mg, 0.512 mmol), 2M sodium carbonate (0.427 mL, 0.854 mmol), and tetrakis(triphenylphosphine)palladium(0)(35 mg, 0.030 mmol). This reaction mixture was flushed with N₂ and heated at 90 °C for 24 h. Upon completion of the reaction, the reaction mixture was partitioned between EtOAc and water. The organic phase was washed with water(3x), dried(MgSO₄), filtered, and concentrated in vacuo to give the crude product as a brown oil. This was purified by Biotage chromatography(0-40% EtOAc/hexanes) to give 233 mg (86% yield) of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate as a colorless oil. LCMS (M+H).= 637.

Intermediate 68




15

Methyl (2S)-2-(tert-butoxy)-2-[(23Z)-4,27-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (116 mg, 0.182 mmol) was dissolved in DCE (150 mL). The solution was heated to 75 °C in an oil bath under an N₂ atmosphere. Once the reaction flask had reached 75 °C the Hoveyda-Grubbs Catalyst 2nd generation (11.45 mg, 0.018 mmol) was added. The yellow reaction mixture turned green. Stirring at 85 °C was continued for 2 h at which time the reaction appeared complete by TLC(4:1 hexane/EtOAc) and HPLC(~4:1 mixture of E/Z isomers). The cooled reaction mixture was concentrated in vacuo and purified by Biotage chromatography (0-50% EtOAc/hexanes) to give 84 mg of the desired product as a colorless oil. LCMS (M+H).= 609.


25

Example 18



(2S)-2-(tert-Butoxy)-2-[4,27-dimethyl-26-oxa-1,5,7,8-
 5 tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: The
 intermediate **68** (82 mg, 0.135 mmol) was dissolved in MeOH (6 mL) and treated
 with 0.4 mL of 1N NaOH. After stirring at rt for 18 h, the reaction mixture was
 heated at 60 °C for 3 h. To drive the hydrolysis to completion another 0.4 mL of 1N
 10 NaOH was added and the reaction mixture was heated at 75 °C for 3 h. The mixture
 was concentrated in vacuo to remove methanol and the residue was partitioned
 between 0.1N HCl and EtOAc. The organic phase was dried (Na₂SO₄), filtered, and
 concentrated in vacuo to give 65 mg (77% yield, 95% purity) of the desired product
 as an off-white solid. Two olefin isomers are present in a 78:22 E/Z ratio or roughly
 15 4:1 E/Z, respectively. LCMS (M+H). = 595.


Example 19



(2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8-
 20 tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: The example **18** (15
 mg, 0.025 mmol) was dissolved in MeOH (2 mL), and the solution was flushed
 briefly with N₂. 10% Pd/C (2.68 mg, 0.025 mmol) was added, and the reaction
 25 mixture was stirred under a hydrogen balloon for 1.5 h. It was then filtered through

celite and purified by prep-HPLC to isolate 12 mg of 90% pure product as a white solid. It was purified further by biotage chromatography(4g) eluting with 0-10% MeOH/DCM to isolate 7 mg (44% yield, 95% purity) of the desired product as a white solid. ¹H NMR (500 MHz, METHANOL-d₄) δ: 8.11 (s, 1H), 7.86 (d, J=6.8 Hz, 1H), 7.56 (t, J=7.6 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.27 (d, J=7.6 Hz, 1H), 7.23 (t, J=7.4 Hz, 1H), 7.19 - 7.14 (m, 1H), 6.94 (s, 1H), 5.95 - 5.87 (m, 1H), 4.63 - 4.53 (m, 1H), 3.96 - 3.86 (m, 1H), 3.54 - 3.47 (m, 1H), 3.40 (br. s., 2H), 3.03 (d, J=10.4 Hz, 1H), 2.79 - 2.71 (m, 1H), 2.68 (s, 3H), 2.65 - 2.57 (m, 1H), 2.13 (d, J=12.8 Hz, 1H), 1.94 (br. s., 1H), 1.88 (m, 2H), 1.79 (br. s., 1H), 1.66 (m, 3H), 1.60 - 1.51 (m, 2H), 1.28 (m, 12H). LCMS (M+H) = 597.

Intermediate 69



15


(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. To a 25 ml microwave tube was added intermediate **65**, 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.128 g, 5.12 mmol) and 2.0 M aqueous potassium carbonate (3.42 mL, 6.83 mmol) in 1,4-Dioxane (12.00 ml) and Water (3ml). The reaction was sparged with nitrogen for 10 minutes, treated with (Ph₃P)₄Pd (0.395 g, 0.342 mmol), then sparged with N₂ for 1 min. The reaction tube was sealed and then heated at 90°C in a microwave tube for 1h. The reaction was concentrated, then diluted with water (15 mL) and extracted with EtOAc. The EtOAc layer was washed with brine, then dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by biotage (0% - 40% EtOAc in hexanes) to isolate 1.98 g (97%) of the desired product as an off-white foam. ¹H NMR at 60°C (500MHz, CD₃OD) δ 8.23 (t, J=1.5 Hz, 1H), 7.97 (dt, J=7.7, 1.4 Hz, 1H), 7.59 (dt,

25

J=7.9, 1.3 Hz, 1H), 7.51 - 7.47 (m, 1H), 7.36 - 7.31 (m, 1H), 7.23 - 7.17 (m, 1H), 6.99 - 6.92 (m, 2H), 6.85 (s, 1H), 6.06 - 5.91 (m, 2H), 5.34 (dq, J=17.2, 1.8 Hz, 1H), 5.04 (dd, J=10.4, 1.5 Hz, 1H), 4.08 - 4.01 (m, 2H), 3.77 (s, 3H), 4.50-3.00 (m, 4H), 2.59 (s, 3H), 2.14 - 1.91 (m, 3H), 1.82 - 1.72 (m, 1H), 1.35 (s, 3H), 1.28 (s, 9H).

5 LCMS(M+1)= 599.43.

Intermediate 70




10 (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(allyloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a mixture of intermediate **69** (80 mg, 0.134 mmol), prop-2-en-1-ol (23.28 mg, 0.401 mmol), triphenylphosphine (105 mg, 0.401 mmol) in THF (2 mL) was added DIAD (0.078 mL, 0.401 mmol) and stirred at rt for 16h. It was then concentrated and

15 purified by biotage, eluting with 20% EtOAc/hexane to isolate 80 mg oil. It was then purified by prep HPLC to isolate 50 mg (58.6%) of the desired product as an off-white solid. ¹H NMR (500MHz, CD₃OD) δ 8.23 (t, J=1.5 Hz, 1H), 7.98 (dt, J=7.7, 1.4 Hz, 1H), 7.58 - 7.52 (m, 1H), 7.51 - 7.46 (m, 1H), 7.39 (dd, J=7.6, 1.8 Hz, 1H), 7.36 - 7.30 (m, 1H), 7.13 - 7.04 (m, 2H), 6.85 (s, 1H), 6.05 - 5.92 (m, 3H), 5.33

20 (dquin, J=17.2, 2.0 Hz, 2H), 5.14 (dq, J=10.7, 1.6 Hz, 1H), 5.01 (d, J=10.5 Hz, 1H), 4.57 (dt, J=4.9, 1.7 Hz, 3H), 4.30-3.30 (m, 3H), 4.05 - 4.00 (m, 2H), 3.77 (s, 3H), 2.59 (s, 3H), 2.08 - 1.92 (m, 3H), 1.80 - 1.72 (m, 1H), 1.34 (s, 3H), 1.28 (s, 9H). LCMS(M+1)= 639.7.

25

Intermediate 71




5 *Methyl (2S)-2-(tert-butoxy)-2-[(23E)-4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1⁶,9.1¹⁰,14.0²,7.0¹⁵,20]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate*: A mixture of intermediate **70** (50 mg, 0.078 mmol), Hoveyda-Grubbs catalyst 2nd generation (9.81 mg, 0.016 mmol) in DCE (60 mL) was refluxed for 2 h. It was then concentrated and purified by biotage, eluting with 20% EtOAc/hexane to isolate 48 mg (100%) of the

10 desired product as an off-white solid. ¹H NMR (400MHz, CDCl₃) δ 8.54 (t, J=1.5 Hz, 1H), 7.72 (dt, J=7.7, 1.4 Hz, 1H), 7.54 (t, J=7.7 Hz, 1H), 7.45 (dt, J=7.6, 1.5 Hz, 1H), 7.38 (dd, J=7.4, 1.6 Hz, 2H), 7.08 - 7.00 (m, 2H), 6.82 (s, 1H), 6.37 - 6.28 (m, 1H), 6.14 - 6.03 (m, 2H), 4.72 (d, J=4.3 Hz, 2H), 4.64 (t, J=11.4 Hz, 1H), 4.06 - 3.96 (m, 3H), 3.74 (s, 3H), 3.14 (d, J=13.3 Hz, 1H), 2.72 (d, J=11.5 Hz, 1H), 2.64 (s, 3H),

15 2.02 (d, J=14.3 Hz, 1H), 1.96 - 1.89 (m, 1H), 1.84 (dd, J=12.3, 4.5 Hz, 1H), 1.67 - 1.61 (m, 1H), 1.32 (s, 3H), 1.29 - 1.25 (m, 9H). LCMS(M+1)= 611.6.

Example 20



20


20 *(2S)-2-(tert-Butoxy)-2-[(23E)-4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1⁶,9.1¹⁰,14.0²,7.0¹⁵,20]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid*: A mixture of intermediate **71** (48 mg, 0.079 mmol), 1 N NaOH (0.393 mL, 0.393 mmol) in MeOH

25 (2 mL) was heated at reflux for 3 h. It was then purified by prep HPLC

(NH₄OAc/CH₃CN) (35%-65% B) to isolate 30 mg (71%, 95% pure) of the desired product as a white solid. ¹H NMR (500MHz, CDCl₃) δ 8.54 (s, 1H), 7.72 (d, J=7.7 Hz, 1H), 7.54 (t, J=7.6 Hz, 1H), 7.46 (d, J=7.7 Hz, 1H), 7.38 (dd, J=7.5, 1.7 Hz, 1H), 7.36 - 7.31 (m, 1H), 7.08 - 7.00 (m, 2H), 6.84 (s, 1H), 6.31 (dt, J=15.6, 5.5 Hz, 1H), 6.13 - 6.06 (m, 1H), 6.02 (br. s., 1H), 4.76 - 4.65 (m, 3H), 4.09 - 3.96 (m, 3H), 3.37 (d, J=10.9 Hz, 1H), 2.75 (d, J=11.7 Hz, 1H), 2.64 (s, 3H), 2.07 - 2.01 (m, 1H), 1.95 (d, J=13.7 Hz, 1H), 1.77 (td, J=13.2, 4.6 Hz, 1H), 1.61 (td, J=13.3, 4.4 Hz, 1H), 1.35 - 1.29 (m, 12H). LCMS (M+1)=597.39.


10

Example 21




(2*S*)-2-(*tert*-Butoxy)-2-{4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: A mixture of example **20** (30 mg, 0.050 mmol), 10% Pd/C (5.35 mg, 5.03 μmol) in MeOH was stirred under a H₂ balloon for 3 h. It was then filtered and concentrated to obtain 28 mg (93%) of the desired product as a white solid. ¹H NMR (500MHz, CDCl₃) δ 8.51 (br. s., 1H), 7.70 (d, J=7.1 Hz, 1H), 7.54 (t, J=7.6 Hz, 1H), 7.47 (d, J=7.3 Hz, 1H), 7.40 (d, J=6.6 Hz, 1H), 7.34 (t, J=7.2 Hz, 1H), 7.04 (d, J=7.1 Hz, 2H), 6.81 (s, 1H), 6.01 (br. s., 1H), 4.59 (t, J=11.9 Hz, 1H), 4.13 (br. s., 2H), 3.91 (t, J=11.5 Hz, 1H), 3.53 (d, J=3.5 Hz, 1H), 3.42 (d, J=4.9 Hz, 2H), 2.84 (d, J=9.9 Hz, 1H), 2.63 (br. s., 3H), 2.36 (br. s., 1H), 2.16 (br. s., 1H), 2.10 - 2.02 (m, 1H), 1.93 (d, J=12.5 Hz, 1H), 1.80 (d, J=9.0 Hz, 2H), 1.70 - 1.54 (m, 2H), 1.36 - 1.20 (m, 12H). LCMS(M+1)=599.38.

Intermediate 72



5 (2*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-2-
yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-
butoxy)acetate. Intermediate **72** was prepared using intermediate **69** and but-3-en-2-
ol by following the procedure to prepare intermediate **70**. ¹H NMR 60°C (500MHz,
CD₃OD) δ 8.25 - 8.21 (m, 1H), 7.98 (d, J=7.6 Hz, 1H), 7.57 - 7.53 (m, 1H), 7.51 -
10 7.46 (m, 1H), 7.38 (dd, J=7.5, 1.7 Hz, 1H), 7.32 - 7.27 (m, 1H), 7.09 (d, J=8.1 Hz,
1H), 7.05 (td, J=7.5, 1.1 Hz, 1H), 6.85 (s, 1H), 6.02 - 5.92 (m, 2H), 5.91 - 5.82 (m,
1H), 5.33 (dd, J=17.2, 1.6 Hz, 1H), 5.17 (ddt, J=17.3, 2.7, 1.4 Hz, 1H), 5.07 (dq,
J=10.6, 1.5 Hz, 1H), 5.01 (d, J=10.1 Hz, 1H), 4.78 (quin, J=6.3 Hz, 1H), 4.40-3.00
15 (m, 4H), 4.05 - 4.01 (m, 2H), 3.77 (s, 3H), 2.59 (s, 3H), 2.10 - 1.92 (m, 3H), 1.81 -
1.72 (m, 1H), 1.35 (s, 3H), 1.31 (dd, J=6.3, 2.1 Hz, 3H), 1.28 (s, 9H).
LCMS(M+1)= 653.58.

Intermediate 73



20

Methyl (2*S*)-2-(tert-butoxy)-2-[4,22,27-trimethyl-21,26-dioxa-1,5,7,8-
tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: A mixture of
intermediate **72** (50 mg, 0.077 mmol), Hoveyda-Grubbs catalyst

2nd generation (9.60 mg, 0.015 mmol) in DCE (60 mL) was refluxed for 2 h. It was then concentrated and purified by prep HPLC to isolate 47 mg (98%) of the desired product as an off-white solid. NMR: 1:1 mixture of two isomers. LCMS (M+1)=625.54.


5

Example 22 and 23

A mixture of intermediate **73** (47 mg, 0.075 mmol), NaOH (0.393 mL, 0.393 mmol) in MeOH (2 mL) was heated at reflux for 3 h. It was then purified by prep-HPLC (NH₄OAc/CH₃CN) to afford two compounds.

10


Example 22



(2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: The first eluting compound, white solid (18 mg, 37%). ¹H NMR (500MHz, CDCl₃) δ 8.69 (s, 1H), 7.73 (d, J=7.7 Hz, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.46 (d, J=7.7 Hz, 1H), 7.38 (dd, J=7.4, 1.6 Hz, 1H), 7.30-7.26 (m, 1H), 7.02 (t, J=7.5 Hz, 1H), 6.94 (d, J=8.4 Hz, 1H), 6.85 (s, 1H), 6.13 - 6.05 (m, 1H), 6.03 - 5.94 (m, 2H), 5.02 - 4.95 (m, 1H), 4.65 (t, J=11.8 Hz, 1H), 4.14 - 3.99 (m, 3H), 3.22 (d, J=10.4 Hz, 1H), 2.70 (d, J=10.9 Hz, 1H), 2.66 (s, 3H), 2.02 (br. s., 1H), 1.89 (d, J=12.3 Hz, 1H), 1.75 (td, J=13.1, 4.7 Hz, 1H), 1.63 (td, J=13.2, 3.8 Hz, 1H), 1.36 - 1.26 (m, 15H). LCMS (M+H) = 611.4.

25


Example 23



5 *(2S)-2-(tert-Butoxy)-2-[(22S)-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2⁰]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid*: The second compound, white solid (15 mg, 31%). ¹H NMR (500MHz, CDCl₃) δ 8.68 (s, 1H), 7.78 (d, J=7.7 Hz, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.42 (d, J=7.6 Hz, 1H), 7.35 (dd, J=7.4, 1.6 Hz, 1H), 7.32 - 7.29 (m, 1H), 7.05 - 6.99 (m, 2H), 6.92 (s, 1H), 6.28 (dd, J=15.6, 7.1 Hz, 1H), 6.06 (br. s., 1H), 5.97 (dt, J=15.6, 3.7 Hz, 1H), 5.09 (quin, J=6.4 Hz, 1H), 4.83 (t, J=12.1 Hz, 1H), 4.07 - 3.92 (m, 3H), 3.38 (d, J=10.7 Hz, 1H), 2.75 (d, J=11.7 Hz, 1H), 2.63 (s, 3H), 1.98 (t, J=14.2 Hz, 2H), 1.75 - 1.59 (m, 2H), 1.38 - 1.26 (m, 15H). LCMS (M+H) = 611.4.

15

Example 24




20 *(2S)-2-(tert-Butoxy)-2-[(22S)-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2⁰]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid*: Example **24** was prepared using example **23** by following the procedure to prepare example **21**. ¹H NMR (500MHz, CDCl₃) δ 8.33 (br. s., 1H), 7.66 (d, J=7.4 Hz, 1H), 7.52 (d, J=6.9 Hz, 1H), 7.43 (d, J=6.8 Hz, 1H), 7.35 - 7.31 (m, 2H), 7.00 (br. s., 2H), 6.81 - 6.68 (m, 1H), 5.95 (br. s., 1H), 4.49 (d, J=19.4 Hz, 2H), 3.93 (br. s., 1H), 3.49 (br. s., 1H),

3.36 (br. s., 2H), 2.68 (br. s., 1H), 2.60 (br. s., 3H), 2.36 (br. s., 2H), 2.03 (d, J=13.1 Hz, 2H), 1.92 - 1.71 (m, 2H), 1.69 - 1.52 (m, 2H), 1.39 - 1.09 (m, 15H). LCMS (M+H) = 613.4.

5


Example 25



(2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **25** was prepared using example **22** by following the procedure to prepare example **21**. ¹H NMR (500MHz, CDCl₃) δ 8.58 (br. s., 1H), 7.71 (d, J=5.4 Hz, 1H), 7.46 (br. s., 1H), 7.41 - 7.30 (m, 3H), 7.11 - 6.95 (m, 2H), 6.83 (br. s., 1H), 5.85 (br. s., 1H), 4.66 (br. s., 1H), 4.52 (br. s., 1H), 3.72 (br. s., 1H), 3.61 (br. s., 1H), 3.39 (d, J=15.4 Hz, 2H), 2.81 (d, J=7.9 Hz, 1H), 2.55 (br. s., 3H), 2.28-1.65 (m, 8H), 1.27 - 1.03 (m, 15H). LCMS (M+H) = 613.44.

20

Intermediate 74




(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-1-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. Intermediate **74** was prepared using intermediate **69** and 3-buten-1-ol by following the procedure to prepare intermediate **70**. ¹H NMR (500 MHz, CDCl₃)

δ 8.16 (t, $J=1.5$ Hz, 1H), 8.04 (d, $J=7.7$ Hz, 1H), 7.60 (d, $J=7.7$ Hz, 1H), 7.52 - 7.47 (m, 1H), 7.44 (dd, $J=7.6, 1.7$ Hz, 1H), 7.35 (td, $J=7.8, 1.7$ Hz, 1H), 7.11 - 7.06 (m, 1H), 7.03 (d, $J=8.4$ Hz, 1H), 6.84 (s, 1H), 6.08 - 5.93 (m, 2H), 5.85 (ddt, $J=17.1, 10.3, 6.8$ Hz, 1H), 5.42 (dd, $J=17.2, 1.7$ Hz, 1H), 5.18 - 5.02 (m, 3H), 4.50-2.50 (m, 4H), 4.06 (t, $J=6.6$ Hz, 2H), 4.02 (d, $J=4.7$ Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.54 - 2.47 (m, 2H), 2.08 - 1.92 (m, 2H), 1.74 (br. s., 1H), 1.38 (br. s., 3H), 1.27 (s, 9H).
 LCMS (M+1) = 653.7.

Intermediate 75


10



Intermediate **75** was prepared using intermediate **74** by following the procedure to prepare intermediate **71**. The product was a mixture of two isomers (trans/cis), the ratio is 1: 4. LCMS (M+1) = 625.35.

15

Example 26




20 *(2S)-2-(tert-Butoxy)-2-[4,28-dimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid*: Example **26** was prepared using intermediate **75** by following the procedure to prepare example **20**. ¹H NMR (500 MHz, CDCl₃) δ 8.55 (s, 1H), 7.78 (d, $J=7.7$ Hz, 1H), 7.53 (t, $J=7.7$ Hz, 1H), 7.40 (d, $J=7.9$ Hz, 1H), 7.38 - 7.32 (m, 2H), 7.07 - 7.01 (m, 2H), 6.89

25

(s, 1H), 6.22 (d, $J=6.1$ Hz, 1H), 5.98 (br. s., 1H), 4.72 (t, $J=11.7$ Hz, 1H), 4.58 (dt, $J=8.5, 6.0$ Hz, 1H), 4.20 (dt, $J=9.4, 6.4$ Hz, 1H), 4.06 - 3.98 (m, 1H), 3.81 (t, $J=12.0$ Hz, 1H), 3.51 (d, $J=8.7$ Hz, 1H), 2.96 (d, $J=12.8$ Hz, 1H), 2.76 (dq, $J=14.7, 7.4$ Hz, 1H), 2.63 - 2.58 (m, 4H), 2.20 - 1.65 (m, 6H), 1.39 (s, 3H), 1.33 - 1.29 (m, 9H).

5 LCMS (M+H) = 611.6.

Example 27




10

(2S)-2-(tert-Butoxy)-2-{4,28-dimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example **27** was prepared using example **26** by following the procedure to prepare example **21**. ¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H), 7.81 (d, $J=7.8$ Hz, 1H), 7.60 - 7.46 (m, 1H), 7.41 - 7.32 (m, 3H), 7.13 - 7.00 (m, 2H), 6.92 (s, 1H), 5.98 (s, 1H), 4.74 - 4.63 (m, 1H), 4.34 - 4.25 (m, 1H), 3.98 - 3.90 (m, 1H), 3.82 - 3.73 (m, 1H), 3.57 - 3.49 (m, 2H), 3.43 - 3.34 (m, 1H), 2.97 (d, $J=12.5$ Hz, 1H), 2.60 (s, 3H), 2.2-1.95 (m, 4 H), 1.72 - 1.49 (m, 6H), 1.30 (s, 9H), 1.27 (s, 3H). LCMS (M+H) = 613.4.

20


Intermediate 76



(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-((*R*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: To a mixture of intermediate **69** (50 mg, 0.084 mmol), (*S*)-pent-4-en-2-ol (21.58 mg, 0.251 mmol), triphenylphosphine (65.7 mg, 0.251 mmol) in THF (2 mL) was added DIAD (0.049 mL, 0.251 mmol) stirred at rt for 48 h. It was then concentrated and purified by prep HPLC to isolate 40 mg (72%) of intermediate **76** as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.16 (t, *J*=1.6 Hz, 1H), 8.05 (d, *J*=7.3 Hz, 1H), 7.59 (d, *J*=7.7 Hz, 1H), 7.54 - 7.46 (m, 1H), 7.44 (dd, *J*=7.6, 1.7 Hz, 1H), 7.36 - 7.31 (m, 1H), 7.12 - 7.00 (m, 2H), 6.85 (s, 1H), 6.11 - 5.89 (m, 2H), 5.78 (ddt, *J*=17.1, 10.1, 7.1 Hz, 1H), 5.42 (dd, *J*=17.1, 1.5 Hz, 1H), 5.13 (d, *J*=9.6 Hz, 1H), 5.08 - 4.97 (m, 2H), 4.50-2.50 (m, 4H), 4.42 (sxt, *J*=6.0 Hz, 1H), 4.03 (d, *J*=4.7 Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.45 (qd, *J*=6.9, 5.5 Hz, 1H), 2.30 (dt, *J*=14.0, 6.9 Hz, 1H), 2.10 - 1.93 (m, 2H), 1.74 (br. s., 1H), 1.60 (m, 1H), 1.38 (br. s., 3H), 1.27 (s, 9H), 1.26 (s, 3H). LCMS (*M*+1) = 667.44.

15


Intermediate 77



Methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*R*)-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0².7.0¹⁵.2⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: A mixture of intermediate **76** (38 mg, 0.057 mmol), Hoveyda-Grubbs catalyst 2nd generation (7.14 mg, 0.011 mmol) in DCE (40 mL) was refluxed for 2 h. It was then concentrated and purified by biotage, eluting with 20% EtOAc/hexane to isolate 35 mg (100%) of the desired product as light green solid. It's a mixture of *cis*/*trans* isomers. LCMS (*M*+1) = 639.42.


25

Intermediate 78




5 *Methyl (2S)-2-(tert-butoxy)-2-[(22R)-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-*
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate. A mixture of
intermediate **77** (34 mg, 0.053 mmol), 10% Pd/C (5.66 mg, 5.32 μ mol) in MeOH (2
mL) was stirred under a H₂ balloon for 2 h. It was then concentrated to obtain 30 mg
10 (88%) of the desired product as a light green solid. LCMS (M+1) = 641.6.

Example 28



15 *(2S)-2-(tert-Butoxy)-2-[(22R)-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-*
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: A mixture of
intermediate **78** (35 mg, 0.055 mmol), 1N NaOH (273 μ l, 0.273 mmol) in MeOH (2
mL) was refluxed for 3 h. It was then filtered and purified by prep HPLC to isolate
20 20 mg (56%) of the desired product as a white solid. ¹H NMR (500 MHz, CDCl₃) δ
8.28 (t, J=1.5 Hz, 1H), 7.74 (dt, J=7.8, 1.4 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.39 (dt,
J=7.8, 1.4 Hz, 1H), 7.35 - 7.28 (m, 2H), 7.07 - 7.02 (m, 2H), 6.85 (s, 1H), 5.97 (br. s.,
1H), 4.51 (t, J=11.3 Hz, 1H), 4.37 - 4.29 (m, 1H), 3.98 (t, J=11.1 Hz, 1H), 3.47 - 3.35
(m, 2H), 3.20 (d, J=11.3 Hz, 1H), 2.84 (d, J=11.8 Hz, 1H), 2.65 (s, 3H), 2.15 - 1.51
25 (m, 10H), 1.32 (s, 9H), 1.25 (s, 3H), 1.15 (d, J=6.1 Hz, 3H). LCMS (M+H) = 627.6.

Intermediate 79




5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a mixture of intermediate **69** (50 mg, 0.084 mmol), (*R*)-pent-4-en-2-ol (21.58 mg, 0.251 mmol), triphenylphosphine (65.7 mg, 0.251 mmol) in THF (2 mL) was added DIAD (0.049 mL, 0.251 mmol) stirred at rt for 48 h. It was then concentrated and purified by prep HPLC 55 mg (99%) of the desired product as a

10 white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.16 (t, J=1.6 Hz, 1H), 8.04 (d, J=7.3 Hz, 1H), 7.59 (d, J=7.7 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.44 (dd, J=7.6, 1.7 Hz, 1H), 7.37 - 7.31 (m, 1H), 7.13 - 7.00 (m, 2H), 6.87 - 6.82 (m, 1H), 6.10 - 5.89 (m, 2H), 5.78 (ddt, J=17.2, 10.2, 7.1 Hz, 1H), 5.42 (dd, J=17.2, 1.6 Hz, 1H), 5.22 - 5.09 (m, 1H), 5.09 - 4.95 (m, 2H), 4.50-2.50 (m, 4 H), 4.42 (sxt, J=6.0 Hz, 1H), 4.03 (d, J=4.9 Hz, 2H),

15 3.76 (s, 3H), 2.64 (s, 3H), 2.45 (qd, J=7.0, 5.6 Hz, 1H), 2.30 (dt, J=14.0, 6.9 Hz, 1H), 2.09 - 1.94 (m, 2H), 1.74 (br. s., 1H), 1.60 (m, 1 H), 1.38 (br. s., 3H), 1.30 - 1.25 (m, 12H). LCMS (M+1) = 667.44.

Intermediate 80




20

25 *Methyl (2S)*-2-(tert-butoxy)-2-[(22*S*)-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate. A mixture of intermediate **79** (60 mg, 0.090 mmol), Hoveyda-Grubbs catalyst

2nd generation (11.28 mg, 0.018 mmol) in DCE (60 mL) was refluxed for 2 h. It was then concentrated and purified by biotage, eluting with 20% EtOAc/hexane to isolate 40 mg (70%) of the desired product as a light green solid. It's a mixture of cis/trans isomers, the ratio is 1: 4. LCMS (M+1) = 639. 37.

5


Intermediate 81



Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
 10 *2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate*: Intermediate **81** was prepared using intermediate **80** by following the procedure to prepare intermediate **78**. ¹H NMR (500 MHz, CDCl₃) δ 8.68 - 8.55 (m, 1H), 7.86 - 7.77 (m, 1H), 7.54 - 7.48 (m, 1H), 7.39 - 7.33 (m, 3H), 7.05 - 7.00 (m, 2H), 6.91 (s, 1H), 5.91 (s, 1H), 4.68 -
 15 4.57 (m, 2H), 3.84 - 3.75 (m, 4H), 3.56-3.49 (m, 1 H), 3.43 - 3.35 (m, 1H), 3.25 (d, *J*=9.8 Hz, 1H), 2.90 (d, *J*=10.6 Hz, 1H), 2.61 (s, 3H), 2.09 - 1.95 (m, 3H), 1.92 - 1.81 (m, 1H), 1.81 - 1.70 (m, 3H), 1.70-1.50 (m, 3H), 1.28 - 1.23 (m, 12H), 1.19 (d, *J*=6.1 Hz, 3H). LCMS (M+1) = 641.7.

20

Example 29




(2S)-2-(tert-Butoxy)-2-[(22S)-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
 25 *2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid*: Example **29** was

prepared using intermediate **81** by following the procedure to prepare example **28**.

¹H NMR (500 MHz, CDCl₃) δ 8.64 (s, 1H), 7.81 (dt, J=7.8, 1.4 Hz, 1H), 7.55 - 7.48 (m, 1H), 7.40 - 7.32 (m, 3H), 7.05 - 6.99 (m, 2H), 6.93 (s, 1H), 5.97 (br. s., 1H), 4.73 - 4.64 (m, 1H), 4.64 - 4.57 (m, 1H), 3.82 (t, J=11.7 Hz, 1H), 3.56-3.48 (m., 2H), 3.39 (td, J=7.8, 3.2 Hz, 1H), 2.95 (d, J=12.8 Hz, 1H), 2.60 (s, 3H), 2.15-1.50 (m, 10H), 1.30(s, 9H), 1.26(s, 3H), 1.19 (d, J=6.0 Hz, 3H). LCMS (M+1) = 627.6.

Intermediate 82




10

(2-(Pent-4-en-1-yl)phenyl)boronic acid: This compound was prepared according to the procedure described by Watson, I.D.G.; Ritter, S.; Toste, F.D. *J.Am.Chem.Soc.* **2009**, *131*, 2056-2057. 1-Bromo-2-(pent-4-en-1-yl)benzene (480 mg, 2.132 mmol) was dissolved in a mixture of toluene (8 mL) and THF (2 mL). Then triisopropyl borate (0.490 mL, 2.132 mmol) was added. While under N₂ atmosphere, the reaction mixture was cooled to -78°C. Using a manual syringe, n-butyllithium (0.853 mL, 2.132 mmol)(2.5 M in hexanes) was added dropwise over the course of 30 min. The resulting nearly colorless solution was stirred at -78°C for 60 min and then at -20°C for 15 min. The reaction was quenched with 10 mL of 2 N HCl and allowed to stir to warm to rt. The aqueous layer was extracted with ether. The organic phase was dried(Na₂SO₄), filtered, and concentrated in vacuo. Biotage purification eluting with 5-50% EtOAc/hexanes gave the desired product (65 mg, 0.342 mmol, 16.04 % yield) as an off-white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.27 - 8.18 (m, 1H), 7.51 (td, J=7.5, 1.4 Hz, 1H), 7.36 - 7.31 (m, 2H), 5.90 - 5.80 (m, 1H), 5.04 - 4.91 (m, 2H), 3.26 - 3.18 (m, 2H), 2.18 (q, J=6.9 Hz, 2H), 1.83 (dt, J=15.3, 7.7 Hz, 2H).

30


Intermediate 83



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-(pent-4-en-1-yl)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **65** (159 mg, 0.272 mmol) was dissolved in DMF (5 mL). While flushing solution with N₂, add intermediate **82** (62 mg, 0.326 mmol), sodium carbonate (0.272 mL, 0.544 mmol), and (Ph₃P)₄Pd (21.99 mg, 0.019 mmol). This reaction mixture was flushed with N₂ and heated at 90 °C for 18 h. Upon completion
 10 of the reaction, the reaction mixture was partitioned between EtOAc and water. The organic phase was washed with water(3x), dried (MgSO₄), filtered, and concentrated in vacuo to give the crude product as a brown oil. This was purified by Biotage chromatography(0-50% EtOAc/hexanes) to gave 121 mg (68%) of the desired product as a colorless oil. LCMS(M+1)=651.45.


15

Intermediate 84



20 *Methyl (2S)-2-(tert-butoxy)-2-[(24E)-4,28-dimethyl-27-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate*: Intermediate **84** was prepared using intermediate **83** by following the procedure to prepare intermediate **68**. It's a mixture of cis/trans products. LCMS (M+1) = 623.36.


Intermediate 85



(2*S*)-2-(*tert*-Butoxy)-2-{4,28-dimethyl-27-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl}acetic acid: Intermediate **85** was prepared using intermediate **84** by following the procedure to prepare example **18**. LCMS(*M*+1) = 609.35.


10

Example 30



(2*S*)-2-(*tert*-Butoxy)-2-{4,28-dimethyl-27-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example **30** was prepared using intermediate **85** by following the procedure to prepare example **19**. ¹H NMR (500 MHz, CDCl₃) δ 8.16 - 8.06 (m, 1H), 7.76 (d, *J*=7.7 Hz, 1H), 7.53 - 7.48 (m, 1H), 7.35 - 7.30 (m, 3H), 7.28 - 7.25 (m, 1H), 7.24 - 7.20 (m, 1H), 6.87 (s, 1H), 6.04 - 5.91 (m, 1H), 4.55 (t, *J*=11.7 Hz, 1H), 3.79 (t, *J*=11.7 Hz, 1H), 3.44 - 3.34 (m, 2H), 3.28 - 3.20 (m, 1H), 2.89 (d, *J*=12.1 Hz, 1H), 2.82 (dt, *J*=13.9, 6.8 Hz, 1H), 2.62 (s, 3H), 2.60 - 2.54 (m, 1H), 1.98 (t, *J*=11.7 Hz, 2H), 1.72 - 1.47 (m, 7H), 1.33 - 1.27 (m, 11H), 1.24 (s, 3H). LCMS (*M*+H) = 611.46.


Intermediate 86



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-hydroxy-
 [1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate:
 Intermediate **86** was prepared using intermediate **65** and 5-chloro-2-
 hydroxyphenylboronic acid following the procedure to prepare intermediate **69**. ¹H
 NMR (500 MHz, CDCl₃) δ 8.10 (s, 1H), 8.05 (d, *J*=7.6 Hz, 1H), 7.57 (t, *J*=7.6 Hz,
 1H), 7.46 (d, *J*=7.6 Hz, 1H), 7.33 (d, *J*=2.7 Hz, 1H), 7.25 (dd, *J*=8.7, 2.5 Hz, 1H),
 10 6.98 (d, *J*=8.7 Hz, 1H), 6.86 - 6.82 (m, 1H), 6.11 - 5.80 (m, 3H), 5.41 (dq, *J*=17.2,
 1.7 Hz, 1H), 5.18 - 5.03 (m, 1H), 5.00-2.50 (m, 4H), 4.02 (d, *J*=4.9 Hz, 2H), 3.76 (s,
 3H), 2.61 (s, 3H), 2.06 - 1.92 (m, 3H), 1.73 (br. s., 1H), 1.43 - 1.33 (m, 3H), 1.27 (s,
 9H). LCMS (M+1) = 633.34.

15

Intermediate 87




20 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(allyloxy)-5'-
 chloro-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-
 butoxy)acetate: Intermediate **86** (205 mg, 0.296 mmol) was dissolved in DMF (3
 mL). Solid potassium carbonate (82 mg, 0.593 mmol) was added and the mixture was
 heated to 90 °C for 1 h. The reaction was then cooled to rt and treated with 3-
 bromoprop-1-ene (0.051 mL, 0.593 mmol) and allowed to stir at rt for 18 h. The

reaction was partitioned between EtOAc and water. The organic phase was washed with water, dried (Na₂SO₄), filtered, and concentrated in vacuo to give 192 mg (83 % yield) of the desired product as a yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 8.17 (s, 1H), 8.05 (d, *J*=6.3 Hz, 1H), 7.66 - 7.47 (m, 2H), 7.47 - 7.35 (m, 1H), 7.32 - 7.27 (m, 1H), 6.98 - 6.91 (m, 1H), 6.85 (s, 1H), 6.10 - 5.91 (m, 3H), 5.46 - 5.33 (m, 2H), 5.21 (dq, *J*=10.6, 1.4 Hz, 1H), 5.16 - 5.06 (m, 1H), 5.00-2.50 (m, 4H), 4.56 (dt, *J*=4.8, 1.6 Hz, 2H), 4.03 (d, *J*=4.7 Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.06 - 1.95 (m, 2H), 1.75 - 1.70 (m, 2H), 1.39 (br. s., 3H), 1.29 - 1.24 (m, 9H). LCMS(M+1)=674.24.

10


Intermediate 88



Methyl (2S)-2-(tert-butoxy)-2-[17-chloro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Intermediate 88
 was prepared using intermediate **87** by following the procedure to prepare intermediate **71**. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (t, *J*=1.6 Hz, 1H), 7.75 (dt, *J*=7.8, 1.4 Hz, 1H), 7.58 - 7.52 (m, 1H), 7.44 - 7.40 (m, 1H), 7.35 (d, *J*=2.7 Hz, 1H), 7.27 (dd, *J*=8.7, 2.7 Hz, 1H), 6.93 (d, *J*=8.8 Hz, 1H), 6.83 (s, 1H), 6.34 - 6.26 (m, 1H), 6.10 - 6.03 (m, 2H), 4.71 - 4.67 (m, 2H), 4.64 (td, *J*=12.5, 2.4 Hz, 1H), 4.08 - 3.96 (m, 3H), 3.74 (s, 3H), 3.14 (dt, *J*=11.4, 2.1 Hz, 1H), 2.76 - 2.70 (m, 1H), 2.65 (s, 3H), 2.02 (dd, *J*=13.9, 2.2 Hz, 1H), 1.95 - 1.89 (m, 1H), 1.82 (td, *J*=13.0, 4.7 Hz, 1H), 1.63 (td, *J*=13.4, 4.4 Hz, 1H), 1.32 (s, 3H), 1.28 (s, 9H). LCMS (M+1) = 645.20.

25


Example 31



5 *(2S)-2-(tert-Butoxy)-2-[17-chloro-4,27-dimethyl-21,26-dioxo-1,5,7,8-*
tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Example 31
 was prepared using intermediate **88** by following the procedure to prepare example
20. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (t, J=1.6 Hz, 1H), 7.74 (dt, J=7.8, 1.4 Hz,
 1H), 7.55 (t, J=7.7 Hz, 1H), 7.43 (dt, J=7.9, 1.3 Hz, 1H), 7.35 (d, J=2.7 Hz, 1H), 7.28
 10 - 7.25 (m, 1H), 6.94 (d, J=9.0 Hz, 1H), 6.85 (s, 1H), 6.34 - 6.25 (m, 1H), 6.12 - 5.99
 (m, 2H), 4.69 (d, J=5.0 Hz, 3H), 4.08 - 3.97 (m, 3H), 3.37 (d, J=11.3 Hz, 1H), 2.75
 (d, J=12.5 Hz, 1H), 2.64 (s, 3H), 2.04 (d, J=10.4 Hz, 1H), 1.96 (dd, J=13.6, 2.3 Hz,
 1H), 1.76 (td, J=13.2, 4.9 Hz, 1H), 1.65 (m, 1H), 1.35 - 1.30 (m, 12H). LCMS
 (M+H) = 631.6.

15


Example 32



20 *(2S)-2-(tert-Butoxy)-2-{17-chloro-4,27-dimethyl-21,26-dioxo-1,5,7,8-*
tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example 32 was
 prepared using example **31** by following the procedure to prepare example **21**. ¹H
 NMR (500 MHz, CDCl₃) δ 8.46 (s, 1H), 7.72 (d, J=7.7 Hz, 1H), 7.55 (t, J=7.6 Hz,


1H), 7.45 (d, $J=7.9$ Hz, 1H), 7.38 (d, $J=2.5$ Hz, 1H), 7.28 - 7.23 (m, 1H), 6.96 (d, $J=8.8$ Hz, 1H), 6.82 (s, 1H), 6.01 (br. s., 1H), 4.58 (br. s., 1H), 4.18 - 4.03 (m, 2H), 3.91 (br. s., 1H), 3.53 (d, $J=3.5$ Hz, 1H), 3.42 (br. s., 2H), 2.86 (br. s., 1H), 2.63 (s, 3H), 2.35 (d, $J=3.5$ Hz, 2H), 2.23 - 1.55 (m, 6H), 1.38 - 1.20 (m, 12H). LCMS
5 (M+H) = 633.6.

Intermediate 89



10 (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-hydroxy-5'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of ((S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.375 g, 0.640 mmol), 2-hydroxy-5-methylphenylboronic acid (0.195 g, 1.281
15 mmol) and 2.0 M aq. Na_2CO_3 (0.961 mL, 1.921 mmol) in DMF (5 mL) was sparged with nitrogen for 10 min, treated with $\text{Pd}(\text{Ph}_3\text{P})_4$ (0.052 g, 0.045 mmol), then sparged for 5 min. The reaction was stirred with heating (85°C) for 7 h, then cooled, diluted with water (50 mL) and extracted into Et_2O (2 x 50 mL). The combined extracts were dried (MgSO_4), filtered, and concentrated, and the residue was purified by
20 biotage (40 g SiO_2 , 0% (3 CV), 0-60% (15 CV), 60% (2 CV), EtOAc in hexanes) to afford the desired product (0.303 g, 0.494 mmol, 77 % yield), as a pale yellow glassy solid. ^1H NMR (500 MHz, CDCl_3) δ : 8.08 (s, 1H), 8.04 (d, $J=7.9$ Hz, 1H), 7.57 (t, $J=7.6$ Hz, 1H), 7.50 - 7.43 (m, 1H), 7.14 (d, $J=1.9$ Hz, 1H), 7.10 (dd, $J=8.4, 2.0$ Hz, 1H), 6.92 (d, $J=8.2$ Hz, 1H), 6.83 (s, 1H), 6.05 - 5.94 (m, 1H), 5.39 (dd, $J=17.2, 1.6$
25 Hz, 1H), 5.21 - 5.13 (m, 1H), 5.13 - 5.03 (m, 1H), 4.00 (d, $J=4.7$ Hz, 2H), 3.74 (s, 3H), 2.61 (s, 3H), 2.35 (s, 3H), 2.06 (s, 4H), 2.04 - 1.93 (m, 2H), 1.72 (br. s., 1H), 1.36 (br. s., 2H), 1.28 (s, 1H), 1.27 (s, 2H), 1.25 (s, 9H). LCMS (M+H) = 613.5.


Intermediate 90



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(allyloxy)-5'-
 methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-
 butoxy)acetate: Intermediate **90** was prepared using intermediate **89** by following the
 procedure to prepare intermediate **87**. ¹H NMR (500 MHz, CDCl₃) δ 8.34 - 8.12 (m,
 1H), 8.03 (d, J=5.2 Hz, 1H), 7.59 (d, J=7.4 Hz, 1H), 7.55 - 7.46 (m, 1H), 7.25 (d,
 J=1.7 Hz, 1H), 7.14 (dd, J=8.3, 2.0 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 6.84 (s, 1H),
 10 6.14 - 5.85 (m, 3H), 5.50 - 5.33 (m, 2H), 5.24 - 5.07 (m, 2H), 4.58 - 4.51 (m, 2H),
 4.50-2.50 (m, 4 H), 4.02 (d, J=4.7 Hz, 2H), 3.76 (s, 3H), 2.62 (s, 3H), 2.38 (s, 3H),
 2.06 - 1.92 (m, 2H), 1.75 (br. s., 1H), 1.59 (m, 1H), 1.39 (br. s., 3H), 1.31 - 1.20 (s,
 9H). LCMS (M+1) = 653.7.

15

Intermediate 91



20 *Methyl (2S)*-2-(tert-butoxy)-2-[4,17,27-trimethyl-21,26-dioxa-1,5,7,8-
 tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Intermediate **91**
 was prepared using intermediate **90** by following the procedure to prepare
 intermediate **71**. ¹H NMR (400 MHz, CDCl₃) δ 8.52 (t, J=1.5 Hz, 1H), 7.78 - 7.67
 (m, 1H), 7.59 - 7.50 (m, 1H), 7.49 - 7.40 (m, 1H), 7.18 (d, J=2.0 Hz, 1H), 7.12 (d,
 J=8.3 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 6.82 (s, 1H), 6.39 - 6.24 (m, 1H), 6.18 - 6.00
 25 (m, 2H), 4.77 - 4.58 (m, 3H), 4.10 - 3.95 (m, 3H), 3.74 (s, 3H), 3.14 (d, J=11.5 Hz,


1H), 2.71 (d, J=11.8 Hz, 1H), 2.64 (s, 3H), 2.36 (s, 3H), 2.02 (d, J=11.5 Hz, 1H), 1.97 - 1.89 (m, 1H), 1.89 - 1.76 (m, 1H), 1.65 (s, 1H), 1.32 (s, 3H), 1.27 (s, 9H). LCMS (M+1) = 625.22.

5

Example 33 and 34

Saponification of intermediate **91** by following the procedure to prepare example **20** provided examples **33** and **34**.


Example 33



10


(2S)-2-(tert-Butoxy)-2-[4,17,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: ¹H NMR (500
 15 MHz, CDCl₃) δ 8.52 (s, 1H), 7.71 (d, J=7.7 Hz, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.48 - 7.43 (m, 1H), 7.18 (d, J=1.9 Hz, 1H), 7.12 (dd, J=8.3, 1.8 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 6.84 (s, 1H), 6.31 (dt, J=15.5, 5.4 Hz, 1H), 6.12 - 6.00 (m, 2H), 4.77 - 4.64 (m, 3H), 4.08 - 3.96 (m, 3H), 3.36 (d, J=10.2 Hz, 1H), 2.74 (d, J=12.1 Hz, 1H), 2.64 (s, 3H), 2.36 (s, 3H), 1.95 (d, J=14.8 Hz, 1H), 1.91 - 1.72 (m, 2H), 1.66 - 1.55 (m, 1H),
 20 1.34 - 1.26 (m, 12H). LCMS (M+H) = 611.23.

Example 34



(2*S*)-2-(*tert*-Butoxy)-2-[4,17,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: ¹H NMR (500 MHz, C₆D₆) δ 9.26 (s, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.42 (d, J=7.6 Hz, 1H), 7.28 (t, J=7.6 Hz, 1H), 7.21 (d, J=1.7 Hz, 1H), 7.05 (s, 1H), 6.93 (dd, J=8.3, 1.7 Hz, 1H), 6.73 (d, J=8.4 Hz, 1H), 6.05 (d, J=5.7 Hz, 1H), 6.00 (br. s., 1H), 5.04 (t, J=11.6 Hz, 1H), 4.47 (q, J=7.0 Hz, 1H), 4.05 (ddd, J=12.4, 7.8, 5.1 Hz, 1H), 4.00 - 3.92 (m, 1H), 3.77 (t, J=11.0 Hz, 1H), 3.59 - 3.41 (m, 2H), 2.80 (br. s., 3H), 2.63 (d, J=10.7 Hz, 1H), 2.51 (dq, J=11.9, 6.1 Hz, 1H), 2.18 (s, 3H), 1.78 - 1.47 (m, 4H), 1.05 (s, 3H), 0.98 (br. s., 9H). LCMS (M+H)= 611.23.


Example 35



(2*S*)-2-(*tert*-Butoxy)-2-{4,17,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example **35** was prepared using example **33** by following the procedure to prepare example **21**. ¹H NMR (500 MHz, CDCl₃) δ 8.49 (s, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.56 - 7.45 (m, 2H), 7.21 (s, 1H), 7.13 (d, J=6.5 Hz, 1H), 6.94 (d, J=8.4 Hz, 1H), 6.82 (s, 1H), 6.02 (br. s., 1H), 4.60 (t, J=11.8 Hz, 1H), 4.10 (t, J=8.2 Hz, 2H), 3.92 (t, J=11.5 Hz, 1H), 3.57 - 3.53 (m, 1H), 3.43 (d, J=4.1 Hz, 2H), 2.83 (d, J=11.2 Hz, 1H), 2.63 (s, 3H), 2.36 (s, 3H), 2.18 - 1.96 (m, 8H), 1.36 - 1.22 (m, 12H). LCMS (M+H) = 613.35.


25

Intermediate 92



3-Bromo-4-(but-3-en-1-yl)pyridine: This compound was prepared according to Zhang, Z; Dwoskin, L and Crooks, P. *Tetrahedron Lett.* **2011**, 52, 2667-2669.

Intermediate 93 (60)




5

(4-(But-3-en-1-yl)pyridin-3-yl)boronic acid: A stirred solution of intermediate **92** (200 mg, 0.943 mmol) and triisopropyl borate (0.282 mL, 1.226 mmol) in toluene (4 mL) and THF (1 mL) cooled to -78 °C. To this mixture was added 2.5M BuLi (0.490 mL, 1.226 mmol) over the course of 15 min. During this time period, the reaction color changed from yellow to orange. The reaction was stirred at -78°C for 2 h then warmed to 0°C for 15min, the solution became pale yellow again. To this was added 2N HCl (5 mL) and stirred at rt for 10 min. The solution became a slurry (pH was found to be ~3). It was then diluted with ether and the organic layer was discarded. The aqueous layer was adjusted pH=7 by using 1N NaOH, a white ppt was formed. It was then extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 150 mg oil, which triturated with 2 mL of CH₃CN and a white solid was formed was dried to obtain the desired product (150 mg, 0.847 mmol, 90 % yield) as a white solid. LCMS (M+1) = 178.1.

20

Intermediate 94




(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-(4-(but-3-en-1-yl)pyridin-3-yl)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a microwave tube was added intermediate **65** (200 mg, 0.342 mmol), intermediate **93** (121 mg, 0.683 mmol), and 2M aqueous sodium carbonate (0.342 mL, 0.683 mmol) in DMF (2 mL), was sparged with nitrogen for 1 minutes,

25

treated (Ph₃P)₄Pd (39.5 mg, 0.034 mmol), and then sparged with N₂ for 1 min. The reaction tube was sealed and heated at 95 °C in a microwave tube for 1 h. The reaction was then concentrated, diluted with water (15 mL) and extracted with EtOAc. The EtOAc layer was washed with brine, then dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was then purified by biotage, eluting with 30% acetone/hexane to isolate 220 mg (100%) of the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, J=5.1 Hz, 1H), 8.53 (d, J=0.5 Hz, 1H), 8.09 (d, J=7.8 Hz, 1H), 7.94 (t, J=1.6 Hz, 1H), 7.59 - 7.53 (m, 1H), 7.36 - 7.31 (m, 1H), 7.27 (d, J=5.1 Hz, 1H), 6.84 (s, 1H), 6.03 - 5.91 (m, 2H), 5.72 (ddt, J=16.9, 10.2, 6.6 Hz, 1H), 5.42 - 5.35 (m, 1H), 5.12 - 5.00 (m, 1H), 4.98 - 4.91 (m, 2H), 4.50-2.50 (m, 4 H), 4.00 (d, J=4.9 Hz, 2H), 3.76 (s, 3H), 2.80 - 2.74 (m, 2H), 2.63 (s, 3H), 2.31 (td, J=7.8, 6.6 Hz, 2H), 2.06 - 1.86 (m, 3H), 1.71 (d, J=13.2 Hz, 1H), 1.35 (s, 3H), 1.27 (s, 9H). LCMS (M+1) = 638.4.

15

Intermediate 95




Methyl (2S)-2-(tert-butoxy)-2-[(23E)-4,27-dimethyl-26-oxa-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: A mixture of intermediate **94** (190 mg, 0.298 mmol), (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (18.67 mg, 0.030 mmol), tosic acid (56.7 mg, 0.298 mmol) in DCE (150mL) was heated at reflux for 2 h. It was then concentrated, the residue was added 10 mL sat. NaHCO₃, extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 200 mg yellow oil, which was then purified by biotage, eluted with 30% acetone/hexane to isolate 150 mg (83%) of the desired product as a white solid and mixture of cis/trans isomers. LCMS (M+1) = 610.3.

Example 36 and 37

A mixture of intermediate **95** (100 mg, 0.164 mmol), sodium hydroxide (0.820 mL, 0.820 mmol) in MeOH (2 mL) was refluxed for 3 h. It was then concentrated and adjusted pH= 6 using 1N HCl. It was then extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 100 mg white solid. 20 mg of this mixture was purified by prep HPLC to afford example **36** and **37**.

10


Example 36



(2*S*)-2-(*tert*-Butoxy)-2-[(23*E*)-4,27-dimethyl-26-oxa-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Major isomer (19 mg) and as white solid. ¹H NMR (500 MHz, DMSO-d₆) δ 8.52 (br. s., 1H), 8.33 (d, J=2.4 Hz, 1H), 7.98 - 7.90 (m, 2H), 7.66 - 7.56 (m, 1H), 7.47 (br. s., 1H), 7.33 (d, J=7.6 Hz, 1H), 6.99 (d, J=2.1 Hz, 1H), 5.74 (br. s., 1H), 5.68 (br. s., 1H), 5.57 (d, J=14.0 Hz, 1H), 4.53 (t, J=11.9 Hz, 1H), 3.78 (br. s., 2H), 3.70 (t, J=10.8 Hz, 1H), 3.32 (br. s., 1H), 2.83 (d, J=11.9 Hz, 1H), 2.68 (br. s., 1H), 2.60 (d, J=9.8 Hz, 2H), 2.54(s, 3H), 2.44-2.38 (m, 1 H), 1.95 (br. s., 1H), 1.75 (d, J=12.5 Hz, 1H), 1.67 (d, J=11.9 Hz, 1H), 1.56 - 1.43 (m, 1H), 1.16 (d, J=2.4 Hz, 12H). LCMS (M+H) = 596.39.


25

Example 37



(2S)-2-(tert-Butoxy)-2-[(23Z)-4,27-dimethyl-26-oxa-1,5,7,8,17-
 5 pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Minor isomer
 (1 mg). ¹H NMR (400 MHz, MeOH-d₄) δ 8.54 - 8.31 (m, 2H), 8.23 (s, 1H), 7.92 (d,
 J=7.8 Hz, 1H), 7.62 (t, J=7.7 Hz, 1H), 7.47 (d, J=4.8 Hz, 1H), 7.34 (d, J=7.5 Hz, 1H),
 6.91 - 6.86 (m, 1H), 5.91 - 5.79 (m, 2H), 5.78 - 5.68 (m, 1H), 4.64 - 4.51 (m, 1H),
 10 4.15 - 4.04 (m, 1H), 3.90 - 3.78 (m, 2H), 3.53 - 3.42 (m, 1H), 2.97 - 2.85 (m, 2H),
 2.80-2.68 (m, 3H), 2.66 (s, 3H), 2.15 (d, J=12.5 Hz, 1H), 1.89 - 1.74 (m, 2H), 1.66
 (td, J=13.1, 4.4 Hz, 1H), 1.31 - 1.18 (m, 12H). LCMS (M+H) = 596.35.

Example 38




15

(2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8,17-
 pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: A mixture of
 20 examples 36 and 37 (60 mg, 0.101 mmol), tosic acid (19.16 mg, 0.101 mmol), Pd/C
 (10.72 mg, 10.07 μmol) in MeOH (2 mL) was stirred under a H₂ balloon for 2 h. It
 was then filtered and purified by prep HPLC (CH₃CN/TFA system). The fractions
 were collected, adjusted pH = 6 using 1 N NaOH and concentrated. The residue was
 extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and
 25 concentrated to obtain 26.5 mg (42%) of the desired product as a white solid. ¹H


NMR (400 MHz, CDCl₃) δ 8.55 (d, J =5.4 Hz, 1H), 8.45 (s, 1H), 8.12 (s, 1H), 7.83 (d, J =7.8 Hz, 1H), 7.56 (t, J =7.7 Hz, 1H), 7.37 (d, J =5.4 Hz, 1H), 7.26 (s, 1H), 6.89 (s, 1H), 6.00 (s, 1H), 4.55 (t, J =11.4 Hz, 1H), 3.91 - 3.83 (m, 1H), 3.47 - 3.41 (m, 1H), 3.34 (d, J =9.0 Hz, 2H), 2.89 - 2.76 (m, 2H), 2.73 - 2.65 (m, 1H), 2.64 (s, 3H), 1.88 (m, 3H), 1.79 - 1.48 (m, 7H), 1.30 (s, 9H), 1.25 (s, 3H). LCMS (M+H) = 598.5.

Intermediate 96



tert-Butyl 4-formyl-4-methylpiperidine-1-carboxylate: To a solution of *tert*-butyl 4-formylpiperidine-1-carboxylate (4.5 g, 21.10 mmol) in CH₂Cl₂ (50 mL) at 0°C was added *t*-BuOK (3.08 g, 27.4 mmol) followed by MeI (3.96 mL, 63.3 mmol) at 0 °C. The resulting mixture was stirred 30 min, and then warmed to room temp and stirred for 1.5 h. The reaction mixture was then poured into brine and the mixture was extracted with dichloromethane, dried (Na₂SO₄), filtered and concentrated. The residue was then purified by Biotage (0-20% EtOAc/hexane) to afford *tert*-butyl 4-formyl-4-methylpiperidine-1-carboxylate (1.8 g, 7.92 mmol, 37.5 % yield) as colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 9.48 (s, 1H), 3.71-3.66 (m, 2H), 3.19 - 3.05 (m, 2H), 1.93 (dt, J =13.7, 4.1 Hz, 2H), 1.47 (s, 9H), 1.46 - 1.37 (m, 2H), 1.10 (s, 3H). LCMS (M+H) = 228.1.

Intermediate 97




((E))-tert-butyl 4-(buta-1,3-dien-1-yl)-4-methylpiperidine-1-carboxylate: To a solution of diethyl allylphosphonate (2.82 g, 15.84 mmol) in THF (50 mL) at -78°C

was added added 1.6 M MeLi (9.90 mL, 15.84 mmol) and the resulting mixture was stirred for 30 min. Then, HMPT (9.68 mL, 52.8 mmol) followed by (E)-tert-butyl 4-(buta-1,3-dien-1-yl)-4-methylpiperidine-1-carboxylate (1.8 g, 7.16 mmol, 54.3 % yield) in THF (10 mL) was added and the mixture was stirred at -78 °C for 1 h and then allowed to warm to room temp. After 16 h, the mixture was quenched with sat.NH₄Cl solution and extracted with ether (2 x 100 mL). The combined organic extracts were dried (Na₂SO₄), filtered and concentrated. The residue was purified via Biotage (0-20% EtOAc/hexane; 80g column) to afford ((E)-tert-butyl 4-(buta-1,3-dien-1-yl)-4-methylpiperidine-1-carboxylate (1.8 g, 7.16 mmol, 54.3 % yield) as colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 6.42 - 6.27 (m, 1H), 6.05 (dd, *J*=15.8, 10.2 Hz, 1H), 5.68 (d, *J*=15.8 Hz, 1H), 5.21 - 5.09 (m, 1H), 5.08 - 4.91 (m, 1H), 3.61 - 3.44 (m, 2H), 3.37 - 3.15 (m, 2H), 1.61 (dd, *J*=9.5, 2.8 Hz, 2H), 1.47 (s, 9H), 1.45 - 1.37 (m, 2H), 1.07 (s, 3H).

15


Intermediate 98



(*E*)-4-(Buta-1,3-dien-1-yl)-4-methylpiperidine•HCl: A mixture of (E)-tert-butyl 4-(buta-1,3-dien-1-yl)-4-methylpiperidine-1-carboxylate (1.8 g, 7.16 mmol) and 4M HCl/dioxane (8.95 ml, 35.8 mmol) was stirred at room temp for 3 h. Mixture was then concentrated and the solids were triturated with ether/hexane, filtered and dried under high vac to afford (E)-4-(buta-1,3-dien-1-yl)-4-methylpiperidine•HCl (1.2 g, 6.39 mmol, 89 % yield) as off-white solid. ¹H NMR (500MHz, DMSO-d₆) δ 6.35 (dt, *J*=16.9, 10.2 Hz, 1H), 6.12 (dd, *J*=15.7, 10.3 Hz, 1H), 5.78 - 5.73 (m, 1H), 5.21 (d, *J*=17.0 Hz, 1H), 5.06 (d, *J*=10.1 Hz, 1H), 3.14 - 3.00 (m, 2H), 2.97 - 2.79 (m, 2H), 1.83 - 1.69 (m, 2H), 1.64 - 1.53 (m, 2H), 1.06 (s, 3H). LCMS (M+H) = 152.1.

30


Intermediate 99



5 *(S,E)*-Methyl 2-(2-(3-bromophenyl)-7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate:
 Intermediate **61** (207 mg, 0.444 mmol) was dissolved in DMF (3 mL) and treated
 with (E)-4-(buta-1,3-dien-1-yl)-4-methylpiperidine•HCl (100 mg, 0.533 mmol)
 followed by Hunig's Base (0.233 mL, 1.332 mmol). The light brown homogeneous
 reaction mixture was allowed to stir at rt for 18 h. Concentrated at 50 °C and
 10 partition between 50 mL of EtOAc and 5 mL 0.1 N HCl. The organic phase was
 washed with water (5mL) and dry over Na₂SO₄, filtered and concentrated in vacuo to
 give a yellow oil. It was then purified by biotage, eluting with 20% EtOAc/hexane to
 isolate 219 mg (81%) of the desired product as a white solid. ¹H NMR (500 MHz,
 CDCl₃) δ 8.14 (s, 1H), 8.03 - 7.87 (m, 1H), 7.53 (dd, J=8.0, 0.9 Hz, 1H), 7.34 (t,
 15 J=7.9 Hz, 1H), 6.81 (s, 1H), 6.49 (br. s., 1H), 6.27 - 6.14 (m, 1H), 6.07 (s, 1H), 6.01 -
 5.84 (m, 1H), 5.25 (d, J=17.0 Hz, 1H), 5.12 (d, J=9.9 Hz, 1H), 5.00-2.50 (m, 4H),
 3.75 (s, 3H), 2.64 (s, 3H), 1.93 (d, J=9.3 Hz, 1H), 1.87 - 1.73 (m, 2H), 1.67 (br. s.,
 1H), 1.34 - 1.21 (m, 12H). LCMS (M+1) = 581.11.

20

Intermediate 100



25 *Methyl (2S)*-2-(2-{3-[2-(but-3-en-1-yl)phenyl]phenyl}-7-{4-[(1E)-buta-1,3-dien-1-yl]-4-methylpiperidin-1-yl}-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A mixture of intermediate **26** (56.8 mg, 0.258 mmol), intermediate


99 (100 mg, 0.172 mmol), 2.0 M aqueous K_2CO_3 (0.172 mL, 0.344 mmol) in dioxane (1.6 mL), water (0.4 mL) was sparged with nitrogen for 5 minute, treated with $(Ph_3P)_4Pd$ (19.87 mg, 0.017 mmol), then sparged under N_2 for 1 min. The reaction tube was sealed and then heated at 90 °C in a microwave tube for 1 h. The reaction
 5 was concentrated, then diluted with water (5 mL) and extracted with EtOAc. The EtOAc layer was washed with brine, then dried (Na_2SO_4), filtered, and concentrated under reduced pressure. The residue was purified by biotage (0% - 20% EtOAc in hexanes) to isolate 75 mg (69%) of the desired product as an off-white foam. 1H NMR (500 MHz, $CDCl_3$) δ 8.06 - 8.02 (m, 1H), 7.94 (s, 1H), 7.55 - 7.48 (m, 1H),
 10 7.38 - 7.30 (m, 5H), 6.84 (s, 1H), 6.43 - 6.31 (m, 1H), 6.16 (dd, $J=15.8, 10.0$ Hz, 1H), 6.07 (s, 1H), 5.88 (d, $J=15.6$ Hz, 1H), 5.74 (ddt, $J=17.0, 10.3, 6.7$ Hz, 1H), 5.19 (d, $J=17.3$ Hz, 1H), 5.04 (d, $J=10.1$ Hz, 1H), 5.00-2.00 (m, 4 H), 4.97 - 4.86 (m, 2H), 3.75 (s, 3H), 2.79 - 2.73 (m, 2H), 2.63 (s, 3H), 2.33 - 2.26 (m, 2H), 1.95 - 1.85 (m, 1H), 1.85 - 1.62 (m, 3H), 1.29 - 1.25 (m, 12H). LCMS ($M+1$) = 633.4.

15

Intermediate 101 and 102

A mixture of intermediate **100** (75 mg, 0.119 mmol), Hoveyda-Grubbs catalyst 2nd generation (14.85 mg, 0.024 mmol) in DCE (75 mL) was heated at 70 °C
 20 for 2 h. It was then concentrated and purified by biotage, eluting with 20% EtOAc/hexane to afford two compounds.

Intermediate 101




25

Methyl (2S)-2-(tert-butoxy)-2-[(23Z,25E)-4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetate: Isolate 20 mg (25%, 90% pure) as a white solid. 1H NMR (500 MHz, $CDCl_3$) δ 7.90 (s, 1H), 7.71

(d, J=7.7 Hz, 1H), 7.52 (t, J=7.6 Hz, 1H), 7.46 - 7.41 (m, 1H), 7.41 - 7.36 (m, 1H), 7.28 - 7.22 (m, 2H), 7.20 - 7.14 (m, 1H), 6.75 (s, 1H), 6.49 (dd, J=15.8, 10.8 Hz, 1H), 6.02 (t, J=10.7 Hz, 1H), 5.97 (s, 1H), 5.51 (td, J=9.6, 4.7 Hz, 1H), 5.45 (d, J=15.8 Hz, 1H), 4.91 - 4.77 (m, 1H), 3.77 (s, 3H), 3.54 - 3.43 (m, 1H), 3.19 (d, J=12.3 Hz, 1H), 2.98 - 2.82 (m, 3H), 2.77 - 2.66 (m, 1H), 2.61 (s, 3H), 2.52 (br. s., 1H), 2.23 - 2.13 (m, 1H), 1.87 - 1.76 (m, 1H), 1.71 (td, J=13.3, 4.9 Hz, 1H), 1.63 (d, J=14.0 Hz, 1H), 1.29 - 1.23 (m, 12H). LCMS (M+1) = 605.29.

Intermediate 102




10

Methyl (2S)-2-(tert-butoxy)-2-[(23E,25E)-4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetate: Isolate 62 mg (78%, 90% pure) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 7.83 (s, 1H), 7.75 - 7.66 (m, 1H), 7.47 - 7.42 (m, 2H), 7.41 - 7.37 (m, 1H), 7.25 - 7.19 (m, 2H), 7.13 (d, J=7.4 Hz, 1H), 6.78 (s, 1H), 6.26 (s, 1H), 6.03 (dd, J=15.8, 9.9 Hz, 2H), 5.74 (br. s., 1H), 5.45 (d, J=16.4 Hz, 1H), 5.39 - 5.33 (m, 1H), 3.71 (s, 3H), 2.91 - 2.80 (m, 2H), 2.65 (s, 3H), 2.62 (d, J=8.0 Hz, 2H), 2.54 - 2.40 (m, 3H), 1.82 (d, J=12.8 Hz, 1H), 1.76 - 1.64 (m, 3H), 1.31 - 1.26 (m, 12H). LCMS (M+1) = 605.29.

20


Example 39



(2*S*)-2-(*tert*-Butoxy)-2-[(23*Z*,25*E*)-4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid: A mixture of intermediate **101** (20 mg, 0.033 mmol), NaOH (0.165 mL, 0.165 mmol) in MeOH (2 mL) was refluxed for 3 h. It was then filtered and purified by prep HPLC to isolate 10.8 mg (53%) of the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.52 (t, J=7.5 Hz, 1H), 7.46 - 7.40 (m, 1H), 7.37 (td, J=7.5, 1.4 Hz, 1H), 7.30 - 7.23 (m, 2H), 7.16 (dd, J=7.5, 1.3 Hz, 1H), 6.75 (s, 1H), 6.47 (dd, J=15.9, 10.7 Hz, 1H), 6.06 - 5.94 (m, 2H), 5.50 (td, J=9.7, 4.6 Hz, 1H), 5.43 (d, J=16.1 Hz, 1H), 4.88 (t, J=11.8 Hz, 1H), 3.46 (d, J=7.3 Hz, 2H), 2.96 - 2.81 (m, 3H), 2.75 - 2.63 (m, 1H), 2.58 (s, 3H), 2.52 (d, J=15.6 Hz, 1H), 2.20 (d, J=13.6 Hz, 1H), 1.83 - 1.57 (m, 3H), 1.29 (s, 9H), 1.12 (s, 3H). LCMS (M+H) = 591.4.


15

Example 40



(2*S*)-2-(*tert*-Butoxy)-2-[(23*E*,25*E*)-4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid: Example **40** was prepared using intermediate **102** by following the procedure to prepare example **39**. ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.52 - 7.35 (m, 3H), 7.26 - 7.16 (m, 2H), 7.12 (d, J=7.5 Hz, 1H), 6.89 - 6.69 (m, 1H), 6.01 (dd, J=16.1, 10.0 Hz, 2H), 5.74 (br. s., 1H), 5.49 - 5.23 (m, 2H), 4.85 (br. s., 1H), 4.06 - 3.00 (m, 2H), 3.07 (d, J=10.8 Hz, 1H), 2.87 - 2.56 (m, 5H), 2.57 - 2.34 (m, 2H), 1.93 - 1.77 (m, 1H), 1.75 - 1.60 (m, 3H), 1.34 - 1.20 (s, 9H), 1.05 (s, 3H). LCMS (M+H) = 591.4.

Example 41




5 *(2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid*: A mixture of example **40** (32 mg, 0.054 mmol), Pd/C (5.76 mg, 5.42 μ mol) in MeOH (5 mL), DCM (0.5 mL) was stirred under a H₂ balloon for 48 h. It was then purified by prep HPLC to isolate 2.2 mg (6.5%) of the desired product as a white solid. ¹H NMR (400

10 MHz, CDCl₃) δ 7.91 (s, 1H), 7.73 (d, J=7.8 Hz, 1H), 7.49 (t, J=7.7 Hz, 1H), 7.42 - 7.34 (m, 2H), 7.26 - 7.19 (m, 2H), 7.17 - 7.12 (m, 1H), 6.82 (s, 1H), 5.99 (br. s., 1H), 4.53 (t, J=11.3 Hz, 1H), 3.87 (t, J=11.2 Hz, 1H), 3.19 (d, J=9.8 Hz, 1H), 2.76 - 2.58 (m, 5H), 2.08 (br. s., 1H), 1.84 - 1.46 (m, 7H), 1.39 - 1.17 (m, 19H). LCMS (M+H) = 595.4.

15

Intermediate 103




20 *(S,E)-Methyl 2-(7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate*: To a microwave tube was added (S,E)-methyl 2-(2-(3-bromophenyl)-7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (100 mg, 0.172 mmol),

25 (5-chloro-2-hydroxyphenyl)boronic acid (44.5 mg, 0.258 mmol), and 2.0 M aqueous

K₂CO₃ (0.086 mL, 0.172 mmol) in dioxane (2 mL) and water (0.5 mL). The reaction was sparged with nitrogen for 1 minutes, treated Pd(PPh₃)₄ (19.87 mg, 0.017 mmol) then sparged for 1 min. The reaction tube was sealed and then heated at 90 °C in a microwave tube for 1 h. LCMS analysis showed 40% completion. Additional 10 mg
 5 of Pd(PPh₃)₄ added and heated at 90 °C for another 2 h. The reaction was concentrated, diluted with water (15 mL) and extracted with EtOAc. The EtOAc layer was washed with brine, then dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by biotage (0% - 40% EtOAc in hexanes) to isolate 80 mg (74%) of the product as off-white foam. ¹H NMR (500 MHz,
 10 CDCl₃) δ 8.09 (br. s., 1H), 8.06 (d, J=7.9 Hz, 1H), 7.60 (t, J=7.5 Hz, 1H), 7.50 - 7.45 (m, 1H), 7.34 (d, J=2.5 Hz, 1H), 6.99 (d, J=8.7 Hz, 1H), 6.85 (s, 1H), 6.39 (dt, J=16.9, 10.2 Hz, 1H), 6.17 (dd, J=15.4, 10.4 Hz, 1H), 6.07 (s, 1H), 5.88 (d, J=15.3 Hz, 1H), 5.33 (br. s., 1H), 5.19 (d, J=17.2 Hz, 1H), 5.04 (d, J=9.6 Hz, 1H), 4.50-2.50 (m, 4 H), 3.75 (s, 3H), 2.64 (s, 3H), 1.93 (d, J=12.9 Hz, 1H), 1.87 - 1.73 (m, 2H),
 15 1.67 (br. s., 1H), 1.29 - 1.24 (m, 12H). LCMS (M+1) = 629.08.

Intermediate 104




20 (S,E)-Methyl 2-(2-(2'-(allyloxy)-5'-chloro-[1,1'-biphenyl]-3-yl)-7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: (S,E)-Methyl 2-(7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (90 mg, 0.143 mmol) was dissolved in DMF (3 mL).
 25 Solid K₂CO₃ (39.5 mg, 0.286 mmol) was added and the mixture was heated to 90°C for 1 h. The reaction was then cooled to rt and treated with 3-bromoprop-1-ene (0.024 mL, 0.286 mmol) and allowed to stir at rt for 18 h. The reaction was partitioned between EtOAc and water. The organic phase was washed with water, dried(Na₂SO₄), filtered, and concentrated in vacuo to yield (S,E)-methyl 2-(2-(2'-

(allyloxy)-5'-chloro-[1,1'-biphenyl]-3-yl)-7-(4-(buta-1,3-dien-1-yl)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (90 mg, 0.134 mmol, 94 % yield) as a white solid. ¹H NMR (400MHz, CDCl₃) δ 8.18 (br. s., 1H), 8.07 - 8.00 (m, 1H), 7.60 - 7.48 (m, 2H), 7.42 (d, J=2.7 Hz, 1H), 7.31 (d, J=2.7 Hz, 1H), 6.95 (d, J=8.8 Hz, 1H), 6.85 (s, 1H), 6.39 (dt, J=17.0, 10.1 Hz, 1H), 6.16 (dd, J=15.5, 10.1 Hz, 1H), 6.08 (s, 1H), 5.98 (ddt, J=17.3, 10.6, 4.8 Hz, 1H), 5.88 (d, J=15.7 Hz, 1H), 5.40 - 5.33 (m, 1H), 5.25 - 5.15 (m, 2H), 5.03 (d, J=10.0 Hz, 1H), 5.00-2.50 (m, 4 H), 4.56 (dt, J=4.8, 1.6 Hz, 2H), 3.74 (s, 3H), 2.64 (s, 3H), 1.97 - 1.63 (m, 4H), 1.32 - 1.23 (m, 12H). LCMS (M+1) = 669.3.

10

Intermediate 105




Methyl (2S)-2-(tert-butoxy)-2-[(23Z,25E)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetate: Intermediate **105** was prepared using intermediate **104** by following the procedure to prepare intermediate **101**. It's a 5:3 mixture of trans/cis isomers. LCMS (M+1) = 641.3.

20

Examples 42 and 43

A mixture of intermediate **105** (80 mg, 0.078 mmol), NaOH (0.390 mL, 0.390 mmol) in MeOH (2mL) /THF (1 mL) was heated at reflux for 2 h. It was then concentrated, adjusted pH=5 using 1 N HCl. It was then extracted with EtOAc, dried over MgSO₄, filtered and concentrated to obtain 63 mg (76%) white solid. 20 mg of it was purified by prep HPLC to afford two compounds.


Example 42



5 *(2S)-2-(tert-Butoxy)-2-[(23Z,25E)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid*: Isolated 4.1 mg as a white solid. ¹H NMR (500 MHz, DMSO-d₆) δ 7.84 (d, J=7.6 Hz, 1H), 7.79 (br. s., 1H), 7.54 (t, J=7.3 Hz, 1H), 7.40 (d, J=8.9 Hz, 1H), 7.35 - 7.25 (m, 2H), 7.14 (br. s., 1H), 6.99 (s, 1H), 6.29 - 6.18 (m, 1H), 6.18 - 6.07 (m, 2H), 6.00 (br. s., 1H),
 10 5.65 (d, J=14.0 Hz, 1H), 4.84 (d, J=14.3 Hz, 1H), 4.70 (d, J=15.3 Hz, 1H), 4.53 (t, J=11.6 Hz, 1H), 3.96 - 3.84 (m, 1H), 2.96 (d, J=9.8 Hz, 1H), 2.61 (d, J=10.1 Hz, 1H), 2.55 (s, 3H), 1.77 - 1.54 (m, 4H), 1.21 (s, 9H), 1.09 (br. s., 3H). LCMS (M+H) = 627.8.

15

Example 43



20 *(2S)-2-(tert-Butoxy)-2-[(23E,25E)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid*: Isolated 1.1 mg. ¹H NMR (500 MHz, DMSO-d₆) δ 8.11 (s, 1H), 7.81 (d, J=7.6 Hz, 1H), 7.57 (t, J=7.5 Hz, 1H), 7.45 - 7.28 (m, 3H), 7.25 (d, J=2.4 Hz, 1H), 6.89 (s, 1H), 6.74 (dd, J=15.6, 11.3 Hz, 1H), 6.37 (t, J=10.7 Hz, 1H), 5.90 - 5.78 (m, 1H), 5.72 (d, J=15.6 Hz, 1H), 5.67 (br. s., 1H), 5.01 (t, J=11.3 Hz, 1H), 4.71 (t, J=12.5 Hz, 1H), 4.61 (dd,


J=11.4, 5.3 Hz, 1H), 2.83 (d, J=13.1 Hz, 1H), 2.50 (m, 5 H), 2.30 (d, J=11.9 Hz, 1H), 1.83 - 1.55 (m, 3H), 1.18 (s, 9H), 1.10 (s, 3H). LCMS (M+H) = 627.4.

Example 44 and 45

- 5 A mixture of examples **42** and **43** (40 mg, 0.040 mmol), Pd/C(4.24 mg, 3.99 μ mol) in MeOH (5 mL) was hydrogenated using Parr shaker at 60 psi for 6 h. It was then filtered and purified by prep HPLC (CH₃CN/NH₄OAc) to afford two compounds.


10

Example 44



- 15 *(2S)-2-(tert-Butoxy)-2-{17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid*: Isolated 12 mg (43%, 90% pure) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H), 7.74 (d, J=7.6 Hz, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.43 - 7.37 (m, 1H), 7.33 - 7.28 (m, 2H), 6.99 (d, J=9.0 Hz, 1H), 6.82 (s, 1H), 6.01 (br. s., 1H), 4.58 (t, J=12.0 Hz, 1H), 4.13 - 4.05 (m, 2H), 3.86 (t, J=11.4 Hz, 1H), 3.41 (d, J=12.7 Hz, 1H), 2.84 (d, J=12.5 Hz, 1H), 2.63 (s, 3H), 2.11 - 1.41 (m, 12H), 1.35 - 1.29 (m, 12H). LCMS (M+H) = 631.3.
- 20


Example 45



(2*S*)-2-(*tert*-Butoxy)-2-[(25*E*)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,25-undecaen-3-yl]acetic acid: Isolated 2 mg (7%, 90% pure) as a white solid. ¹H NMR (400 MHz, C₆D₆) δ 8.65 (s, 1H), 7.50 (dt, J=6.8, 1.8 Hz, 1H), 7.39 - 7.33 (m, 2H), 7.20-7.10 (m, 2H), 6.95 (s, 1H), 6.93 (s, 1H), 6.60 (d, J=8.8 Hz, 1H), 6.02 (br. s., 1H), 5.49 - 5.39 (m, 1H), 5.39 - 5.28 (m, 1H), 4.66 - 4.51 (m, 1H), 3.85 - 3.68 (m, 3H), 3.49 (d, J=11.0 Hz, 1H), 2.68 (s, 3H), 2.07 - 1.84 (m, 2H), 1.77 - 1.26 (m, 7H), 1.03 (s, 3H), 0.88 (s, 9H). LCMS (M+H) = 629.3.

10

Intermediate 106




(2-(*But*-3-en-1-yl)pyridin-3-yl)boronic acid: To a stirring solution of 3-bromo-2-(but-3-en-1-yl)pyridine (Ref. Zhang, Z; Dwoskin, L and Crooks, P. *Tetrahedron Lett.* **2011**, 52, 2667-2669, 550 mg, 2.59 mmol) and triisopropyl borate (0.775 mL, 3.37 mmol) in toluene (4 mL) and THF (1 mL) cooled to -78 °C was added 2.5 M n-BuLi (1.349 mL, 3.37 mmol) over the course of 15 min. During this time period, the reaction color changed from yellow to orange. The reaction was stirred at -78°C for 2 h then warmed to 0 °C for 15 min. It was then quenched with 2 N HCl (5 mL) and stirred for 10 min. The solution became a slurry (pH was found to be ~3). It was then diluted with ether, the ether layer was discarded. The aqueous layer was adjusted pH = 7-8. A white cloud was formed. It was then extracted with EtOAc, the organic layer was dried over MgSO₄, filtered and concentrated to obtain 450 mg (98%) of the desired product as a white foam. LCMS (M+1) = 178.1.

25

30


Intermediate 107



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-(2-(but-3-en-1-yl)pyridin-3-yl)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **107** was prepared using intermediates **65** and **106** by following the procedure to prepare intermediate **94**. ¹H NMR (400 MHz, CDCl₃) δ 8.68 - 8.59 (m, 1H), 8.07 (d, J=7.8 Hz, 1H), 7.99 - 7.90 (m, 1H), 7.61 (dd, J=7.6, 1.7 Hz, 1H), 7.54 (t, J=7.7 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H), 7.24 (dd, J=7.6, 4.9 Hz, 1H), 6.84 (s, 1H), 6.04 - 5.89 (m, 2H), 5.78 (ddt, J=17.0, 10.2, 6.7 Hz, 1H), 5.38 (dd, J=17.1, 1.7 Hz, 1H), 5.05 (br. s., 1H), 4.99 - 4.91 (m, 1H), 4.91 - 4.86 (m, 1H), 4.50-2.50 (m, 4 H), 3.99 (d, J=4.6 Hz, 2H), 3.75 (s, 3H), 2.93 (dd, J=9.0, 6.8 Hz, 2H), 2.62 (s, 3H), 2.52 - 2.45 (m, 2H), 2.08 - 1.68 (m, 4H), 1.35 (s, 3H), 1.26 (s, 9H). LCMS (M+1) = 638.4.

15


Intermediate 108



20 *Methyl (2S)-2-(tert-butoxy)-2-[(23E)-4,27-dimethyl-26-oxa-1,5,7,8,19-pentaazahexacyclo[25.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0¹⁵,2⁰]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate*: Intermediate **108** was prepared using intermediate **107** by following the procedure to prepare intermediate **95**. LCMS (M+1) = 610.3.


25

Intermediate 109



Methyl (2*S*)-2-(*tert*-butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8,19-
 5 pentaazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetate: A mixture of
 intermediate **108** (32 mg, 0.052 mmol), Pd/C (5.58 mg, 5.25 μ mol) in MeOH (2 mL)
 was stirred under a H₂ balloon for 2 h. It was then filtered and concentrated to obtain
 30 mg (93%) of the desired product as an off-white solid. ¹H NMR (400 MHz,
 10 CDCl₃) δ 8.64 (dd, *J*=4.6, 1.7 Hz, 1H), 8.15 (s, 1H), 7.82 (d, *J*=8.1 Hz, 1H), 7.57 -
 7.50 (m, 2H), 7.26 - 7.17 (m, 2H), 6.86 (s, 1H), 6.03 (s, 1H), 4.59 - 4.47 (m, 1H),
 3.89 (t, *J*=11.0 Hz, 1H), 3.74 (s, 3H), 3.43 (d, *J*=5.4 Hz, 1H), 3.40 - 3.33 (m, 1H),
 3.09 (d, *J*=11.0 Hz, 1H), 2.97 (ddd, *J*=14.4, 9.1, 5.6 Hz, 1H), 2.87 - 2.73 (m, 2H),
 2.64 (s, 3H), 2.25 - 2.11 (m, 1H), 2.01 (d, *J*=15.2 Hz, 1H), 1.89 (d, *J*=11.5 Hz, 2H),
 15 1.77 (td, *J*=13.0, 4.8 Hz, 1H), 1.75-1.53 (m, 5 H), 1.27 - 1.24 (m, 12H). LCMS (*M*+1)
 = 612.3.

Example 46




20

(2*S*)-2-(*tert*-Butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8,19-
 pentaazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-
 2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: A mixture of
 intermediate **109** (30 mg, 0.049 mmol), NaOH (0.245 mL, 0.245 mmol) in MeOH (2
 25 mL) was refluxed for 3 h. It was then filtered and purified by prep HPLC

(NH₄OAc/CH₃CN) to isolate 25 mg (81%) of the desired product as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.68 (br. s., 1H), 8.15 (br. s., 1H), 7.81 (d, J=7.6 Hz, 1H), 7.54 (br. s., 2H), 7.23 (d, J=6.4 Hz, 2H), 6.88 (s, 1H), 6.02 (br. s., 1H), 4.57 (t, J=12.7 Hz, 1H), 3.96 - 3.83 (m, 1H), 3.49 - 3.30 (m, 3H), 3.02 - 2.72 (m, 3H), 2.64 (s, 3H), 2.23 - 1.85 (m, 4H), 1.80 - 1.51 (m, 6H), 1.38 - 1.20 (m, 12H). LCMS (M+H) = 598.5.

Intermediate 110




10

(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **110** (**73**) was prepared using intermediate **65** and 4-fluoro-2-hydroxyphenylboronic acid by following the procedure to prepare intermediate **69** (**31**). LCMS (M+1) = 617.3.

15

Intermediate 111



20


(S)-Methyl 2-(2-(2'-(allyloxy)-4'-fluoro-[1,1'-biphenyl]-3-yl)-7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **111** was prepared using intermediate **110** by following the procedure to prepare intermediate **87**. ¹H NMR (400 MHz, CDCl₃) δ 8.09 - 7.94 (m, 2H), 7.59 - 7.46 (m, 2H), 7.42 - 7.35 (m, 1H), 6.84 (s, 1H), 6.82 - 6.73 (m, 2H), 6.07 - 5.93 (m, 3H), 5.46 - 5.34 (m, 2H), 5.23 (dq, J=10.6, 1.5 Hz, 1H), 5.12 (d,

25

J=10.0 Hz, 1H), 5.00-2.50 (m, 4 H), 4.57 (dt, J=4.8, 1.6 Hz, 2H), 4.02 (d, J=5.1 Hz, 2H), 3.75 (s, 3H), 2.63 (s, 3H), 2.09 - 1.90 (m, 3H), 1.74 (br. s., 1H), 1.37 (s, 3H), 1.25 (s, 9H). LCMS (M+1) = 657.4.

5

Intermediate 112




Methyl (2S)-2-(tert-butoxy)-2-[(23Z)-18-fluoro-4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-
 10 *2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Intermediate 112*
 was prepared using intermediate **111** by following the procedure to prepare
 intermediate **71**. It's a mixture of trans/cis isomers. LCMS (M+1) = 629.3.

Examples 47 and 48

15

Saponification of intermediate **112** by following the procedure to prepare
 example **20** afforded two compounds.

Example 47




20

(2S)-2-(tert-Butoxy)-2-[(23Z)-18-fluoro-4,27-dimethyl-21,26-dioxo-1,5,7,8-
tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: ¹H NMR (400
 25 *MHz, CDCl₃) δ 8.70 (s, 1H), 7.75 (d, J=7.5 Hz, 1H), 7.51 (t, J=7.7 Hz, 1H), 7.44 -*

7.32 (m, 2H), 6.88 (s, 1H), 6.80 - 6.69 (m, 2H), 6.31 (br. s., 1H), 5.97 (br. s., 1H), 4.90 (t, J=12.2 Hz, 1H), 4.71 - 4.58 (m, 1H), 4.11 - 3.95 (m, 2H), 3.67 (br. s., 1H), 3.48 - 3.26 (m, 2H), 2.83 (d, J=12.5 Hz, 1H), 2.60 (br. s., 3H), 2.43 (br. s., 1H), 2.04 - 1.85 (m, 2H) 1.74 (d, J=9.3 Hz, 2H), 1.40 (br. s., 3H), 1.26 (br. s., 9H). LCMS (M+H) = 615.4.


Example 48



10 (2S)-2-(tert-Butoxy)-2-[(23E)-18-fluoro-4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2²⁰]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: ¹H NMR (400 MHz, CDCl₃) δ 8.48 (t, J=1.6 Hz, 1H), 7.72 (dt, J=7.8, 1.4 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.40 (dt, J=7.8, 1.4 Hz, 1H), 7.34 - 7.29 (m, 1H), 6.84 (s, 1H), 6.76 - 6.71 (m, 2H), 6.35 - 6.23 (m, 1H), 6.08 (dt, J=15.7, 4.2 Hz, 1H), 6.02 (br. s., 1H), 4.76 - 4.62 (m, 3H), 4.10 - 3.93 (m, 3H), 3.36 (d, J=11.5 Hz, 1H), 2.75 (d, J=12.0 Hz, 1H), 2.64 (s, 3H), 2.08 - 2.00 (m, 1H), 1.95 (dd, J=13.7, 2.0 Hz, 1H), 1.77 (td, J=13.1, 4.6 Hz, 1H), 1.62 (td, J=13.4, 4.3 Hz, 1H), 1.34 - 1.28 (m, 12H). LCMS (M+H) = 615.4.

20

Example 49




25 (2S)-2-(tert-Butoxy)-2-{18-fluoro-4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2²⁰]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example 49 was

prepared using mixture of examples **47** and **48** following the procedure to prepare example **21**. ^1H NMR (400 MHz, CDCl_3) δ 8.43 (t, $J=1.5$ Hz, 1H), 7.68 (dt, $J=7.9$, 1.3 Hz, 1H), 7.56 - 7.49 (m, 1H), 7.41 (dt, $J=7.8$, 1.5 Hz, 1H), 7.33 (dd, $J=8.0$, 7.0 Hz, 1H), 6.80 (s, 1H), 6.78 - 6.70 (m, 2H), 6.00 (s, 1H), 4.62 - 4.52 (m, 1H), 4.13 - 4.05 (m, 2H), 3.90 (dd, $J=12.2$, 10.2 Hz, 1H), 3.57 - 3.49 (m, 1H), 3.41 (td, $J=8.5$, 3.3 Hz, 2H), 2.83 (d, $J=12.3$ Hz, 1H), 2.62 (s, 3H), 2.35 (ddt, $J=16.3$, 10.9, 5.6 Hz, 1H), 2.20 - 2.11 (m, 1H), 2.09-2.04 (m, 1 H), 1.93 (dd, $J=13.6$, 2.0 Hz, 1H), 1.85 - 1.73 (m, 2H), 1.70 - 1.53 (m, 2H), 1.30 (s, 9H), 1.26 (s, 3 H). LCMS ($\text{M}+\text{H}$) = 617.4.

10

Intermediate 113




15

(S)-Methyl 2-(7-(4-(but-3-en-1-yl)-4-methylpiperidin-1-yl)-2-(3-(4-(but-3-en-1-yl)pyridin-3-yl)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **113** was prepared using intermediate **65** and intermediate **93** by following the procedure to prepare intermediate **94**. ^1H NMR (400 MHz, CDCl_3) δ 8.58 - 8.53 (m, 2H), 8.07 (d, $J=7.8$ Hz, 1H), 7.96 (t, $J=1.5$ Hz, 1H), 7.57 (t, $J=7.7$ Hz, 1H), 7.35 (dt, $J=7.8$, 1.3 Hz, 1H), 7.28 - 7.26 (m, 1H), 6.84 (s, 1H), 6.07 (s, 1H), 5.94 - 5.79 (m, 1H), 5.72 (ddt, $J=16.9$, 10.3, 6.7 Hz, 1H), 5.06 (d, $J=15.7$ Hz, 1H), 5.00-2.50 (m, 4 H), 4.99 - 4.91 (m, 3H), 3.75 (s, 3H), 2.81 - 2.75 (m, 2H), 2.63 (s, 3H), 2.32 (td, $J=7.8$, 6.5 Hz, 2H), 2.10 (br. s., 2H), 1.81 - 1.69 (m, 1H), 1.62 (t, $J=5.5$ Hz, 2H), 1.57 - 1.49 (m, 2H), 1.28 (s, 10H), 1.14 (br. s., 3H). LCMS ($\text{M}+1$) = 636.4.

20

Intermediate 114



25


Methyl (2S)-2-(tert-butoxy)-2-[(23E)-4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Intermediate **114** was prepared using intermediate **113** by following the procedure to prepare intermediate **95**. It's a mixture of cis/trans isomers. LCMS (M+1) = 608.3.

Example 50 (39) and 51 (40)

Hydrolysis of intermediate **114** by following the procedure to prepare example **20** provided two compounds.

10


Example 50



(2S)-2-(tert-Butoxy)-2-[(23E)-4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, J=5.4 Hz, 1H), 8.33 (s, 1H), 7.95 (s, 1H), 7.78 (d, J=7.7 Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 7.35 (d, J=5.4 Hz, 1H), 7.22 (d, J=7.7 Hz, 1H), 6.81 (s, 1H), 6.02 (br. s., 1H), 5.30 - 5.20 (m, 1H), 5.19 - 5.11 (m, 1H), 4.68 - 4.55 (m, 1H), 4.04 (br. s., 1H), 3.10 (d, J=12.6 Hz, 1H), 2.85 - 2.74 (m, 2H), 2.67 (s, 3H), 2.64 (d, J=3.6 Hz, 1H), 2.52 - 2.36 (m, 2H), 1.85 - 1.75 (m, 2H), 1.70 (br. s., 1H), 1.64 - 1.53 (m, 2H), 1.53 - 1.39 (m, 3H), 1.30 (s, 9H), 0.93 (s, 3H). LCMS (M+H) = 594.45.

20

Example 51




25

(2*S*)-2-(*tert*-Butoxy)-2-[(23*Z*)-4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: ¹H NMR (500 MHz, CDCl₃) δ 8.53 (d, J=5.0 Hz, 1H), 8.45 (s, 1 H), 8.12 (s, 1H), 7.83 (d, J=7.9 Hz, 1H), 7.57 (t, J=7.6 Hz, 1H), 7.32 - 7.30 (m, 2H), 6.84 (s, 1H), 5.89 (br. s., 1H), 5.63 - 5.50 (m, 2H), 4.40 (t, J=11.0 Hz, 1H), 3.79 (t, J=11.0 Hz, 1H), 3.50 - 3.41 (m, 1H), 2.84 (dt, J=13.8, 7.0 Hz, 1H), 2.72 - 2.65 (m, 2H), 2.61 (s, 3H), 2.59 - 2.53 (m, 3H), 2.11 - 1.97 (m, 2H), 1.87 (d, J=7.9 Hz, 2H), 1.58 (d, J=10.1 Hz, 1H), 1.50 (d, J=13.2 Hz, 1H), 1.42 (t, J=10.6 Hz, 1H), 1.28 (s, 9H), 1.03 (s, 3H). LCMS (M+H) = 594.5.

10


Example 52



(2*S*)-2-(*tert*-Butoxy)-2-{4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example **52** was prepared using mixture of examples **50** and **51** by following the procedure to prepare example **21**. ¹H NMR (400 MHz, CDCl₃) δ 8.79 - 8.22 (m, 1H), 7.92 (s, 1H), 7.79 (d, J=7.6 Hz, 1H), 7.60 - 7.49 (m, 1H), 7.44-7.31 (m, 1 H), 7.23 (d, J=7.3 Hz, 1H), 6.82 (s, 1H), 6.02 (br. s., 1H), 4.50 (t, J=11.0 Hz, 1H), 3.90 (br. s., 1H), 3.18 (br. s., 1H), 2.77 - 2.61 (m, 6H), 1.82 - 1.43 (m, 7H), 1.41 - 1.13 (m, 17H), 0.96 (s, 3H). LCMS (M+H) = 596.5.


25

Intermediate 115



(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(5'-methyl-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: A mixture of intermediate **89** (600 mg, 0.979 mmol), (*R*)-pent-4-en-2-ol (253 mg, 2.94 mmol), triphenylphosphine (514 mg, 1.958 mmol), DEAD (0.310 mL, 1.958 mmol) in THF (5 ml) was stirred at rt for 2 days. It was then diluted with EtOAc. The organic was washed with water, dried over MgSO₄, filtered, concentrated and purified by biotage, eluting with 20% EtOAc/hexane to isolate 500 mg of the desired product as an oil. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H), 8.04 (d, *J*=6.8 Hz, 1H), 7.58 (d, *J*=7.8 Hz, 1H), 7.51 - 7.45 (m, 1H), 7.25 (d, *J*=1.7 Hz, 1H), 7.13 (dd, *J*=8.1, 1.7 Hz, 1H), 6.94 (d, *J*=8.3 Hz, 1H), 6.85 (s, 1H), 6.12 - 5.91 (m, 2H), 5.77 (ddt, *J*=17.1, 10.1, 7.1 Hz, 1H), 5.43 (d, *J*=17.1 Hz, 1H), 5.14 (d, *J*=10.8 Hz, 1H), 5.07 - 4.98 (m, 2H), 5.00-2.50 (m, 4H), 4.33 (sxt, *J*=6.1 Hz, 1H), 4.03 (d, *J*=4.9 Hz, 2H), 3.75 (s, 3H), 2.62 (s, 3H), 2.46 - 2.36 (m, 4H), 2.27 (dt, *J*=13.9, 6.9 Hz, 1H), 2.07 - 1.85 (m, 3H), 1.74 (br. s., 1H), 1.39 (s, 3H), 1.27 (s, 9H), 1.24 - 1.20 (m, 3H). LCMS (*M*+1) = 681.4.

Intermediate 116




Methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*S*)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: A mixture of intermediate **115** (600 mg, 0.881 mmol), (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (55.2 mg, 0.088 mmol), copper(I) iodide (168 mg, 0.881 mmol) in DCE (750 mL) was refluxed for 1 h. It was then concentrated to obtain 600 mg dark green solid. LCMS (*M*+1) = 653.5. The product is a mixture of *cis*/*trans* product. This material was used in the next step without purification.

Examples 53 (42) and 54 (43)


A mixture of intermediate **116** (40 mg, 0.061 mmol), NaOH (0.613 mL, 0.613 mmol) in MeOH (2 mL) was refluxed for 3 h. It was then filtered and purify by prep
5 HPLC to two compounds.

Example 53



10 (2S)-2-(tert-Butoxy)-2-[(22S,24E)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,1}.4.0^{2,7}.0^{1,5,2}.0]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: Isolate 17.6 mg (44%) as a white solid. ¹H NMR (500 MHz, DMSO-d₆) δ 8.43 (s, 1H), 8.01 - 7.87 (m, 1H), 7.52 (t, J=7.6 Hz, 1H), 7.31 (d, J=7.3 Hz, 1H), 7.17 - 6.97 (m, 4H), 6.28 (br.
15 s., 1H), 5.78 - 5.55 (m, 2H), 4.86 - 4.66 (m, 1H), 4.51 (br. s., 1H), 4.02 - 3.91 (m, 1H), 3.92 - 3.82 (m, 1H), 3.70-3.10 (m, 3 H), 2.50 (s, 3H), 2.35 - 2.23 (m, 4H), 2.22 - 2.07 (m, 1H), 2.02 (d, J=14.0 Hz, 1H), 1.86 (d, J=11.0 Hz, 1H), 1.70 - 1.50 (m, 2H), 1.21 (s, 3H), 1.16 (s, 9H), 1.02 (d, J=5.8 Hz, 3H). LCMS (M+1) = 639.5.

Example 54




20 (2S)-2-(tert-Butoxy)-2-[(22S,24Z)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,1}.4.0^{2,7}.0^{1,5,2}.0]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: Isolate 1.8 mg
25

(4.5%) as a white solid. ^1H NMR (500 MHz, DMSO- d_6) δ 8.58 (s, 1H), 7.86 (d, $J=7.9$ Hz, 1H), 7.52 (t, $J=7.8$ Hz, 1H), 7.40 (d, $J=7.6$ Hz, 1H), 7.21 (s, 1H), 7.18 - 7.12 (m, 1H), 7.12 - 7.07 (m, 1H), 7.01 (s, 1H), 5.79 - 5.62 (m, 2H), 5.46 (s, 1H), 4.64 - 4.55 (m, 1H), 4.26 (t, $J=11.9$ Hz, 1H), 4.02 - 3.96 (m, 1H), 3.78 (dd, $J=9.9, 5.0$ Hz, 1H), 3.70-3.20 (m, 2H), 3.07 (d, $J=11.6$ Hz, 1H), 2.86 (br. s., 1H), 2.60 - 2.53 (m, 1H), 2.51 (s, 3 H), 2.30 (s, 3H), 2.07 (d, $J=12.5$ Hz, 1H), 1.86 - 1.73 (m, 2H), 1.59 - 1.47 (m, 1H), 1.21 (s, 3H), 1.19 (d, $J=5.8$ Hz, 3H), 1.14 (s, 9H). LCMS (M+1) = 639.5.


10

Intermediate 117



Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: To a crude mixture of intermediate **116** (700 mg, 1.072 mmol), in MeOH (30 mL) was added NaBH₄ (203 mg, 5.36 mmol) five times in 1 h. After 1 h, it was quenched with water, extracted with EtOAc. The organic was dried over MgSO₄, filtered and concentrated to obtain 800 mg white solid. It was then purified by biotage, eluting with 20% EtOAc/hexane to isolate 480 mg (68%) of the desired product as a white solid. ^1H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 7.80 (d, $J=7.8$ Hz, 1H), 7.50 (t, $J=7.7$ Hz, 1H), 7.35 (d, $J=7.6$ Hz, 1H), 7.17 (s, 1H), 7.13 (d, $J=8.3$ Hz, 1H), 6.95 - 6.88 (m, 2H), 5.90 (s, 1H), 4.67 - 4.51 (m, 2H), 3.84 - 3.78 (m, 1H), 3.77 (s, 3H), 3.49 (d, $J=7.6$ Hz, 1H), 3.42 - 3.34 (m, 1H), 3.25 (d, $J=13.4$ Hz, 1H), 2.89 (d, $J=11.5$ Hz, 1H), 2.60 (s, 3H), 2.36 (s, 3H), 2.09 - 1.67 (m, 8H), 1.64 - 1.54 (m, 2H), 1.26 (s, 3H), 1.24 (s, 9H), 1.17 (d, $J=5.9$ Hz, 3H). LCMS (M+1) = 655.3.


Example 55



(2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **55** was prepared using intermediate **117** by following the procedure to prepare example **28**. ¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 7.79 (d, J=7.6 Hz, 1H), 7.50 (t, J=7.7 Hz, 1H), 7.37 (d, J=7.6 Hz, 1H), 7.18 (d, J=2.0 Hz, 1H), 7.16 - 7.10 (m, 1H), 6.95 - 6.88 (m, 2H), 5.97 (br. s., 1H), 4.67 (t, J=11.7 Hz, 1H), 4.61 - 4.48 (m, 1H), 3.82 (t, J=11.6 Hz, 1H), 3.61 - 3.44 (m, 2H), 3.42 - 3.33 (m, 1H), 2.95 (d, J=12.0 Hz, 1H), 2.59 (s, 3H), 2.36 (s, 3H), 2.09 - 1.96 (m, 3H), 1.92 - 1.63 (m, 7H), 1.29 (s, 9H), 1.26 (s, 3H), 1.17 (d, J=6.1 Hz, 3H). LCMS (M+1) = 641.3.


15

Intermediate 118



3-Bromo-4-(but-3-en-2-yloxy)pyridine: A mixture of 3-bromopyridin-4-ol (0.6 g, 3.45 mmol), but-3-en-2-ol (0.746 g, 10.35 mmol), triphenylphosphine (2.71 g, 10.35 mmol), DIAD (2.011 mL, 10.35 mmol) in THF (1 mL) was stirred at rt for 16 h. It was then diluted with EtOAc, washed with water. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 1 g oil, which was then purified by biotage, eluting with 30% acetone/hexane to isolate 750 mg (95%) of the desired product as an oil. ¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 8.34 (d, J=5.6 Hz, 1H), 6.83 - 6.80 (m, 1H), 5.98 - 5.87 (m, 1H), 5.40 - 5.25 (m, 2H), 5.00 - 4.92 (m, 1H), 1.55 (d, J=6.4 Hz, 3H). LCMS (M+1) = 229.9.

Intermediate 119




5 *(2S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-(4-(but-3-en-2-
 yloxy)pyridin-3-yl)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-
 butoxy)acetate: To a microwave tube was added intermediate **65** (100 mg, 0.171
 mmol), (4-(but-3-en-2-yloxy)pyridin-3-yl)boronic acid (49.4 mg, 0.256 mmol)
 (prepared using intermediate **118** following the procedure to prepare intermediate **93**
 10 and 2.0 M aqueous sodium carbonate (0.171 mL, 0.342 mmol) in DMF (2 mL), was
 sparged with nitrogen for 1 minutes, treated with (Ph₃)₄Pd (19.74 mg, 0.017 mmol),
 then sparged with N₂ for 1 min. The reaction tube was sealed and then heated at 95
 °C in a microwave tube for 1 h. The reaction was then concentrated, diluted with
 water (15 mL) and extracted with EtOAc. The EtOAc layer was washed with brine,
 dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was
 15 purified by biotage, eluting with 30% acetone/hexane to isolate 80 mg (72%) of the
 desired product as a white solid. LCMS (M+1) = 654.4.

Intermediate 120 and 121

20 A mixture of intermediate **119** (100 mg, 0.153 mmol), (1,3-
 dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride
 (9.58 mg, 0.015 mmol), tosic acid (29.1 mg, 0.153 mmol) in DCE (100 mL) was
 heated at reflux for 2 h. It was then concentrated, and purified by prep HPLC to
 afford two compounds.

25


Intermediate 120



5 *Methyl (2S)-2-(tert-butoxy)-2-[(22R,23E)-4,22,27-trimethyl-21,26-dioxo-*
1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritiaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Isolate 5.9 mg (6%)
 as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (t, J=1.6 Hz, 1H), 8.23 - 8.20
 (m, 1H), 7.85 (d, J=2.4 Hz, 1H), 7.78 (dt, J=7.8, 1.3 Hz, 1H), 7.52 (t, J=7.7 Hz, 1H),
 7.41 (dd, J=7.6, 2.4 Hz, 1H), 6.88 (s, 1H), 6.60 (d, J=7.3 Hz, 1H), 6.24 - 6.17 (m,
 10 1H), 6.13 - 6.01 (m, 2H), 4.72 - 4.58 (m, 2H), 4.13 - 4.07 (m, 2H), 3.83 (t, J=11.1 Hz,
 1H), 3.75 (s, 3H), 3.07 (d, J=11.2 Hz, 1H), 2.76 (d, J=11.7 Hz, 1H), 2.66 (s, 3H), 2.07
 - 1.98 (m, 3H), 1.89 - 1.66 (m, 3H), 1.62 (d, J=6.6 Hz, 3H), 1.34 (s, 3H), 1.28 (s, 9H).
 LCMS (M+1) = 626.3.

15

Intermediate 121




20 *Methyl (2S)-2-(tert-butoxy)-2-[(22S,23E)-4,22,27-trimethyl-21,26-dioxo-*
1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritiaconta-
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Isolate 5 mg (5%)
 as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.24 - 8.19 (m, 1H), 8.11 (t, J=1.6
 Hz, 1H), 7.87 (d, J=2.7 Hz, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.41
 (dd, J=7.5, 2.6 Hz, 1H), 6.84 (s, 1H), 6.56 (d, J=7.6 Hz, 1H), 6.18 - 6.02 (m, 3H),
 25 4.62 (t, J=6.4 Hz, 1H), 4.54 - 4.45 (m, 1H), 4.09 (d, J=2.7 Hz, 2H), 4.02 (t, J=10.9

Hz, 1H), 3.72 (s, 3H), 3.02 (d, J=10.8 Hz, 1H), 2.72 (br. s., 1H), 2.67 (s, 3H), 2.02 (d, J=13.9 Hz, 2H), 1.88 - 1.72 (m, 2H), 1.63 (d, J=6.8 Hz, 3H), 1.35 (s, 3H), 1.29 (s, 9H). LCMS (M+1) = 626.4.

5


Example 56



(2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{0,1}.0^{2,7}.0^{1,5,2}0]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Example **56** was prepared using intermediate **120** by following the procedure to prepare example **20**. LCMS (M+H) = 612.4.

15


Example 57



(2S)-2-(tert-Butoxy)-2-[(22S)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{0,1}.0^{2,7}.0^{1,5,2}0]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Example **57** was prepared using intermediate **121** by following the procedure to prepare example **20**. LCMS (M+H) = 612.3.

25


Intermediate 122



5 *(2S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-2-yloxy)-5'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **122** was prepared using intermediate **89** and but-3-en-2-ol by following the procedure to prepare intermediate **70**. LCMS (M+1) = 667.5.

10

Intermediate 123




15 *Methyl (2S)*-2-(tert-butoxy)-2-[4,17,22,27-tetramethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Intermediate **123** was prepared by using intermediate **122** by following the procedure to prepare intermediate **71**. LCMS (M+1) = 639.2.

Example 58 and 59

20

A mixture of intermediate **123** (116 mg, 0.182 mmol), NaOH (0.908 mL, 0.908 mmol) in MeOH (2 mL) was refluxed for 2 h. It was then filtered and purified by prep HPLC to afford two products.


Example 58



5 *(2S)-2-(tert-Butoxy)-2-[(22R)-4,17,22,27-tetramethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2⁰]tritriaconta-*
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Obtained 11.8
 mg (10%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 1H), 7.70 (dt,
J=7.7, 1.3 Hz, 1H), 7.55 - 7.48 (m, 1H), 7.47 - 7.41 (m, 1H), 7.17 (d, *J*=2.0 Hz, 1H),
 7.07 (dd, *J*=8.3, 1.8 Hz, 1H), 6.86 - 6.77 (m, 2H), 6.10 - 5.92 (m, 3H), 5.02 - 4.86 (m,
 10 1H), 4.63 (t, *J*=11.4 Hz, 1H), 4.16 - 3.93 (m, 3H), 3.26 - 3.13 (m, 1H), 2.73 - 2.60 (m,
 4H), 2.34 (s, 3H), 2.08 - 1.96 (m, 1H), 1.92 - 1.82 (m, 1H), 1.74 (td, *J*=13.1, 4.6 Hz,
 1H), 1.62 (td, *J*=13.4, 4.4 Hz, 1H), 1.30 (s, 9H), 1.28 (s, 3H), 1.26 (d, *J*=6.3 Hz, 3H).
 LCMS (M+1) = 625.5.

15

Example 59




20 *(2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,27-tetramethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0¹⁵.2⁰]tritriaconta-*
2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Obtained 10.3
 mg (8.6%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 1H), 7.78 - 7.73
 (m, 1H), 7.50 (t, *J*=7.7 Hz, 1H), 7.42 - 7.38 (m, 1H), 7.14 (d, *J*=2.0 Hz, 1H), 7.08 (dd,
J=8.4, 1.9 Hz, 1H), 6.94 - 6.88 (m, 2H), 6.26 (dd, *J*=15.6, 7.3 Hz, 1H), 6.03 (br. s.,
 1H), 5.94 (dt, *J*=15.6, 3.7 Hz, 1H), 5.03 (quin, *J*=6.5 Hz, 1H), 4.82 (t, *J*=11.7 Hz,

1H), 4.05 - 3.89 (m, 3H), 3.36 (d, J=11.0 Hz, 1H), 2.73 (d, J=11.8 Hz, 1H), 2.62 (s, 3H), 2.34 (s, 3H), 1.95 (t, J=13.7 Hz, 2H), 1.75 - 1.55 (m, 2H), 1.32 - 1.23 (m, 15H). LCMS (M+H) = 625.5.

5


Example 60



(2S)-2-(tert-Butoxy)-2-[(22R)-4,17,22,27-tetramethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **60** was prepared using example **58** by following the procedure to prepare example **21**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.23 (s, 1H), 7.74 (d, J=7.6 Hz, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 7.17 - 7.06 (m, 2H), 7.01 (d, J=8.2 Hz, 1H), 6.89 (s, 1H), 5.86 (s, 1H), 4.62 - 4.46 (m, 1H), 4.28 (t, J=12.2 Hz, 1H), 3.77 (d, J=7.0 Hz, 2H), 3.12 (d, J=11.3 Hz, 2H), 2.65 (d, J=10.7 Hz, 1H), 2.55 (s, 3H), 2.27 (s, 3H), 2.18 (br. s., 1H), 2.02 (d, J=12.8 Hz, 1H), 1.83 - 1.68 (m, 4H), 1.63 - 1.51 (m, 2H), 1.21 (s, 3H), 1.20 (s, 9H), 1.15 (d, J=5.8 Hz, 3H). LCMS (M+H) = 627.5.

20


Example 61



(2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,27-tetramethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **61** was


prepared using example **59** by following the procedure to prepare example **21**. ^1H NMR (500 MHz, DMSO- d_6) δ 8.47 (s, 1H), 7.87 (d, $J=7.6$ Hz, 1H), 7.52 (t, $J=7.5$ Hz, 1H), 7.36 (d, $J=8.2$ Hz, 1H), 7.17 - 7.06 (m, 3H), 7.03 (s, 1H), 5.65 (br. s., 1H), 4.61 - 4.43 (m, 2H), 3.60-3.20 (m, 7 H), 2.70 (br. s., 1H), 2.56 (s, 3H), 2.28 (s, 3H), 2.12 (br. s., 1H), 1.96 - 1.46 (m, 7H), 1.19 (s, 3H), 1.15 (s, 9H). LCMS (M+H) = 627.5.

Intermediate 124




(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **124** was prepared by using intermediate **65** and 5-fluoro-2-hydroxyphenylboronic acid by following the procedure to prepare intermediate **69**. ^1H NMR (400 MHz, CDCl_3) δ 8.11 (t, $J=1.6$ Hz, 1H), 8.06 (d, $J=7.8$ Hz, 1H), 7.60 (t, $J=7.7$ Hz, 1H), 7.48 (d, $J=7.6$ Hz, 1H), 7.07 (dd, $J=8.9, 2.3$ Hz, 1H), 7.02 - 6.95 (m, 2H), 6.85 (s, 1H), 6.11 - 5.88 (m, 2H), 5.40 (dd, $J=17.1, 2.0$ Hz, 1H), 5.33 (s, 1H), 5.11 (br. s., 1H), 5.00-2.50 (m, 4 H), 4.02 (d, $J=5.1$ Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.11 - 1.91 (m, 2H), 1.73 (br. s., 1H), 1.37 (br. s., 3H), 1.29 - 1.25 (s, 9H). LCMS (M+1) = 617.2.

Intermediate 125



(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-(allyloxy)-5'-fluoro-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: Intermediate **125** was prepared using intermediate **124** by following the procedure to prepare intermediate **87**. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1H), 8.05 (d, J=7.3 Hz, 1H), 7.61 - 7.56 (m, 1H), 7.54 - 7.48 (m, 1H), 7.17 (dd, J=9.0, 2.9 Hz, 1H), 7.07 - 6.99 (m, 1H), 6.99 - 6.94 (m, 1H), 6.84 (s, 1H), 6.11 - 5.89 (m, 3H), 5.46 - 5.35 (m, 2H), 5.20 (dq, J=10.6, 1.5 Hz, 1H), 5.17 - 5.01 (m, 1H), 5.00 - 2.50 (m, 4H), 4.53 (dt, J=4.8, 1.6 Hz, 2H), 4.02 (d, J=4.9 Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.06 - 1.91 (m, 3H), 1.74 (br. s., 1H), 1.38 (br. s., 3H), 1.28 - 1.22 (s, 9H). LCMS (M+1) = 657.3.

Intermediate 126




15

Methyl (2*S*)-2-(*tert*-butoxy)-2-[17-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetate: Intermediate **126** was prepared using intermediate **125** by following the procedure to prepare intermediate **71**. LCMS (M+1) = 629.3. It's a mixture of *cis/trans* isomers.

20

Example 62




(2*S*)-2-(*tert*-Butoxy)-2-[17-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Example **62** was prepared using intermediate **126** by following the procedure to prepare example

5 **20**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.66 (s, 1H), 7.93 (d, J=7.9 Hz, 1H), 7.60 - 7.52 (m, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.26 (dd, J=9.5, 2.4 Hz, 1H), 7.21 - 7.13 (m, 2H), 7.08 (s, 1H), 6.46 (d, J=5.8 Hz, 1H), 5.71 (s, 1H), 4.78 - 4.67 (m, 1H), 4.66 - 4.58 (m, 1H), 4.16 - 4.06 (m, 1H), 3.96 - 3.89 (m, 1H), 3.50 - 3.43 (m, 1H), 3.37 (br. s., 1H), 3.20 - 3.12 (m, 1H), 2.78 (br. s., 1H), 2.55 (s, 3H), 2.34 (td, J=12.1, 6.1 Hz, 1H), 1.89 (br. s., 1H), 1.85 - 1.79 (m, 1H), 1.75 - 1.67 (m, 1H), 1.38 (s, 3H), 1.18 (s, 9H). LCMS (M+H) = 615.2.

10

Intermediate 127




15

Methyl (2*S*)-2-(*tert*-butoxy)-2-{17-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetate: Intermediate **127** was prepared using intermediate **126** by following the procedure to prepare intermediate

20 **78**. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.62 - 7.51 (m, 1H), 7.44 (d, J=8.1 Hz, 1H), 7.14 (dd, J=9.3, 3.2 Hz, 1H), 7.07 - 6.91 (m, 2H), 6.85 (br. s., 1H), 5.98 (br. s., 1H), 4.55 (t, J=12.6 Hz, 1H), 4.16 - 4.02 (m, 2H), 3.99 - 3.86 (m, 1H), 3.82 - 3.71 (m, 3H), 3.59 - 3.50 (m, 1H), 3.43 (td, J=8.7, 3.2 Hz, 1H), 3.21 (s, 1H), 2.94 - 2.76 (m, 1H), 2.68 (s, 3H), 2.46 - 2.28 (m, 1H), 2.27 - 2.00 (m, 2H), 1.96 - 1.75 (m, 3H), 1.72 - 1.62 (m, 2H), 1.31 (s, 3H), 1.27 (s, 9H). LCMS (M+1) = 631.3.

25


Example 63



(2S)-2-(tert-Butoxy)-2-{17-fluoro-4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tritiaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example **63** was prepared using intermediate **127** by following the procedure to prepare example **28**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.41 (s, 1H), 7.82 (d, J=7.9 Hz, 1H), 7.57 (t, J=7.6 Hz, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.22 (d, J=9.5 Hz, 1H), 7.17 (d, J=6.1 Hz, 2H), 6.95 (s, 1H), 5.73 (s, 1H), 4.40 (t, J=11.6 Hz, 1H), 4.12 - 4.05 (m, 2H), 3.70 - 3.63 (m, 1H), 3.46 - 3.42 (m, 1H), 3.37 (dd, J=9.0, 5.6 Hz, 1H), 3.31 (d, J=9.8 Hz, 1H), 2.74 (s, 1H), 2.54 (s, 3H), 2.15 (br. s., 1H), 2.01 (d, J=12.8 Hz, 2H), 1.80 (br. s., 2H), 1.67 (dd, J=8.9, 4.6 Hz, 1H), 1.61 - 1.47 (m, 2H), 1.21 (s, 3H), 1.17 (s, 9H). LCMS (M+H) = 617.4.

15


Intermediate 128



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-((S)-hex-5-en-2-yloxy)-5'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **128** was prepared using intermediate **89** and (R)-hex-5-en-2-ol by following the procedure to prepare intermediate **78**. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (s, 1H), 8.03 (d, J=6.5 Hz, 1H), 7.57 (d, J=7.7 Hz, 1H), 7.53 -

7.44 (m, 1H), 7.24 (d, J=1.9 Hz, 1H), 7.13 (dd, J=8.3, 1.7 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 6.84 (s, 1H), 6.03 (ddt, J=17.2, 10.4, 5.2 Hz, 2H), 5.77 - 5.69 (m, 1H), 5.42 (d, J=15.6 Hz, 1H), 5.14 (d, J=8.7 Hz, 1H), 5.05 (dd, J=17.3, 1.7 Hz, 1H), 5.00-2.50 (m, 4 H), 4.94 - 4.85 (m, 1H), 4.31 (dq, J=12.1, 6.1 Hz, 1H), 4.03 (d, J=4.9 Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.38 (s, 3H), 2.17 - 1.94 (m, 5H), 1.76 (ddt, J=13.5, 8.5, 6.6 Hz, 1H), 1.43 - 1.37 (m, 3H), 1.33 - 1.25 (m, 11H), 1.25 - 1.20 (m, 3H). LCMS (M+1) = 695.4.

Intermediate 129




10

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,17,22,29-tetramethyl-21,28-dioxo-1,5,7,8-tetraazahexacyclo[27.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]pentatriaconta-2,4,6(35),8,10(34),11,13,15(20),16,18,25-undecaen-3-yl]acetate: Intermediate 129
 was prepared using intermediate 128 by following the procedure to prepare intermediate 116. LCMS (M+1)= 667.4. It's a mixture of cis/trans product.

15

Example 64




20

(2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,29-tetramethyl-21,28-dioxo-1,5,7,8-tetraazahexacyclo[27.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]pentatriaconta-2,4,6(35),8,10(34),11,13,15(20),16,18,25-undecaen-3-yl]acetic acid: Example 64
 was prepared using intermediate 129 by following the procedure to prepare example 20. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (t, J=1.5 Hz, 1H), 7.67 (dt, J=7.5, 1.4 Hz,

25

1H), 7.54 - 7.49 (m, 1H), 7.48 - 7.42 (m, 1H), 7.14 - 7.06 (m, 2H), 7.05 - 7.00 (m, 1H), 6.78 (s, 1H), 6.00 (br. s., 1H), 5.76 - 5.62 (m, 1H), 5.47 (dt, J=15.5, 5.5 Hz, 1H), 4.82 (t, J=11.4 Hz, 1H), 4.35 - 4.25 (m, 1H), 3.85 - 3.74 (m, 3H), 3.27 (d, J=11.0 Hz, 2H), 2.65 (s, 3H), 2.34 (s, 3H), 2.03 - 1.90 (m, 2H), 1.87 - 1.72 (m, 2H), 1.72 - 1.61 (m, 2H), 1.60 - 1.47 (m, 1H), 1.42 - 1.32 (m, 1H), 1.31 - 1.28 (m, 9H), 1.27 - 1.24 (m, 6H). LCMS (M+1)= 653.3.

Intermediate 130




10

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,17,22,29-tetramethyl-21,28-dioxo-1,5,7,8-tetraazahexacyclo[27.2.2.1^{6,9}.1^{0,1}.4^{0,2}.7.0^{1,5,2}]⁰]pentatriaconta-2,4,6(35),8,10(34),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **130** was prepared using intermediate **129** by following the procedure to prepare intermediate **117**. ¹H NMR (400 MHz, CDCl₃) δ 8.10 - 8.05 (m, 1H), 7.73 - 7.65 (m, 1H), 7.48 - 7.45 (m, 2H), 7.16 - 7.10 (m, 2H), 7.05 - 7.00 (m, 1H), 6.79 (s, 1H), 5.99 (s, 1H), 4.70 - 4.60 (m, 1H), 4.28 - 4.19 (m, 1H), 3.83 - 3.70 (m, 4H), 3.41 - 3.32 (m, 1H), 3.31 - 3.22 (m, 1H), 3.10 (d, J=11.5 Hz, 1H), 2.96 (d, J=12.2 Hz, 1H), 2.62 (s, 3H), 2.36 (s, 3H), 2.02 - 1.90 (m, 2H), 1.76-1.14 (m, 10H), 1.26 (s, 9H), 1.24 (s, 3H), 1.12 (d, J=6.1 Hz, 3H). LCMS (M+1) = 669.5.

20


Example 65



(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-4,17,22,29-tetramethyl-21,28-dioxa-1,5,7,8-tetraazahexacyclo[27.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]pentatriaconta-2,4,6(35),8,10(34),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **65** was prepared using intermediate **130** by following the procedure to prepare example **28**.

- 5 ¹H NMR (400 MHz, CDCl₃) δ 8.12 (s, 1H), 7.74 - 7.66 (m, 1H), 7.51 - 7.41 (m, 2H), 7.18 - 7.08 (m, 2H), 7.06 - 6.99 (m, 1H), 6.79 (s, 1H), 5.88 (s, 1H), 4.71 - 4.58 (m, 1H), 4.23 (sxt, J=5.9 Hz, 1H), 3.81 - 3.69 (m, 1H), 3.49 - 3.41 (m, 1H), 3.41 - 3.31 (m, 1H), 3.31 - 3.20 (m, 1H), 3.03 (d, J=12.0 Hz, 1H), 2.62 (s, 3H), 2.36 (s, 3H), 2.02 - 1.89 (m, 2H), 1.75 - 1.30 (m, 8H), 1.26 (s, 9H), 1.23 (s, 3H), 1.21-1.17 (m 2 H),
10 1.10 (d, J=6.1 Hz, 3H). LCMS (M+1) = 655.4.

Intermediate 131




- 15 (4-Chloro-2-hydroxy-5-methylphenyl)boronic acid: A mixture of (4-chloro-2-methoxy-5-methylphenyl)boronic acid (100 mg, 0.499 mmol) in DCM (2 mL) was cooled to 0°C and BBr₃ (0.142 mL, 1.497 mmol) was added. The mixture was then stirred at rt for 2 h. It was then poured into ice and extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 150 mg
20 (97% yield, 60% pure) of the desired product as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.59 (br. s., 1H), 7.11 (br. s., 1H), 4.30 - 4.11 (m, 1H), 4.01 (br. s., 1H), 2.37 (s, 3H).

25

30


Intermediate 132



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-chloro-2'-hydroxy-5'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **132** was prepared using intermediates **65** and **131** by following the procedure to prepare intermediate **89**. ¹H NMR (400MHz, CDCl₃) δ 8.11 - 7.99 (m, 2H), 7.58 (t, J=7.7 Hz, 1H), 7.48 - 7.37 (m, 2H), 7.19 (s, 1H), 7.07 (s, 1H), 6.85 (br. s., 1H), 6.13 - 5.86 (m, 2H), 5.40 (dd, J=17.2, 1.8 Hz, 1H), 5.50-2.50
10 (m, 4 H), 5.10 (br. s., 1H), 4.02 (d, J=5.1 Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.37 (s, 3H), 2.10 - 1.90 (m, 2H), 1.74 (br. s., 1H), 1.63-1.65 (m, 1H), 1.37 (br. s., 3H), 1.30 - 1.23 (s, 9H). LCMS (M+1) = 647.4.

15

Intermediate 133




20 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-chloro-5'-methyl-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **133** was prepared using intermediate **132** and (*R*)-pent-4-en-2-ol by following the procedure to prepare intermediate **115**. ¹H NMR (400 MHz, CDCl₃) δ 8.11 (s, 1H), 8.03 (d, J=6.6 Hz, 1H), 7.57 - 7.43 (m, 2H), 7.27 (s, 1H), 7.02 (s, 1H), 6.84 (s, 1H), 6.14 - 5.90 (m, 2H), 5.80 - 5.72 (m, 1H), 5.42 (d, J=17.1 Hz, 1H), 5.13 (d, J=10.5 Hz, 1H), 5.05 (d, J=7.6 Hz, 1H), 5.00-2.50 (m, 4H),

5.02 (s, 1H), 4.39 - 4.32 (m, 1H), 4.05 - 3.97 (m, 2H), 3.75 (s, 3H), 2.62 (s, 3H), 2.47 - 2.34 (m, 4H), 2.29 (dt, J=14.0, 6.8 Hz, 1H), 2.09 - 1.88 (m, 3H), 1.74 (br. s., 1H), 1.41 - 1.36 (m, 3H), 1.29 - 1.24 (m, 12H). LCMS (M+1) = 715.4.


5

Intermediate 134



Methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
 10 *2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate 134*
 was prepared using intermediate **133** by following the procedure to prepare
 intermediate **116**. LCMS (M+1) = 687.4. It's a mixture of cis/trans isomers.

Example 66




15

(2S)-2-(tert-Butoxy)-2-[(22S)-18-chloro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
 20 *2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: Example 66*
 was prepared using intermediate **134** by following the procedure to prepare example
20. ¹H NMR (500 MHz, DMSO-d₆) δ 8.39 (s, 1H), 7.96 (d, J=7.6 Hz, 1H), 7.53 (t, J=7.8 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 7.26 - 7.17 (m, 2H), 7.11 (s, 1H), 6.25 (br. s., 1H), 5.75 - 5.62 (m, 2H), 4.75 (t, J=12.1 Hz, 1H), 4.58 (br. s., 1H), 4.03 - 3.84 (m, 2H), 3.56 - 3.49 (m, 1H), 3.40-2.50 (m, 1 H), 2.75 (d, J=9.5 Hz, 1H), 2.51 (br. s.,
 25 3H), 2.35 - 2.26 (m, 4H), 2.16 (br. s., 1H), 2.03 (d, J=13.7 Hz, 1H), 1.85 (d, J=12.5

Hz, 1H), 1.69 - 1.55 (m, 2H), 1.22 (s, 3H), 1.17 (s, 9H), 1.04 (d, J=5.8 Hz, 3H).

LCMS (M+1) = 673.3.

Intermediate 135




5

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **135** was prepared using intermediate **134** by following the procedure to prepare intermediate **117**. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (s, 1H), 7.81 (d, J=7.8 Hz, 1H), 7.49 (t, J=7.7 Hz, 1H), 7.31 (d, J=7.8 Hz, 1H), 7.19 (s, 1H), 7.00 (s, 1H), 6.90 (s, 1H), 5.90 (s, 1H), 4.63 (t, J=11.7 Hz, 1H), 4.58 - 4.48 (m, 1H), 3.83 - 3.72 (m, 4H), 3.55 - 3.48 (m, 1H), 3.39 (td, J=7.8, 2.9 Hz, 1H), 3.25 (d, J=11.7 Hz, 1H), 2.88 (d, J=12.0 Hz, 1H), 2.60 (s, 3H), 2.37 (s, 3H), 2.08 - 1.28 (m, 10H) 1.27 (s, 3H), 1.25 (s, 9H), 1.18 (d, J=5.9 Hz, 3H). LCMS (M+1) = 689.4.

15

Example 67




20

(2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **67** was prepared using intermediate **135** by following the procedure to prepare example **28**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.45 (s, 1H), 7.94 (d, J=7.9 Hz, 1H), 7.52 (t, J=7.6

25


Hz, 1H), 7.33 (d, J=7.0 Hz, 1H), 7.27 (s, 1H), 7.23 (s, 1H), 7.10 (s, 1H), 5.66 (br. s., 1H), 4.68 (d, J=5.5 Hz, 1H), 4.48 (t, J=12.2 Hz, 1H), 3.75-3.00 (m, 4 H), 2.79 (d, J=10.7 Hz, 1H), 2.51 (br. s., 3H), 2.30 (s, 3H), 2.00 - 1.85 (m, 3H), 1.68 (br. s., 4H), 1.60 - 1.41 (m, 3H), 1.18 (s, 3H), 1.16 (s, 9H), 1.07 (d, J=5.8 Hz, 3H). LCMS (M+1) = 675.3.

Intermediate 136



(2-Fluoro-6-hydroxy-3-methylphenyl)boronic acid: A mixture of (2-fluoro-6-methoxy-3-methylphenyl)boronic acid (200 mg, 1.087 mmol) was cooled to 0 °C and BBr₃ (0.308 mL, 3.26 mmol) was added. The mixture was then stirred at rt for 2 h. It was then poured into ice and extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 185 mg (95%) of the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.25 - 7.15 (m, 1H), 6.71 - 6.61 (m, 1H), 5.76 - 5.53 (m, 2H), 2.20 (d, J=2.0 Hz, 3H). LCMS (M+23) = 193.


Intermediate 137



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-fluoro-6'-hydroxy-3'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **137** was prepared using intermediates **65** and **136** by following the procedure to prepare intermediate **89**. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, J=7.3 Hz, 1H), 8.03 (s, 1H), 7.61 (t, J=7.7 Hz, 1H), 7.44 (d, J=7.6 Hz, 1H),

7.11 (t, J=8.4 Hz, 1H), 6.83 (s, 1H), 6.77 (d, J=8.3 Hz, 1H), 6.17 - 5.84 (m, 2H), 5.50-2.50 (m, 4 H), 5.40 (dd, J=17.1, 1.5 Hz, 1H), 5.27 (brs, 1 H), 5.12 (br. s., 1H), 4.01 (d, J=4.9 Hz, 2H), 3.76 (s, 3H), 2.62 (s, 3H), 2.28 (d, J=1.7 Hz, 3H), 2.07 - 1.92 (m, 2H), 1.75 (d, J=7.3 Hz, 1H), 1.59 (s, 1H), 1.36 (br. s., 3H), 1.27 (s, 9H). LCMS (M+1) = 631.3.


Intermediate 138



10 (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-fluoro-3'-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **138** was prepared using intermediate **137** and (R)-pent-4-en-2-ol by following the procedure to prepare intermediate **115**. LCMS (M+1) = 699.4. It's a mixture of cis/trans mixture.

15

Intermediate 139



Methyl (2S)-2-(tert-butoxy)-2-[(22S)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate **139** was prepared using intermediate **138** by following the procedure to prepare intermediate **116**. LCMS (M+1) = 671.4. The product is a mixture of cis/trans product.


25

Example 68 and 69

Saponification of intermediate **139** by following the procedure to prepare example **20** afforded two compounds.

5


Example 68



(2S)-2-(tert-Butoxy)-2-[(22S,24E)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: ¹H NMR (500 MHz, DMSO-d₆) δ 8.17 (s, 1H), 7.95 (d, J=7.9 Hz, 1H), 7.52 (t, J=7.6 Hz, 1H), 7.32 - 7.17 (m, 2H), 7.08 (s, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.20 - 6.04 (m, 1H), 5.74 (br. s., 1H), 5.64 (d, J=15.6 Hz, 1H), 4.76 (t, J=12.1 Hz, 1H), 4.52 (br. s., 1H), 3.97 - 3.80 (m, 2H), 3.54 - 3.47 (m, 1H), 3.40-3.20 (m, 1H), 2.74 (d, J=10.1 Hz, 1H), 2.52 (br. s., 3H), 2.31 - 2.23 (m, 1H), 2.20 (s, 3H), 2.11 (br. s., 1H), 2.01 (d, J=13.7 Hz, 1H), 1.87 (d, J=12.2 Hz, 1H), 1.70 - 1.56 (m, 2H), 1.21 (s, 3H), 1.18 (s, 9H), 1.06 (d, J=5.8 Hz, 3H). LCMS (M+1) = 657.4.

20


Example 69



(2S)-2-(tert-Butoxy)-2-[(22S,24Z)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: ¹H NMR (500

MHz, DMSO-d₆) δ 8.22 (br. s., 1H), 7.89 (d, $J=7.0$ Hz, 1H), 7.52 (t, $J=7.0$ Hz, 1H), 7.35 (br. s., 1H), 7.22 (d, $J=7.9$ Hz, 1H), 7.05 - 6.92 (m, 2H), 5.78 - 5.59 (m, 2H), 5.53 (br. s., 1H), 4.59 (br. s., 1H), 4.27 (t, $J=12.7$ Hz, 1H), 3.96 (d, $J=8.5$ Hz, 1H), 3.79 (br. s., 1H), 3.74-3.15 (m, 2H), 3.04 (d, $J=10.7$ Hz, 1H), 2.82 (d, $J=13.1$ Hz, 1H), 2.52 (s, 3H), 2.46 (d, $J=9.2$ Hz, 1H), 2.21 (br. s., 3H), 2.06 (d, $J=13.7$ Hz, 1H), 1.79 (d, $J=15.9$ Hz, 2H), 1.54 (br. s., 1H), 1.21 (br. s., 3H), 1.15 (br. s., 12H). LCMS (M+1) = 657.4.

Intermediate 140




10

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **140** was prepared using intermediate **139** by following the procedure to prepare intermediate **117**. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H), 7.89 - 7.77 (m, 1H), 7.58 - 7.44 (m, 1H), 7.34 (d, $J=7.6$ Hz, 1H), 7.11 (t, $J=8.7$ Hz, 1H), 6.73 - 6.66 (m, 1H), 5.94 (s, 1H), 4.65 (t, $J=11.9$ Hz, 1H), 4.59 - 4.44 (m, 1H), 3.83 - 3.72 (m, 4H), 3.48 (td, $J=7.5, 3.3$ Hz, 1H), 3.37 (td, $J=7.7, 3.2$ Hz, 1H), 3.20 (d, $J=11.5$ Hz, 1H), 2.85 (d, $J=12.0$ Hz, 1H), 2.61 (s, 3H), 2.27 (s, 3H), 2.03 - 1.89 (m, 3H), 1.83 - 1.70 (m, 3H), 1.66 - 1.43 (m, 5H), 1.41 - 1.29 (m, 3H), 1.25 (s, 9H), 1.19 - 1.12 (m, 3H). LCMS (M+1) = 673.4.

20

Example 70




25

(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **70** was prepared using intermediate **140** by following the procedure to prepare example **20**.

¹H NMR (500 MHz, DMSO-d₆) δ 8.24 (s, 1H), 7.94 (d, J=7.3 Hz, 1H), 7.50 (t, J=7.9 Hz, 1H), 7.35 - 7.16 (m, 2H), 7.16 - 7.02 (m, 1H), 6.93 (d, J=8.5 Hz, 1H), 5.81 - 5.56 (m, 1H), 4.62 (br. s., 1H), 4.52 (t, J=11.7 Hz, 1H), 3.60-3.20 (m, 4H), 2.82 - 2.72 (m, 1H), 2.51 (br. s., 3H), 2.20 (s, 3H), 1.98 - 1.85 (m, 3H), 1.71 - 1.53 (m, 5H), 1.41 (br. s., 2H), 1.21 - 1.13 (m, 12H), 1.10 - 1.04 (m, 3H). LCMS (M+1) = 659.6.

10

Intermediate 141




(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-cyano-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: Intermediate **141** was prepared using intermediate **65** and 5-cyano-2-

hydroxyphenylboronic acid by following the procedure to prepare intermediate **89**.
¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 8.08 (d, J=7.6 Hz, 1H), 7.66 (d, J=2.2 Hz, 1H), 7.63 - 7.56 (m, 2H), 7.44 (d, J=7.6 Hz, 1H), 7.11 (d, J=8.3 Hz, 1H), 6.85 (s, 1H), 6.23 - 5.74 (m, 2H), 5.41 (dd, J=17.1, 1.7 Hz, 1H), 5.10 (d, J=10.0 Hz, 1H), 5.00-2.50 (m, 4H), 4.02 (d, J=4.9 Hz, 2H), 3.77 (s, 3H), 2.61 (s, 3H), 2.10 - 1.94 (m, 2H), 1.74 (br. s., 1H), 1.60 (s, 1H), 1.37 (s, 3H), 1.26 (s, 9H). LCMS (M+1) = 624.24.

25


Intermediate 142



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-cyano-2'-((*S*)-
pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-
(tert-butoxy)acetate: Intermediate **142** was prepared using intermediate **141** and (*R*)-
 pent-4-en-2-ol by following the procedure to prepare intermediate **115**. ¹H NMR
 (400 MHz, CDCl₃) δ 8.15 - 8.03 (m, 2H), 7.70 (d, *J*=2.0 Hz, 1H), 7.64 (dd, *J*=8.6, 2.0
 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.06 (d, *J*=8.6 Hz, 1H), 6.84 (s, 1H), 6.09 - 5.90 (m,
 10 2H), 5.82 - 5.71 (m, 1H), 5.41 (d, *J*=15.7 Hz, 1H), 5.07 (d, *J*=12.0 Hz, 3H), 5.00-2.50
 (m, 4 H), 4.63 - 4.54 (m, 1H), 4.02 (d, *J*=4.9 Hz, 2H), 3.76 (s, 3H), 2.63 (s, 3H), 2.51
 - 2.41 (m, 1H), 2.40 - 2.30 (m, 1H), 2.02 (d, *J*=10.5 Hz, 3H), 1.74 (br. s., 1H), 1.38
 (br. s., 3H), 1.34 (d, *J*=6.1 Hz, 3H), 1.27 (s, 9H). LCMS(*M*+1)=692.4.

15

Intermediate 143




20 *Methyl (2S)*-2-(*tert*-butoxy)-2-[(22*S*)-17-isocyano-4,22,28-trimethyl-21,27-
dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate **142**
 was prepared using intermediate **142** following the procedure to prepare intermediate
116. LCMS (*M*+1) = 664.4. The product is a mixture of *cis/trans* isomers.

25

Examples 71 and 72

A mixture of intermediate **143** (12 mg, 0.018 mmol), NaOH (0.090 mL, 0.090 mmol) in MeOH (1 mL) heated at reflux for 3 h. Then the reaction mixture cooled,
 5 filtered and purified by prep HPLC to afford two compounds.


Example 71



10 *(2S)-2-(tert-Butoxy)-2-[(22S)-17-isocyano-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,1}.0^{2,7}.0^{1,5,2}]*tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: Isolated 3.3 mg
 (27%) as a white solid. ¹H NMR (500MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.01 (d, J=7.6
 Hz, 1H), 7.83 (d, J=8.5 Hz, 1H), 7.73 (d, J=1.5 Hz, 1H), 7.57 (t, J=7.6 Hz, 1H), 7.43 -
 15 7.33 (m, 2H), 7.08 (s, 1H), 6.26 (br. s., 1H), 5.70 (d, J=14.6 Hz, 1H), 5.52 (br. s.,
 1H), 4.81 - 4.69 (m, 2H), 4.02 - 3.93 (m, 1H), 3.91 - 3.84 (m, 1H), 3.59 (br. s., 1H),
 3.51 - 3.42 (m, 1H), 2.77 - 2.69 (m, 1H), 2.52 (s, 3H), 2.42 - 2.32 (m, 1H), 2.23 (br.
 s., 1H), 2.00 (d, J=14.0 Hz, 1H), 1.85 (d, J=12.5 Hz, 1H), 1.68 - 1.52 (m, 2H), 1.21
 (s, 3H), 1.15 (s, 9H), 1.10 (d, J=5.8 Hz, 3H). LCMS (M+1) = 650.7.


20

Example 72



(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-17-carbamoyl-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid: Isolated 1.5 mg (12%) as a white solid. ¹H NMR (500MHz, DMSO-d₆) δ 8.45 (s, 1H), 7.98 (d, J=7.9 Hz, 1H), 7.95 - 7.86 (m, 2H), 7.84 (s, 1H), 7.57 (t, J=7.5 Hz, 1H), 7.37 (d, J=7.6 Hz, 1H), 7.25 (d, J=8.5 Hz, 1H), 7.20 (br. s., 1H), 7.10 (s, 1H), 6.29 (br. s., 1H), 5.70 (d, J=15.6 Hz, 1H), 5.61 (br. s., 1H), 4.77 (t, J=11.7 Hz, 1H), 4.68 (br. s., 1H), 4.02 - 3.93 (m, 1H), 3.93 - 3.84 (m, 1H), 3.54 - 3.24 (m, 5H), 2.75 (br. s., 1H), 2.52 (br. s., 3H), 2.41 - 2.31 (m, 1H), 2.22 (br. s., 1H), 2.02 (d, J=13.7 Hz, 1H), 1.87 (d, J=13.1 Hz, 1H), 1.61 (d, J=12.8 Hz, 2H), 1.22 (s, 3H), 1.17 (s, 9H), 1.09 (d, J=5.5 Hz, 3H). LCMS (M+1) = 668.6.


Intermediate 144



15


Methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*S*)-17-isocyano-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: A mixture of intermediate **143** (40 mg, 0.060 mmol), Pd/C (0.641 mg, 6.03 μmol) in MeOH (1 mL) was stirred at rt under a H₂ balloon for 3 h. It was then filtered. The filtrate was concentrated and purified by biotage, eluting with 20% EtOAc/hexane to isolate 25 mg (62%) of the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.53 (s, 1H), 7.86 (d, J=8.1 Hz, 1H), 7.70 - 7.61 (m, 2H), 7.54 (t, J=7.7 Hz, 1H), 7.32 (m, 1H), 7.05 (d, J=9.3 Hz, 1H), 6.92 (s, 1H), 5.90 (s, 1H), 4.74 - 4.58 (m, 2H), 3.87 - 3.70 (m, 4H), 3.59 - 3.49 (m, 1H), 3.47 - 3.36 (m, 1H), 3.26 (d, J=12.0 Hz, 1H), 2.99 - 2.85 (m, 1H), 2.61 (s, 3H), 2.08 - 1.93 (m, 3H), 1.93 - 1.69 (m, 5H), 1.70 - 1.63 (m, 2H), 1.29 - 1.21 (m, 15H). LCMS (M+1) = 666.4.

Example 73



5 *(2S)-2-(tert-Butoxy)-2-[(22S)-17-cyano-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,1}.0^{2,7}.0^{1,5,2}]*tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **73** was
 prepared using intermediate **144** by following the procedure to prepare example **28**.
¹H NMR (500 MHz, DMSO-d₆) δ 8.47 (br. s., 1H), 7.99 (d, *J*=7.3 Hz, 1H), 7.83 (d,
¹⁰ *J*=8.9 Hz, 1H), 7.75 (br. s., 1H), 7.56 (t, *J*=7.8 Hz, 1H), 7.39 (d, *J*=8.5 Hz, 2H), 7.11
 (s, 1H), 5.59 (br. s., 1H), 4.82 (d, *J*=4.9 Hz, 1H), 4.45 (t, *J*=11.6 Hz, 1H), 3.71-3.10
 (m, 4H), 2.80 (d, *J*=10.7 Hz, 1H), 2.51 (br. s., 3H), 2.00 - 1.81 (m, 3H), 1.80 - 1.60
 (m, 4H), 1.52 (d, *J*=15.0 Hz, 3H), 1.21 - 1.07 (m, 15H). LCMS (M+1) = 652.6.

Intermediate 145




15

20 *(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-hydroxy-4'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate*: Intermediate **145** was prepared using intermediate **65** and 5-methyl-
 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol by following the procedure to
 prepare intermediate **89**. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H), 8.04 (d, *J*=7.3
 Hz, 1H), 7.61 - 7.54 (m, 1H), 7.53 - 7.46 (m, 1H), 7.25 - 7.18 (m, 1H), 6.89 - 6.81
 (m, 3H), 6.19 - 5.80 (m, 2H), 5.41 (dd, *J*=17.1, 1.7 Hz, 1H), 5.37 - 5.30 (m, 1H), 5.12
 (d, *J*=9.8 Hz, 1H), 5.00-2.50 (m, 4 H), 4.11 - 3.93 (m, 2H), 3.76 (s, 3H), 2.62 (s, 3H),

2.40 (s, 3H), 2.10 - 1.95 (m, 3H), 1.73 (br. s., 1H), 1.37 (d, J=2.2 Hz, 3H), 1.26 (s, 9H). LCMS (M+1) = 613.3.

Intermediate 146




5

(S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(4'-methyl-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: Intermediate **146** was prepared using intermediate **145** and (*R*)-pent-4-en-2-ol by following the procedure to prepare intermediate **115**. LCMS (M+1) = 681.5.

10

Intermediate 147




15

Methyl (2S)-2-(*tert*-butoxy)-2-[(22*S*)-4,18,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate **147** was prepared using intermediate **146** by following the procedure to prepare intermediate **116**. LCMS (M+1) = 653.4. The product is a mixture of *cis/trans* isomers.

20

25


Intermediate 148



5 *Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,18,22,28-tetramethyl-21,27-dioxo-*
1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **148** was
 prepared using **147** by following the procedure to prepare intermediate **117**. ¹H
 NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.49 (t, J=7.7 Hz,
 1H), 7.33 (d, J=7.8 Hz, 2H), 7.24 (d, J=8.1 Hz, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 5.90
 10 (s, 1H), 4.67 - 4.54 (m, 2H), 3.85 - 3.72 (m, 4H), 3.57 - 3.46 (m, 1H), 3.44 - 3.35 (m,
 1H), 3.25 (d, J=12.2 Hz, 1H), 2.89 (d, J=12.2 Hz, 1H), 2.60 (s, 3H), 2.43 (s, 3H), 2.05
 - 1.50 (m, 10H), 1.27 (s, 3H), 1.25 (s, 9H), 1.18 (d, J=6.1 Hz, 3H). LCMS (M+1) =
 655.3.

15


Example 74



20 *(2S)-2-(tert-Butoxy)-2-[(22S)-4,18,22,28-tetramethyl-21,27-dioxo-1,5,7,8-*
tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **74** was
 prepared using intermediate **148** by following the procedure to prepare example **28**.
¹H NMR (500 MHz, DMSO-d₆) δ 8.49 (s, 1H), 7.90 (d, J=7.3 Hz, 1H), 7.50 (t, J=7.8
 Hz, 1H), 7.29 (d, J=7.6 Hz, 1H), 7.17 (d, J=7.3 Hz, 1H), 7.07 (s, 1H), 6.99 (s, 1H),
 6.81 (d, J=7.6 Hz, 1H), 5.59 (br. s., 1H), 4.67 (d, J=6.4 Hz, 1H), 4.50 (t, J=13.1 Hz,
 25 1H), 3.60-3.20 (m, 4H), 2.80 (d, J=10.1 Hz, 1H), 2.51 (br. s., 3H), 2.37 (s, 3H), 2.05 -

1.84 (m, 3H), 1.77 - 1.64 (m, 4H), 1.60 - 1.41 (m, 3H), 1.18 (s, 3H), 1.16 (s, 9H), 1.09 (d, J=5.5 Hz, 3H). LCMS (M+1) = 641.4.

Intermediate 149




5

2-Bromo-4,5-dimethylphenol: A mixture of 3,4-dimethylphenol (2 g, 16.37 mmol) in DCM (10 mL) at -78°C was added bromine (0.843 mL, 16.37 mmol) dropwise and the reaction was stirred for 1 h at this temperature. Sat. sodium sulfite solution was added and it was then stirred 5 min at rt and then extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated to obtain 2 g oil. It was then purified with 5% EtOAc/hexane to isolate 800 mg (24%) of the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.22 (s, 1H), 6.84 (s, 1H), 5.33 - 5.23 (m, 1H), 2.20 (s, 3H), 2.19 (s, 3H).


15

Intermediate 150



(S)-1-Bromo-4,5-dimethyl-2-(pent-4-en-2-yloxy)benzene: A mixture of intermediate **149** (200 mg, 0.995 mmol), (R)-pent-4-en-2-ol (171 mg, 1.989 mmol), triphenylphosphine (522 mg, 1.989 mmol), (Z)-diethyl diazene-1,2-dicarboxylate (346 mg, 1.989 mmol) in THF (5ml) was stirred at rt for 2 h. It was then diluted with EtOAc, washed with water, dried over MgSO₄. The organic layer was filtered, concentrated and purified by biotage, eluting with 3% EtOAc/hexane to isolate 220 mg (82%) of the desired product as an oil. ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 1H), 6.74 (s, 1H), 5.93 (ddt, J=17.2, 10.1, 7.0 Hz, 1H), 5.20 - 5.07 (m, 2H), 4.39 (sxt, J=6.1 Hz, 1H), 2.55 (qd, J=7.0, 5.6 Hz, 1H), 2.46 - 2.35 (m, 1H), 2.22 (s, 3H), 2.19 (s, 3H), 1.35 (d, J=6.1 Hz, 3H).

Intermediate 151




5 *(S)*-2-(4,5-Dimethyl-2-(pent-4-en-2-yloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane: To a mixture of intermediate **150** (120 mg, 0.446 mmol) in THF (2 mL) was added 2.5M n-BuLi (0.214 mL, 0.535 mmol) at -78 °C. It was then stirred at this temperature for 1 h, then added 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (100 mg, 0.535 mmol) and stirred at -78 °C for 30 min, then warmed to rt and stirred at rt for 3 h. It was then quenched with water, extracted with EtOAc.

10 The organic was dried over MgSO₄, filtered and concentrated to obtain 0.108 g (45%) of the desired product as an oil. ¹H NMR (500 MHz, CDCl₃) δ 7.42 (s, 1H), 6.72 (s, 1H), 6.03 - 5.96 (m, 1H), 5.14 - 5.06 (m, 2H), 4.35-4.30 (m, 1H), 2.55 - 2.49 (m, 1H), 2.44 - 2.36 (m, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 1.37 - 1.35 (m, 12H), 1.30 - 1.29 (m, 3H).

15

Intermediate 152




20 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4',5'-dimethyl-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A mixture of intermediate **65** (50 mg, 0.085 mmol), intermediate **151** (108 mg, 0.171 mmol), Na₂CO₃ (0.107 mL, 0.213 mmol) in DMF (1.5 mL) was vacuum, back-filled with N₂ for 3 times. It was then added (Ph₃P)₄Pd (9.87 mg, 8.54 μmol) and heated at 95 °C in a microwave tube for 1 h. It was then

25 diluted with EtOAc, washed with water. The organic was dried over MgSO₄, filtered and concentrated to obtain 150 mg oil, which was then purified by biotage, eluting

with 25% acetone/hexane to isolate 80 mg(94%) of the desired product as a white solid. LCMS (M+1) = 695.5.

Intermediate 153



5


Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-

2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate 153

was prepared using intermediate **152** by following the procedure to prepare intermediate **116**. LCMS (M+1) = 667.4. The product is a mixture of cis/trans isomers.

10

Example 75



15

(2S)-2-(tert-Butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-


2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: Example 75

was prepared using intermediate **153** by following the procedure to prepare example **20**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.42 (s, 1H), 7.91 (d, J=7.9 Hz, 1H), 7.50 (t, J=7.6 Hz, 1H), 7.29 (d, J=7.6 Hz, 1H), 7.10 (s, 1H), 7.02 (s, 1H), 6.96 (s, 1H), 6.29 (br. s., 1H), 5.80 - 5.60 (m, 2H), 4.85 - 4.66 (m, 1H), 4.54 (br. s., 1H), 4.06 - 3.82 (m, 2H), 3.57 - 3.48 (m, 1H), 3.40-3.25 (m, 1 H), 2.75 (d, J=10.7 Hz, 1H), 2.52 (br. s., 3H), 2.35 - 2.22 (m, 4H), 2.22 - 2.12 (m, 4H), 2.03 (d, J=13.4 Hz, 1H), 1.85 (d,

25

J=11.6 Hz, 1H), 1.70 - 1.56 (m, 2H), 1.22 (s, 3H), 1.17 (s, 9H), 1.03 (d, J=5.8 Hz, 3H). LCMS (M+1) = 653.4.

Intermediate 154




5

*Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,1}.4.0^{2,7}.0^{1,5,2}]*tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **154** was prepared using intermediate **153** by following the procedure to prepare intermediate **117**. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.55 - 7.43 (m, 1H), 7.35 (d, J=7.6 Hz, 1H), 7.12 (s, 1H), 6.90 (s, 1H), 6.82 (s, 1H), 5.90 (s, 1H), 4.68 - 4.50 (m, 2H), 3.85 - 3.72 (m, 4H), 3.50 (d, J=7.1 Hz, 1H), 3.43 - 3.35 (m, 1H), 3.25 (d, J=12.0 Hz, 1H), 2.88 (d, J=11.0 Hz, 1H), 2.60 (s, 3H), 2.34 (s, 3H), 2.27 (s, 3H), 2.09 - 1.94 (m, 3H), 1.89 - 1.66 (m, 4H), 1.65-1.50 (m, 3 H), 1.27 - 1.23 (m, 12H), 1.17 (d, J=6.1 Hz, 3H). LCMS (M+1) = 669.5.

15

Example 76




20

*(2S)-2-(tert-Butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,1}.4.0^{2,7}.0^{1,5,2}]*tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **76** was prepared using intermediate **154** by following the procedure to prepare example **28**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.49 (s, 1H), 7.90 (d, J=7.3 Hz, 1H), 7.50 (t, J=7.8

25


Hz, 1H), 7.29 (d, J=7.6 Hz, 1H), 7.17 (d, J=7.3 Hz, 1H), 7.07 (s, 1H), 6.99 (s, 1H),
 6.81 (d, J=7.6 Hz, 1H), 5.59 (br. s., 1H), 4.67 (d, J=6.4 Hz, 1H), 4.50 (t, J=13.1 Hz,
 1H), 3.60-3.20 (m, 4H), 2.80 (d, J=10.1 Hz, 1H), 2.51 (br. s., 3H), 2.37 (s, 3H), 2.05 -
 1.84 (m, 3H), 1.77 - 1.64 (m, 4H), 1.60 - 1.41 (m, 3H), 1.18 (s, 3H), 1.16 (s, 9H),
 5 1.09 (d, J=5.5 Hz, 3H). LCMS (M+1) = 641.4.

Intermediate 155




10 (2-Hydroxy-6-methylphenyl)boronic acid: Intermediate **155** was prepared
 using (2-methoxy-6-methylphenyl)boranediol by following the procedure to prepare
 intermediate **136**. ¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (br. s., 1H), 7.44 - 7.25 (m,
 1H), 6.94 - 6.81 (m, 1H), 6.78 (d, J=8.1 Hz, 1H), 2.51(s, 3H).

Intermediate 156



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-hydroxy-6'-
 methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-
 20 butoxy)acetate: Intermediate **156** was prepared using intermediates **65** and **155** by
 following the procedure to prepare intermediate **89**. ¹H NMR (400 MHz, CDCl₃) δ
 8.12 (d, J=6.8 Hz, 1H), 7.91 (s, 1H), 7.61 (t, J=7.5 Hz, 1H), 7.33 (d, J=7.3 Hz, 1H),
 7.22 (t, J=7.8 Hz, 1H), 6.91 (d, J=8.6 Hz, 2H), 6.83 (s, 1H), 6.07 - 5.90 (m, 2H), 5.40
 (d, J=17.9 Hz, 1H), 5.09 (br. s., 1H), 5.00-2.50 (m, 4H), 4.88 (s, 1H), 4.00 (d, J=4.4
 25 Hz, 2H), 3.75 (s, 3H), 2.63 (s, 3H), 2.15 (s, 3H), 2.06 - 1.92 (m, 2H), 1.73 (br. s.,
 1H), 1.62-1.57 (m, 1 H), 1.36 (br. s., 3H), 1.26 (s, 9H). LCMS (M+1) = 613.3.


Intermediate 157



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-methyl-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: Intermediate **157** was prepared intermediate **156** and (*R*)-pent-4-en-2-ol by following the procedure to prepare intermediate **115**. LCMS (M+1) = 681.5.

10

Intermediate 158




15

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,16,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{0,14}.0^{2,7}.0^{1,5,20}]]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate **158** was prepared using intermediate **157** by following the procedure to prepare intermediate **116**. LCMS (M+1) = 653.5. The product is a mixture of *cis/trans* isomers.

20

Intermediate 159




Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,16,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **159** was prepared using intermediate **158** by following the procedure to prepare intermediate

5 **117**. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (s, 1H), 7.76 (d, J=7.6 Hz, 1H), 7.49 (t, J=7.6 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H), 7.16 (d, J=7.6 Hz, 1H), 6.92 - 6.79 (m, 3H), 6.00 (s, 1H), 4.70 (t, J=11.7 Hz, 1H), 4.50 (br. s., 1H), 3.81 - 3.66 (m, 4H), 3.45 (d, J=6.6 Hz, 1H), 3.36 (d, J=4.4 Hz, 1H), 3.13 (d, J=11.2 Hz, 1H), 2.87 - 2.77 (m, 1H), 2.61 (s, 3H), 2.10 (s, 3H), 2.03 - 1.84 (m, 3H), 1.79 - 1.44 (m, 7H), 1.26 (s, 12H),

10 1.17 (d, J=5.9 Hz, 3H). LCMS (M+1) = 655.5.

Example 77




15 *(2S)-2-(tert-Butoxy)-2-[(22S)-4,16,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid*: Example **77** was prepared using intermediate **159** by following the procedure to prepare example **28**.

¹H NMR (500 MHz, DMSO-d₆) δ 8.14 - 8.00 (m, 1H), 7.88 (d, J=7.6 Hz, 1H), 7.50 (t, J=7.6 Hz, 1H), 7.28 - 7.19 (m, 1H), 7.15 (d, J=7.3 Hz, 1H), 7.05 (s, 1H), 6.96 (d, J=8.5 Hz, 1H), 6.86 (d, J=7.6 Hz, 1H), 5.75 (br. s., 1H), 4.57 (br. s., 2H), 3.70-3.20 (m, 4H), 2.73 (d, J=11.3 Hz, 1H), 2.58 - 2.47 (m, 12H), 2.00 (s, 3H), 1.98 - 1.76 (m, 3H), 1.71 - 1.46 (m, 5H), 1.37 (br. s., 2H), 1.17 (s, 12H), 1.07 (d, J=5.5 Hz, 3H).

20 LCMS (M+1) = 641.4.

25


Intermediate 160



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-hydroxy-5'-methyl-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **160** was prepared using intermediate **65** and (4-fluoro-2-hydroxy-5-methylphenyl)boronic acid by following the procedure to prepare intermediate **89**. ¹H NMR (400 MHz, CDCl₃) δ 8.17 - 7.99 (m, 2H), 7.60 - 7.52 (m, 1H), 7.44 (d, J=7.8 Hz, 1H), 7.13 (d, J=8.6 Hz, 1H), 6.84 (s, 1H), 6.74 (d, J=10.8 Hz, 1H), 6.12 - 5.86 (m, 2H), 5.72 (d, J=18.8 Hz, 1H), 5.41 (d, J=17.1 Hz, 1H), 5.11 (d, J=9.5 Hz, 1H), 5.00-2.50 (m, 4H), 4.02 (d, J=4.9 Hz, 2H), 3.76 (s, 3H), 2.62 (s, 3H), 2.27 (s, 3H), 2.09 - 1.94 (m, 2H), 1.75 (d, J=7.3 Hz, 1H), 1.58 - 1.47 (m, 1H), 1.37 (br. s., 3H), 1.27 (s, 9H). LCMS (M+1) = 631.4.

15


Intermediate 161



20 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-5'-methyl-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Intermediate **161** was prepared using intermediate **161** and (R)-pent-4-en-2-ol by following the procedure to prepare intermediate **115**. LCMS (M+1) = 699.5.

25


Intermediate 162



Methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: Intermediate 162 was prepared using intermediate 161 by following the procedure to prepare intermediate 116. LCMS (M+1) = 671.4. The product is a mixture of cis/trans isomers.

10


Example 78



(2S)-2-(tert-Butoxy)-2-[(22S)-18-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: Example 78 was prepared using intermediate 162 by following the procedure to prepare example 20. ¹H NMR (500 MHz, DMSO-d₆) δ 8.39 (s, 1H), 7.95 (d, *J*=7.6 Hz, 1H), 7.56 - 7.47 (m, 1H), 7.30 (d, *J*=7.3 Hz, 1H), 7.17 (d, *J*=9.2 Hz, 1H), 7.11 (s, 1H), 7.05 (d, *J*=12.2 Hz, 1H), 6.26 (br. s., 1H), 5.77 - 5.64 (m, 2H), 4.76 (t, *J*=12.5 Hz, 1H), 4.54 (br. s., 1H), 4.01 - 3.93 (m, 1H), 3.91 - 3.84 (m, 1H), 3.56 - 3.50 (m, 1H), 3.50-3.25 (m, 1H), 2.79 - 2.71 (m, 1H), 2.52 (br. s., 3H), 2.36 - 2.26 (m, 1H), 2.25 - 2.14 (m, 4H), 2.03 (d, *J*=13.1 Hz, 1H), 1.86 (d, *J*=11.9 Hz, 1H), 1.63 (d, *J*=11.3 Hz, 2H), 1.22 (s, 3H), 1.17 (s, 9H), 1.05 (d, *J*=5.5 Hz, 3H). LCMS (M+1) = 657.6.

25


Intermediate 163



5 *Methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-fluoro-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,2}]*tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Intermediate **163** was prepared using intermediate **162** by following the procedure to prepare intermediate **117**. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (s, 1H), 7.80 (d, J=7.6 Hz, 1H), 7.49 (t, J=7.7 Hz, 1H), 7.31 (br. s., 1H), 7.14 (d, J=9.3 Hz, 1H), 6.90 (s, 1H), 6.71 (d, J=12.0 Hz, 1H), 5.90 (s, 1H), 4.63 (t, J=12.1 Hz, 1H), 4.48 (br. s., 1H), 3.82 - 3.74 (m, 4H), 3.51 (d, J=7.3 Hz, 1H), 3.40 (br. s., 1H), 3.25 (d, J=8.1 Hz, 1H), 2.89 (d, J=11.5 Hz, 1H), 2.60 (s, 3H), 2.27 (s, 3H), 2.05-1.94 (m, 3H), 1.82-1.69 (m, 5H), 1.66 - 1.51 (m, 2H), 1.27 (s, 3H), 1.25 (s, 9H), 1.19 (d, J=6.1 Hz, 3H). LCMS (M+1) = 673.6.

15

Example 79




20 *(2S)-2-(tert-Butoxy)-2-[(22S)-18-fluoro-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰,1⁴.0^{2,7}.0^{15,2}]*tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Example **79** was prepared using intermediate **163** by following the procedure to prepare example **28**. ¹H NMR (500 MHz, DMSO-d₆) δ 8.46 (s, 1H), 7.92 (d, J=7.9 Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 7.20 (d, J=9.2 Hz, 1H), 7.10 (s, 1H), 7.05 (d, J=12.2 Hz, 1H), 5.65 (br. s., 1H), 5.71 - 5.57 (m, 1H), 4.64 (d, J=5.5 Hz, 1H), 4.48 (t, J=12.4 Hz, 1H), 3.63 - 3.54 (m, 1H), 3.52-3.22 (m, 2 H), 2.80 (d, J=11.3 Hz, 1H), 2.52 (s,

25

3H), 2.21 (s, 3H), 2.00 - 1.84 (m, 3H), 1.69 (br. s., 4H), 1.60 - 1.41 (m, 3H), 1.20 - 1.12 (m, 12H), 1.08 (d, J=5.8 Hz, 3H). LCMS (M+1) = 659.5.

Intermediate 164




5

(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-hydroxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. A mixture of (2-hydroxy-5-(trifluoromethyl)phenyl)boronic acid (106 mg, 0.512 mmol), (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (150 mg, 0.256 mmol), Na₂CO₃ (0.320 mL, 0.640 mmol) in DMF (1 mL) was evacuated and back-filled with N₂ for 3 times. To this was added (Ph₃P)₄Pd (29.6 mg, 0.026 mmol) and heated at 95 °C in a microwave tube for 1 h. Then, cooled, diluted with EtOAc and washed with water. The organic was dried over MgSO₄, filtered and concentrated to obtain 150 mg oil, which was purified by biotage eluting with 50% EtOAc/hexane to isolate 89 mg (52%) of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-hydroxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (s, 1H), 8.07 (d, J=7.8 Hz, 1H), 7.65 - 7.54 (m, 3H), 7.49 (d, J=7.6 Hz, 1H), 7.12 (d, J=8.3 Hz, 1H), 6.85 (s, 1H), 6.28 (br. s., 1H), 6.05 - 5.83 (m, 2H), 5.39 (d, J=17.4 Hz, 1H), 5.09 (br. s., 1H), 5.00-2.50 (m, 4H), 4.01 (d, J=4.4 Hz, 2H), 3.76 (s, 3H), 2.62 (s, 3H), 2.08 - 1.93 (m, 3H), 1.73 (br. s., 1H), 1.36 (s, 3H), 1.29 - 1.22 (m, 9H). LCMS (M+1) = 667.6.


25

Intermediate 165



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-((*S*)-
pent-4-en-2-yloxy)-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-
a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A mixture of (*S*)-methyl 2-(7-(4-(allyloxy)-
 4-methylpiperidin-1-yl)-2-(2'-hydroxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-5-
 methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (89 mg, 0.133 mmol),
 10 (*R*)-pent-4-en-2-ol (34.5 mg, 0.400 mmol), triphenylphosphine (105 mg, 0.400
 mmol) and DEAD (69.7 mg, 0.400 mmol) in THF (2 mL) was stirred at rt for 3 h. It
 was then diluted with EtOAc and washed with water. The organic was dried over
 MgSO₄, filtered and concentrated to obtain 100 mg yellow oil, which was purified by
 biotage eluting with 30% EtOAc/hexane to isolate 74 mg (75%) of (*S*)-methyl 2-(7-
 (4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-((*S*)-pent-4-en-2-yloxy)-5'-
 15 (trifluoromethyl)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-
 butoxy)acetate as an oil. LCMS (M+1) = 735.8.

Intermediate 166




20 *Methyl (2S)*-2-(tert-butoxy)-2-[(22*S*)-4,22,28-trimethyl-17-(trifluoromethyl)-
 21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: A mixture of (*S*)-
 methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(2'-((*S*)-pent-4-en-2-
 25 yloxy)-5'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-

(tert-butoxy)acetate (74 mg, 0.101 mmol), (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (6.31 mg, 10.07 μ mol), copper(i) iodide (19.18 mg, 0.101 mmol) in $\text{ClCH}_2\text{CH}_2\text{Cl}$ (80 mL) was refluxed for 3 h. It was then concentrated and purified by biotage eluting with 20% EtOAc/hexane to isolate 50 mg (70%) of methyl (2S)-2-(tert-butoxy)-2-[(22S,24Z)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate as an off-white solid. The product is a mixture of cis/trans product. LCMS (M+1) = 707.3.


10

Intermediate 167




Methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: A mixture of methyl (2S)-2-(tert-butoxy)-2-[(22S,24Z)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate (50 mg, 0.071 mmol), 10%Pd/C (7.53 mg, 7.07 μ mol) in MeOH (2 mL) was stirred under a H₂ balloon for 2 h. It was then filtered, concentrated and purified by biotage eluting with 20% EtOAc/hexane to isolate 38 mg of methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate as an off-white solid. LCMS (M+1) = 709.3.

Example 80



(2S)-2-(tert-Butoxy)-2-[(22S)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-
 5 dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: A mixture of methyl
 (2S)-2-(tert-butoxy)-2-[(22S)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxo-
 1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (38 mg, 0.054 mmol),
 10 NaOH (0.268 mL, 0.268 mmol) in MeOH (2 mL) was refluxed for 3 h. It was then
 filtered and purified by prep HPLC to isolate the desired product as a white solid.
 LCMS (M+1) = 695.3.

Intermediate 168




15

(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-2'-hydroxy-
 [1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate:
 To (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-
 20 methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.24 g, 0.41 mmol, 1
 equiv), (5-fluoro-2-hydroxyphenyl)boronic acid (96 mg, 0.62 mmol, 1.5 equiv), and
 Pd(PPh₃)₄ (47 mg, 0.041 mmol, 0.1 equiv) was added DMF (4.1 mL that had been
 degassed by sparging with nitrogen for 10 min). Na₂CO₃ (0.41 mL of a 2 M aqueous
 solution, 0.82 mmol, 2 equiv) was added and the reaction was heated to 90 °C for 3 h.
 25 Upon cooling to ambient temperature, the reaction was diluted with EtOAc and
 washed with water. The EtOAc layer was dried (Na₂SO₄) and concentrated *in vacuo*.

The crude product was purified by flash column chromatography (0-60% acetone in hexane) to provide the product as a yellow foam (0.19 g, 75%). ¹H NMR (400 MHz, CDCl₃) δ 8.13 - 8.08 (m, 1H), 8.05 - 8.00 (m, 1H), 7.67 - 7.48 (m, 3H), 7.09 - 6.94 (m, 4H), 6.07 - 5.92 (m, 1H), 5.45 - 5.36 (m, 1H), 5.22 - 5.07 (m, 2H), 4.04 - 3.97 (m, 2H), 3.81 - 3.77 (m, 3H), 3.77 - 3.74 (m, 4H), 2.74 - 2.65 (m, 3H), 2.08 - 1.94 (m, 3H), 1.80 - 1.68 (m, 1H), 1.36 (s, 3H), 1.24 (s, 9H). LCMS (M+1) = 617.35.

Intermediate 169




10

(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a solution of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.19 g, 0.31 mmol, 1 equiv), (R)-pent-4-en-2-ol (0.095 mL, 0.92 mmol, 3 equiv), and PPh₃ (0.16 g, 0.62 mmol, 2 equiv) in THF (1.54 mL) was added DEAD (0.098 mL, 0.62 mmol, 2 equiv). After stirring 2 h, dilute with ether and wash with water. The ether layer was dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-60% EtOAc in hexane) to provide the product as a white foam (0.17 g, 81%). ¹H NMR (500 MHz, CDCl₃) [note: 4H of piperidine not observed and are likely very broad] δ 8.16 (s, 1H), 8.08 - 7.99 (m, 1H), 7.61 - 7.56 (m, 1H), 7.51 (d, *J* = 7.6 Hz, 1H), 7.16 (dd, *J* = 9.1, 2.8 Hz, 1H), 7.04 - 6.95 (m, 2H), 6.92 - 6.82 (m, 1H), 6.08 - 5.97 (m, 1H), 5.74 (s, 1H), 5.42 (d, *J* = 17.3 Hz, 1H), 5.22 - 5.08 (m, 2H), 5.06 - 4.99 (m, 2H), 4.27 (d, *J* = 6.0 Hz, 1H), 4.03 (d, *J* = 4.7 Hz, 2H), 3.77 (s, 3H), 2.65 (br. s., 3H), 2.45 - 2.35 (m, 1H), 2.28 (s, 1H), 2.06 - 1.95 (m, 3H), 1.79 - 1.69 (m, 1H), 1.38 (br. s., 3H), 1.27 (s, 9H), 1.21 (d, *J* = 6.0 Hz, 3H). LCMS (M+1) = 685.4.


30

Intermediate 170



- Methyl (2S)-2-(tert-butoxy)-2-[(22S)-17-fluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate*: A solution of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.17 g, 0.25 mmol, 1 equiv) in DCE (50 mL) was heated to 80 °C. The Hoyveda Grubbs 2nd generation catalyst (31 mg, 0.05 mmol, 0.2 equiv) was added. The pale green brown solution was stirred for 1.5 h and then allowed to cool to ambient temperature. The reaction was concentrated *in vacuo*. The dark residue was then taken up in MeOH (5 mL) and NaBH₄ (13 mg, 0.35 mmol, 1.4 equiv) was added. After stirring 30 min, the reaction was diluted with EtOAc and washed with water. The EtOAc layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-100% EtOAc in hexane) to provide the product as a colorless film (62 mg, 38%). ¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 7.80 (s, 1H), 7.51 (s, 1H), 7.39 - 7.31 (m, 1H), 7.09 (s, 1H), 7.05 - 6.87 (m, 3H), 5.93 - 5.82 (m, 1H), 4.68 - 4.42 (m, 2H), 4.27 - 4.17 (m, 1H), 3.84 - 3.68 (m, *J* = 3.5 Hz, 4H), 3.56 - 3.22 (m, 2H), 3.03 - 2.85 (m, 1H), 2.62 (br. s., 3H), 2.02 - 1.70 (m, *J* = 12.8 Hz, 10H), 1.26 - 1.21 (m, 12H), 1.15 (d, *J* = 6.0 Hz, 3H). LCMS (M+1) = 659.45.


Example 81



(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-17-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: To a solution of methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*S*)-17-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (62 mg, 0.094 mmol, 1 equiv) in MeOH (0.85 mL) and water (0.09 mL) was added LiOH·H₂O (79 mg, 1.88 mmol, 20 equiv). The reaction was heated to 60 °C for 1.5 h. Upon cooling to ambient temperature, DMF (1 mL) added to solubilize milky white opaque solution.

The reaction was then filtered and purified via preparative LC/MS with the following conditions: Column: XBridge Phenyl, 19 x mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 20-60% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Product (13.7 mg, 22%) isolated. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.53 (s, 1H), 7.95 (d, *J* = 7.3 Hz, 1H), 7.53 (t, *J* = 7.8 Hz, 1H), 7.37 (d, *J* = 7.9 Hz, 1H), 7.22 - 7.14 (m, 3H), 7.09 (s, 1H), 5.59 (br. s., 1H), 4.63 (d, *J* = 6.1 Hz, 1H), 4.52 - 4.42 (m, 1H), 3.61 - 3.49 (m, 4H), 2.82 (d, *J* = 11.3 Hz, 1H), 2.51 (br. s., 3H), 1.98 - 1.87 (m, 3H), 1.71 (br. s., 4H), 1.59 - 1.45 (m, 3H), 1.18 (s, 3H), 1.16 (s, 9H), 1.07 (d, *J* = 5.8 Hz, 3H). LCMS (M+1) = 645.4.


Intermediate 171



(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-hydroxy[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: Prepared from (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate and (5-chloro-2-hydroxyphenyl)boronic acid using the same procedure as intermediate **168**

in 69% yield. ^1H NMR (400 MHz, CDCl_3) [note: 4H of piperidine not observed] δ 8.08 (s, 1H), 8.04 (d, $J = 6.3$ Hz, 1H), 7.58 (t, $J = 7.7$ Hz, 1H), 7.46 (d, $J = 7.5$ Hz, 1H), 7.32 (d, $J = 2.5$ Hz, 1H), 7.27 - 7.23 (m, 1H), 6.97 (d, $J = 8.8$ Hz, 1H), 6.85 (br. s., 1H), 5.98 (dd, $J = 11.2, 5.9$ Hz, 1H), 5.93 - 5.83 (m, 1H), 5.64 - 5.57 (m, 1H), 5.40 (dd, $J = 17.1, 1.5$ Hz, 1H), 5.16 - 5.07 (m, 1H), 4.01 (d, $J = 4.8$ Hz, 2H), 3.76 (s, 3H), 2.62 (s, 3H), 2.09 - 1.90 (m, 3H), 1.78 - 1.68 (m, 1H), 1.36 (br. s., 3H), 1.25 (s, 9H). LCMS (M+1) = 633.34.


Intermediate 172



10

(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Prepared from S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate **169** in 94% yield. LCMS (M+1) = 701.35.

Intermediate 172




20

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-17-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Prepared from (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate **170** in 47% yield. ^1H NMR

(400 MHz, CDCl₃) δ 8.62 - 8.51 (m, 1H), 7.85 - 7.80 (m, 1H), 7.55 - 7.48 (m, 1H), 7.36 - 7.31 (m, 2H), 7.27 - 7.25 (m, 1H), 6.95 - 6.88 (m, 2H), 5.90 - 5.78 (m, 1H), 4.66 - 4.51 (m, 2H), 4.26 - 4.17 (m, 2H), 3.77 (s, 3H), 3.55 - 3.21 (m, 3H), 2.66 - 2.59 (m, 3H), 2.02 - 1.59 (m, 10H), 1.32 - 1.21 (m, 15H). LCMS (M+1) = 675.5.


5

Example 82



(2S)-2-(tert-Butoxy)-2-[(22S)-17-chloro-4,22,28-trimethyl-21,27-dioxo-
 10 1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Prepared from methyl
 (2S)-2-(tert-butoxy)-2-[(22S)-17-chloro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-
 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate using the same procedure
 15 as example **81** in 47% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.47 (s, 1H), 7.95
 (br. s., 1H), 7.57 - 7.49 (m, 1H), 7.35 (t, *J* = 9.0 Hz, 2H), 7.30 (d, *J* = 2.1 Hz, 1H),
 7.19 (d, *J* = 8.9 Hz, 1H), 7.09 (s, 1H), 5.63 (br. s., 1H), 4.67 - 4.60 (m, 1H), 4.50 -
 4.41 (m, 1H), 3.91 - 3.87 (m, 1H), 3.39 (br. s., 3H), 2.81 - 2.76 (m, 1H), 2.50 (br. s.,
 3H), 1.99 - 1.24 (m, 10H), 1.15 (br. s., 3H), 1.14 (s, 9H), 1.06 (d, *J* = 5.8 Hz, 3H).
 20 LCMS (M+1) = 661.4.


Intermediate 173



25


(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Prepared from (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate and (4-fluoro-2-hydroxyphenyl)boronic acid using the same procedure as intermediate **168** in 69% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.08 (s, 1H), 8.02 (d, *J* = 7.5 Hz, 1H), 7.54 (t, *J* = 7.7 Hz, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.31 - 7.24 (m, 1H), 6.84 (s, 1H), 6.81 - 6.70 (m, 2H), 6.67 - 6.52 (m, 1H), 6.09 - 5.81 (m, 2H), 5.40 (dd, *J* = 17.1, 1.8 Hz, 1H), 5.18 - 5.04 (m, 1H), 4.00 (d, *J* = 5.0 Hz, 2H), 3.76 (s, 3H), 2.04 - 1.91 (m, 2H), 1.78 - 1.55 (m, 2H), 1.36 (s, 3H), 1.25 (s, 9H). LCMS (M+1) = 617.35.

Intermediate 174



(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Prepared from (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate **169** in 95% yield. ¹H NMR (500 MHz, CDCl₃) [note: 4H of piperidine not observed and are likely very broad] δ 8.11 - 8.08 (m, 1H), 8.06 - 7.99 (m, 1H), 7.57 - 7.46 (m, 2H), 7.39 - 7.33 (m, 1H), 6.96 - 6.82 (m, 1H), 6.81 - 6.73 (m, 2H), 6.08 - 5.94 (m, 1H), 5.84 - 5.71 (m, 1H), 5.46 - 5.38 (m, 1H), 5.22 - 5.00 (m, 4H), 4.47 - 4.35 (m, 1H), 4.05 - 4.01 (m, 2H), 3.77 (d, *J* = 2.0 Hz, 3H), 2.68 - 2.61 (m, 3H), 2.51 - 2.42 (m, 1H), 2.38 - 2.28 (m, 1H), 2.06 - 1.92 (m, 3H), 1.82 - 1.67 (m, 1H), 1.30 (s, 3H), 1.29 (d, *J* = 1.1 Hz, 3H), 1.27 - 1.26 (m, 9H). LCMS (M+1) = 685.4.


Intermediate 175



Methyl (2*S*)-2-(*tert*-butoxy)-2-[(22*S*)-18-fluoro-4,22,28-trimethyl-21,27-
 5 dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Prepared from (S)-
 methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-hydroxy-[1,1'-
 biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate using
 the same procedure as intermediate **170** in 21% yield. ¹H NMR (400 MHz, CDCl₃) δ
 10 8.55 (s, 1H), 7.80 (d, *J* = 7.8 Hz, 1H), 7.49 (t, *J* = 7.7 Hz, 1H), 7.31 - 7.25 (m, 2H),
 6.96 - 6.88 (m, 1H), 6.78 - 6.68 (m, 2H), 5.95 - 5.82 (m, 1H), 4.63 (s, 1H), 4.53 (br.
 s., 1H), 3.83 - 3.73 (m, 4H), 3.52 (br. s., 1H), 3.39 (br. s., 1H), 3.32 - 3.19 (m, 1H),
 2.97 - 2.82 (m, 1H), 2.61 (br. s., 3H), 2.04 - 1.53 (m, 10H), 1.27 (s, 3H), 1.24 (s, 9H),
 1.20 (d, *J* = 6.0 Hz, 3H). LCMS (M+1) = 659.4.

15

Example 83




(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-18-fluoro-4,22,28-trimethyl-21,27-dioxo-
 20 1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Prepared from methyl
 (2*S*)-2-(*tert*-butoxy)-2-[(22*S*)-18-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-
 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate using the same procedure
 25 as example **81** in 47% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.47 (s, 1H), 7.92 (d,
J = 7.6 Hz, 1H), 7.51 (t, *J* = 7.6 Hz, 1H), 7.37 - 7.26 (m, 2H), 7.11 (d, *J* = 10.7 Hz,

1H), 7.05 (s, 1H), 6.83 (t, $J = 8.1$ Hz, 1H), 5.50 (br. s., 1H), 4.70 (d, $J = 6.1$ Hz, 1H), 4.47 (t, $J = 12.7$ Hz, 1H), 3.68 - 3.52 (m, 3H), 2.88 - 2.78 (m, 2H), 2.55 (s, 3H), 1.91 (s, 3H), 1.77 - 1.63 (m, 4H), 1.58 - 1.44 (m, 3H), 1.18 (s, 3H), 1.14 (s, 9H), 1.10 (d, $J = 5.8$ Hz, 3H). LCMS (M+1) = 645.5.

5


Intermediate 176



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-fluoro-6'-hydroxy-
 10 [1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate:
 Prepared from (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate and (2-fluoro-6-hydroxyphenyl)boronic acid using the same procedure as intermediate **168**
 in 75% yield. ^1H NMR (400 MHz, CDCl_3) δ 8.19 - 7.99 (m, 2H), 7.61 (t, $J = 7.8$
 15 Hz, 1H), 7.46 (br. s., 1H), 7.25 (d, $J = 6.5$ Hz, 1H), 6.92 - 6.74 (m, 3H), 6.13 - 5.78 (m, 2H), 5.59 - 5.47 (m, 1H), 5.39 (dd, $J = 17.2, 1.6$ Hz, 1H), 5.20 - 4.99 (m, 1H), 4.00 (d, $J = 4.8$ Hz, 2H), 3.76 (s, 3H), 2.72 - 2.54 (m, 3H), 2.05 - 1.87 (m, 3H), 1.79 - 1.64 (m, 1H), 1.35 (s, 3H), 1.25 (s, 9H). LCMS (M+1) = 617.35.

20


Intermediate 177



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-fluoro-6'-((*S*)-
 pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-
 25 (tert-butoxy)acetate: Prepared from (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-fluoro-6'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate

169 in 80% yield. ^1H NMR (400 MHz, CDCl_3) [note: 4H of piperidine not observed and are likely very broad] δ 8.03 (s, 2H), 7.59 - 7.40 (m, 2H), 7.30 - 7.21 (m, 2H), 6.92 - 6.75 (m, 2H), 6.10 - 5.94 (m, 1H), 5.78 - 5.63 (m, 1H), 5.41 (d, $J = 16.8$ Hz, 1H), 5.21 - 5.04 (m, 1H), 5.03 - 4.95 (m, 2H), 4.39 (d, $J = 6.0$ Hz, 1H), 4.26 - 4.17 (m, 1H), 4.01 (d, $J = 4.5$ Hz, 2H), 3.75 (s, 3H), 2.62 (br. s., 3H), 2.35 (s, 1H), 2.25 (d, $J = 6.5$ Hz, 2H), 2.00 (br. s., 3H), 1.36 (br. s., 3H), 1.31 - 1.13 (m, 12H). LCMS (M+1) = 685.45.

Example 84




10

(2S)-2-(tert-Butoxy)-2-[(22S)-16-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Prepared from (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-fluoro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedures as intermediate **170** and example **81** in 12% yield. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.26 (br. s., 1H), 7.95 (d, $J = 7.0$ Hz, 1H), 7.51 (t, $J = 7.6$ Hz, 1H), 7.37 (d, $J = 7.3$ Hz, 1H), 7.28 (d, $J = 6.7$ Hz, 1H), 7.08 (s, 1H), 7.04 (d, $J = 8.2$ Hz, 1H), 6.87 (t, $J = 8.7$ Hz, 1H), 5.63 (br. s., 1H), 4.66 (br. s., 1H), 4.52 (t, $J = 12.1$ Hz, 1H), 3.58 - 3.49 (m, 1H), 3.41 (br. s., 2H), 3.31 (br. s., 1H), 2.77 (d, $J = 11.6$ Hz, 1H), 2.51 (br. s., 3H), 1.94 - 1.84 (m, 4H), 1.64 (d, $J = 6.1$ Hz, 5H), 1.56 (d, $J = 13.4$ Hz, 1H), 1.43 (br. s., 3H), 1.15 (s, 9H), 1.08 (d, $J = 5.5$ Hz, 3H). LCMS (M+1) = 645.5.


25

Intermediate 178



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6'-hydroxy-
 [1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate:
 Prepared from *(S)*-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-
 bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate and (2-
 chloro-6-hydroxyphenyl)boronic acid using the same procedure as intermediate **168**
 in 81% yield. ¹H NMR (400 MHz, CDCl₃) [note: 4H of piperidine and phenolic -
 10 OH not observed] δ 8.13 - 8.06 (m, 1H), 7.97 (s, 1H), 7.62 (t, *J* = 7.8 Hz, 1H), 7.38
 (d, *J* = 7.5 Hz, 1H), 7.26 - 7.20 (m, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 8.3 Hz,
 1H), 6.89 - 6.77 (m, 1H), 6.06 - 5.90 (m, 1H), 5.39 (dd, *J* = 17.1, 1.5 Hz, 1H), 5.29 -
 5.20 (m, 1H), 5.15 - 5.04 (m, 1H), 3.99 (d, *J* = 4.8 Hz, 2H), 3.76 (s, 3H), 2.63 (br. s.,
 3H), 2.07 - 1.91 (m, 3H), 1.79 - 1.65 (m, 1H), 1.35 (s, 3H), 1.25 (s, 9H). LCMS
 15 (M+1) = 633.3.


Intermediate 179



20 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6'-((*S*)-
 pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-
 (tert-butoxy)acetate: Prepared from *(S)*-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-
 1-yl)-2-(2'-chloro-6'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-
 a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate
 25 **169** in 83% yield. ¹H NMR (400 MHz, CDCl₃) [note: 2H of piperidine not observed
 and are likely very broad] δ 8.10 - 7.97 (m, 1H), 7.91 (s, 1H), 7.50 (t, *J* = 7.7 Hz,

1H), 7.33 (d, $J = 7.3$ Hz, 1H), 7.26 - 7.22 (m, 1H), 7.13 (d, $J = 8.0$ Hz, 1H), 6.92 (d, $J = 8.3$ Hz, 1H), 6.86 - 6.77 (m, 1H), 5.98 (dd, $J = 11.2, 5.9$ Hz, 2H), 5.71 - 5.57 (m, 1H), 5.40 (d, $J = 16.6$ Hz, 1H), 5.11 (br. s., 2H), 5.00 - 4.89 (m, 2H), 4.32 (d, $J = 6.0$ Hz, 1H), 4.21 (br. s., 1H), 4.00 (d, $J = 5.0$ Hz, 2H), 3.75 (s, 3H), 2.62 (br. s., 3H),
 5 2.28 (d, $J = 6.8$ Hz, 1H), 2.19 (d, $J = 6.8$ Hz, 1H), 1.99 (br. s., 3H), 1.77 - 1.69 (m, 1H), 1.35 (br. s., 3H), 1.25 (s, 9H), 1.18 (d, $J = 6.0$ Hz, 3H). LCMS (M+1) = 701.35.


Intermediate 180



10

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-16-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Prepared from (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate **170** in 32% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.14 - 8.09 (m, 1H), 7.83 - 7.77 (m, 1H), 7.56 - 7.49 (m, 1H), 7.24 (s, 2H), 7.09 - 7.04 (m, 1H), 6.92 - 6.84 (m, 2H), 6.25 - 6.11 (m, 1H), 6.05 - 5.94 (m, 1H), 5.68 - 5.56 (m, 1H), 4.54 - 4.40 (m, 1H), 4.20 (br. s., 2H), 3.94 - 3.84 (m, 2H), 3.77 - 3.70 (m, 5H), 2.64 (br. s., 3H), 2.40 - 2.16 (m, 2H), 2.04 - 1.63 (m, 4H),
 15 20 2H), 3.77 - 3.70 (m, 5H), 2.64 (br. s., 3H), 2.40 - 2.16 (m, 2H), 2.04 - 1.63 (m, 4H), 1.32 - 1.23 (m, 12H), 1.16 (d, $J = 6.0$ Hz, 3H). LCMS (M+1) = 673.35.


Example 85



25


(2S)-2-(tert-Butoxy)-2-[(22S)-16-chloro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Prepared from methyl (2S)-2-(tert-butoxy)-2-[(22S)-16-chloro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate using the same procedures as example **81** in 32% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.06 (br. s., 1H), 7.92 (d, *J* = 7.6 Hz, 1H), 7.52 (t, *J* = 7.8 Hz, 1H), 7.39 - 7.32 (m, 1H), 7.21 (d, *J* = 7.6 Hz, 1H), 7.17 (d, *J* = 8.5 Hz, 1H), 7.12 (d, *J* = 7.9 Hz, 1H), 7.05 (s, 1H), 5.69 (br. s., 1H), 4.63 (br. s., 1H), 4.56 (t, *J* = 13.1 Hz, 1H), 3.56 - 3.43 (m, *J* = 11.9 Hz, 3H), 2.79 - 2.71 (m, 2H), 2.55 (s, 3H), 1.87 - 1.32 (m, 10H), 1.16 (s, 12H), 1.08 (d, *J* = 5.8 Hz, 3H). LCMS (M+1) = 661.5.

Intermediate 181




(S)-1-Bromo-4-chloro-2-(pent-4-en-2-yloxy)benzene: To a solution of 2-bromo-5-chlorophenol (0.40 g, 1.93 mmol, 1 equiv), (R)-pent-4-en-2-ol (0.397 mL, 3.86 mmol, 2 equiv), and PPh₃ (1.01 g, 3.86 mmol, 2 equiv) in THF (6.4 mL) was added DEAD (0.61 mL, 3.86 mmol, 2 equiv). After stirring 20 h, reaction diluted with ether and washed with 1 N NaOH. The ether layer was dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-10% EtOAc in hexane) to provide the product as a colorless oil (0.49 g, 92%). ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.3 Hz, 1H), 6.89 (d, *J* = 2.3 Hz, 1H), 6.83 (dd, *J* = 8.5, 2.3 Hz, 1H), 5.90 (ddt, *J* = 17.1, 10.1, 7.2 Hz, 1H), 5.21 - 5.11 (m, 2H), 4.49 - 4.39 (m, 1H), 2.60 - 2.50 (m, 1H), 2.48 - 2.38 (m, 1H), 1.37 (d, *J* = 6.3 Hz, 3H).

Intermediate 182



5 *(S)*-2-(4-Chloro-2-(pent-4-en-2-yloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane: A solution of (*S*)-1-bromo-4-chloro-2-(pent-4-en-2-yloxy)benzene
 (0.49 g, 1.78 mmol, 1 equiv) in THF was cooled to -78 °C (IPA/CO₂). *n*BuLi (1.33
 mL of a 1.6 M solution in hexane, 2.13 mmol, 1.2 equiv) was added. No color
 change observed. After stirring 30 min, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-
 10 *dioxaborolane* (0.44 mL, 3.13 mmol, 1.2 equiv) was added and the reaction was
 allowed to warm to ambient temperature. Upon stirring for 3 h, the reaction was
 diluted with EtOAc and washed with water. The EtOAc layer was dried (Na₂SO₄)
 and concentrated *in vacuo* to provide the product as a tan oil (0.59 g, ~100%). ¹H
 NMR (400 MHz, CDCl₃) δ 7.55 (d, *J* = 7.8 Hz, 1H), 6.93 (dd, *J* = 8.0, 1.8 Hz, 1H),
 6.87 (d, *J* = 1.5 Hz, 1H), 6.04 - 5.89 (m, 1H), 5.20 - 5.04 (m, 2H), 4.38 (d, *J* = 6.0 Hz,
 15 1H), 2.56 - 2.35 (m, 2H), 1.35 (s, 12H), 1.27 (d, *J* = 6.3 Hz, 3H).


Intermediate 183



20 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-chloro-2'-((*S*)-
pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-
(tert-butoxy)acetate: Prepared from (*S*)-2-(4-chloro-2-(pent-4-en-2-yloxy)phenyl)-
 4,4,5,5-tetramethyl-1,3,2-dioxaborolane and (*S*)-methyl 2-(7-(4-(allyloxy)-4-
 methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-
 25 *(tert-butoxy)acetate* using the same procedure as intermediate **168** in 92% yield. ¹H
 NMR (400 MHz, CDCl₃) [*note: 4H of piperidine not observed*] δ 8.09 (s, 1H), 8.05 -
 7.98 (m, 1H), 7.57 - 7.44 (m, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.08 - 7.02 (m, 1H), 7.00


(d, $J = 1.8$ Hz, 1H), 6.06 - 5.69 (m, 3H), 5.46 - 5.35 (m, 1H), 5.18 - 5.10 (m, 1H), 5.09 - 5.04 (m, 1H), 5.03 (s, 1H), 4.47 - 4.36 (m, 1H), 4.01 (d, $J = 5.0$ Hz, 2H), 3.76 (d, $J = 3.3$ Hz, 3H), 2.66 - 2.61 (m, 3H), 2.49 - 2.39 (m, 1H), 2.36 - 2.25 (m, 1H), 2.00 - 1.91 (m, 2H), 1.84 - 1.63 (m, 2H), 1.36 (br. s., 3H), 1.28 (d, $J = 6.3$ Hz, 3H),
 5 1.25 (s, 9H). LCMS (M+1) = 701.35.

Intermediate 184



10 *Methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate*: Prepared from (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-chloro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-
 15 butoxy)acetate using the same procedure as intermediate **170** in 57% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (s, 1H), 7.81 (d, $J = 7.8$ Hz, 1H), 7.56 - 7.46 (m, 1H), 7.31 - 7.25 (m, 3H), 7.03 - 6.97 (m, 2H), 5.84 (br. s., 1H), 4.68 - 4.52 (m, 2H), 3.83 - 3.74 (m, 4H), 3.51 (d, $J = 6.3$ Hz, 1H), 3.41 (d, $J = 5.3$ Hz, 1H), 3.29 (br. s., 1H), 2.92 (br. s., 1H), 2.63 (br. s., 3H), 2.01 (d, $J = 12.5$ Hz, 3H), 1.88 - 1.69 (m, 4H), 1.66 - 1.59
 20 (m, 3H), 1.27 (s, 3H), 1.24 (s, 9H), 1.19 (d, $J = 6.0$ Hz, 3H). LCMS (M+1) = 675.35.

Example 86




25 *(2S)-2-(tert-Butoxy)-2-[(22S)-18-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid*: Prepared from methyl

(2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate using the same procedure as example **81** in 82% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.46 (br. s., 1H), 7.95 (d, *J* = 7.6 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.33 - 7.25 (m, 3H), 7.10 (s, 1H), 7.05 (d, *J* = 8.2 Hz, 1H), 5.63 (br. s., 1H), 4.73 (br. s., 1H), 4.54 - 4.42 (m, 1H), 3.63 - 3.48 (m, *J* = 11.3 Hz, 4H), 2.80 (d, *J* = 9.8 Hz, 1H), 2.50 (s, 3H), 1.95 - 1.86 (m, 3H), 1.70 (br. s., 4H), 1.58 - 1.44 (m, 3H), 1.18 (br. s., 3H), 1.16 (s, 9H), 1.08 (d, *J* = 5.5 Hz, 3H). LCMS (M+1) = 661.5.

10


Intermediate 185



(*S*)-4-Bromo-3-(pent-4-en-2-yloxy)benzonitrile: To a solution of 4-bromo-3-fluorobenzonitrile (1.0 g, 5.00 mmol, 1 equiv) and (*S*)-pent-4-en-2-ol (0.52 g, 6.00 mmol, 1.2 equiv) in THF (25 mL) was added NaH (0.24 g of a 60% suspension in mineral oil, 6.00 mmol, 1.2 equiv). Slow gas evolution with considerable foaming observed. After 5 h, dilute with ether then wash with water and brine. The ether layer was dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-10% EtOAc in hexane) to provide the product as a colorless oil (0.94 g, 71%). ¹H NMR (400 MHz, CDCl₃) δ 7.69 - 7.62 (m, 1H), 7.15 - 7.08 (m, 2H), 5.89 (ddt, *J* = 17.1, 10.1, 7.2 Hz, 1H), 5.23 - 5.12 (m, 2H), 4.54 - 4.42 (m, 1H), 2.61 - 2.51 (m, 1H), 2.51 - 2.40 (m, 1H), 1.39 (d, *J* = 6.0 Hz, 3H).


25

Intermediate 186



(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-cyano-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a solution of (S)-4-bromo-3-(pent-4-en-2-yloxy)benzonitrile (0.136 g, 0.51 mmol, 1.5 equiv) in THF (3.4 mL) was added Reike zinc (0.67 mL of a 10 g/100 mL slurry in THF, 1.03 mmol, 3 equiv). The reaction was then heated at 60 °C for 2 h. Upon cooling to ambient temperature, the zincate solution was filtered and added to a solution of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.20 g, 0.34 mmol, 1 equiv) in THF (1.7 mL). The reaction was then heated at 60 °C for 18 h. Upon cooling to ambient temperature, the reaction was diluted with EtOAc and washed with a saturated aqueous solution of NaHCO₃. The EtOAc layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-100% EtOAc in hexane) to provide the product as a colorless oil (0.14 g, 59%). ¹H NMR (400 MHz, CDCl₃) [*note: 4H of piperidine not observed*] δ 8.12 (s, 1H), 8.07 (d, *J* = 6.8 Hz, 1H), 7.56 - 7.48 (m, 3H), 7.36 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.24 (s, 1H), 6.85 (br. s., 1H), 6.06 - 5.92 (m, *J* = 11.2, 11.2, 5.0 Hz, 2H), 5.72 (s, 1H), 5.40 (dd, *J* = 17.1, 1.5 Hz, 1H), 5.13 - 5.05 (m, *J* = 3.5 Hz, 2H), 5.03 (s, 1H), 4.52 - 4.43 (m, *J* = 5.8 Hz, 1H), 4.01 (d, *J* = 4.5 Hz, 2H), 3.75 (s, 3H), 2.63 (s, 3H), 2.48 - 2.39 (m, 1H), 2.38 - 2.28 (m, *J* = 7.5 Hz, 1H), 2.05 - 1.94 (m, 2H), 1.78 - 1.68 (m, 1H), 1.59 (br. s., 1H), 1.36 (br. s., 3H), 1.30 (d, *J* = 6.0 Hz, 3H), 1.26 (s, 9H). LCMS (M+1) = 692.35.

Intermediate 187




25

Methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-cyano-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate: Prepared from (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-cyano-2'-((S)-pent-4-en-2-yloxy)-

[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedure as intermediate **170** in 16% yield. LCMS (M+1) = 666.4.

Example 87




5

(2S)-2-(tert-Butoxy)-2-[(22S)-18-cyano-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Prepared from methyl (2S)-2-(tert-butoxy)-2-[(22S)-18-cyano-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate using the same procedure as example **81** in 19% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.49 (br. s., 1H), 8.00 (d, *J* = 7.3 Hz, 1H), 7.70 (s, 1H), 7.57 (t, *J* = 7.2 Hz, 1H), 7.52 - 7.44 (m, 2H), 7.36 (d, *J* = 7.3 Hz, 1H), 7.12 (s, 1H), 5.65 (br. s., 1H), 4.82 (br. s., 1H), 4.46 (t, *J* = 12.1 Hz, 1H), 3.62 - 3.53 (m, 4H), 2.80 (d, *J* = 9.5 Hz, 1H), 2.51 (br. s., 3H), 2.01 - 1.86 (m, 3H), 1.71 (br. s., 4H), 1.60 - 1.43 (m, 3H), 1.18 (br. s., 3H), 1.16 (s, 9H), 1.09 (d, *J* = 5.5 Hz, 3H). LCMS (M+1) = 652.7.

20

Intermediates 188 and 189




2-Bromo-4-chloro-5-methylphenol and 2-bromo-4-chloro-3-methylphenol: To a solution of 4-chloro-3-methylphenol (2.2 g, 15.4 mmol, 1 equiv) in AcOH (69 mL) was added slowly a solution of bromine (0.80 mL, 15.4 mmol, 1 equiv) in water (8 mL) with some AcOH (to solubilize bromine). After stirring 2 h, the reaction was concentrated under a stream of nitrogen. The residue was taken up in ether and washed with 1 N NaS₂O₃ and a saturated aqueous solution of NaHCO₃. The ether

25

layer was dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-30% EtOAc in hexane) to provide the an inseperable mixture of the products as a colorless oil (2.7 g, 79%) and 2:1 ratio of 2-bromo-4-chloro-5-methylphenol: ¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 1H), 6.92 (s, 1H), 5.41 (br. s., 1H) and 2-bromo-4-chloro-3-methylphenol: ¹H NMR (400 MHz, CDCl₃) δ 7.24 (d, *J* = 8.8 Hz, 1H), 6.86 (d, *J* = 8.8 Hz, 1H), 5.67 - 5.52 (m, 1H).

Intermediates 190 and 191




10

(*S*)-1-Bromo-5-chloro-4-methyl-2-(pent-4-en-2-yloxy)benzene and (*S*)-2-bromo-4-chloro-3-methyl-1-(pent-4-en-2-yloxy)benzene: Prepared from a 2:1 mixture of 2-bromo-4-chloro-5-methylphenol and 2-bromo-4-chloro-3-methylphenol using the same procedure as intermediate 7a to provide an inseperable mixture of the products in 90% yield and 2:1 ratio. (*S*)-1-bromo-5-chloro-4-methyl-2-(pent-4-en-2-yloxy)benzene: ¹H NMR (400 MHz, CDCl₃) δ 7.51 (s, 1H), 6.78 (s, 1H), 5.97 - 5.82 (m, 1H), 5.20 - 5.09 (m, 2H), 4.41 (qd, *J* = 6.0, 3.3 Hz, 1H), 2.54 (s, 3H), 2.52 - 2.49 (m, 1H), 2.46 - 2.39 (m, 1H), 1.35 (dd, *J* = 6.1, 1.6 Hz, 3H) and (*S*)-2-bromo-4-chloro-3-methyl-1-(pent-4-en-2-yloxy)benzene: ¹H NMR (400 MHz, CDCl₃) δ 7.25 (d, *J* = 8.8 Hz, 1H), 6.72 (d, *J* = 8.8 Hz, 1H), 5.97 - 5.82 (m, 1H), 5.20 - 5.09 (m, 2H), 4.41 (qd, *J* = 6.0, 3.3 Hz, 1H), 2.54 (s, 3H), 2.52 - 2.49 (m, 1H), 2.46 - 2.39 (m, 1H), 1.35 (dd, *J* = 6.1, 1.6 Hz, 3H).

20

Intermediates 192 and 193



25

(S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-4'-methyl-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate and (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3'-chloro-2'-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Prepared from a 2:1 mixture of (S)-1-bromo-5-chloro-4-methyl-2-(pent-4-en-2-yloxy)benzene and (S)-2-bromo-4-chloro-3-methyl-1-(pent-4-en-2-yloxy)benzene using the same procedures as intermediate **182** and **168** to provide an inseparable mixture of the products in 98% yield and 2:1 ratio. (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-4'-methyl-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. LCMS (M+1) = 715.4. (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3'-chloro-2'-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. LCMS (M+1) = 715.4.


15

Examples 88, 89 and 90

Prepared from a 2:1 mixture of (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-chloro-4'-methyl-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate and (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3'-chloro-2'-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using the same procedures as intermediate **170** and example **81** to afford three compounds.

25


Example 88



(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-17-chloro-4,18,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: 5% yield. ¹H NMR (400 MHz, methanol-*d*₄) δ 8.51 (s, 1H), 7.80 (d, *J* = 7.6 Hz, 1H), 7.45 (t, *J* = 7.7 Hz, 1H), 7.26 - 7.18 (m, 2H), 6.99 (s, 1H), 6.85 (s, 1H), 5.72 (br. s., 1H), 4.60 (d, *J* = 11.5 Hz, 2H), 3.68 (s, 2H), 2.90 (d, *J* = 11.2 Hz, 1H), 2.59 (br. s., 3H), 2.38 (s, 3H), 2.04 - 1.88 (m, 4H), 1.81 - 1.66 (m, 4H), 1.65 - 1.45 (m, 4H), 1.24 (br. s., 3H), 1.19 (s, 9H), 1.08 (d, *J* = 5.9 Hz, 4H). LCMS (M+1) = 675.6.

10


Example 89



(2*S*)-2-(*tert*-Butoxy)-2-[(22*S*)-17-chloro-4,16,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: 2% yield. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.08 (s, 1H), 7.79 (d, *J* = 7.3 Hz, 1H), 7.47 (t, *J* = 7.6 Hz, 1H), 7.31 (d, *J* = 8.8 Hz, 1H), 7.05 (d, *J* = 7.6 Hz, 1H), 6.91 (d, *J* = 8.8 Hz, 1H), 6.80 (s, 1H), 5.72 (br. s., 1H), 4.54 (br. s., 2H), 3.49 - 3.39 (m, 2H), 2.87 (d, *J* = 11.2 Hz, 1H), 2.63 (br. s., 3H), 2.05 (s, 3H), 1.99 - 1.91 (m, 4H), 1.68 (d, *J* = 14.7 Hz, 4H), 1.52 (d, *J* = 8.3 Hz, 4H), 1.27 (br. s., 3H), 1.22 (s, 12H), 1.11 (d, *J* = 5.9 Hz, 3H). LCMS (M+1) = 675.6.

20


Example 90



25


(2*S*)-2-(*tert*-Butoxy)-2-[(22*R*)-17-chloro-4,18,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: 2% yield. The inverted stereochemistry likely arises as a minor double inversion byproduct of the earlier Mitsunobu reaction and is carried through. ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.55 (br. s., 1H), 7.80 (t, *J* = 6.7 Hz, 1H), 7.52 - 7.43 (m, 1H), 7.34 - 7.21 (m, 2H), 7.03 (d, *J* = 7.8 Hz, 1H), 6.83 (d, *J* = 4.2 Hz, 1H), 5.64 (br. s., 1H), 4.61 (d, *J* = 12.5 Hz, 2H), 3.44 (br. s., 2H), 3.03 (d, *J* = 13.4 Hz, 1H), 2.62 (br. s., 3H), 2.40 (s, 3H), 1.93 (br. s., 8H), 1.76 (d, *J* = 12.2 Hz, 4H), 1.28 (br. s., 3H), 1.21 (s, 9H), 1.08 (d, *J* = 5.9 Hz, 3H). LCMS (M+1) = 675.6.

Intermediates 194 and 195




2-Bromo-4-fluoro-5-methylphenol and 2-bromo-4-fluoro-3-methylphenol: Prepared from 4-fluoro-3-methylphenol using the same procedures as intermediates **188** and **189** in 59% yield and 2:1 ratio. 2-bromo-4-fluoro-5-methylphenol: ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, *J* = 8.5 Hz, 1H), 6.87 (s, 1H), 5.22 (s, 1H) and 2-bromo-4-fluoro-3-methylphenol: ¹H NMR (400 MHz, CDCl₃) δ 6.98 - 6.91 (m, 1H), 6.88 - 6.85 (m, 2H), 5.38 (s, 1H).

Intermediates 196 and 197




(*S*)-1-Bromo-5-fluoro-4-methyl-2-(pent-4-en-2-yloxy)benzene and (*S*)-2-bromo-4-fluoro-3-methyl-1-(pent-4-en-2-yloxy)benzene: Prepared from a 2:1 mixture of 2-bromo-4-fluoro-5-methylphenol and 2-bromo-4-fluoro-3-methylphenol using the same procedure as intermediate **185** to provide an inseparable mixture of the products in 88% yield and 2:1 ratio. Used in the subsequent step without further purification.

Intermediates 198 and 199



5 *(S)*-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-4'-methyl-
 2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-
 yl)-2-(tert-butoxy)acetate and (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-
 (3'-fluoro-2'-methyl-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-
 methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: Prepared from a 2:1
 mixture of (*S*)-1-bromo-5-fluoro-4-methyl-2-(pent-4-en-2-yloxy)benzene and (*S*)-2-
 10 bromo-4-fluoro-3-methyl-1-(pent-4-en-2-yloxy)benzene using the same procedures
 as intermediate **182** and **168** to provide an inseparable mixture of the products in 63%
 yield and 2:1 ratio. (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-
 fluoro-4'-methyl-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-
 methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. LCMS (M+1) =
 15 699.45. (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3'-fluoro-2'-
 methyl-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-
 a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. LCMS (M+1) = 699.45.

Example 91




20

25 *(2S)*-2-(tert-Butoxy)-2-[(*22S*)-17-fluoro-4,18,22,28-tetramethyl-21,27-dioxa-
 1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: Prepared from a 2:1
 mixture of (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(5'-fluoro-4'-
 methyl-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-
 a]pyrimidin-6-yl)-2-(tert-butoxy)acetate and (*S*)-methyl 2-(7-(4-(allyloxy)-4-

methylpiperidin-1-yl)-2-(3'-fluoro-2'-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-
 biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate using
 the same procedures as intermediates **170** and example **81** in 9% yield. ¹H NMR (400
 MHz, Methanol-*d*₄) δ 8.53 (s, 1H), 7.73 (d, *J* = 7.8 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 1H),
 5 7.19 (d, *J* = 7.6 Hz, 1H), 6.92 - 6.82 (m, 2H), 6.78 (s, 1H), 5.54 (s, 1H), 4.62 - 4.43
 (m, 2H), 3.83 (d, *J* = 10.5 Hz, 1H), 3.67 - 3.58 (m, 1H), 3.38 (d, *J* = 6.8 Hz, 1H), 2.87
 (d, *J* = 12.2 Hz, 1H), 2.58 (s, 3H), 2.24 (s, 3H), 1.93 - 1.84 (m, 3H), 1.78 - 1.59 (m,
 5H), 1.57 - 1.42 (m, 3H), 1.14 (s, 12H), 1.02 (d, *J* = 5.9 Hz, 3H). LCMS (M+1) =
 659.6.

10


Intermediate 200



Ethyl 2-(2-(3-bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate: Prepared according to the procedure for intermediate **4**. ¹H NMR (500
 15 MHz, CDCl₃) δ 8.20 (t, *J* = 1.7 Hz, 1H), 7.95 (qd, *J* = 0.8, 7.8 Hz, 1H), 7.56 (ddd,
J = 1.0, 2.0, 8.0 Hz, 1H), 7.36 (t, *J* = 7.9 Hz, 1H), 6.94 (s, 1H), 4.25 (q, *J* = 7.1 Hz, 2H),
 3.93 (s, 2H), 2.65 (s, 3H), 1.32 (t, *J* = 7.1 Hz, 3H).

20

Intermediate 201




Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate: A mixture of ethyl 2-(2-(3-
 25 bromophenyl)-7-chloro-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (28 g, 68.5
 mmol) in DMF (150 ml) was treated with 4-(allyloxy)-4-methylpiperidine•HCl (14.3
 g, 74.6 mmol) and Hunig'sBase (35.9 ml, 206 mmol), and the mixture was heated

(60°C oil bath) for 16 h. At this point LCMS indicates completion of reaction. Mixture was then cooled, diluted with Et₂O and washed with water (3 x 100 mL) and brine (100 mL), then dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was then purified by Biotage (5-50% EtOAc/hexane) to afford
 5 ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (32.6 g, 61.8 mmol, 90 % yield) as viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 8.16 (t, *J*=1.7 Hz, 1H), 7.94 (dt, *J*=7.8, 1.3 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.37 - 7.30 (m, 1H), 6.79 (s, 1H), 6.13 - 5.99 (m, 1H), 5.51 - 5.40 (m, 1H), 5.26 (dd, *J*=10.4, 1.4 Hz, 1H), 4.24 (q, *J*=7.1 Hz, 2H), 4.03
 10 (dt, *J*=5.2, 1.6 Hz, 2H), 3.82 (br. s, 4H), 3.32 (br. s., 2H), 2.54 (s, 3H), 1.99 (d, *J*=13.2 Hz, 2H), 1.86 (br. s., 2H), 1.36 (s, 3H), 1.31 (t, *J*=7.1 Hz, 3H). LCMS (M+H) = 528.8.

Intermediate 202

15




Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate: To a stirred solution of 1M
 20 KHMDS/THF (49.3 mL, 49.3 mmol) in THF (150 mL) at -78 °C was added dropwise a THF (100 mL) solution of ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (20 g, 37.9 mmol) over 5 min. After 30 min, a THF (100 mL) solution of 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (12.88 g, 49.3 mmol) was added and stirred for additional 30 min at -78
 25 °C. Then, the resulting dark reaction mixture was quenched with sat. NH₄Cl (50 mL), diluted with EtOAc (200 mL), washed with water (100 mL), brine (100 mL), dried (Na₂SO₄), filtered and concentrated. The residue was then purified by Biotage(5-50% EtOAc/hexane) to afford ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate

(17 g, 31.3 mmol, 82 % yield) as white foam. Impurities were present by NMR. Used as is in the next step without further purification. ¹H NMR (500 MHz, CDCl₃) δ 8.16 (t, *J*=1.7 Hz, 1H), 7.99 - 7.92 (m, 1H), 7.58 - 7.50 (m, 2H), 7.34 (t, *J*=7.9 Hz, 1H), 6.83 (s, 1H), 6.18 - 6.06 (m, 1H), 5.57 (d, *J*=5.4 Hz, 1H), 5.48 (d, *J*=17.0 Hz, 1H), 5.27 (d, *J*=10.2 Hz, 1H), 4.83 (br. s., 2H), 4.35 (dq, *J*=10.8, 7.1 Hz, 1H), 4.23 (dq, *J*=10.9, 7.1 Hz, 1H), 4.06 - 3.99 (m, 2H), 2.65 (s, 3H), 2.00 (d, *J*=14.2 Hz, 2H), 1.84 (d, *J*=13.4 Hz, 2H), 1.36 (s, 3H), 1.29 - 1.26 (m, 3H). LCMS (M+H) = 545.3.

Intermediate 203

10




Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate: To a solution of ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (32 g, 58.9 mmol) in dry DCM (500 mL) was added Dess-Martin periodinane (24.97 g, 58.9 mmol). The resulting bright orange-red solution was stirred for 90 min. The reaction was quenched by stirring with a saturated solution of Na₂S₂O₃ (100 mL) and sat. NaHCO₃ (100 mL) for 25 min to quench any unreacted Dess-Martin reagent. The reaction mixture was poured into a separatory funnel and organic layer separated. The aqueous layer was further extracted with EtOAc. The two organic components were separately washed with brine, then combined, dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was then purified via Biotage (5-40%) EtOAc/hexane to afford ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate (22.6 g, 41.7 mmol, 70.9 % yield) as off-white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.12 (t, *J*=1.7 Hz, 1H), 7.91 (dt, *J*=7.8, 1.3 Hz, 1H), 7.56 (ddd, *J*=8.0, 2.0, 0.9 Hz, 1H), 7.37 (t, *J*=7.9 Hz, 1H), 6.82 (s, 1H), 6.00 (ddt, *J*=17.2, 10.4, 5.2 Hz, 1H), 5.44 - 5.36 (m, 1H), 5.24 - 5.17 (m,

1H), 4.46 - 4.35 (m, 2H), 3.98 (dt, $J=5.1$, 1.5 Hz, 2H), 3.80 - 3.71 (m, 2H), 3.69 - 3.60 (m, 2H), 2.60 (s, 3H), 2.03 - 1.88 (m, 4H), 1.46 - 1.40 (m, 3H), 1.31 (s, 3H).
LCMS (M+H) = 543.3.

5

Intermediate 204




(*S*)-Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate: To a stirred yellow solution of ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate (22 g, 40.6 mmol) in anhydrous toluene (800 mL) was added 1M (R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole/toluene (16.25 mL, 16.25 mmol). The mixture was cooled to -35 °C and catechoborane (7.11 mL, 56.9 mmol) was added over 5 min. After 30 min, the reaction mixture was slowly warmed to -15 °C and stirred for additional 2 h. At this point LCMS indicated approx 60% conversion, so mixture was cooled to -35°C and 3.5 mL of catechoborane was added and stirred at -15°C for 2 h. At his point LCMS indicates completion of reaction. Mixture was then dluted with EtOAc (1L) and sat. Na₂CO₃ (300 mL). The mixture was stirred vigorously for 30 min, and the organic phase washed with sat Na₂CO₃ (2 X 200 mL) each time vigarously stirring for 30 min, dried (Na₂SO₄), filtered, concentrated and the residue was purified by silica gel chromatography (5-70% EtOAc/hexane) to afford desired (*S*)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (17 g, 31.3 mmol, 77 % yield) as off-white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.19 - 8.10 (m, 1H), 7.95 (d, $J=7.9$ Hz, 1H), 7.58 - 7.52 (m, 1H), 7.33 (t, $J=7.8$ Hz, 1H), 6.86 - 6.82 (m, 1H), 6.10 (dd, $J=10.8$, 5.1 Hz, 1H), 5.57 (d, $J=5.2$ Hz, 1H), 5.48 (d, $J=16.9$ Hz, 1H), 5.27 (d, $J=10.2$ Hz, 1H), 4.35 (dq, $J=10.8$, 7.2 Hz, 1H), 4.23 (dq, $J=10.7$, 7.1 Hz, 1H), 4.03 (dt, $J=5.2$, 1.5 Hz, 2H),

2.65 (s, 3H), 2.00 (d, $J=14.5$ Hz, 2H), 1.84 (br. s., 2H), 1.36 (s, 3H), 1.29 - 1.24 (m, 3H). LCMS (M+H) = 543.4.


Intermediate 205

5




(*S*)-Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To a stirred solution of
 10 (*S*)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (8.5 g, 15.64 mmol) in DCM (250 mL) and t-butyl acetate (175 mL) was added perchloric acid (4.03 mL, 46.9 mmol) at rt. After 3h, the reaction mixture was diluted with DCM (100 mL), carefully quenched with sat. NaHCO₃ (50 mL), organic layer separated and washed
 15 with brine (100 mL), dried (Na₂SO₄), filtered and concentrated to give yellow liquid. This was purified by flash column chromatography on silica gel column using (10-50% EtOAc/Hex as eluant) to afford the desired (*S*)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (5 g, 8.34 mmol, 53.3 % yield) as light yellow solid. 3 g of
 20 starting material was also recovered. ¹H NMR (500 MHz, CDCl₃) δ 8.23 - 8.11 (m, 1H), 7.94 (d, $J=7.7$ Hz, 1H), 7.56 - 7.51 (m, 1H), 7.33 (t, $J=7.9$ Hz, 1H), 6.81 (s, 1H), 6.10 (br. s., 1H), 6.00 (br. s., 1H), 5.49 (d, $J=16.6$ Hz, 1H), 5.28 (d, $J=10.2$ Hz, 1H), 4.30 - 4.14 (m, 2H), 4.10 - 4.00 (m, 2H), 2.65 (s, 3H), 2.09 - 1.85 (m, 3H), 1.74 (br. s., 1H), 1.38 (s, 3H), 1.28 - 1.16 (m, 12H). 4 missing piperidine hydrogens. LCMS
 25 (M+H) = 601.5.

Intermediate 206



5 *2-Bromo-4-methyl-1-((3-methylpent-4-en-2-yl)oxy)benzene*: To a solution of
 2-bromo-4-methylphenol (1 g, 5.35 mmol) and 3-methylpent-4-en-2-ol (2.68 g, 26.7
 mmol) in THF (20 mL) was added Ph_3P (7.01 g, 26.7 mmol) followed by DEAD
 (4.23 mL, 26.7 mmol) and the resulting mixture was stirred at room temp for 16 h.
 Water was then added and the mixture was extracted with ether (2 X 50 mL), dried
 (Na_2SO_4), filtered and concentrated. The residue was then purified by Biotage (0-
 10 20% EtOAc/hexane) to afford 2-bromo-4-methyl-1-((3-methylpent-4-en-2-
 yl)oxy)benzene (860 mg, 3.19 mmol, 59.8 % yield) as yellow oil. Product is approx
 2:1 mixture of trans/cis isomers. ^1H NMR (400 MHz, CDCl_3) δ 7.38 (d, $J=2.0$ Hz,
 1H), 7.08 - 7.01 (m, 1H), 6.83 - 6.79 (m, 1H), 6.02 - 5.89 (m, 1H), 5.16 (q, $J=1.8$ Hz,
 0.5H), 5.14 - 5.08 (m, 1.5H), 4.31 - 4.37 (m, 0.3H), 4.28 - 4.19 (m, 0.7H), 2.64 - 2.50
 15 (m, 1H), 2.29 (s, 3H), 1.30 - 1.24 (m, 3H), 1.19 - 1.14 (m, 3H).


Intermediate 207



20 *4,4,5,5-Tetramethyl-2-((5-methyl-2-((3-methylpent-4-en-2-yl)oxy)phenyl)-*
1,3,2-dioxaborolane: To a solution of 2-bromo-4-methyl-1-((3-methylpent-4-en-2-
 yl)oxy)benzene (820 mg, 3.05 mmol) in THF (15.200 mL) at -78°C was added 1.6M
 n-BuLi/THF (2.285 mL, 3.66 mmol) and the mixture was stirred for 30 min. 2-
 Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.746 mL, 3.66 mmol) was then
 25 added and after 30min, bath removed and reaction allowed to warm to rt. After 3h,

partitioned between EtOAc and water. EtOAc layer was dried (Na₂SO₄), filtered and concentrated. Crude was used as-is in the next step without further purification.

Intermediate 208




5

(2*S*)-Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(5'-methyl-2'-((3-methylpent-4-en-2-yl)oxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of ((*S*)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (300 mg, 0.500 mmol), 4,4,5,5-tetramethyl-2-(5-methyl-2-((3-methylpent-4-en-2-yl)oxy)phenyl)-1,3,2-dioxaborolane (316 mg, 1.001 mmol) and 2.0 M aq. Na₂CO₃ (0.751 mL, 1.501 mmol) in DMF (5mL) was degassed for 10 min. Pd(Ph₃P)₄ (40.5 mg, 0.035 mmol), was added and the degassing was continued for another 5 min. The reaction was then heated at 90°C for 5 h. At this point LCMS indicates completion of reaction. The mixture was then cooled to room temp and diluted with water (25 mL) and extracted with Et₂O (2 x 50 mL). The combined extracts were dried (Na₂SO₄), filtered, and concentrated under reduced pressure, and the residue was purified by biotage (0-25% EtOAc/hexane) to afford (2*S*)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(5'-methyl-2'-((3-methylpent-4-en-2-yl)oxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (260 mg, 0.367 mmol, 73.3 % yield) as viscous oil (inseparable mixture of diastereomers). ¹H NMR (500 MHz, CDCl₃) δ 8.13 (br. s., 1H), 8.04 (br. s., 1H), 7.59 - 7.53 (m, 1H), 7.51 - 7.44 (m, 1H), 7.24 (s, 1H), 7.13 (d, *J*=8.2 Hz, 1H), 6.96 - 6.91 (m, 1H), 6.85 (s, 1H), 6.09 - 5.97 (m, 2H), 5.85 - 5.68 (m, 1H), 5.43 (d, *J*=16.7 Hz, 1H), 5.20 - 5.08 (m, 1H), 5.02 - 4.92 (m, 2H), 4.33 - 4.11 (m, 4H), 4.03 (d, *J*=4.3 Hz, 2H), 2.66 - 2.61 (m, 3H), 2.49 - 2.41 (m, 1H), 2.38 (s, 3H), 2.07 - 1.95 (m, 2H),

25

1.85 - 1.69 (m, 1H), 1.39 (br. s., 3H), 1.28 - 1.22 (m, 12H), 1.17 - 1.12 (m, 3H), 1.01 - 0.94 (m, 3H). 4 missing piperidine hydrogens. LCMS (M+H) = 709.4.

Intermediate 209




5

Ethyl (2S)-2-(tert-butoxy)-2-[4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate: To a mixture of (2S)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(5'-methyl-2'-((3-methylpent-4-en-2-yl)oxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (250 mg, 0.353 mmol) and CuI (67.2 mg, 0.353 mmol) in DCE (200 mL) at 70°C was added (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (22.10 mg, 0.035 mmol) and the resulting mixture was refluxed for 2h. At this point LCMS indicates completion of reaction. Mixture was then concentrated and used as is in the next step without further purification. LCMS (M+H)= 681.4.

15

Intermediate 210



20

Ethyl (2S)-2-(tert-butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetate: To a mixture of ethyl (2S)-2-(tert-butoxy)-2-[4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-

25


tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate (250 mg, 0.367
mmol) in MeOH (10 mL) was added NaBH₄ (69.5 mg, 1.836 mmol) (gas evolution)
and the mixture was stirred at room temp for 1h. More NaBH₄ (2X 70 mg) was then
5 added and the mixture was stirred for another 2 h. Mixture was then quenched with
water (20 mL), extracted with EtOAc (50 mL), dried (Na₂SO₄), filtered and
concentrated. The crude was then used as is in the next step without further
purification. LCMS (M+H) = 683.7

10

Examples 92, 93, 94 and 95

To a solution of ethyl (2S)-2-(tert-butoxy)-2-{4,17,22,23,28-pentamethyl-
21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl} acetate (100 mg, 0.146 mmol) in
15 MeOH (4 mL) was added 1N NaOH (0.439 mL, 0.439 mmol) and the resulting
mixture was heated at 75°C for 5 h. Mixture was then cooled and purified by prep
HPLC to afford 4 diastereomers.

Example 92




20

(2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-
tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Diastereomer 1, First
25 eluting, (2.1 mg, 3.21 μmol, 2.190 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 8.53
(s, 1H), 7.90 (d, *J*=7.3 Hz, 1H), 7.51 (t, *J*=7.5 Hz, 1H), 7.35 (d, *J*=7.3 Hz, 1H), 7.18 -
7.11 (m, 2H), 7.09 - 7.02 (m, 2H), 5.59 (br. s., 1H), 4.56 (t, *J*=12.4 Hz, 1H), 4.46 (d,
J=5.5 Hz, 1H), 3.92 (s, 1H), 3.60 (d, *J*=10.7 Hz, 4H), 2.82 (d, *J*=11.0 Hz, 1H), 2.29
(s, 3H), 2.09 (br. s., 1H), 2.03 (d, *J*=8.5 Hz, 1H), 2.00 - 1.86 (m, 3H), 1.64 (d, *J*=13.7

Hz, 2H), 1.56 (br. s., 2H), 1.35 (br. s., 1H), 1.19 (s, 3H), 1.16 (br. s., 9H), 1.04 (br. s., 1H), 0.95 (d, $J=5.5$ Hz, 3H), 0.82 (d, $J=6.4$ Hz, 3H). LCMS (M+H) = 655.0.

Example 93




5

(2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Diastereomer 2, second eluting, (7.3 mg, 0.011 mmol, 7.61 % yield) ¹H NMR (500 MHz, DMSO-d₆) δ 8.50 (s, 1H), 7.92 (d, $J=7.3$ Hz, 1H), 7.51 (t, $J=7.6$ Hz, 1H), 7.31 (d, $J=7.3$ Hz, 1H), 7.14 (d, $J=7.9$ Hz, 1H), 7.10 (d, $J=4.9$ Hz, 2H), 7.04 (d, $J=8.2$ Hz, 1H), 5.70 (br. s., 1H), 4.67 (d, $J=7.3$ Hz, 2H), 3.62 (t, $J=11.7$ Hz, 1H), 3.46 (br. s., 2H), 3.41 - 3.20 (m, 4H), 2.68 (d, $J=9.2$ Hz, 1H), 2.29 (s, 3H), 2.15 (d, $J=14.0$ Hz, 1H), 2.04 (d, $J=12.2$ Hz, 1H), 1.83 (d, $J=13.1$ Hz, 1H), 1.72 (br. s., 1H), 1.68 - 1.52 (m, 3H), 1.45 (br. s., 1H), 1.30 (br. s., 1H), 1.19 (br. s., 3H), 1.17 (s, 9H), 1.01 (d, $J=5.8$ Hz, 3H), 0.69 (d, $J=6.7$ Hz, 3H). LCMS (M+H) = 655.7.

15

Example 94




20

(2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Diastereomer 3, third eluting, (7 mg, 10.69 μmol, 7.30 % yield) ¹H NMR (500 MHz, DMSO-d₆) δ 8.13 (s,

25

1H), 7.85 (d, $J=7.6$ Hz, 1H), 7.54 (t, $J=7.5$ Hz, 1H), 7.34 (d, $J=7.3$ Hz, 1H), 7.14 (d, $J=7.6$ Hz, 1H), 7.06 (s, 1H), 7.02 - 6.96 (m, 2H), 5.87 (s, 1H), 4.34 (t, $J=11.9$ Hz, 1H), 4.01 (t, $J=6.0$ Hz, 1H), 3.78 (t, $J=11.3$ Hz, 1H), 3.55-3.35 (m, 2H), 2.97 (br. s., 1H), 2.74 (d, $J=6.4$ Hz, 1H), 2.56 (s, 3H), 2.29 (s, 3H), 1.91 (d, $J=13.4$ Hz, 1H), 1.83 (d, $J=13.4$ Hz, 1H), 1.75 - 1.64 (m, 2H), 1.63 - 1.54 (m, 1H), 1.52 (br. s., 1H), 1.46 (br. s., 3H), 1.21 (s, 9H), 1.18 (s, 3H), 0.84 (d, $J=5.8$ Hz, 6H). LCMS (M+H) = 655.6.

Example 95




10

(2*S*)-2-(*tert*-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,9.1¹⁰,14.0²,7.0¹⁵,20]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Diastereomer 4, fourth eluting, (19.9 mg, 0.030 mmol, 20.75 % yield). ¹H NMR (500 MHz, DMSO-_d₆) δ 8.25 (s, 1H), 7.87 (d, $J=7.9$ Hz, 1H), 7.52 (t, $J=7.6$ Hz, 1H), 7.31 (d, $J=7.3$ Hz, 1H), 7.14 (d, $J=8.5$ Hz, 1H), 7.05 (s, 1H), 7.03 - 6.98 (m, 2H), 5.89 (br. s., 1H), 4.47 (br. s., 1H), 4.20 - 4.12 (m, 1H), 4.02 (br. s., 2H), 2.87 (br. s., 1H), 2.75 (s, 1H), 2.57 (s, 3H), 2.28 (s, 3H), 2.04 (d, $J=13.4$ Hz, 2H), 1.74 (br. s., 4H), 1.59 - 1.50 (m, 1H), 1.45 (br. s., 1H), 1.22 (s, 9H), 1.20 (br. s., 3H), 1.02 (d, $J=5.8$ Hz, 3H), 0.68 (d, $J=6.4$ Hz, 3H). LCMS (M+H) = 655.7.

20

Intermediate 211




25

tert-Pentyl acetate : To a solution of 2-methylbutan-2-ol (10 g, 113 mmol) in DCM (100 mL) was added DMAP (0.693 g, 5.67 mmol) and TEA (17.39 mL, 125 mmol). Mixture was then cooled to 0°C and acetic anhydride (15.56 mL, 125 mmol)

was added and the mixture was stirred at room temp for 24 h. The mixture was then washed with sat. NaHCO₃ (100 mL), 1N HCl (100 mL), 10% NaOH (100 mL), brine (100 mL), dried (Na₂SO₄), filtered and concentrated to afford dark oil which was distilled by short path distillation (product distilled at 90-95°C) to afford tert-pentyl acetate (8 g, 61.5 mmol, 54.2 % yield) as colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 1.98 (s, 3H), 1.78 (q, *J*=7.5 Hz, 2H), 1.43 (s, 6H), 0.89 (t, *J*=7.5 Hz, 3H).

Intermediate 212




10

Methyl (2S)-2-hydroxy-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate : To a solution of methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (88 mg, 0.134 mmol) in DCM (3 mL) at room temp was added TFA (0.311 mL, 4.03 mmol) and the mixture was stirred at room temp for 16 h. Then, mixture was concentrated and purified by biotage (0-40% EtOAc/hexane) to afford methyl (2S)-2-hydroxy-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (60 mg, 0.100 mmol, 74.6 % yield) as viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 8.53 - 8.42 (m, 1H), 7.79 (d, *J*=7.7 Hz, 1H), 7.50 (t, *J*=7.6 Hz, 1H), 7.36 (d, *J*=7.6 Hz, 1H), 7.16 - 7.11 (m, 2H), 6.96 - 6.85 (m, 2H), 5.56 (s, 1H), 4.62 - 4.38 (m, 2H), 4.15 (q, *J*=7.1 Hz, 1H), 3.89 - 3.83 (m, 1H), 3.81 (s, 3H), 3.47 (br. s., 1H), 3.41 - 3.29 (m, 1H), 3.18 (d, *J*=10.9 Hz, 1H), 2.76 (d, *J*=11.8 Hz, 1H), 2.66 (s, 2H), 2.36 (s, 3H), 2.05 - 1.96 (m, 1H), 1.90 (t,

$J=12.5$ Hz, 2H), 1.82 - 1.72 (m, 2H), 1.68 - 1.56 (m, 2H), 1.50 (br. s., 2H), 1.29 (t, $J=7.1$ Hz, 2H), 1.24 (s, 3H), 1.15 (d, $J=6.0$ Hz, 3H). LCMS (M+H) = 599.4.

Intermediate 213



5

Methyl (2S)-2-[(2-methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate : To a stirred solution of methyl (2S)-2-hydroxy-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (50 mg, 0.084 mmol) in DCM (2 mL) and *tert*-pentyl acetate (0.692 mL, 5.85 mmol) at rt was added 70 wt% perchloric acid (0.022 mL, 0.251 mmol). After 3 h, the reaction mixture was diluted with DCM (25 mL), carefully quenched with sat. NaHCO₃ (5 mL), organic layer separated and washed with brine (10 mL), dried (Na₂SO₄), filtered and concentrated to give yellow liquid. This was purified by flash column chromatography on silica gel column using (10-50% EtOAc/Hex as eluant) to afford the desired methyl (2S)-2-[(2-methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (10 mg, 0.015 mmol, 17.90 % yield) as viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 7.82 - 7.76 (m, 1H), 7.50 (t, $J=7.7$ Hz, 1H), 7.39 - 7.34 (m, 1H), 7.18 (d, $J=1.9$ Hz, 1H), 7.13 (dd, $J=8.5$, 2.0 Hz, 1H), 6.92 (d, $J=8.5$ Hz, 1H), 6.90 (s, 1H), 5.90 (s, 1H), 4.66 - 4.59 (m, 1H), 4.58 - 4.52 (m, 1H), 3.84 - 3.79 (m, 1H), 3.77 (s, 3H), 3.50 (td, $J=7.7$, 3.1 Hz, 1H), 3.44 - 3.35 (m, 1H), 3.27 (d, $J=12.3$ Hz, 1H), 2.89 (d, $J=11.3$ Hz, 1H), 2.61 (s, 3H), 2.36 (s, 3H), 2.07 - 1.96 (m, 3H), 1.89 - 1.80 (m, 1H), 1.79 - 1.70 (m, 3H), 1.63 - 1.47 (m, 6H), 1.26 (s, 3H), 1.23 (s, 3H), 1.17 (d, $J=6.0$ Hz, 3H), 1.15 (s, 3H), 0.83 (t,


10

15

25

$J=7.5$ Hz, 3H). LCMS (M+H) = 669.4. 35 mg of starting material was also recovered.

Example 96




5

(2S)-2-[(2-Methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: To a solution of methyl (2S)-2-[(2-methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (10 mg, 0.015 mmol) in MeOH (1 mL) was added 1N NaOH (0.150 mL, 0.150 mmol) solution and the resulting mixture was heated at 75°C for 3 h. Then, the mixture was cooled and purified by prep HPLC to afford (2S)-2-[(2-methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid (6.4 mg, 9.77 μmol, 65.4 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 8.50 (s, 1H), 7.92 (d, $J=8.2$ Hz, 1H), 7.51 (t, $J=7.6$ Hz, 1H), 7.33 (d, $J=7.0$ Hz, 1H), 7.17 - 7.08 (m, 3H), 7.05 (d, $J=8.5$ Hz, 1H), 5.65 (br. s., 1H), 4.62 (d, $J=6.1$ Hz, 1H), 4.49 (t, $J=12.5$ Hz, 1H), 3.64 - 3.54 (m, 1H), 3.48 - 3.42 (m, 2H), 2.80 (d, $J=10.4$ Hz, 1H), 2.29 (s, 3H), 2.03 - 1.86 (m, 3H), 1.72-1.62 (m, 4H), 1.60 - 1.41 (m, 5H), 1.19 (s, 3H), 1.15 (s, 3H), 1.11 - 1.03 (m, 6H), 0.72 (t, $J=7.3$ Hz, 3H). 4 missing piperidine hydrogens. LCMS (M+H) = 655.8.


25

Intermediate 214



1-Methylcyclobutanol: Ref: PCT 2010009195: To a solution of cyclobutanone
 5 (5 g, 71.3 mmol) in diethyl ether (400 mL) at 0°C was added dropwise 3M
 MeMgBr/diethyl ether (47.6 mL, 143 mmol) and the resulting mixture was stirred for
 3 h at 0°C. Then, the reaction mixture was poured over cooled 1N HCl and extracted
 twice with ether, dried (Na₂SO₄), filtered and concentrated to afford 1-
 methylcyclobutanol (6.1 g, 70.8 mmol, 99 % yield) as colorless oil. ¹H NMR (500
 10 MHz, CDCl₃) δ 2.17 - 1.97 (m, 4H), 1.90 - 1.67 (m, 2H), 1.61 - 1.47 (m, 1H), 1.39 (t,
J=0.8 Hz, 3H).

Intermediate 215




15

1-Methylcyclobutyl acetate: To a solution of 1-methylcyclobutanol (6.2 g,
 72.0 mmol) in DCM (50 mL) was added DMAP (0.440 g, 3.60 mmol) and TEA
 (15.05 mL, 108 mmol). Then, the mixture was cooled to 0°C and acetic anhydride
 (13.46 mL, 108 mmol) was added and stirred at room temp for 24 h. The mixture
 20 was then washed with sat.NaHCO₃ (100 mL), 1N HCl (100 mL), 10% NaOH (100
 mL), brine (100 mL), dried (Na₂SO₄), filtered and concentrated to afford 1-
 methylcyclobutyl acetate (8 g, 62.4 mmol, 87 % yield) as light yellow oil which was
 used in the next step as is without further purification. ¹H NMR (500 MHz, CDCl₃)
 δ 2.36 - 2.26 (m, 2H), 2.18 - 2.11 (m, 2H), 2.01 - 1.98 (m, 3H), 1.87 - 1.76 (m, 1H),
 25 1.72 - 1.63 (m, 1H), 1.55 (s, 3H).


30

Example 97




5 *(2S)-2-(1-Methylcyclobutoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxo-*
1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid: To a stirred solution
 of methyl (2S)-2-hydroxy-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-
 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetate (40 mg, 0.067 mmol) in
 10 DCM (2 mL) and 1-methylcyclobutyl acetate (599 mg, 4.68 mmol) at rt was added
 70 wt% perchloric acid (0.017 mL, 0.200 mmol). After 3 h, the reaction mixture was
 diluted with DCM (25 mL), carefully quenched with sat. NaHCO₃ (5 mL), organic
 layer separated and washed with brine (10 mL), dried (Na₂SO₄), filtered and
 concentrated to give yellow paste. The crude was then treated with 1N NaOH (0.334
 15 mL, 0.334 mmol) in MeOH (1 mL) at 75°C for 3 h. Mixture was then cooled and
 purified by prep HPLC to afford (2S)-2-(1-methylcyclobutoxy)-2-[(22S)-4,17,22,28-
 tetramethyl-21,27-dioxo-1,5,7,8-
 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid (15.8 mg, 0.024 mmol,
 20 36.2 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 8.52 (s, 1H), 7.91 (d, *J*=7.9 Hz,
 1H), 7.51 (t, *J*=7.6 Hz, 1H), 7.33 (d, *J*=7.6 Hz, 1H), 7.17 - 7.11 (m, 2H), 7.08 (s, 1H),
 7.05 (d, *J*=8.2 Hz, 1H), 5.49 (s, 1H), 4.62 (d, *J*=5.5 Hz, 1H), 4.45 (t, *J*=12.2 Hz, 1H),
 3.61 - 3.53 (m, 1H), 3.40-3.20 (m, 7H), 2.83 (d, *J*=10.4 Hz, 1H), 2.29 (s, 3H), 2.22
 (q, *J*=10.0 Hz, 1H), 2.01 - 1.86 (m, 4H), 1.82 (br. s., 1H), 1.70-1.62 (m, 5H), 1.58 -
 25 1.41 (m, 4H), 1.28 (s, 3H), 1.17 (s, 3H), 1.07 (d, *J*=5.8 Hz, 3H). LCMS (M+H) =
 653.6.

Intermediate 216



5 *(S)*-Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-hydroxy-
 [1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate:
 To *(S)*-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-
 methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.38 g, 0.63 mmol, 1
 equiv), (4-fluoro-2-hydroxyphenyl)boronic acid (148 mg, 0.95 mmol, 1.5 equiv), and
 Pd(PPh₃)₄ (73 mg, 0.063 mmol, 0.1 equiv) was added DMF (6.3 mL that had been
 10 degassed by sparging with nitrogen for 10 min). Na₂CO₃ (0.63 mL of a 2 M aqueous
 solution, 1.27 mmol, 2 equiv) was added and the reaction was heated to 90 °C for 18
 h. Upon cooling to ambient temperature, the reaction was diluted with EtOAc and
 washed with water. The EtOAc layer was dried (Na₂SO₄) and concentrated *in vacuo*.
 The crude product was purified by flash column chromatography (0-100% EtOAc in
 15 hexane) to provide the product as a yellow glass (0.27 g, 68%). LCMS (M+1) =
 631.4.

Intermediate 217




20

20 *(S)*-Ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-((*S*)-pent-
 4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-
 butoxy)acetate: To a solution of *(S)*-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-
 2-(4'-fluoro-2'-hydroxy-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-
 25 yl)-2-(tert-butoxy)acetate (0.27 g, 0.43 mmol, 1 equiv), (*R*)-pent-4-en-2-ol (0.132
 mL, 1.28 mmol, 3 equiv), and PPh₃ (0.23 g, 0.86 mmol, 2 equiv) in THF (2.1 mL)
 was added DIAD (0.166 mL, 0.86 mmol, 2 equiv). After stirring 18 h, diluted with

EtOAc and washed with water. The EtOAc layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-100% EtOAc in hexane) to provide the product as a colorless glass (0.29 g, 97%). LCMS (M+1) = 699.45.

5


Intermediate 218



(S)-Ethyl-2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of (S)-ethyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (0.10 g, 0.14 mmol, 1 equiv) in toluene (29 mL) was heated to reflux for 30 min to degas the solvent. 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(isopropoxy)-5-(N,N-dimethylaminosulfonyl)phenyl]methylenruthenium(II) dichloride (0.5 mg, 0.0007 mmol, 0.005 equiv) was added. The pale green yellow solution was refluxed for 18 h. More 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(isopropoxy)-5-(N,N-dimethylaminosulfonyl)phenyl]methylenruthenium(II) dichloride (5 mg, 0.007 mmol, 0.05 equiv) was added. After 3 h, 2-mercaptonicotinic acid (5 mg, 0.2 equiv) was added and the reaction was removed from heat. Upon cooling, the reaction was concentrated *in vacuo*. The crude product was purified by flash column chromatography (0-30% EtOAc in hexane) to provide the product as a tan glass (33 mg, 34%). LCMS (M+1) = 671.4.

25


Example 98



(*S*)-2-(7-(4-(*Allyloxy*)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetic acid: To a solution of (*S*)-ethyl-2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(4'-fluoro-2'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate (32 mg, 0.048 mmol, 1 equiv) in MeOH (1.0 mL) and water (0.1 mL) was added LiOH·H₂O (60 mg, 1.43 mmol, 30 equiv). The reaction was heated to 60 °C for 2 h. Upon cooling to ambient temperature, the reaction was then filtered and purified via preparative HPLC with the following conditions: Column: XBridge Phenyl, 19 x mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 20-60% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Product (7 mg, 23%) isolated. ¹H NMR (600 MHz, DMSO-*d*₆) δ 8.41 (s, 1H), 7.89 (d, *J* = 7.7 Hz, 1H), 7.52 (t, *J* = 7.7 Hz, 1H), 7.36 - 7.30 (m, 2H), 7.10 (d, *J* = 11.6 Hz, 1H), 7.04 (s, 1H), 6.88 - 6.81 (m, 1H), 6.31 (d, *J* = 6.1 Hz, 1H), 5.58 (s, 1H), 4.66 - 4.60 (m, 1H), 4.53 (q, *J* = 7.0 Hz, 1H), 4.37 (t, *J* = 12.1 Hz, 1H), 3.64 - 3.55 (m, 4H), 2.88 (br. s., 1H), 2.53 (s, 3H), 2.40 - 2.32 (m, 1H), 2.31 - 2.24 (m, 1H), 1.96 - 1.59 (m, 4H), 1.32 (s, 3H), 1.16 (s, 9H), 1.13 (d, *J* = 6.1 Hz, 3H). LCMS (M+1) = 643.5.

20


Intermediate 219



Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)acetate: A solution of methyl 2-(2-bromo-7-chloro-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)acetate (prepared according to the procedure for intermediate 4 starting from 3-bromo-1H-pyrazol-5-amine; 13.4 g, 41.9 mmol, 1 equiv), 4-(allyloxy)-4-methylpiperidine (7.16 g, 46.1 mmol, 1.1 equiv), and DIEA (17.6 mL, 101 mmol, 2.4 equiv) in DMF (84 mL) was heated at 60 °C for 2 h. The reaction was then added to water and extracted with ether (x2). Combined ether extracts dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified

by silica gel flash chromatography (0-50% EtOAc/hex) to provide methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (17.7 g, 97%). ¹H NMR (500 MHz, CDCl₃) δ 6.52 (s, 1H), 6.02 (ddt, *J* = 17.2, 10.4, 5.2 Hz, 1H), 5.43 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.22 (dq, *J* = 10.4, 1.5 Hz, 1H), 3.99 (dt, *J* = 5.2, 1.6 Hz, 2H), 3.77 (s, 3H), 3.79 - 3.76 (m, 2H), 3.70 - 3.56 (m, *J* = 7.4 Hz, 2H), 3.33 (br. s., 2H), 2.50 (s, 3H), 1.97 - 1.89 (m, 2H), 1.87 - 1.78 (m, *J* = 9.3 Hz, 2H), 1.32 (s, 3H). LCMS (*M*+1) = 437.20.

Intermediate 220




10

Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate: A solution of methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)acetate (17.7 g, 40.5 mmol, 1 equiv) in THF (200mL) was cooled to -78 °C (IPA/CO₂). KHMDS (72 mL of a 0.91 M solution in THF, 64.9 mmol, 1.6 equiv) was added dropwise over ~2 min. Reaction turned a deep orange color. After 30 min, 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (15.9 g, 60.8 mmol, 1.2 equiv) was added in a single portion. The reaction significantly darkened. After 30min, the reaction was added to saturated aqueous sodium bicarbonate and extracted with ether (x2). The combined ether extracts were dried (MgSO₄) and concentrated *in vacuo* to provide the crude product as a brown oil. This was taken up in DCM (200 mL) and Dess-Martin periodinane (20.6 g, 48.6 mmol, 1.2 equiv). After 30 min, the reaction was added to saturated aqueous sodium bicarbonate and extracted with DCM (x3). Combined DCM extracts were dried (Na₂SO₄) and concentrated *in vacuo* to provide the crude product. The crude product was purified via silica gel flash chromatography (0-50% EtOAc/hex) to provide methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-oxoacetate (9.2 g, 50%). ¹H NMR (500 MHz, CDCl₃) δ 6.55 (s, 1H), 6.07 - 5.87 (m, 1H), 5.38

(dq, $J = 17.2, 1.7$ Hz, 1H), 5.20 (dq, $J = 10.4, 1.6$ Hz, 1H), 3.95 - 3.92 (m, 5H), 3.69 (d, $J = 12.6$ Hz, 2H), 3.59 - 3.50 (m, 2H), 2.56 (s, 3H), 1.96 - 1.82 (m, 4H), 1.28 (s, 3H). LCMS ($M+1$) = 450.95.

5

Intermediate 221




(*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: A solution of methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-oxoacetate (9.20 g, 20.3 mmol, 1 equiv) and (*R*)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-*c*][1,3,2]oxazaborole (12.2 mL of a 1 M solution in toluene, 12.2 mmol, 0.6 equiv) in toluene (200 mL) was cooled to -25 °C (MeCN/CO₂). Catecholborane (6.8 mL of a 50% solution in toluene, 28.4 mmol, 1.4 equiv) was then added and temperature was held between -15 °C and -25 °C for 18 h. At this point, more and (*R*)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-*c*][1,3,2]oxazaborole (4 mL of a 1 M solution in toluene, 4 mmol, 0.2 equiv) and catecholborane (3 mL of a 50% solution in toluene, 12.5 mmol, 0.6 equiv) were added. The reaction was then stirred a further 4 h. The reaction was then quenched with 10% aqueous K₂CO₃ (100mL) and EtOAc (100 mL) and removed from cooling bath. After stirring 45 min, the mixture was added to water and extracted with ether (x4). The combined ether extracts were dried (MgSO₄) and concentrated *in vacuo* to provide the crude product as a yellow foam. This was taken up in DCM (50 mL) and tBuOAc (150 mL). To this solution was added 70% perchloric acid (3.7 mL, 60.9 mmol, 3 equiv) to give a cloudy orange solution. After stirring 3 h, the reaction was added cautiously to saturated aqueous sodium bicarbonate and extracted with DCM (x3). The combined DCM extracts were dried (Na₂SO₄) and concentrated *in vacuo* to provide the crude product. The crude product was purified via silica gel flash chromatography (0-100% EtOAc/hex) to provide (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-

butoxy)acetate (3.56 g, 34%) ^1H NMR (500 MHz, CDCl_3) δ 6.54 (s, 1H), 6.09 - 5.97 (m, 1H), 5.83 (br. s., 1H), 5.48 (d, $J = 17.8$ Hz, 1H), 5.24 (d, $J = 9.8$ Hz, 1H), 4.50 - 3.00 (very broad m, 4H), 4.05 - 3.98 (m, 2H), 3.76 (s, 3H), 2.59 (s, 3H), 2.04 - 1.90 (m, 2H), 1.36 (s, 3H), 1.24 (s, 9H). LCMS ($M+1$) = 509.09.


- 5 And recovered (S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-hydroxyacetate (4.53 g, 49%). ^1H NMR (500 MHz, CDCl_3) δ 6.57 (s, 1H), 6.12 - 5.97 (m, 1H), 5.56 - 5.47 (m, 2H), 5.28 - 5.22 (m, 1H), 4.50 - 3.00 (very broad m, 4H), 4.00 (dt, $J = 5.0, 1.6$ Hz, 2H), 3.82 (s, 3H), 2.59 (s, 3H), 2.01 - 1.91 (m, 2H), 1.80 (d, $J = 11.7$ Hz, 2H), 1.33 (s, 3H).
- 10 LCMS ($M+1$) = 453.00.

Intermediate 222



- 15 *5'-Bromo-2',6-difluoro-[1,1'-biphenyl]-2-ol*: (2-Fluoro-6-hydroxyphenyl)boronic acid (50 mg, 0.321 mmol, 1.0 equiv), $\text{Pd}(\text{PPh}_3)_4$ (37.1 mg, 0.032 mmol, 0.1 equiv) and aqueous Na_2CO_3 (2 M, 401 μl , 0.802 mmol, 2.5 equiv) were mixed with toluene (2 mL) in a sealed microwave tube. 4-Bromo-1-fluoro-2-iodobenzene (96 mg, 0.321 mmol, 1.0 equiv) in MeOH (1.00 mL) was added to the
- 20 above mixture. The resulted mixture was heated at 105 $^\circ\text{C}$ overnight. TLC showed the starting material disappeared and a new spot was produced. The reaction was allowed to cool to ambient temperature and then loaded on 12 g ISCO column and purified by 30% EtOAc/hexane to afford 5'-bromo-2',6-difluoro-[1,1'-biphenyl]-2-ol (81 mg, 89%). ^1H NMR (400 MHz, CHLOROFORM-d) δ 7.54 (dd, $J = 6.3, 2.5$ Hz, 1H), 7.48 (ddd, $J = 8.7, 4.5, 2.6$ Hz, 1H), 7.21 (td, $J = 8.2, 6.7$ Hz, 1H), 7.07 (t, $J = 8.9$ Hz, 1H), 6.81 (d, $J = 8.3$ Hz, 1H), 6.71 (t, $J = 8.8$ Hz, 1H). LCMS ($M+1$) = 286.1.
- 25


Intermediate 223



5 *5-Bromo-2,2'-difluoro-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl*: 5-Bromo-2',6-difluoro-[1,1'-biphenyl]-2-ol (520 mg, 1.82 mmol, 1.0 equiv) were mixed with (R)-pent-4-en-2-ol (314 mg, 3.65 mmol, 2.0 equiv) and Ph₃P (957 mg, 3.65 mmol, 2.0 equiv) in THF (6 mL). To this solution was added DEAD (1661 μ l, 3.65 mmol, 2.0 equiv) dropwise and stirred overnight. The solution was mixed with silica gel and concentrated and purified by 40 g ISCO column with 0-10% EtOAc/hexane to
10 afford 5-bromo-2,2'-difluoro-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl (500 mg, 78%). ¹H NMR (400 MHz, CDCl₃) δ 7.52 - 7.42 (m, 2H), 7.34 - 7.28 (m, 1H), 7.03 (t, *J* = 9.0 Hz, 1H), 6.81 - 6.74 (m, 2H), 5.81 - 5.62 (m, 1H), 5.12 - 4.96 (m, 2H), 4.41 (dq, *J* = 11.7, 5.9 Hz, 1H), 2.44 - 2.18 (m, 2H), 1.23 (dd, *J* = 7.3, 6.3 Hz, 3H). LCMS (M+1) = 353.1.

15


Intermediate 224



20 *2-(2',6-Difluoro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane*: A mixture of 5-bromo-2,2'-difluoro-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl (300 mg, 0.849 mmol, 1.0 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (324 mg, 1.274 mmol, 1.5 equiv), potassium acetate (167 mg, 1.699 mmol, 2.0 equiv) and dioxane (8494 μ l) was de-oxygenated by vacuum/nitrogen purge and treated with Pd(dppf)Cl₂•CH₂Cl₂ (34.7 mg, 0.042

mmol, 0.05 equiv). The mixture was stirred at reflux under nitrogen for 2 h, cooled and used in the next reaction without further purification. LCMS (M+1) = 401.2.



Intermediate 225



5


(2*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2',6-difluoro-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To solution of above crude product was added (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (100 mg, 0.196 mmol, 1.0 equiv), PdCl₂(dppf)-CH₂Cl₂ (16.03 mg, 0.020 mmol, 0.1 equiv), DMF (0.5 mL) and 2 M K₃PO₄ (0.294 mL, 0.589 mmol, 3.0 equiv). The mixture was stirred at 90 °C for 2 h, cooled, diluted with EtOAc and washed with saturated NaHCO₃. The organic solution was dried over MgSO₄ and concentrated with silica gel and purified on 24 g ISCO column to afford (2*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2',6-difluoro-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(tert-butoxy)acetate (100 mg, 72.5 % yield) as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.06 (br. s., 1H), 7.92 (br. s., 1H), 7.35 - 7.28 (m, 1H), 7.21 (t, *J* = 8.8 Hz, 1H), 6.86 - 6.73 (m, 3H), 6.09 - 5.86 (m, 2H), 5.77 - 5.60 (m, 1H), 5.40 (d, *J* = 17.3 Hz, 1H), 5.11 (br. s., 1H), 5.04 - 4.92 (m, 2H), 4.47 - 4.34 (m, 1H), 4.00 (br. s., 2H), 3.74 (s, 3H), 2.60 (s, 3H), 2.41 - 2.31 (m, 1H), 2.29 - 2.18 (m, 1H), 2.09 - 2.06 (m, 2H), 2.03 - 1.90 (m, 2H), 1.71 (br. s., 1H), 1.62 - 1.59 (m, 1H), 1.27 (s, 3H), 1.25 (s, 9H), 1.24 - 1.21 (m, 3H). LCMS (M+1) = 703.4.

25



THF (1 mL) and water (0.8 mL). To this solution was added LiOH (89 mg, 3.70 mmol, 25 equiv) and stirred at 60 °C for 2 h. After filtration, the solution was purified by HPLC, Column: XBridge C18, 19 x 200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 40-80% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford (2*S*)-[(22*S*)-16-chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid (6.7 mg, 10.11 μmol, 7 % yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.20 (d, *J* = 6.7 Hz, 1H), 8.03 (br. s., 1H), 7.47 - 7.35 (m, 2H), 7.11 - 7.03 (m, 2H), 6.88 (t, *J* = 8.7 Hz, 1H), 5.61 (br. s., 1H), 4.68 (br. s., 1H), 4.50 (t, *J* = 11.7 Hz, 1H), 3.39 (br. s., 2H), 3.30 (br. s., 2H), 2.80 - 2.69 (m, 1H), 2.52 - 2.50 (m, 3H), 1.95 - 1.83 (m, 3H), 1.61 (br. s., 5H), 1.41 (br. s., 2H), 1.15 (br. s., 12H), 1.10 (d, *J* = 5.2 Hz, 3H). LCMS (ESI, M+1): 663.3.

Intermediate 227




20

5'-Bromo-6-chloro-2'-methyl-[1,1'-biphenyl]-2-ol: (2-Chloro-6-hydroxyphenyl)boronic acid (250 mg, 1.450 mmol, 1 equiv), Pd(PPh₃)₄ (168 mg, 0.145 mmol, 0.1 equiv) and aqueous Na₂CO₃ (2 M, 1.8 ml, 3.63 mmol, 2.5 equiv) were mixed with toluene (2 mL) in a sealed microwave tube. 4-Bromo-2-iodo-1-methylbenzene (431 mg, 1.450 mmol, 1.0 equiv) in MeOH (1.00 mL) was to the above mixture. The mixture was heated at 105 °C overnight. Then, the crude reaction mixture was loaded on 12 g column and purified at 30% EtOAc/hexane to afford 5'-bromo-6-chloro-2'-methyl-[1,1'-biphenyl]-2-ol (345 mg, 80%). LCMS (M+1) = 299.0.


30

Intermediate 228

*5-Bromo-2'-chloro-2-methyl-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl: 5'-*

- 5 Bromo-6-chloro-2'-methyl-[1,1'-biphenyl]-2-ol (540 mg, 1.82mmol, 1.0 equiv) were mixed with (R)-pent-4-en-2-ol (313 mg, 3.63 mmol, 2.0 equiv) and Ph₃P (952 mg, 3.63 mmol, 2.0 equiv) in THF (6 ml). To this solution was added DEAD (1653 μ l, 3.63 mmol, 2.0 equiv) dropwise and stirred overnight. The solution was mixed with silica gel and concentrated and purified by 40 g ISCO column with 0-10% EtOAc/hex to afford 5-bromo-2'-chloro-2-methyl-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl (350 mg, 52.7%). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (dd, *J* = 8.2, 2.1 Hz, 1H), 7.25 - 7.21 (m, 2H), 7.14 (d, *J* = 7.5 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 6.86 (dd, *J* = 8.0, 5.3 Hz, 1H), 5.66 - 5.50 (m, 1H), 5.05 - 4.90 (m, 2H), 4.35 - 4.24 (m, 1H), 2.30 - 2.12 (m, 2H), 2.01 (s, 3H), 1.16 (dd, *J* = 11.0, 6.0 Hz, 3H). LCMS (M+1) = 365.0.

Intermediate 229




- 20 *2-(2'-Chloro-6-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane*: A mixture of 5-bromo-2'-chloro-2-methyl-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl (400 mg, 1.094 mmol, 1.0 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (417 mg, 1.641 mmol, 1.5 equiv), potassium acetate (215 mg, 2.188 mmol, 2.0 equiv) and dioxane (1.1 ml) was de-oxygenated by vacuum/nitrogen purge and treated with Pd(dppf)Cl₂•CH₂Cl₂ (44.7

mg, 0.055 mmol, 0.05 equiv). The mixture was stirred at reflux under nitrogen overnight. It was cooled down to room temperature and used for next reaction without further purification. LCMS (M+1) = 413.2.


5

Intermediate 230



(2S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6-methyl-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To the crude reaction mixture of the previous step was added (*S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (130 mg, 0.254 mmol, 1.0 equiv), PdCl₂(dppf)-CH₂Cl₂ (21 mg, 0.025 mmol, 0.1 equiv), DMF (2 mL) and 2 M K₃PO₄ (0.382 mL, 0.763 mmol, 3.0 equiv). The mixture was stirred at 90 °C for 1 h, cooled, diluted with EtOAc and washed with saturated NaHCO₃. The organic solution was dried over MgSO₄ and concentrated with silica gel and purified on 24 g ISCO column to afford (*2S*)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6-methyl-6'-((*S*)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (120 mg, 0.168 mmol, 66 %) as pale yellow oil. LCMS (M+1) = 715.3.

Intermediate 231




Methyl (2S)-[(22S)-16-chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19,24-undecaen-3-yl][(2-methyl-2-propanyl)oxy]acetate: To a solution of (2S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6-methyl-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (100 mg, 0.140 mmol, 1.0 equiv) in DCE (7 mL) was added Hoveyda-Grubbs Catalyst 2nd Generation (8.76 mg, 0.014 mmol, 0.1 equiv) and stirred for 3 h at 95 °C. The solvent was evaporated to give a grey solid which was used in the next step without further purification. LCMS (M+1) = 687.3.

Examples 100 and 101

The crude product from the previous step was dissolved in 2 mL methanol. To this solution was added sodium borohydride (27.5 mg, 0.728 mmol, 5 equiv) in several batches until the alkene was reduced. The reaction was quenched with 0.5 M HCl and extracted with ethyl acetate. The organic layer was collected and concentrated down to a grey solid. This solid was redissolved in 1.5 mL methanol, 1 mL THF and 0.8 mL water. To this solution was added LiOH (89 mg, 3.70 mmol, 25 equiv) and stirred at 60 °C for 2 h. After filtration, the solution was purified by HPLC (Column: XBridge C18, 19 x 200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammoniumacetate; Gradient: 40-80% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.) to afford two atropisomers.


Example 100



(2*S*)-[*(22S)*-16-Chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid: ¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.83 (d, *J* = 1.5 Hz, 1H), 7.64 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.33 - 7.23 (m, 2H), 7.00 (t, *J* = 7.8 Hz, 2H), 6.75 (s, 1H), 5.91 (s, 1H), 4.73 (t, *J* = 11.5 Hz, 1H), 4.55 (t, *J* = 6.4 Hz, 1H), 3.65 (t, *J* = 11.1 Hz, 1H), 3.44 - 3.30 (m, 3H), 2.78 (d, *J* = 11.5 Hz, 1H), 2.58 (s, 3H), 1.99 (s, 3H), 1.95 - 1.87 (m, 2H), 1.80 - 1.58 (m, 4H), 1.53 (dd, *J* = 8.4, 4.8 Hz, 1H), 1.49 - 1.34 (m, 3H), 1.21 (s, 9H), 1.17 (s, 3H), 1.12 (d, *J* = 5.9 Hz, 3H). LCMS (M+1) = 675.3.

10


Example 101



(2*S*)-[*(22S)*-16-Chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid: ¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.71 - 7.62 (m, 2H), 7.41 (d, *J* = 7.8 Hz, 1H), 7.34 - 7.25 (m, 2H), 7.03 (d, *J* = 7.6 Hz, 1H), 6.68 (s, 1H), 5.93 (s, 1H), 4.36 - 4.22 (m, 1H), 4.10 - 3.91 (m, 2H), 3.36 (d, *J* = 9.0 Hz, 3H), 2.66 (s, 3H), 2.61 (d, *J* = 9.5 Hz, 1H), 2.07 (s, 3H), 2.03 (d, *J* = 5.6 Hz, 1H), 1.76 (d, *J* = 11.0 Hz, 3H), 1.58 (dd, *J* = 13.3, 4.0 Hz, 2H), 1.43 - 1.28 (m, 3H), 1.25 (s, 9H), 1.21 (s, 3H), 0.85 (d, *J* = 6.1 Hz, 3H). LCMS (M+1) = 675.3.

20


Intermediate 232



25

5'-Bromo-6-chloro-2'-fluoro-[1,1'-biphenyl]-2-ol: (2-Chloro-6-hydroxyphenyl)boronic acid (250 mg, 1.450 mmol, 1.0 equiv), Pd(PPh₃)₄ (168 mg, 0.145 mmol, 0.1 equiv) and aqueous Na₂CO₃ (2 M, 1.8 mL, 3.63 mmol, 2.5 equiv) were mixed with toluene (3 mL) in a sealed microwave tube. 4-Bromo-1-fluoro-2-iodobenzene (436 mg, 1.450 mmol) in MeOH (1.50 mL) was added to the above mixture. The mixture was heated at 105 °C overnight. Then, the reaction mixture was loaded on 12 g column and purified using 30% EtOAc/Hex to afford 5'-bromo-6-chloro-2'-fluoro-[1,1'-biphenyl]-2-ol (400 mg, 91% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.57 (ddd, *J* = 8.8, 4.5, 2.5 Hz, 1H), 7.47 (dd, *J* = 6.3, 2.5 Hz, 1H), 7.24 (t, *J* = 8.2 Hz, 1H), 7.17 - 7.06 (m, 2H), 6.90 (d, *J* = 8.0 Hz, 1H). LCMS (M+1) = 302.9.

Intermediate 233




15

5-Bromo-2'-chloro-2-fluoro-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl: 5'-Bromo-6-chloro-2'-fluoro-[1,1'-biphenyl]-2-ol (750mg, 2.49 mmol, 1.0equiv) were mixed with (R)-pent-4-en-2-ol (428 mg, 4.97 mmol, 2.0 equiv) and PPh₃ (1305 mg, 4.97 mmol, 2.0 equiv) in tetrahydrofuran (8 mL). To this solution was added DEAD (2266 µl, 4.97 mmol, 2.0 equiv) dropwise and stirred overnight. The solution was mixed with silica gel and concentrated and purified by 40 g ISCO column with 0-10% EtOAc/hexane to afford 5-bromo-2'-chloro-2-fluoro-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl (385 mg, 42%). ¹H NMR (400 MHz, CDCl₃) δ 7.49 - 7.44 (m, 1H), 7.41 - 7.36 (m, 1H), 7.29 (s, 1H), 7.11 - 6.99 (m, 2H), 6.87 (dd, *J* = 8.3, 2.0 Hz, 1H), 5.73 - 5.56 (m, 1H), 5.07 - 4.93 (m, 2H), 4.36 (dq, *J* = 8.8, 6.0 Hz, 1H), 2.37 - 2.16 (m, 2H), 1.20 (dd, *J* = 6.0, 3.0 Hz, 3H). LCMS (M+1) = 369.0.


25

Intermediate 234



2-(2'-Chloro-6-fluoro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane: A mixture of 5-bromo-2'-chloro-2-fluoro-6'-((S)-pent-4-en-2-yloxy)-1,1'-biphenyl (220 mg, 0.595 mmol, 1.0 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (227 mg, 0.893 mmol, 1.5 equiv), potassium acetate (117 mg, 1.190 mmol, 2.0 equiv) and 1,4-dioxane (6 mL) were de-oxygenated by vacuum/nitrogen purge and treated with Pd(dppf)Cl₂•CH₂Cl₂ (24.30 mg, 0.030 mmol, 0.05 equiv). The mixture was stirred at reflux under nitrogen until all the starting material was consumed. It was cooled down to room temperature and used in the next step without further purification. LCMS (M+1) = 417.2.

Intermediate 235



15


(2S)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6-fluoro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate: To 3.0 mL solution of above crude product was added (S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-bromo-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (150 mg, 0.294 mmol, 1.0 equiv), PdCl₂(dppf)-CH₂Cl₂ (24.05 mg, 0.029 mmol, 0.1 equiv), DMF (3 mL) and 2 M K₃PO₄ (442 µl, 0.883 mmol, 3.0 equiv). The mixture was stirred at 90 °C for 2 h, cooled, diluted with EtOAc and washed with saturated NaHCO₃. The organic solution was dried over MgSO₄ and concentrated with silica gel and purified on 24 g

25

ISCO column to afford (2S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6-fluoro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (100 mg, 0.139 mmol, 47%) as a pale yellow oil. LCMS (M+1) = 719.3.

5


Intermediate 236



Methyl (2S)-[(22S)-16-chloro-13-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19,24-undecaen-3-yl][(2-methyl-2-propanyl)oxy]acetate: To a solution of (2S)-methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-2-(2'-chloro-6-fluoro-6'-((S)-pent-4-en-2-yloxy)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate (120 mg, 0.167 mmol, 1.0 equiv) in DCE (83 mL) was added Hoveyda-Grubbs Catalyst 2nd Generation (10.45 mg, 0.017 mmol, 0.1 equiv) and stirred for 2 h at 95 °C. The solvent was evaporated and the residue was used as is. LCMS (M+1) = 687.3.

20

Example 102




25

(2S)-[(22S)-16-Chloro-13-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid: The residue from the last step was dissolved in 2 mL methanol. To this

solution was added sodium borohydride (32.8 mg, 0.868 mmol, 5.0 equiv) in several batches until the alkene was reduced. The reaction was quenched by 0.5 M HCl and extracted with ethyl acetate. The organic layer was collected and concentrated down to a grey solid which was redissolved in 1.5 mL methanol, 1 mL THF and 0.8 mL
 5 water. To this solution was added LiOH (89 mg, 3.70 mmol, 25 equiv) and stirred at 60 °C for 2 h to give the title compound. LCMS (M+1) = 679.3.


Intermediate 237



10

(2*S*)-Methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(5'-methyl-2'-((2-methylbut-3-en-1-yl)oxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate. A solution of methyl (2*S*)-2-(tert-butoxy)-2-{2-[3-(2-hydroxy-5-methylphenyl)phenyl]-5-methyl-7-[4-methyl-4-(prop-2-en-1-yl)oxy]piperidin-1-yl}pyrazolo[1,5-a]pyrimidin-6-yl}acetate (0.297 g, 0.485 mmol) in
 15 dry THF (5 mL) was treated sequentially with 2-methylbut-3-en-1-ol (0.167 g, 1.939 mmol), Ph₃P (0.509 g, 1.939 mmol) and DEAD (0.307 mL, 1.939 mmol), and the reaction was stirred for 16 h. The reaction was diluted with water (20 mL), extracted into Et₂O (2 x 20 mL), dried (MgSO₄), filtered, and concentrated. The residue was
 20 purified by flash column chromatography (40 g SiO₂, 0-100% (38.1 CV), EtOAc in hexanes) to afford the desired product (0.300 g, 0.419 mmol, 86 % yield). ¹H NMR (500 MHz, CDCl₃) δ: 8.12 (s, 1H), 8.03 (d, *J*=6.8 Hz, 1H), 7.57 (d, *J*=7.6 Hz, 1H), 7.50 - 7.41 (m, 1H), 7.23 (d, *J*=1.9 Hz, 1H), 7.16 - 7.09 (m, 1H), 6.90 (d, *J*=8.4 Hz, 1H), 6.83 (s, 1H), 6.08 - 5.90 (m, 2H), 5.78 (ddd, *J*=17.3, 10.4, 6.9 Hz, 1H), 5.41 (dd, *J*=17.2, 1.3 Hz, 1H), 5.18 - 5.07 (m, 1H), 5.02 (dt, *J*=17.3, 1.3 Hz, 1H), 4.97 (dq, *J*=10.5, 1.2 Hz, 1H), 4.01 (d, *J*=4.9 Hz, 2H), 3.87 (dd, *J*=8.8, 6.1 Hz, 1H), 3.79 - 3.75 (m, 1H), 3.74 (s, 3H), 2.61 (s, 4H), 2.36 (s, 3H), 2.05 - 1.92 (m, 2H), 1.81 - 1.67 (m, 1H), 1.42 - 1.35 (m, 2H), 1.26 (s, 9H), 1.04 (dd, *J*=6.8, 0.6 Hz, 3H). LCMS (M+H) = 681.6.


Intermediate 238



5 *Methyl (2S)-2-(tert-butoxy)-2-[(24E/Z)-4,17,23,28-tetramethyl-21,27-dioxo-*
1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate. A solution of (2S)-
 methyl 2-(7-(4-(allyloxy)-4-methylpiperidin-1-yl)-5-methyl-2-(5'-methyl-2'-((2-
 methylbut-3-en-1-yl)oxy)-[1,1'-biphenyl]-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)-2-
 (tert-butoxy)acetate (0.300 g, 0.441 mmol) in DCE (110 ml) was heated (85°C) then
 10 treated with Hoveyda-Grubbs cat., 2nd gen. (0.019 g, 0.031 mmol), and stirred for 2
 h, then cooled and stirred for 16 h. The solvent was removed and the residue was
 purified by biotage (12 g SiO₂, 0% (3 CV), 0-60% (15 CV), 60% (2 CV), EtOAc in
 hexanes) to afford the desired product (0.203 g, 0.311 mmol, 70.6 % yield) as a 1:1
 mixture of diastereomers. LCMS (M+H) = 653.6.

15

Intermediate 239



20 *Methyl (2S)-2-(tert-butoxy)-2-{4,17,23,28-tetramethyl-21,27-dioxo-1,5,7,8-*
tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetate. A solution of methyl
 (2S)-2-(tert-butoxy)-2-[(24E/Z)-4,17,23,28-tetramethyl-21,27-dioxo-1,5,7,8-
 tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate (0.203 g, 0.311
 25 mmol) in MeOH (4 mL) was treated with 10 wt% Pd/C (0.033 g, 0.031 mmol), and


then three times evacuated and back-filled with H₂ gas (balloon). The reaction was stirred for 2.5 hrs, then the reaction was filtered (0.45 µm syringe tip filter), and concentrated to afford the desired product (0.191 g, 0.292 mmol, 94 % yield) as a pale yellow oil and mixture of diastereomers. LCMS (M+H) = 655.4.

5

Examples 103 and 104


A solution of methyl (2*S*)-2-(tert-butoxy)-2-{4,17,23,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 10 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl} acetate (0.191 g, 0.292 mmol) in MeOH (2 mL) was treated with 5.0 M NaOH (0.3 mL, 1.458 mmol), resulting in a thick gummy deposit, so THF (2 mL) was added, and the solution was then heated (75°C) for 2 h. The reaction was cooled and then diluted with CH₂Cl₂ (15 mL) and washed with 1.0 N HCl (5 mL), then brine, concentrated, and purified by prep-HPLC
 15 to afford two diastereomers.

Example 103



(2*S*)-2-(tert-Butoxy)-2-{4,17,23,28-tetramethyl-21,27-dioxa-1,5,7,8-
 20 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid (early eluting diastereomer, 0.0125 g, 0.019 mmol, 13.24 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ: 8.58 (s, 1H), 7.89 (d, *J*=7.0 Hz, 1H), 7.51 (t, *J*=7.6 Hz, 1H), 7.36 (d, *J*=7.3 Hz, 1H), 7.17 (s, 1H), 7.14 (d, *J*=7.9 Hz, 1H), 7.07 - 7.02 (m, 2H), 5.59 (s, 1H), 4.50 -
 25 4.40 (m, 1H), 4.16 (t, *J*=7.5 Hz, 1H), 2.93 - 2.85 (m, 1H), 2.35 (br. s., 1H), 2.29 (s, 3H), 1.99 - 1.88 (m, 3H), 1.82 (br. s., 1H), 1.73 - 1.49 (m, 4H), 1.37 (br. s., 1H), 1.19 (s, 3H), 1.15 (s, 9H), 0.81 (d, *J*=6.7 Hz, 3H). Note: piperidine protons broaden into baseline, and/or are solvent obscured. LCMS (M+H) = 641.7.


Example 104



(2S)-2-(tert-Butoxy)-2-{4,17,23,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid (later eluting diastereomer, 0.015 g, 0.023 mmol, 15.57 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ: 8.47 (s, 1H), 7.92 (d, *J*=7.6 Hz, 1H), 7.50 (t, *J*=7.6 Hz, 1H), 7.29 (d, *J*=7.3 Hz, 1H), 7.17 - 7.07 (m, 3H), 7.04 (d, *J*=8.5 Hz, 1H), 5.69 (s, 1H), 4.65 - 4.55 (m, 1H), 4.32 (d, *J*=9.5 Hz, 1H), 3.52 (d, *J*=11.6 Hz, 1H), 2.71 (d, *J*=11.6 Hz, 1H), 2.28 (s, 3H), 2.19 (d, *J*=13.4 Hz, 1H), 2.03 (d, *J*=13.4 Hz, 1H), 1.86 - 1.76 (m, 2H), 1.75 - 1.52 (m, 3H), 1.46 (br. s., 1H), 1.18 (s, 3H), 1.16 (s, 9H), 0.74 (d, *J*=6.7 Hz, 3H). Note: piperidine protons broaden into baseline, and/or are solvent obscured. LCMS (M+H) = 641.6.

15


Example 105



(2S)-2-(tert-Butoxy)-2-[(22S)-4,18,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid: A mixture of methyl (2S)-2-(tert-butoxy)-2-[(22S)-4,18,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetate (8 mg, 0.012 mmol), NaOH (0.061 mL, 0.061 mmol) in MeOH (1.5 mL) was refluxed for 3 h. It was then filtered and prep-HPLC to isolate 1.4 mg (18%) of the desired product. ¹H NMR

(500 MHz, DMSO- d_6) δ 8.43 (s, 1H), 7.92 (d, $J=7.9$ Hz, 1H), 7.51 (t, $J=7.6$ Hz, 1H), 7.28 (d, $J=7.6$ Hz, 1H), 7.14 (d, $J=7.6$ Hz, 1H), 7.09 (s, 1H), 6.99 (s, 1H), 6.82 (d, $J=7.3$ Hz, 1H), 6.30 (br. s., 1H), 5.75 - 5.59 (m, 2H), 4.77 (t, $J=11.6$ Hz, 1H), 4.58 (br. s., 1H), 4.01 - 3.92 (m, 1H), 3.91 - 3.83 (m, 1H), 3.60-3.20 (m, 2H), 2.75 (d, $J=7.3$ Hz, 1H), 2.51 (s, 3H), 2.40 - 2.26 (m, 4H), 2.17 (br. s., 1H), 2.03 (d, $J=13.7$ Hz, 1H), 1.86 (d, $J=12.5$ Hz, 1H), 1.68 - 1.53 (m, 2H), 1.22 (s, 3H), 1.16 (s, 9H), 1.05 (d, $J=6.1$ Hz, 3H). LCMS ($M+1$) = 639.3.

Intermediate 240




10

tert-Butyl 4-(hydroxymethyl)-4-methylpiperidine-1-carboxylate: A suspension of 1-(tert-butoxycarbonyl)-4-methylpiperidine-4-carboxylic acid (0.750 g, 3.08 mmol) in THF (5 mL) at rt under N_2 was treated with 2M THF solution of $BH_3 \cdot SMe_2$ (1.541 mL, 3.08 mmol). After 18 h, the reaction was cooled in an ice bath and quenched by the addition of 5 mL of 1N NaOH. Partitioned between ether and water. Organic phase dried ($MgSO_4$), filtered, and concentrated in vacuo to give 700 mg (99%) of *tert-butyl 4-(hydroxymethyl)-4-methylpiperidine-1-carboxylate* as a colorless oil. 1H NMR (400 MHz, $CDCl_3$) δ 3.86 - 3.64 (m, 3H), 3.41 (s, 2H), 3.15 (ddd, $J=13.6, 10.2, 3.5$ Hz, 2H), 1.94 - 1.80 (m, 1H), 1.52 - 1.43 (m, 10H), 1.31 (dt, $J=13.5, 3.8$ Hz, 2H), 1.01 (s, 3H).

20

Intermediate 241




25

tert-Butyl 4-((allyloxy)methyl)-4-methylpiperidine-1-carboxylate: To a solution of *tert-butyl 4-(hydroxymethyl)-4-methylpiperidine-1-carboxylate* (479 mg, 2.089 mmol) in DMA (3 mL) was added 60 wt% sodium hydride (125 mg, 3.13


mmol). Reaction immediately turned yellow. Stirred for 5 min and added 3-bromoprop-1-ene (1263 mg, 10.44 mmol). After 3h, partitioned between EtOAc and sat.aq.NH₄Cl. The organic phase was washed with water (3x), brine and dried (MgSO₄), filtered, and concentrated to give 471 mg (75%) of tert-butyl 4-((allyloxy)methyl)-4-methylpiperidine-1-carboxylate as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ 5.91 (ddt, *J*=17.2, 10.5, 5.3 Hz, 1H), 5.29 (dq, *J*=17.1, 1.7 Hz, 1H), 5.19 (dq, *J*=10.4, 1.5 Hz, 1H), 3.98 (dt, *J*=5.3, 1.5 Hz, 2H), 3.62 (br. s., 2H), 3.23 - 3.14 (m, 4H), 1.56 - 1.49 (m, 2H), 1.48 (s, 9H), 1.37 - 1.28 (m, 2H), 1.02 (s, 3H). LCMS (M+1) = 270.25.

10




4-((*Allyloxy*)methyl)-4-methylpiperidine: tert-Butyl 4-((allyloxy)methyl)-4-methylpiperidine-1-carboxylate (300 mg, 1.114 mmol) was placed in a 25 mL RBF. A 2N solution of HCl/ether was added (7 mL) and the vessel was sealed with a septa. The colorless homogeneous solution was stirred for 24 h. An aliquot was removed and analyzed by ¹H NMR which indicated that the reaction was complete. The reaction mixture was concentrated in vacuo to give 221 mg (96%) of 4-((allyloxy)methyl)-4-methylpiperidine as a white sticky solid. ¹H NMR (500MHz, DMSO-d₆) δ 8.88 - 8.42 (m, 2H), 5.90 (ddt, *J*=17.3, 10.5, 5.2 Hz, 1H), 5.35 - 5.12 (m, 2H), 3.96 (dt, *J*=5.2, 1.5 Hz, 2H), 3.24 - 3.16 (m, 2H), 3.12 - 2.93 (m, 4H), 1.70 (ddd, *J*=14.3, 10.0, 4.3 Hz, 2H), 1.43 (dt, *J*=14.2, 4.4 Hz, 2H), 0.98 (s, 3H).

25



(*S*)-Methyl 2-(7-(4-((allyloxy)methyl)-4-methylpiperidin-1-yl)-2-(3-bromophenyl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: Intermediate **61** (558 mg, 1.195 mmol) was dissolved in DMF (100 mL). After flushing with N₂, 4-((allyloxy)methyl)-4-methylpiperidine, hydrochloride and Hunig'sBase (0.626 mL, 3.59 mmol) were added to the reaction mixture. After stirring for 18 h at rt, the reaction was heated at 50°C for 3 h. The reaction mixture was diluted with EtOAc. It was then added water. The organic layer was separated and dried over MgSO₄, filtered and concentrated to obtain 230 mg oil, which was then purified by prep HPLC (NH₄OAc/CH₃CN, 90%-100%B) to isolate 200 mg (28%) of the desired product as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.18 (s, 1H), 7.93 (d, J=7.7 Hz, 1H), 7.67 - 7.52 (m, 1H), 7.35 (t, J=7.9 Hz, 1H), 6.81 (s, 1H), 6.06 (s, 1H), 6.03 - 5.93 (m, 1H), 5.35 (dd, J=17.3, 1.5 Hz, 1H), 5.21 (dd, J=10.5, 1.7 Hz, 1H), 4.72 - 4.29 (m, 1H), 4.08 (br. s., 2H), 3.75 (s, 3H), 3.58 - 2.87 (m, 5H), 2.63 (s, 3H), 1.99 - 1.90 (m, 1H), 1.82 (ddd, J=13.0, 9.4, 4.0 Hz, 1H), 1.52 (d, J=13.4 Hz, 2H), 1.31 - 1.25 (m, 9H), 1.23 (br. s., 3H). LCMS (M+1) = 599.15.

Intermediate 241




(*S*)-Methyl 2-(7-(4-((allyloxy)methyl)-4-methylpiperidin-1-yl)-2-(2'-(but-3-en-1-yl)-[1,1'-biphenyl]-3-yl)-5-methylpyrazolo[1,5-*a*]pyrimidin-6-yl)-2-(*tert*-butoxy)acetate: A mixture of (2-(but-3-en-1-yl)phenyl)boronic acid (66.1 mg, 0.300 mmol), intermediate **240** (120 mg, 0.200 mmol), 2.0 M aqueous K₂CO₃ (0.200 mL, 0.400 mmol) in DMF (2 mL). The reaction was sparged with nitrogen for 10 minutes, treated with tetrakis(triphenylphosphine)palladium(0) (23.13 mg, 0.020 mmol) then sparged with nitrogen for 1 min. The reaction tube was sealed and then heated at 90°C in a microwave tube for 1 h. The reaction was concentrated, then diluted with water (15 mL) and extracted with EtOAc. The EtOAc layer was washed

with brine, then dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by biotage (0% - 20% EtOAc in hexanes) to isolate 100 mg (77%) of the desired product as an off-white foam. ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, J=7.9 Hz, 1H), 7.98 (s, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.39 - 7.30 (m, 5H), 6.84 (s, 1H), 6.07 (s, 1H), 5.99 - 5.84 (m, 1H), 5.74 (ddt, J=17.0, 10.3, 6.6 Hz, 1H), 5.35 - 5.26 (m, 1H), 5.18 (d, J=9.3 Hz, 1H), 4.97 - 4.86 (m, 2H), 4.60-2.80 (m, 2 H), 4.00 (br. s., 2H), 3.74 (s, 3H), 3.58 - 2.87 (m, 4H), 2.80 - 2.70 (m, 2H), 2.63 (s, 3H), 2.34 - 2.24 (m, 2H), 1.96 - 1.86 (m, 1H), 1.85 - 1.74 (m, 1H), 1.65 - 1.47 (m, 2H), 1.33 - 1.17 (m, 12H). LCMS (M+1) = 651.41.

10


Intermediate 242



Methyl (2S)-2-(tert-butoxy)-2-[(23E)-4,28-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,23-undecaen-3-yl]acetate: A mixture of intermediate **241** (80 mg, 0.123mmol), (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (7.70 mg, 0.012 mmol) in DCE (100 mL) was heated at 70° C for 3 h. It was then concentrated and purified by biotage, eluting with 20% EtOAc/hexane to afford 75 mg (98%) of the desired product as an oil. It was a mixture of isomers. LCMS (M+1) = 623.4.

20


Intermediate 243



25

Methyl (2S)-2-(tert-butoxy)-2-{4,28-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetate: A mixture of intermediate **242** (75 mg, 0.120 mmol), 10%Pd/C (12.82 mg, 0.012 mmol) in MeOH (1 mL) was stirred at rt for 1 h. It was then filtered and concentrated to obtain 70 mg (98%) of the desired product as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.07 (t, J=1.5 Hz, 1H), 7.81 - 7.71 (m, 1H), 7.51 (t, J=7.8 Hz, 1H), 7.37 - 7.33 (m, 2H), 7.30 (d, J=1.2 Hz, 1H), 7.27 - 7.21 (m, 2H), 6.83 (s, 1H), 5.92 (s, 1H), 4.36 (t, J=10.1 Hz, 1H), 3.86 - 3.79 (m, 1H), 3.75 (s, 3H), 3.50 (d, J=9.3 Hz, 1H), 3.46 - 3.35 (m, 2H), 3.31 (d, J=9.0 Hz, 1H), 3.23 (d, J=11.5 Hz, 1H), 2.96 (d, J=12.2 Hz, 1H), 2.80 - 2.70 (m, 2H), 2.61 (s, 3H), 2.06 (d, J=13.4 Hz, 1H), 1.77 - 1.30 (m, 9H), 1.28-1.26 (m, 12H). LCMS (M+1) = 625.5.

Example 106



15

(2S)-2-(tert-Butoxy)-2-{4,28-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1¹⁰.1⁴.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid: Example **104** was prepared using intermediate **243** by following to the procedure to prepare example **26**. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.75 (d, J=7.5 Hz, 1H), 7.50 (t, J=7.7 Hz, 1H), 7.34 (d, J=3.5 Hz, 2H), 7.31 - 7.21 (m, 3H), 6.83 (s, 1H), 5.84 (br. s., 1H), 4.41 (t, J=10.2 Hz, 1H), 3.92 - 3.83 (m, 1H), 3.47 - 3.32 (m, 4H), 3.24 (d, J=9.3 Hz, 1H), 3.01 (d, J=12.5 Hz, 1H), 2.80 - 2.69 (m, 2H), 2.60 (s, 3H), 2.13 (br. s., 1H), 1.76 - 1.32 (m, 9H), 1.31 - 1.23 (m, 12H). LCMS (M+H) = 611.3.

25

It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore


desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

5

CLAIMS

We claim:

- 5 1. A compound of Formula I



I

where:

10

R^1 is hydrogen, alkyl, or cycloalkyl;

R^2 is hydrogen or alkyl;

- 15 R^3 is hydrogen, alkyl or halo;

R^4 is cycloalkyl or Ar^3 ;

or R^4 is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,

- 20 homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 alkyl substituents;

R^5 is hydrogen or alkyl;

- 25 Ar^1 is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

Ar² is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or trizainyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂;

- 5 Ar³ is phenyl, chromanyl, or dihydrobenzoxazinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

X¹ is CH, CH₂, O, S, or NR⁵;

- 10 X² is alkylene or alkenylene; and

X³ is CH, CH₂, CH₂O, O, S, or NR⁵;

or a pharmaceutically acceptable salt thereof.

15

2. A compound of claim 1 where R¹ is alkyl; R² is alkyl; R³ is hydrogen; R⁴ is Ar³ or is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl substituted with 0-3 alkyl substituents; Ar¹ is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ar² is phenyl substituted with 0-3 substituents selected from selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂; Ar³ is dihydrobenzoxazinyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; X¹ is CH₂ or O; X² is alkylene or alkenylene; and X³ is CH, CH₂ or O; or a pharmaceutically acceptable salt thereof.
- 20
- 25

3. A compound of claim 2 where R¹ is alkyl; R² is alkyl; R³ is hydrogen; R⁴ is piperidinyl substituted with 0-1 alkyl substituents; Ar¹ is phenyl; Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂; X¹ is CH₂ or O; X² is alkylene or alkenylene; and X³ is CH, CH₂ or O; or a pharmaceutically acceptable salt thereof.
- 30

4. A compound of claim 1 where R¹ is alkyl, R² is alkyl and R³ is hydrogen.

5. A compound of claim 1 where R⁴ is piperidiny1 substituted with 0-3 alkyl substituents.
6. A compound of claim 1 where Ar¹ is phenyl.
7. A compound of claim 1 where Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and CON(R⁵)₂.
8. A compound of claim 1 where Ar³ is chromanyl or dihydrobenzoxazinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.
9. A compound of claim 1 where X¹ is CH₂ or O; X² is alkylene or alkenylene; and X³ is CH, CH₂ or O.
10. A compound of claim 1 selected from the group consisting of
 - (2S)-2-(tert-Butoxy)-2-[(22Z)-32-chloro-4-methyl-28-oxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{29,33}]hexatriaconta-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetic acid;
 - (2S)-2-(tert-Butoxy)-2-[(22E)-32-chloro-4-methyl-28-oxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{29,33}]hexatriaconta-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,22,29,32-tetradecaen-3-yl]acetic acid;
 - (2S)-2-(tert-Butoxy)-2-{32-chloro-4-methyl-20,28-dioxa-5,7,8,25-tetraazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.1^{15,19}.0^{2,7}.0^{29,33}]hexatriaconta-1(31),2,4,6(36),8,10(35),11,13,15(34),16,18,29,32-tridecaen-3-yl}acetic acid;
 - (2S)-2-(tert-Butoxy)-2-[(33-chloro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetic acid;

- (2S)-2-(tert-Butoxy)-2-{35-chloro-4-methyl-21,31-dioxa-5,7,8,28-tetraazaheptacyclo[26.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{32,36}]octatriaconta-1(34),2,4,6(38),8,10(37),11,13,15(20),16,18,32,35-tridecaen-3-yl}acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-{32-fluoro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- (2S)-2-(tert-Butoxy)-2-{4,32-dimethyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- 10 (2S)-2-(tert-butoxy)-2-{4-methyl-29-oxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- 15 (2S)-2-(tert-butoxy)-2-{4-methyl-29-oxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- 20 (2S)-2-(tert-butoxy)-2-{4-methyl-29-oxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- (2S)-2-(tert-Butoxy)-2-{4-methyl-28-oxa-5,7,8-triazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{29,33}]pentatriaconta-1(31),2,4,6(35),8,10(34),11,13,15(20),16,18,29,32-tridecaen-3-yl}acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-{4-methyl-28-oxa-5,7,8-triazaheptacyclo[23.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{29,33}]pentatriaconta-1(31),2,4,6(35),8,10(34),11,13,15(20),16,18,29,32-tridecaen-3-yl}acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(26R)-4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetic acid;
- 30

- (2S)-2-(tert-Butoxy)-2-[(26S)-4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[(26S)-4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(26S)-4-methyl-21,29-dioxa-5,7,8-triazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,23,30,33-tetradecaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-{31-fluoro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- (2S)-2-(tert-Butoxy)-2-{33-chloro-4-methyl-29-oxa-5,7,8,26-tetraazaheptacyclo[24.6.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}.0^{30,34}]hexatriaconta-1(32),2,4,6(36),8,10(35),11,13,15(20),16,18,30,33-tridecaen-3-yl}acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[4,27-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid;
- 30 (2S)-2-(tert-Butoxy)-2-[(23E)-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;

- (2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl}acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(22S)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxo-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[4,28-dimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-{4,28-dimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22R)-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 30

- (2S)-2-(tert-Butoxy)-2-[(22S)-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-{4,28-dimethyl-27-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- (2S)-2-(tert-Butoxy)-2-[17-chloro-4,27-dimethyl-21,26-dioxa-1,5,7,8-
- 10 tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-{17-chloro-4,27-dimethyl-21,26-dioxa-1,5,7,8-
- 15 tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- (2S)-2-(tert-Butoxy)-2-[4,17,27-trimethyl-21,26-dioxa-1,5,7,8-
- tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
- 20 2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[4,17,27-trimethyl-21,26-dioxa-1,5,7,8-
- tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
- 25 2,4,6(33),8,10(32),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-{4,17,27-trimethyl-21,26-dioxa-1,5,7,8-
- tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-
- 2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(23E)-4,27-dimethyl-26-oxa-1,5,7,8,17-
- 30 pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;

- (2S)-2-(tert-Butoxy)-2-[(23Z)-4,27-dimethyl-26-oxa-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(23Z,25E)-4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(23E,25E)-4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[(23Z,25E)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-[(23E,25E)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23,25-dodecaen-3-yl]acetic acid;
- 30 (2S)-2-(tert-Butoxy)-2-{17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;

- (2S)-2-(tert-Butoxy)-2-[(25E)-17-chloro-4,27-dimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,25-undecaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-26-oxa-1,5,7,8,19-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(23Z)-18-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(23E)-18-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-{18-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[(23E)-4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-[(23Z)-4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-{4,27-dimethyl-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- 30

- (2S)-2-(tert-Butoxy)-2-[(22S,24E)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[(22S,24Z)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(22R)-4,22,27-trimethyl-21,26-dioxa-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-[(22S)-4,22,27-trimethyl-21,26-dioxa-1,5,7,8,17-pentaazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[(22R)-4,17,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22R)-4,17,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 30

- (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[17-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-{17-fluoro-4,27-dimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl} acetic acid;
- 10
- (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,29-tetramethyl-21,28-dioxa-1,5,7,8-tetraazahexacyclo[27.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]pentatriaconta-2,4,6(35),8,10(34),11,13,15(20),16,18,25-undecaen-3-yl]acetic acid;
- 15
- (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,29-tetramethyl-21,28-dioxa-1,5,7,8-tetraazahexacyclo[27.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]pentatriaconta-2,4,6(35),8,10(34),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 20
- (2S)-2-(tert-Butoxy)-2-[(22S)-18-chloro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- 25
- (2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 30
- (2S)-2-(tert-Butoxy)-2-[(22S,24E)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;

- (2S)-2-(tert-Butoxy)-2-[(22S,24Z)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[(22S)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(22S)-17-isocyano-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-[(22S)-17-carbamoyl-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[(22S)-17-cyano-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- 30 (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;

- (2S)-2-(tert-Butoxy)-2-[(22S)-4,16,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[(22S)-18-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-18-fluoro-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-
10 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
15 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-17-fluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[(22S)-17-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-[(22S)-18-fluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-16-fluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-
30 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;

- (2S)-2-(tert-Butoxy)-2-[(22S)-16-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-[(22S)-18-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 10 (2S)-2-(tert-Butoxy)-2-[(22S)-18-cyano-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 15 (2S)-2-(tert-Butoxy)-2-[(22S)-17-chloro-4,18,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-Butoxy)-2-[(22S)-17-chloro-4,16,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 20 (2S)-2-(tert-Butoxy)-2-[(22R)-17-chloro-4,18,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 25 (2S)-2-(tert-Butoxy)-2-[(22S)-17-fluoro-4,18,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 30 (2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1⁶,⁹.1¹⁰,¹⁴.0²,⁷.0¹⁵,²⁰]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid;

- (2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid;
- 5 (2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid;
- (2S)-2-(tert-Butoxy)-2-{4,17,22,23,28-pentamethyl-21,27-dioxa-1,5,7,8-
10 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl}acetic acid;
- (2S)-2-[(2-Methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
15 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(1-Methylcyclobutoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
20
- (2S)-2-[(2-Methylbutan-2-yl)oxy]-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 25 (2S)-[(22S)-16-Chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid;
- 30 (2S)-[(22S)-16-Chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-

2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid;

(2S)-[(22S)-16-Chloro-4,13,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
5 2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid;

(2S)-[(22S)-16-Chloro-13-fluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
10 2,4,6(34),8,10(33),11,13,15,17,19-decaen-3-yl][(2-methyl-2-propanyl)oxy]acetic acid;

(2S)-2-(tert-Butoxy)-2-{4,17,23,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
15 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl} acetic acid;

(2S)-2-(tert-Butoxy)-2-{4,17,23,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
20 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl} acetic acid;

(2S)-2-(tert-butoxy)-2-[(22S,24E)-4,18,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid; and

25

(2S)-2-(tert-Butoxy)-2-{4,28-dimethyl-26-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-
2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl} acetic acid

30 or a pharmaceutically acceptable salt thereof.

11. A compound of claim 1 selected from the group consisting of

- (2S)-2-(tert-butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- 5 (2S)-2-(tert-butoxy)-2-[(22S)-16-chloro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-butoxy)-2-[(22S)-16-fluoro-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-
- 10 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-butoxy)-2-[(22S)-16-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-
- 15 2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-butoxy)-2-[(22S)-17-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-
- 20 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;
- (2S)-2-(tert-butoxy)-2-[(22S)-18-fluoro-4,22,28-trimethyl-21,27-dioxo-1,5,7,8-
- 25 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;
- (2S)-2-(tert-butoxy)-2-[(22S,24E)-4,17,22,28-tetramethyl-21,27-dioxo-1,5,7,8-
- 30 tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid;


(2S)-2-(tert-butoxy)-2-[(22S)-4,17,18,22,28-pentamethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;

- 5 (2S)-2-(tert-butoxy)-2-[(22S)-18-chloro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid and

- 10 (2S)-2-(tert-butoxy)-2-[(22S)-17-cyano-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;

or a pharmaceutically acceptable salt thereof.

- 15 12. The compound of claim 1: (2S)-2-(tert-butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1^{6,9}.1^{10,14}.0^{2,7}.0^{15,20}]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid;




or a pharmaceutically acceptable salt thereof.

13. A composition useful for treating HIV infection comprising a therapeutic
25 amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

14. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

15. The method of claim 13 further comprising administering a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease
5 inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.



(I)